0001493152-25-010917.txt : 20250319 0001493152-25-010917.hdr.sgml : 20250319 20250319160029 ACCESSION NUMBER: 0001493152-25-010917 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 96 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250319 DATE AS OF CHANGE: 20250319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVD EQUIPMENT CORP CENTRAL INDEX KEY: 0000766792 STANDARD INDUSTRIAL CLASSIFICATION: SPECIAL INDUSTRY MACHINERY, NEC [3559] ORGANIZATION NAME: 06 Technology IRS NUMBER: 112621692 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16525 FILM NUMBER: 25752611 BUSINESS ADDRESS: STREET 1: 355 S. TECHNOLOGY DRIVE CITY: CENTRAL ISLIP STATE: NY ZIP: 11722 BUSINESS PHONE: 6319817081 MAIL ADDRESS: STREET 1: 355 S. TECHNOLOGY DRIVE CITY: CENTRAL ISLIP STATE: NY ZIP: 11722 10-K 1 form10-k.htm
false FY 0000766792 P7Y P10Y P1Y 0000766792 2024-01-01 2024-12-31 0000766792 2024-06-30 0000766792 2025-03-19 0000766792 2024-12-31 0000766792 2023-12-31 0000766792 2023-01-01 2023-12-31 0000766792 us-gaap:CommonStockMember 2022-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000766792 us-gaap:RetainedEarningsMember 2022-12-31 0000766792 2022-12-31 0000766792 us-gaap:CommonStockMember 2023-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000766792 us-gaap:RetainedEarningsMember 2023-12-31 0000766792 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000766792 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000766792 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000766792 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000766792 us-gaap:CommonStockMember 2024-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000766792 us-gaap:RetainedEarningsMember 2024-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember srt:MinimumMember 2024-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember srt:MaximumMember 2024-12-31 0000766792 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2024-12-31 0000766792 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2024-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerMember 2024-01-01 2024-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerOneMember 2024-01-01 2024-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerTwoMember 2024-01-01 2024-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerThreeMember 2024-01-01 2024-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerOneMember 2023-01-01 2023-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerTwoMember 2023-01-01 2023-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerThreeMember 2023-01-01 2023-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerMember 2024-01-01 2024-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerAMember 2024-01-01 2024-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerAMember 2023-01-01 2023-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerBMember 2023-01-01 2023-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerCMember 2023-01-01 2023-12-31 0000766792 CVV:ExportSalesMember us-gaap:CustomerConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2024-01-01 2024-12-31 0000766792 CVV:ExportSalesMember us-gaap:CustomerConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2023-01-01 2023-12-31 0000766792 us-gaap:CargoAndFreightMember 2024-01-01 2024-12-31 0000766792 us-gaap:CargoAndFreightMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:EnergyMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:EnergyMember 2024-01-01 2024-12-31 0000766792 CVV:EnergyMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:AerospaceMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:AerospaceMember 2024-01-01 2024-12-31 0000766792 CVV:AerospaceMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:IndustrialMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:IndustrialMember 2024-01-01 2024-12-31 0000766792 CVV:IndustrialMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:ResearchOneMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:ResearchOneMember 2024-01-01 2024-12-31 0000766792 CVV:ResearchOneMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:EnergyMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:EnergyMember 2023-01-01 2023-12-31 0000766792 CVV:EnergyMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:AerospaceMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:AerospaceMember 2023-01-01 2023-12-31 0000766792 CVV:AerospaceMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:IndustrialMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:IndustrialMember 2023-01-01 2023-12-31 0000766792 CVV:IndustrialMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:ResearchOneMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:ResearchOneMember 2023-01-01 2023-12-31 0000766792 CVV:ResearchOneMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:PVTOneFiftySystemsMember 2024-01-01 2024-12-31 0000766792 CVV:PVTOneFiftySystemsMember 2024-12-31 0000766792 us-gaap:LandMember 2024-12-31 0000766792 us-gaap:LandMember 2023-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000766792 us-gaap:MachineryAndEquipmentMember 2024-12-31 0000766792 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000766792 us-gaap:ConstructionInProgressMember 2024-12-31 0000766792 us-gaap:ConstructionInProgressMember 2023-12-31 0000766792 2022-09-30 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2024-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2024-01-01 2024-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2024-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2024-01-01 2024-12-31 0000766792 2022-01-01 2022-12-31 0000766792 CVV:TwoThousandSevenShareIncentivePlanMember 2007-12-12 0000766792 CVV:TwoThousandSevenShareIncentivePlanMember 2024-12-31 0000766792 CVV:TwoThousandSixteenShareIncentivePlanMember 2016-12-09 0000766792 CVV:TwoThousandSixteenShareIncentivePlanMember 2024-12-31 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2022-07-14 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2024-12-31 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember srt:MinimumMember 2022-07-14 2022-07-14 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember srt:MaximumMember 2022-07-14 2022-07-14 0000766792 us-gaap:RestrictedStockMember srt:DirectorMember 2024-01-01 2024-12-31 0000766792 us-gaap:RestrictedStockMember srt:DirectorMember 2023-01-01 2023-12-31 0000766792 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000766792 us-gaap:EmployeeStockOptionMember 2024-12-31 0000766792 CVV:FiveDirectorsMember 2021-10-11 0000766792 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0000766792 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000766792 CVV:CostOfRevenueMember 2024-01-01 2024-12-31 0000766792 CVV:CostOfRevenueMember 2023-01-01 2023-12-31 0000766792 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0000766792 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000766792 CVV:SellingExpenseMember 2024-01-01 2024-12-31 0000766792 CVV:SellingExpenseMember 2023-01-01 2023-12-31 0000766792 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0000766792 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeOneMember 2024-01-01 2024-12-31 0000766792 CVV:ExercisePriceRangeOneMember 2024-12-31 0000766792 CVV:ExercisePriceRangeTwoMember 2024-01-01 2024-12-31 0000766792 CVV:ExercisePriceRangeTwoMember 2024-12-31 0000766792 CVV:ExercisePriceRangeThreeMember 2024-01-01 2024-12-31 0000766792 CVV:ExercisePriceRangeThreeMember 2024-12-31 0000766792 CVV:ExercisePriceRangeFourMember 2024-01-01 2024-12-31 0000766792 CVV:ExercisePriceRangeFourMember 2024-12-31 0000766792 us-gaap:RestrictedStockMember 2022-12-31 0000766792 us-gaap:RestrictedStockMember 2023-12-31 0000766792 us-gaap:RestrictedStockMember 2024-12-31 0000766792 2022-07-01 2022-07-01 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMember 2024-01-01 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2024-01-01 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:MesoScribeTechnologiesIncMember 2024-01-01 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMember 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:MesoScribeTechnologiesIncMember 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:MesoScribeTechnologiesIncMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:MesoScribeTechnologiesIncMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember 2023-12-31 0000766792 CVV:OtherTantalineMember 2024-01-01 2024-12-31 0000766792 CVV:OtherTantalineMember 2023-01-01 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2024-01-01 2024-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0000766792 srt:AmericasMember 2024-01-01 2024-12-31 0000766792 srt:AmericasMember 2023-01-01 2023-12-31 0000766792 srt:NorthAmericaMember 2024-01-01 2024-12-31 0000766792 srt:NorthAmericaMember 2023-01-01 2023-12-31 0000766792 us-gaap:EMEAMember 2024-01-01 2024-12-31 0000766792 us-gaap:EMEAMember 2023-01-01 2023-12-31 0000766792 srt:AsiaPacificMember 2024-01-01 2024-12-31 0000766792 srt:AsiaPacificMember 2023-01-01 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-08-08 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2024-01-01 2024-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-01-01 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2024-12-31 0000766792 CVV:TantalineASOfNordborgMember 2023-05-26 2023-05-26 0000766792 CVV:TantalineASOfNordborgMember 2023-01-01 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CVV:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 10-K

 

(Mark One)  
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 

 

For the fiscal year ended December 31, 2024

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the transition period from ___ to _____

 

Commission file number: 1-16525

 

CVD EQUIPMENT CORPORATION

(Exact name of registrant as specified in its charter)

 

New York   11-2621692
(State or Other Jurisdiction of
Incorporation or Organization)		   (I.R.S. Employer
Identification No.)

 

355 South Technology Drive
Central Islip, New York 11722

(Address including zip code of registrant’s Principal Executive Offices)

 

(631) 981-7081

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par value $0.01   CVV   NASDAQ Capital Market

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and emerging growth company in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company☒ Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $20,795,415 at June 30, 2024.

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 6,881,838 shares of Common Stock, $0.01 par value at March 19, 2025.

 

DOCUMENTS INCORPORATED BY REFERENCE: None.

 

 

 

 

 

 

CVD EQUIPMENT CORPORATION

INDEX TO ANNUAL REPORT ON FORM 10-K

 

Part I      
       
Item 1. Business   4
Item 1A. Risk Factors   16
Item 1B. Unresolved Staff Comments   29
Item 1C. Cybersecurity   29
Item 2. Properties   29
Item 3. Legal Proceedings   29
Item 4. Mine Safety Disclosures   29
       
Part II      
       
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities   30
Item 6. [Reserved]   30
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations   31
Item 7A. Quantitative and Qualitative Disclosures About Market Risk   39
Item 8. Financial Statements and Supplementary Data   39
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure   39
Item 9A. Controls and Procedures   39
Item 9B. Other Information   40
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections   40
       
Part III      
       
Item 10. Directors, Executive Officers and Corporate Governance   40
Item 11. Executive Compensation   47
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters   50
Item 13. Certain Relationships and Related Transactions and Director Independence   51
Item 14. Principal Accountant Fees and Services   51
       
Part IV      
       
Item 15. Exhibits and Financial Statement Schedules   52
       
Signatures     54

 

2

 

 

INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS

 

Except for historical information contained herein, this Annual Report on Form 10-K contains forward–looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. These statements involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on various factors and are derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include, but are not limited to:

 

  ● uncertainty as to our future growth and return to profitability;
     
  ● uncertainty as to the general state of the silicon carbide wafer end market;
     
  ● competition in our existing and potential future product lines of business, including our PVT150 / PVT 200 systems;
     
  ● uncertainty as to our ability to identify and develop new products for growth markets;
     
  ● our ability to obtain financing on acceptable terms if and when needed;
     
  ● our ability to attract and retain key personnel and employees;
     
  ● uncertainty as to changes to international trade policies including the possible imposition of tariffs; and
     
  ● uncertainty as to our ability to adequately obtain raw materials and on commercially reasonable terms.

 

Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. We assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting such forward-looking statements. Past performance is no guaranty of future results.

 

You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made. When used with this Report, the words “believes”, “anticipates”, “expects”, “estimates”, “plans”, “intends”, “will” and similar expressions are intended to identify forward-looking statements.

 

3

 

 

Item 1. Description of Business.

 

The use of the words “CVD,” “we,” “us,” or “our,” refers to CVD Equipment Corporation, a New York corporation incorporated on October 13, 1982, and its wholly owned subsidiaries, CVD Materials Corporation (including its wholly owned subsidiaries, and CVD MesoScribe Technologies Corporation (“MesoScribe”) and Tantaline CVD Holding ApS (“Tantaline”)), and FAE Holdings 411519R LLC except where the context otherwise requires.

 

Overview

 

CVD has served the advanced materials markets with chemical vapor deposition, physical vapor transport and thermal process equipment for over 40 years. We are headquartered in Central Islip, New York with our SDC division located in Saugerties, New York.

 

We design, develop, and manufacture a broad range of equipment used to develop and produce materials and coatings for the aerospace, compound semiconductor, semiconductor, aerospace, battery energy storage markets as well as advanced industrial applications, and research.

 

We conduct our business through three reportable segments: i) CVD Equipment that designs and manufactures chemical vapor deposition, physical vapor transport and thermal process equipment; ii) SDC that designs and manufactures ultra-high purity gas and chemical delivery control systems; and iii) MesoScribe that provided products related to advanced materials and coatings.

 

Developments

 

On August 8, 2023, we entered into an agreement with a third party to sell certain assets and license certain propriety information of our MesoScribe subsidiary. We fulfilled remaining orders for MesoScribe products during 2024 and sold certain equipment resulting in the recognition of a gain on sale of equipment in 2024.

 

On May 26, 2023, we sold our Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027.

 

The decisions to sell our Tantaline subsidiary and close down the operations of MesoScribe were based on our strategy to focus on the equipment business consisting of the CVD Equipment and SDC segments.

 

Key Company Strengths

 

Based on more than 40 years of equipment experience, we use our capabilities in process development, engineering, and vertical manufacturing to transform emerging applications into mainstream manufacturing solutions.

 

4

 

 

We have built a library of design expertise, know-how and innovative solutions to assist our customers in developing these intricate processes and to accelerate their production and commercialization. This library of equipment design solutions, along with our manufacturing and systems integration facilities, allows us to provide application-specific design, process, and manufacturing solutions to our customers.

 

Our core competencies in equipment and software design, manufacturing and process development are used to engineer our finished products and to accelerate the commercialization path of our customer base. Our proprietary real-time software allows for rapid configuration, and provides our customers with enabling tools to understand, optimize and repeatedly control their processes. These factors reduce cost, improve quality, and reduce the time it takes between customers’ orders and the shipment of our products. Our Application Laboratory allows customers the option to bring their process tools to our laboratory and to work collaboratively with our scientists and engineers to optimize process performance.

 

To expand our presence into our major target markets, we are developing a line of proprietary standard use products to complement our customized legacy systems. Historically, we manufactured products for research and development on an application-specific basis to meet an individual customer’s specific research and production requirements. Our proprietary systems leverage the technological expertise that we have developed through designing these custom systems into a broader standardized product line. The standard product line can be configured from a wide range of available options to meet diverse product and budgetary requirements. Manufacturing these standardized systems in higher volumes may provide us the flexibility to reduce both the cost and delivery time of our systems as well as leverage our engineering development cost. These systems, which we market and sell under the CVD, FirstNano and EasyTube® product names, are sold to commercial companies, universities and research laboratories in the United States and throughout the world.

 

Sales of our proprietary standard systems, custom systems and process solutions have been driven by our installed customer base, which includes many Fortune 500 companies. The performance and success of our products has historically driven repeat orders from existing customers as well as generated business from new customers. Furthermore, with our proprietary solutions and expanded focus on “enabling tomorrow’s technologies”TM we have been developing a new customer base in addition to growing with our existing customers.

 

Key Growth Strategies

 

Our core strategy is to focus on growth applications in end markets related to aerospace, microelectronics, and industrial applications.

 

With respect to aerospace, our systems are being used by our customers to produce ceramic matrix composite materials (“CMCs”) that will be used in next generation gas turbine jet engines with the objective of reducing jet fuel consumption and contributing to the decarbonization of that industry.

 

During 2022, we also received an order from an aerospace company for a production chemical vapor infiltration (CVI) system that will be used to manufacture CMCs for gas turbine jet engine components. We received additional orders from the same aerospace company for three CVI systems in 2023 and one CVI system in 2024.

 

5

 

 

In February 2024, we received a multisystem order from an industrial customer for approximately $10 million that will be used for depositing a silicon carbide protective coating on OEM components and the units are expected to be delivered over 18 to 24 months period.

 

The phrase “electrification of everything” within the microelectronics market refers to the shift from fossil fuels to the use of electricity to power devices, buildings, electric vehicles (“EVs”) and many other applications. Our strategy yielded multisystem orders of PVT150 equipment that was delivered to one company in 2022 and 2023 that manufactures silicon carbide wafers.

 

In February 2024, we received an order from an additional customer for our new PVT200 system used to grow silicon carbide crystals for the manufacture of 200 mm wafers. This represents our second customer for our PVT equipment. This customer is evaluating our equipment performance for potential additional purchases of PVT equipment. We have also received orders from OneD Battery Materials in 2023, a company that is engaged in providing battery nanomaterials. We also provide a line of CVD systems which are used to develop and produce material for the anode portion of batteries.

 

Both technologies are essential for the support of the EV market. These systems should provide us with standard product offering to continue to support the EV focused market as well as energy storage, power conversion and power transmission. We are also evaluating our ability to provide other equipment used in the manufacturing process of silicon carbide wafers.

 

We have observed lower-than-anticipated industrywide electric vehicle sales which may reduce demand for silicon carbide and negatively impact sales of our PVT systems. In addition, the recent global over capacity of 150 mm silicon carbide wafers has reduced the market for 150 mm silicon carbide growth systems.

 

We have generally gained new customers through our industry reputation, as well as limited print advertising and trade show attendance. We have increased the number of trade shows and industry conferences we attend in 2024.

 

Major Target Markets

 

Our major target markets are aerospace & defense and industrial, microelectronics / high power electronics, and EV battery materials / energy storage.

 

Aerospace & Defense

 

CVD is a leading manufacturer of preform CVI and tow-coating systems to manufacture CMCs for aerospace gas turbine jet engine applications. Our customers include two of the leaders in aerospace gas turbine engines.

 

We continue to engage additional customers in the aerospace market regarding CMCs. During 2022, we received an order for a production CVI system. We received additional orders from the same aerospace company for three CVI systems in 2023 and one additional CVI system in 2024. These systems will be used to manufacture CMCs for aerospace gas turbine jet engines.

 

6

 

 

We believe our future growth will be derived from production applications in our major target markets. Our legacy product line continues to provide advanced equipment and subsystems to enable development of emerging technology and research applications.

 

Microelectronics / High Power Electronics

 

Demand for silicon carbide wafers to support high power electronics for energy storage and transmission/charging resulted in a multi-system order from a US-based, silicon carbide wafer manufacturer. Through December 31, 2024, we have received and delivered orders for 30 of our PVT150 physical vapor transport systems from one customer, which planned to use our systems to grow silicon carbide crystals that are made into 150 mm silicon carbide wafers for use in power electronics. In late 2023, we launched our PVT200 system designed to manufacture silicon carbide crystals for 200 mm wafer and in mid-2024 we received our first order from a second customer. We plan to continue to support the market with our PVT 200 system and possible future product development for the PVT200 product line. We will continue to monitor the market dynamics for silicon carbide wafers.

 

EV Battery Materials / Energy Storage

 

We have experienced increased interest and demand for nanotechnology materials including carbon nanotubes (CNTs), graphene and silicon nanowires (Si-NWs) to support the development and manufacturing for battery materials used in electric vehicles.

 

Our major targeted markets are further described as follows (the term “legacy product” refers to products and systems within our product offerings that we have produced in our history):

 

Major Target Markets:   Description and Growth Drivers:   CVD Equipment Products and Services:
Aerospace, Defense and Industrial   Next generation gas turbine jet engines are incorporating CMC material for the hot section or exhaust of the engine to improve fuel efficiency.   Production and R&D Applications:
         
    Silicon carbide coating is used as a protective barrier in many OEM equipment components used in LED and other applications.   - Fiber tow coat system. Mass production system for multi-layer coating for CMCs.
        - Silicon bond coat environmental barrier depositing system. Deposits Si on machined gas turbine jet engine CMC components and other OEM components.
           
        - Chemical Vapor Deposition/ Chemical Vapor Infiltration production coating system for multi-layer CMC coatings on SiC fiber preforms.
           
        - Chemical Vapor Deposition production coating system for high volume low cost deposition of SiC coating.
           

Microelectronics / High Power Electronics

 

 

   The shift to electrification has the objectives of reducing emissions and reducing dependency on fossil fuels. This has driven the demand for electric vehicle and associated high power electronics used in charging and motor power conversion.  

Production Applications:

        - PVT150 SiC crystal growth system launched in 2022.
           
        - PVT200 SiC crystal growth system launched in 2023.
           
        - HVPE400: polycrystalline GaN (legacy product).
           

EV Battery Materials / Energy Storage

 

   The shift to electrification also requires improvements in energy storage, specifically with the use of novel anode materials.  

Production Applications:

        - PowderCoat-1100 production system launched in 2021 grows Si nanowires on carbon nanoparticles.
           
        - Carbon-150: Single substrate system for CNT growth. Versatile substrate format, on wafer or foil.
           
        - Carbon-300: Multiple substrate batch tube system for CNT growth. Versatile substrate format, on wafer or foil.
           
       

R&D Applications:

           
        - ET-3000: Versatile CNT growth system for research and development.

 

7

 

 

Other Markets   CVD Equipment Products:
     
    - Universal liquid and gas storage cabinets, management, and delivery systems (SDC segment).
       
    - Production MOCVD Super Conducting Tape system.
       
    - ET-3000: MOCVD for compound semiconductor R&D.
       
    - ET-3000 for graphene.
       
    - ET-6000: Multi-Tube Chemical Vapor Deposition Tube furnace (metals, oxides and nitrides).
       
    -  PowderCoat-300 for powder material R&D (including battery anode).
       
    - TMD: cluster tool for advanced material development.

 

Bookings

 

During 2024, bookings of new orders from customers was approximately $28.1 million, representing an increase of approximately 8.9% compared to 2023 bookings of $25.8 million. The increase in bookings of $2.3 million was related to an increase in aerospace and industrial orders.

 

Segments

 

CVD Equipment - supplies state-of-the-art chemical vapor deposition and thermal process equipment targeting growth production markets as well as systems for use in research and development. This includes systems marketed under the FirstNano product brand. Utilizing our over 40 years of expertise in the design and manufacture of chemical vapor deposition and thermal process equipment, we provide material processing capability and control at a competitive cost of ownership.

 

The targeted growth production markets include aerospace advanced materials primarily for gas turbine jet engines, high power electronics (both silicon carbide (SiC) and gallium nitride (GaN)), and nanomaterials used in batteries. The product group also consists of legacy products serving the production and R&D applications such as semiconductors, LEDs, carbon nanotubes, nanowires, solar cells and several other industrial & research applications.

 

Our developments and opportunities for the carbon composite business come from achievements in our Applications Laboratory. The Applications Laboratory, along with the sales and marketing team continue to explore carbon-based products and applications that can be made from our CNT, infiltrated carbon/CVI and carbon nano fiber technology (CNF). Some applications include CNT and infiltrated carbon/CVI based battery material and CNF capacitors for 5G technology.

 

8

 

 

To support new emerging applications, we provide equipment to and collaborate with laboratory scientists to bring state-of-the-art processes from the research laboratory into production. CVD Equipment group provides process development value through our Application Laboratory where our personnel interact directly with the scientists and engineers of our customer base to develop solutions to tomorrow’s challenges today. CVD Equipment segment operates from our 128,000 square feet facility in Central Islip, New York.

 

SDC - designs and manufactures ultra-high purity gas and chemical delivery control systems for state-of-the-art semiconductor fabrication processes, aerospace, solar cells, LEDs, carbon nanotubes, nanowires, and a number of industrial applications. Our SDC products are sold on a stand-alone basis and are also integrated into certain CVD equipment. This internal supply of chemical and gas delivery systems and components provide a competitive advantage for our CVD Equipment group over its competition. SDC operates from a 22,000 square foot facility fitted with a clean room manufacturing space located in Saugerties, New York.

 

MesoScribe - consisted of MesoScribe’s direct write printed electronics business. MesoScribe provided MesoPlasma™ printing services and products (heaters, antennas, and sensors) to aerospace, satellite, power generation, defense, and other markets requiring high performance. MesoScribe operations were located at our main facility in Central Islip, New York.

 

On August 8, 2023, we entered into an agreement with a third party to sell certain assets and license certain proprietary information of MesoScribe. We fulfilled remaining orders for MesoScribe products during 2024,completed the sales of the equipment assets and ceased operations as of September 30, 2024.

 

Products and Technology

 

Chemical Vapor Deposition/Infiltration – Chemical vapor deposition is a method of coating or growing material through a chemical disassociation and recombination at elevated temperatures onto or within pores of a substrate material. A single or collection of gases or vapor introduced on to the surface or into pores of a substrate material that is heated to such a degree that the gases decompose and deposits a desired layer onto and or into a substrate material. Chemical vapor infiltration (CVI) is a variant of a chemical vapor deposition process that is performed at low pressures to allow for coating the internal surfaces of a porous material. Using heat and low pressure, precursor vapors penetrate the pores/fiber of the material and deposit to form a conformal coating on the internal surfaces. Both processes are accomplished by combining appropriate gases in a reaction chamber, of the kind we manufacture, at elevated temperatures (typically 500° to 2,500° Celsius). Our chemical vapor deposition and CVI systems are complete and include all necessary heating techniques, precise control instrumentation, gas delivery and abatement subsystems and components and include state-of-the-art proprietary process control software. We provide both standard and emerging applications specified products. Some of the standard systems we offer are for SiC, GaN, Aluminum Nitride (AlN), CMCs, silicon (Si), CNT, graphene, silicon nanowires. The systems are sold under the CVD and FirstNano product brands.

 

9

 

 

Physical Vapor Transport (PVT) – While the PVT150 was officially launched for production in 2022, we have sold PVT systems in prior years and have pioneered both resistive heating and more effectively inductively heated PVT systems. The PVT150 system was specifically designed to address the SiC crystal growth market for 150 mm substrates or wafers. Designed to provide enhanced process parameter control it allows existing and future customers the ability to tightly control and monitor the crystal growth process for 150mm substrates. A 200 mm version called the PVT200 was developed during 2023, and the first order was received in February 2024 and delivered in 2024. The crystal growth technique utilized a high temperature furnace to vaporize from seed granular material of SiC and further deposit out in an ordered crystal structure onto substrate wafer. The process takes days to over a week to complete and yield a SiC crystal ready for further processing into wafers.

 

Rapid Thermal Processing (RTP) – Used to heat semiconductor materials to elevated temperatures of up to 1,200° Celsius at rapid rates of up to 200° Celsius per second. Our RTP systems are offered for implant activation, oxidation, silicide formation and many other processes. We offer systems that can operate both at atmospheric and reduced pressures.

 

Annealing, Diffusion and Low-Pressure Chemical Vapor Deposition (LPCVD) Furnaces – These furnaces are used for dislocation removal in crystals, dopant diffusion, oxidation, for SiC, Si, SiOx and other applications. The systems are normally operated at atmospheric and/or reduced pressure with gaseous atmospheres related to the process. An optional feature of the system allows for the heating element to be moved away from the process chamber allowing the wafers to rapidly cool or be heated in a controlled environment. Our temperature control system enables more precise control of the wafers. The systems are equipped with an automatic process controller, permitting automatic process sequencing and monitoring with safety alarm provisions.

 

Ultra-High Purity Gas and Liquid Control Systems – Our standard and custom designed gas and liquid control systems, which encompass gas cylinder storage cabinets, custom gas and chemical delivery systems, gas and liquid valve manifold boxes and gas isolation boxes, provide safe storage and handling of pressurized gases and chemicals. Our system design allows for automatic or manual control from both a local and remote location. These subsystems and components are provided to the general market as well as support the CVD Equipment segment.

 

Quartzware – The majority of our process equipment solutions, utilize quartz components which we partially manufacturer internally. In addition, the equipment typically requires routine maintenance, consumable and spare parts. One such spare part and consumable which is core to our technology offering is quartz hardware. We provide standard and custom fabricated quartzware used in our equipment and to a lesser extent for other customer tools.

 

Intellectual Property

 

Our success is dependent, in part upon the development and protection of our proprietary technology and other proprietary rights. We have historically and continue to protect our proprietary information and intellectual property such as design specifications, blueprints, technical processes, and employee know-how through the use of patents and non-disclosure agreements. In the area of patents, we believe there is value in having protected intellectual property and will continue to file for patent protection of our proprietary technology that we believe has the potential to be incorporated into our products and sold to multiple customers. We also maintain certain trademarks relating to certain of our products and product lines and claim copyright protection for certain proprietary software and documentation.

 

10

 

 

While patent, copyright and trademark protections for our intellectual property are important to different degrees for our various products and solutions, we believe our future success in highly dynamic markets is most dependent upon the technical competence and creative skills of our personnel and our ability to accelerate the commercialization of next generation intellectual properties. We strive to protect our trade secrets and other proprietary information through non-disclosure agreements with our customers, suppliers, employees and consultants and other security measures.

 

Research and Development

 

We develop new products based on market analysis or by customer request. The technology included in our product development includes mechanical hardware, software and controls systems and overall configuration. Our research and development activities over have yielded a wealth of technology from which systems and solutions can be derived from and productized. Together with a number of leading universities and startup companies with whom we partner from time to time, we conduct research on Si deposition for both aerospace Si bond coat and microelectronic applications, SiC growth, the growth and infiltration of carbon nanotubes, graphene and nanowires as well as on selected aerospace manufacturing processes. Our intention is that together with customers and universities, we will leverage our collective expertise in this field, which we believe will allow us to capitalize on commercial opportunities in the future.

 

Markets and Marketing

 

We serve multiple emerging and mature global markets including compound semiconductor high power electronics, aerospace, defense, battery energy storage, silicon and other microelectronic and micromechanical devices, semiconductor, universities, and research centers. Due to the highly technical nature of our products, we believe it is essential to engage with customers directly through our sales personnel, our network of domestic and international independent sales representatives, and distributors specializing in the type of equipment, products, and services that we sell. Our primary marketing activities include direct sales engagement, participation in trade associations and trade shows and our internet websites. We expanded our marketing activities through attendance at key tradeshows and online marketing.

 

Customers

 

Our systems and products are used in both production applications and advanced materials research. We market and sell primarily to companies that are the engaged in producing aerospace gas turbine jet engine component material, defense, compound semiconductor wafers, battery energy storage, silicon and other microelectronic and micromechanical devices, semiconductor, universities and research centers. We have both a domestic and international customer base.

 

11

 

 

Given the complexity and magnitude of the systems we sell, revenue from a single customer in any one year can exceed 10% of our total sales. During the year ended December 31, 2024, one customer represented 29.5% of our revenues, while in 2023 three customers represented 14.3%, 13.5% and 10.9% of our revenues. While we believe that our relationships with these customers are generally positive, the loss of a large customer would have to be replaced by others, and our inability to do so could have a material adverse effect on our business and financial condition.

 

For the year ended December 31, 2024, approximately 4.3% of our revenues were generated by sales to customers outside the U.S., compared to approximately 17.2% for the year ended December 31, 2023.

 

Competition

 

We can experience intense direct competition from both domestic and international competitors in all our product segments. Our CVD Equipment product lines, including FirstNano, target multiple markets and both production and research customers. Competition is substantial in both the production applications and research. In production application, competition comes from larger companies offering enhanced services. In research applications, the competition comes from small companies that compete with us mostly on price. We are aware of other competitors that offer a substantial number of products and services comparable to ours. Many of our competitors (including customers who may elect to manufacture systems for internal use) have financial, marketing and other resources greater than our own. To date, we believe that each of our product and service segments has been able to compete favorably in markets that include these competitors, primarily based on know-how, technical performance, quality, delivery, price and aftermarket support. We continue to focus on products, which serve markets that are growing and where we have a technical and commercially competitive advantage.

 

CVD Equipment competes with companies located in Asia, Europe, and the US in both the production and research market. In the production and research markets, some of our potential customers built their own equipment. Additionally, there are large established companies who compete with us and pose a competitive risk in the market. Due to budgetary and funding constraints, many customers are price sensitive. We believe that our systems are among the most advanced available for the targeted market and coupled with our vertical integration in engineering and manufacturing, we believe that we can compete effectively.

 

SDC’s gas management and chemical delivery control systems are among the most advanced available. We further believe that SDC is differentiated from our competitors through our deep understanding of how the systems in which our products are incorporated are used in field applications. We have gained this understanding as a result of having designed and built complex process gas systems for our CVD Equipment group as well as for a number of the world’s leading semiconductor, aerospace, medical, solar manufacturers, research laboratories and universities.

 

Sources of Supply

 

Many of the components used in producing our products are purchased from unrelated suppliers. We have OEM status with our suppliers, but we are not obligated to purchase a pre-determined quantity. We are not dependent on a principal or major supplier and alternate suppliers are available. Historically, subject to lead times, the components and raw materials we used in manufacturing our products were readily obtainable.

 

12

 

 

We maintain a fully equipped machine shop that we use to fabricate a significant portion of our metal components in-house, including the most intricately designed parts of our equipment. We expanded our machine shop in 2022 to allow us to expand our ability to fabricate parts. Our quartz fabrication capability is currently sufficient to meet our quartzware needs. We believe our vertical manufacturing integration is a competitive advantage.

 

Materials procured from suppliers and/or manufactured internally undergo a rigorous quality control process to ensure that the parts meet or exceed our requirements and those of our customers. Upon final assembly, all equipment undergoes a final series of complete testing to ensure maximum product performance.

 

Backlog

 

As of December 31, 2024, our backlog was approximately $19.4 million, compared to $18.4 million as of December 31, 2023, an increase of $1.0 million. Our backlog at December 31, 2024 consists of approximately $17.4 million remaining performance obligations for system contracts in progress and not yet started and the balance of approximately $1.9 million represents other non-system orders received from customers. The timing for completion of backlog varies depending on the product mix and can be as long as two years or as short as 30-60 days.

 

There can be no assurance that our backlog will result in actual revenue in any particular period, or at all, or that any contract included in backlog will be profitable. The actual amount and timing of any revenue is subject to various contingencies, many of which are beyond our control, such as cancellations and delays. As a result of these contingencies, we may adjust our backlog if we determine that such orders are no longer firm. In addition to adjustments from these types of contingencies, variations in backlog from time to time are attributable, in part, to changes in sales mix, the timing of contract proposals, the timing of contract awards, delivery schedules on specific contracts. As a result, we believe our backlog and orders, at any point in time, are not necessarily indicative of the total sales anticipated for any future period.

 

Government Regulations

 

We are subject to a variety of federal, state and local government regulations, such as environmental, labor and export control regulations. We believe that we have obtained all necessary permits to operate our business and that we are in material compliance with all laws and regulations applicable to us. These regulations are subject to change and the effect of these changes could materially impact our business in certain technology areas and regions.

 

Utilizing our in-house safety team, engineering expertise and consultants as required, we continue to monitor and comply with applicable Environmental Health and Safety regulations at our facilities as well as the installation of equipment at our customer facilities.

 

13

 

 

With respect to our sales to customers located in China or elsewhere outside the United States, products which (i) are manufactured in the United States, (ii) incorporate controlled U.S. origin parts, technology, or software, or (iii) are based on U.S. technology, are subject to the U.S. Export Administration Regulations (“EAR”). We continue to monitor, review, and maintain ongoing compliance with the EAR with respect to our export sales.

 

Product Liability

 

Our products are used in our customers’ manufacturing processes, which in some cases contain explosive, flammable, corrosive, and toxic gases. There are potential exposures to personal injury as well as property damage, particularly if operated without regard to the design limits of the systems and components. Additionally, the end products of some of our customers are used in areas such as aerospace and high-tech devices where safety is of great concern. Management reviews its insurance coverage on an annual basis or more frequently, if appropriate, and we believe we have the types and amounts of insurance coverage that are sufficient for our business.

 

Human Capital

 

We consider our employees a vital asset to our business and strive to ensure we foster a work environment of respect, communication, objective orientation, and personal life balance. We believe this results in a higher level of employee satisfaction and hence improved performance and employment longevity. On December 31, 2024, we had 118 employees. We had 58 employees in manufacturing, 30 in engineering (including research and development and efforts related to product improvement), 5 in field service, 10 in sales and marketing and 15 in general management, maintenance and administration, compared to 128 employees as of December 31, 2023. None of our employees were subject to a collective bargaining agreement.

 

The implementation of our business strategy depends on our ability to hire, train, and retain qualified and diverse professionals, and we must emphasize employee development and training to do so. We are committed to identifying and developing the talents of our next generation of managers and intend to establish a strong succession-planning program for our critical positions, including internships for technical and engineering resources from local universities. Moreover, a key strategic focus of our management team is to foster and maintain a strong and healthy culture, where collaboration to achieve results and focus on the success of our customers and shareholders is paramount.

 

Employee Safety

 

The health and safety of our employees and partners is our highest priority, and this is consistent with our operating philosophy. We maintain strong environmental, health and safety protocols that focus on implementing policies and training programs, as well as performing self-audits to ensure our colleagues and partners leave the workplace safely on a daily basis.

 

14

 

 

Employee Compensation

 

Management continues to review our employee compensation programs to better align the compensation of our employees with our objectives, performance, and personal performance, and to provide the proper short-term and long-term incentives to attract, retain and motivate them to achieve superior results. We believe we must offer wages that are competitive and consistent with employee positions, skill levels, experience, and knowledge, and in order to do so we may work with a nationally recognized outside compensation and benefits consulting firm to independently evaluate the effectiveness of our executive and non-executive compensation and benefit programs and to provide benchmarking against our peers within our industry.

 

Equal Opportunity

 

We are committed to building and sustaining a culture of equal opportunity that encourages all of our employees to reach their full potential. Our CVD team, like the technologies we enable, is a rich combination of diverse individuals coming together to make a material difference for our people, our customers, and the world. As a company that enables tomorrow’s technologies, we recognize that a diverse employee population makes CVD a stronger, more innovative, and a more engaging place to work. We are always striving to attract talented individuals from a diverse candidate pool.

 

Available Information

 

Our website address is www.cvdequipment.com and the contents of our website, including our investor relations website, is not incorporated by reference into this filing or any other report we file with or furnish to the SEC. We have no duty to update or revise any forward-looking statements in this Annual Report on Form 10-K or in other reports filed with the SEC, whether as a result of new information, future events or otherwise, unless we are required to do so by law. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.

 

15

 

 

Item 1A.Risk Factors

 

In addition to the other information set forth in this Annual Report on Form 10-K, our shareholders should carefully consider the risk factors described below. The risks set forth below may not be the only risk factors relating to the Company. Any of these factors, many of which are beyond our control, could materially adversely affect our business, financial condition, operating results, cash flow and stock price.

 

Risk categories:

 

  ● Risks related to sales and product development
  ● Risks related to manufacturing and supply chain
  ● Risks related to cybersecurity, intellectual property and regulatory compliance
  ● Risks related to financial and accounting matters
  ● Risks related to product liability
  ● Risks related to our stock
  ● General risk factors

 

Risks related to sales and product development

 

Historically, we have maintained a highly concentrated customer base so that changes in ordering patterns, delays or order cancellations could have a material adverse effect on our business and results of operations.

 

During 2024, one customer represented 29.5% of our total revenues. The loss of a major customer would have to be replaced by others, and our inability to do so may have a material adverse effect on our business and financial condition. We expect that contracts or orders from a relatively limited number of customers will, at times, continue to account for a substantial portion of our business. The mix and type of customers, and sales to any single customer, may vary significantly from quarter to quarter and from year to year. If any major customer did not place orders, or if they substantially reduced, delayed, or cancelled orders, we may not be able to replace the business in a timely manner or at all, which can and has had a material adverse effect on our results of operations and financial condition.

 

Our lengthy and variable sales cycle makes it difficult to predict our financial results.

 

The marketing, sale and manufacture of our products, often requires a lengthy sales cycle ranging from several months to over one year before we can complete production and delivery. The lengthy sales cycle makes forecasting the volume and timing of sales difficult and raises additional risks that customers may cancel or decide not to enter into contracts. The length of the sales cycle depends on the size and complexity of the project, the customer’s in-depth evaluation of our products, and, in some cases, the protracted nature of a bidding process.

 

Because a significant portion of our operating expenses are fixed, we have and may continue to incur substantial expense before we earn associated revenue. If customer cancellations occur, they could result in the loss of anticipated sales without allowing us sufficient time to reduce our operating expenses.

 

16

 

 

If any of our customers cancel or fail to accept a large system order, our financial position and results of operations could be materially and adversely affected.

 

Our backlog includes orders for customized systems including our chemical vapor deposition equipment and furnaces which are built to client specifications. These customized systems can have prices up to several million dollars, depending on the configuration, specific options included and any specific requirements of the customer. Because our orders are subject to cancellation or delay by the customer, our backlog at any point in time is not necessarily representative of actual sales for succeeding periods, nor does our backlog provide any assurance of achievement of revenues or that we will realize a profit from completing these orders. Our financial position and results of operations could be materially and adversely affected should any large system order be cancelled prior to shipment or not be accepted by the customer due to alleged non-conformity with product specifications or otherwise. Likewise, a significant change in the liquidity or financial position of any of our customers that purchase large systems, could have a material impact on the collectability of our accounts receivable and our future operating results. Our backlog does not provide any assurance that we will realize a profit from those orders or indicate in which period revenue will be recognized.

 

If demand declines for chemical vapor deposition/infiltration, physical vapor transport, gas control and related equipment, or for carbon nanotube and nanowire deposition systems, our financial position and results of operations could be materially adversely affected.

 

Our products are utilized to develop and manufacture materials and coatings for industrial and research applications that are used in numerous markets including but not limited to power electronics, battery materials, aerospace, nano and advanced electronic components. A significant part of our growth strategy involves continued expansion of the sales of our products for industrial as well as research and development purposes by companies, universities, and government-funded research laboratories. The availability of funds for these purposes may be subject to budgetary and political restrictions, as well as cost-cutting measures by manufacturers in the markets in which we operate.

 

If the availability of funds or the demand for capital equipment in the markets in which we operate declines, the demand for our products would also decline and our financial position and results of operations could be harmed.

 

The demand for our products and the profitability of our products can change significantly from period to period because of numerous factors.

 

The industries in which we operate are characterized by ongoing factors, including:

 

  ● global and regional economic developments and conditions including in Europe and Asia;
  ● governmental budgetary and political constraints;

 

17

 

 

  ● changes in the capacity utilization and production volume for research and industrial applications in the markets in which we operate;
  ● the profitability and capital resources of manufacturers in the markets in which we operate;
  ● changes in technology;
  ● the availability of funds for research and development; and
  ● the effects of supply chain disruptions.

 

For these and other reasons, our results of operations for past periods may not necessarily be indicative of future operating results.

 

Our business might be adversely affected by our dependence on foreign business.

 

Because a material portion of our revenues are traditionally derived from international customers, our operating results could be negatively affected by a decline in the economies of any of the countries or regions in which we do business. Each region can exhibit unique characteristics, which can cause capital equipment investment patterns to vary significantly from period to period. Periodic local or international economic downturns, trade balance issues and political instability including trade disruptions and the imposition of tariffs, as well as fluctuations in interest and currency exchange rates. Any significant increases in tariffs on a broad array of goods, could negatively affect our business and results of operations.

 

The majority of our sales to date have been primarily priced in U.S. dollars. While our business has not been materially affected in the past by currency fluctuations, there is a risk that it may be materially adversely affected in the future. Such risks include possible losses due to both currency exchange rate fluctuations and from possible social and political instability.

 

United States trade policies that restrict imports or increase import tariffs may have a material adverse effect on our business.

 

There have been significant changes and proposed changes in recent years to U.S. trade policies, tariffs, and treaties affecting imports. Any significant increases in tariffs on a broad array of important goods, could negatively affect our business and results of operations.

 

In response to the tariffs announced by the U.S., China and other countries have imposed or proposed additional tariffs on certain exports from the United States. There is current uncertainty about the future relationship between the United States and other countries with respect to trade policies, taxes, government regulations, and tariffs and we cannot predict whether, and to what extent, U.S. trade policies will change in the future, including as a result of changes by the new U.S. presidential administration. A significant proportion of our materials and components are manufactured in China and other regions outside of the United States. Accordingly, such U.S. policy changes have made it and may continue to make it difficult or more expensive for us to obtain certain products manufactured outside the United States, which could affect our revenue and profitability. Any of these factors could depress economic activity and restrict our access to suppliers or customers and could have a material adverse effect on our business, financial condition, and results of operations.

 

18

 

 

Our reputation and operating performance may be negatively affected if our products are not timely delivered.

 

We provide complex products that often require substantial lead-time for design, ordering parts and materials, and for assembly and installation. The time required to design, order parts and materials and to manufacture, assemble and install our products, may in turn lead to delays or shortages in the availability of some products. If a product is delayed or is the subject of shortage because of problems with our ability to design, manufacture or assemble the product on a timely basis, obtain necessary materials and components, or if a product or software otherwise fails to meet performance criteria, we may lose revenue opportunities entirely, or experience delays in revenue recognition associated with a product or service. In addition, we may incur higher operating expenses during the period required to correct the problem.

 

We may not be able to keep pace with the rapid change in the technology we use in our products.

 

We believe that our continued success in the markets in which we operate depends, in part, on our ability to continually improve existing technologies and to develop and manufacture new products and product enhancements on a timely and cost-effective basis. We must be able to introduce these products and product enhancements into the market in a timely manner, in response to customer’s demands for higher-performance research and assembly equipment, customized to address rapid technological advances in capital equipment designs.

 

Technological innovations are inherently complex and require long development cycles and appropriate professional staffing. Our future business success depends on our ability to develop and introduce new products, or new uses for existing products, that successfully address changing customer needs. Our success also depends on our ability to achieve market acceptance of our new products. To maintain our success in the marketplace, we may have to substantially increase our expenditures on research and development. If we do not develop and introduce new products, technologies or uses for existing products in a timely manner and continually find ways to reduce the cost of developing and producing them in response to changing market conditions or customer requirements, our business could be seriously harmed.

 

We face significant competition, and we are relatively small in size and have fewer resources in comparison with many of our competitors.

 

We face significant competition throughout the world, which may increase as certain markets in which we operate continue to evolve. Our future performance depends, in part, upon our ability to continue to compete successfully worldwide. Some of our competitors are diversified companies that have substantially greater financial resources and more extensive research, engineering, manufacturing, marketing and customer service and support capabilities than we can provide. We face competition from companies whose strategy is to provide a broad array of products, some of which compete with the products and services that we offer, as well as companies, universities and research laboratories that have the capacity to design and build their own equipment internally. These competitors may bundle their products and services in a manner that may discourage customers from purchasing our products. In addition, we face competition from smaller emerging processing equipment companies, whose strategy is to provide a portion of the products and services that we offer at often lower prices than ours, using innovative technology to sell products into specialized markets. Loss of competitive position could impair our prices, customer orders, revenue, gross margin, and market share, any of which would negatively affect our financial position and results of operations. Our failure to compete successfully with these other companies would seriously harm our business. There is a risk that larger, better financed competitors will develop and market more advanced products than those we currently offer, or that competitors with greater financial resources may decrease prices, thereby putting us under financial pressure.

 

19

 

 

Risks related to manufacturing and our supply chain

 

Manufacturing interruptions or delays could affect our ability to meet customer demand and lead to higher costs, while the failure to estimate customer demand accurately could result in excess or obsolete inventory.

 

Our business depends on timely supply of equipment, services and related products that meet the rapidly changing technical and volume requirements of our customers. Some key parts to our products are subject to long lead-times and/or obtainable only from a single supplier or limited group of suppliers. Cyclical industry conditions and the volatility of demand for manufacturing equipment increase capital, technical, operational and other risks for us and for companies throughout our supply chain. Further, these conditions may cause some suppliers to scale back operations, exit businesses, merge with other companies, or file for bankruptcy protection and possibly cease operations. We have also experienced and continue to experience significant disruptions in our supply chain, resulting in delays and higher costs to procure certain components and materials that we utilize in our business.

 

We may also experience significant interruptions of our manufacturing operations, delays in our ability to deliver products or services, increased costs or customer order cancellations as a result of:

 

  ● The failure or inability of suppliers to timely deliver sufficient quantities of quality parts on a cost-effective basis;
  ● Volatility in the availability and cost of materials, including rare earth elements;
  ● Difficulties or delays in obtaining required import or export approvals;
  ● Information technology or infrastructure failures; and
  ● Natural disasters or other events beyond our control (such as earthquakes, floods or storms, regional economic downturns, pandemics, social unrest, political instability, terrorism, or acts of war).

 

If a supplier fails to meet our requirements concerning quality, cost, or other performance factors, we may transfer our business to alternative sources, which could entail manufacturing delays, additional costs, or other difficulties. In addition, if we need to rapidly increase our business and manufacturing capacity to meet increases in demand or expedited shipment schedules, this may exacerbate any interruptions in our manufacturing operations and supply chain and the associated effect on our working capital.

 

20

 

 

Supply chain delays and cost increases that may adversely affect our business, including potential cost increases from the imposition of tariffs.

 

Geopolitical developments across Europe and Asia have and may continue to restrict our ability to procure raw materials and components such as nickel and integrated circuits. Since 2021, we have experienced increased costs on certain components as well as delays in supply chain delivery, which may also impact our ability to recognize revenue and reduce our gross profit margins, as well as extend our manufacturing lead times and reduce our manufacturing efficiencies. In addition, political and trade tensions have resulted in the imposition of tariffs which may affect our supply chain and the costs of components and materials. . Any significant increases in tariffs on components and materials that we purchase could negatively affect our business and results of operations. We have begun placing orders with more lead time to help mitigate the manufacturing delays, as well as assessing other suppliers or components to attempt to mitigate the potential cost impacts In addition, we are utilizing our in-house flexible manufacturing to attempt to further mitigate both potential schedule delivery delays and material cost increase, as well as increasing sales prices. While we have taken actions to mitigate the potential negative impacts to our revenue and profitability, there can be no assurance of the ultimate impact and the length of time that the supply chain factors, including tariffs, may impact our revenues and profitability.

 

Inflation has and may continue to adversely affect our business, financial condition, and results of operations.

 

Recent global inflation has adversely affected our costs, including the cost of materials, production, and labor. As such, we have had to implement measures to mitigate the negative impacts of inflation on our costs. As the selling prices in our customer contracts are fixed, any increase in the cost of materials, labor and other costs as we manufacture any system would negatively impact our gross margins and results of operations. Longstanding or increased periods of inflation could perpetuate these material adverse effects on our business, financial condition and results of operations.

 

If our critical suppliers fail to deliver enough quality materials and components in a timely and cost-effective manner, it could negatively affect our business.

 

We use numerous unrelated suppliers of materials and components. Due to geopolitical developments across Europe and Asia, we are experiencing reduced availability of raw materials and components. In turn, any reduction in the availability of these materials and components may reduce our ability to obtain sufficient amounts in a cost-effective manner. We generally do not have guaranteed supply arrangements with our suppliers. Because of the variability and uniqueness of our customer’s orders, we try to avoid maintaining an extensive inventory of materials and components for manufacturing. While we are not dependent on any principal or major supplier for most of our material and component needs, switching to an alternative supplier may take significant amounts of time and added expense, which could result in a disruption of our operations and adversely affect our business. It is not always practical or even possible to ensure that component parts are available from multiple suppliers; accordingly, we procure some key parts from a single supplier or a limited group of suppliers. At certain times, increases in demand for capital equipment can result in longer lead-times for many important system components, which may cause delays in meeting shipments to our customers. The delay in the shipment of even a few systems could cause significant variations in our quarterly revenue, operating results and the market value of our common stock.

 

21

 

 

Our manufacturing facilities in Central Islip, New York and Saugerties, New York could be affected due to multiple weather risks, including risks to our Central Islip facility from hurricanes and similar phenomena.

 

Our manufacturing facilities are in Central Islip, New York and Saugerties, New York and could be affected by multiple weather risks, most notably hurricanes for our Central Islip facility which is located on Long Island, New York. Although we carry property and casualty insurance and business interruption insurance, future possible disruptions of operations or damage to property, plant and equipment due to hurricanes or other weather risks could result in impaired production and affect our ability to meet our commitments to our customers and impair important business relationships, the loss of which could adversely affect our operations and profitability. We do, however, maintain a backup power source at our Central Islip facility.

 

Risks related to cybersecurity, intellectual property and regulatory compliance

 

If we are subject to cyberattacks, we could incur substantial costs and, if such attacks are successful, we could incur significant liabilities, reputational harm, and disruption to our operations.

 

We manage, store, and transmit proprietary information and sensitive data relating to our operations. We may be subject to breaches of the information technology systems we use for these purposes. Experienced computer programmers and hackers may be able to penetrate our network security and misappropriate and/or compromise our confidential information (and or third-party confidential information), create system disruptions, or cause shutdowns. Computer programmers and hackers also may be able to develop and deploy viruses, worms, and other malicious software programs that attack our systems or our products, or that otherwise exploit any security vulnerabilities.

 

While we have an active security training program for all employees during the year, utilize intrusion prevention and detection systems, as well as hardware firewall and virus security, the costs to address the foregoing security problems and security vulnerabilities before or after a cyber-incident could be significant. Our remediation efforts may not be successful and could result in interruptions, delays, or cessation of service, and loss of existing or potential customers, impeding our sales, manufacturing, distribution, or other critical functions. In addition, breaches of our security measures and the unapproved dissemination of proprietary information or sensitive data about us, our customer, or other third parties, could expose us, our customers, or other third parties to a risk of loss or misuse of this information, result in litigation and potential liability for us, damage our reputation, or otherwise harm our business.

 

22

 

 

Our financial position and results of operations may be materially harmed if we are unable to recoup our investment in research and development.

 

The rapid change in technology in our industry requires that we continue to make substantial investments in research and development and selective acquisitions of technologies and products, to enhance the performance and functionality of our product line, to keep pace with competitive products and to satisfy customer demands for improved performance, features and functionality. There can be no assurance that revenue from future products or enhancements will be sufficient to recover the development costs associated with such products, enhancements, or acquisitions, or that we will be able to secure the financial resources necessary to fund future research and development or acquisitions. Research and development costs are typically incurred before we confirm the technical feasibility and commercial viability of a product, and not all development activities result in commercially viable products. In addition, we cannot ensure that products or enhancements will receive market acceptance, or that we will be able to sell these products at prices that are favorable to us. Our business could be seriously harmed if we are unable to sell our products at favorable prices, or if our products are not accepted by the markets in which we operate.

 

We have made investments in our proprietary technologies. If third parties violate our proprietary rights, or accuse us of infringing upon their proprietary rights, such events could result in a loss of value of some of our intellectual property or costly litigation.

 

We attempt to protect certain of our intellectual property rights by obtaining patent and trademark protection where we believe it is appropriate to do so. While patent, copyright and trademark protection for our intellectual property may be important, we believe our future success in highly dynamic markets is most dependent upon the technical competence and creative skills of our personnel. We may also attempt to protect our trade secrets and other proprietary information through confidentiality agreements with our customers, suppliers, employees, and consultants, and through other internal security measures. However, these employees, consultants and third parties may breach these agreements, and we may not have adequate remedies for wrongdoing. In addition, the laws of certain territories in which we sell our products may not protect our intellectual property rights to the same extent as do the laws of the United States.

 

Occasionally, we may receive communications from other parties asserting the existence of patent rights or other intellectual property rights that they believe cover certain of our products, processes, technologies, or information. In addition, it is possible we could have a dispute with a customer concerning the use of intellectual property utilized in their equipment. If such cases arise, we will evaluate our position and consider the available alternatives, which may include seeking licenses to use the technology in question on commercially reasonable terms, developing new alternative technology or defending our position. Nevertheless, we cannot ensure that we will be able to obtain licenses, or, if we are able to obtain licenses, which related terms will be acceptable, or that litigation or other administrative proceedings will not occur. Defending our intellectual property rights through litigation could be very costly. If we are not able to negotiate the necessary licenses on commercially reasonable terms or successfully defend our position, our ability to utilize such intellectual property could substantially inhibit our access to certain markets and our ability to compete in these markets which could have a material adverse effect on our financial position and results of operations.

 

23

 

 

We may be unable to obtain required export licenses for the sale of our products.

 

Whether with respect to sales to customers located in China or otherwise, products which (i) are manufactured in the United States, (ii) incorporate controlled U.S. origin parts, technology, or software, or (iii) are based on U.S. technology, are subject to the U.S. Export Administration Regulations (“EAR”) when exported to and re-exported from international jurisdictions, in addition to the local jurisdiction’s export regulations applicable to individual shipments. Licenses or proper license exceptions may be required for the shipment of our products to certain customers or countries. Obtaining an export license or determining whether an export license exception exists often requires considerable effort by us and cooperation from the customer, which can add time to the order fulfillment process. We may be unable to obtain required export licenses or qualify for export license exceptions and, as a result, we may be unable to export products to our customers and/or meet their servicing needs. Non-compliance with the EAR or other applicable export regulations could result in a wide range of penalties including the denial of export privileges, fines, criminal penalties, and the seizure of commodities. If an export regulatory body determines that any of our shipments violate applicable export regulations, we could be fined significant sums and our export capabilities could be restricted, which could have a material adverse impact on our business.

 

Failure to comply with the United States Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.

 

We are subject to the United States Foreign Corrupt Practices Act, which generally prohibits United States companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. We have agreements with third parties and make sales in countries known to experience corruption, extortion, bribery, pay-offs, theft, and other fraudulent practices. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on our business, financial condition, and results of operations.

 

We are subject to environmental regulations, and our inability or failure to comply with these regulations could adversely affect our business.

 

We are subject to environmental regulations in connection with our business operations, including regulations related to the development and manufacture of our products and our customers’ use of our products. Our failure or inability to comply with existing or future environmental regulations could result in significant remediation liabilities, the imposition of fines or the suspension or termination of development, manufacturing, or use of certain of our products, or affect the operation of our facilities, use or value of our real property, each of which could damage our financial position and results of operations.

 

24

 

 

Regulations related to conflict minerals will force us to incur additional expenses, may make our supply chains more complex, and may result in damage to our relationships with customers.

 

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, the SEC adopted requirements for companies that manufacture products that contain certain minerals and metals known as “conflict minerals”. These rules require public companies to perform diligence and to report annually to the SEC whether such minerals originate from the Democratic Republic of Congo and adjoining countries. The implementation of these requirements could adversely affect the sourcing, availability, and pricing of minerals we use in the manufacture of our products. In addition, we have incurred and will continue to incur additional costs to comply with the disclosure requirements, including costs related to determining the source of any of the relevant minerals used in our products. Given the complexity of our supply chain, we may not be able to ascertain the origins of these minerals used in our products through the due diligence procedures that we implement, which may harm our reputation. We may also face difficulties in satisfying customers who may require that our products be certified as conflict mineral free, which could harm our relationships with these customers and lead to a loss of revenue. These requirements could limit the pool of suppliers that can provide conflict-free minerals, and we may be unable to obtain conflict-free minerals at competitive prices, which could increase our costs and adversely affect our manufacturing operations and our profitability.

 

Risks related to financial and accounting matters

 

Cyclical demand for our products may make it difficult for us to accurately budget our expense levels, which are based in part on our projections of future revenues.

 

Historically, demand for our equipment and related consumable products have been volatile because of changes in supply and demand, and other factors in the manufacturing process. Our orders tend to be more volatile than our revenue, as any change in demand is reflected immediately in orders booked, which are net of cancellations, while revenue, tends to be recognized over multiple quarters because of procurement and production lead times, and the deferral of certain revenue under our revenue recognition policies. The fiscal period in which we can recognize revenue is also at times subject to the length of time that our customers require to evaluate the performance of our equipment. This could cause our quarterly operating results to fluctuate.

 

When cyclical fluctuations result in lower-than-expected revenue levels, operating results have been and may continue to be materially adversely affected and cost reduction measures have been and may continue to be necessary for us to remain competitive and financially sound. During a down cycle, we must be able to make timely adjustments to our cost and expense structure to correspond to the prevailing market conditions. In addition, during periods of rapid growth, we must be able to increase manufacturing capacity and the number of our personnel to meet customer demand, which may require additional liquidity. We can provide no assurance, that these objectives can be met in a timely manner in response to changes within the industry cycles in which we operate. If we fail to respond to these cyclical changes, our business could be seriously harmed.

 

25

 

 

We do not have long-term volume production contracts with our customers, and we do not control the timing or volume of orders placed by our customers. Whether and to what extent our customers place orders for any specific products, and the mix and quantities of products included in those orders are factors beyond our control. Insufficient orders would result in under-utilization of our manufacturing facilities and infrastructure and will negatively affect our financial position and results of operations.

 

We might require additional financing.

 

Our continuing operating losses may make it difficult for us to obtain financing on commercially reasonable terms, if at all. If adequate financing is not available when required on commercially reasonable terms, if at all, our business and operations may be materially and adversely affected. In addition, we could issue additional common stock, to fund our growth initiatives and operations which could materially dilute the ownership interests of the then existing shareholders.

 

We may, in the future, identify deficiencies in controls over financial reporting.

 

While we have concluded that, as of December 31, 2024, our disclosure and reporting controls were effective as included in Part II, Item 9A, there can be no assurance that material weaknesses will not be identified in the future. If we do identify material weaknesses in our internal controls over financial reporting in the future, our ability to analyze, record and report financial information free of material misstatements, and to prepare our financial statements within the time periods specified by the rules and forms of the SEC, may likely be adversely affected.

 

We have and may continue to be required to take impairment charges on assets.

 

We are required to assess our long-lived assets, consisting of our property, plant and equipment, for recoverability and impairment whenever there are indicators or impairment, such as an adverse change in business climate.

 

As part of our long-term strategy, we have pursued acquisitions of other companies or assets, and may pursue future acquisitions of other companies or assets which could potentially increase our assets. Adverse changes in business conditions could materially impact our estimates of future operations and result in impairment charges to these assets. If our assets were impaired, our financial condition and results of operations could be materially and adversely affected.

 

Acquisitions can result in an increase in our operating costs, divert management’s attention away from other operational matters and expose us to other associated risks.

 

We evaluate potential acquisitions of businesses and technologies, and we consider targeted acquisitions that expand our core competencies to be an important part of our future growth strategy. In the past, we have made acquisitions of other businesses with synergistic products, services and technologies, and plan to continue to do so in the future.

 

26

 

 

Acquisitions involve numerous risks, which include but are not limited to:

 

  ● difficulties and increased costs in connection with the integration of the personnel, operations, technologies, services and products of the acquired companies into our existing facilities and operations;
  ● diversion of management’s attention from other operational matters;
  ● failure to commercialize the acquired technology;
  ● the potential loss of key employees of the acquired companies;
  ● lack of synergy, or inability to realize expected synergies, resulting from the acquisitions;
  ● the risk that the issuance of our common stock, if any, in an acquisition or merger could be dilutive to our shareholders;
  ● the inability to obtain and protect intellectual property rights in key technologies; and
  ● the acquired assets becoming impaired as a result of technological advancements or worse-than-expected performance of the acquired assets.

 

Risks related to product liability

 

We face the risk of product liability claims.

 

The manufacture and sale of our products, which in operation sometimes involve the use of toxic materials and extreme temperatures and could result in product liability claims. For example, our rapid thermal processing systems used to heat semiconductor materials to temperatures more than 1000º Celsius have certain inherent risks. A failure of our products at a customer site could also result in losses due to interruption of the business operations of our customer. While we regularly evaluate the nature and limits of our insurance coverages, there can be no assurance that our existing policies of insurance will be adequate to protect us from all liabilities that we might incur in connection with the manufacture and sale of our products in the event of a successful product liability claim or series of successful claims against us.

 

The health and environmental effects of nanotechnology are unknown, and this uncertainty could adversely affect the expansion of our business.

 

The health and environmental effects of nanotechnology are unknown. There is no scientific agreement on the health effects of nanomaterials in general and carbon nanotubes but some scientists believe that in some cases, nanomaterials may be hazardous to an individual’s health or to the environment.

 

The science of nanotechnology is based on arranging atoms in such a way as to modify or build materials not made in nature; therefore, the effects are unknown. Future research into the effects of nanomaterials in general, and carbon nanotubes, on health and environmental issues, may have an adverse effect on products incorporating nanotechnology. Since part of our growth strategy is based on sales of research equipment to produce carbon nanotubes and the sale of such materials, the determination that these materials are harmful could adversely affect the expansion of our business.

 

27

 

 

Risk related to our stock

 

The price of our common shares is volatile and could decline significantly.

 

The stock market in general and the market for technology stocks has experienced volatility. If those industry-based market fluctuations continue, the trading price of our common shares could decline significantly independent of the overall market, and shareholders could lose all or a substantial part of their investment. The market price of our common shares could fluctuate significantly in response to several factors, including, among others:

 

  ● difficult macroeconomic conditions, unfavorable geopolitical events, and general stock market uncertainties, such as those occasioned by a global liquidity crisis and a failure of large financial institutions;
  ● an offering of our common shares to raise capital;
  ● receipt of large orders or cancellations of orders for our products;
  ● issues associated with the performance and reliability of our products;
  ● actual or anticipated variations in our results of operations;
  ● announcements of financial developments or technological innovations;
  ● changes in recommendations and/or financial estimates by investment research analysis;
  ● strategic transactions, such as acquisitions, divestitures, or spin-offs;
  ● offerings of our securities;
  ● the occurrence of major catastrophic events; and
  ● volatile trading volumes.

 

Significant price and value fluctuations have occurred with respect to our publicly traded securities and those of technology companies generally. The price of our common shares is likely to be volatile in the future. In the past, securities class action litigation often has been brought against a company following periods of volatility in the market price of its securities. If similar litigation were pursued against us, it could result in substantial costs and a diversion of management’s attention and resources, which could materially and adversely affect our financial condition, results of operations, and liquidity.

 


General risks

 

Our success is highly dependent on the technical, sales, marketing and managerial contributions of key individuals, including our Chief Executive Officer and President, and we may be unable to retain these individuals or recruit others.

 

We depend on our senior executives including our Chief Executive Officer and President, and certain key managers as well as, engineering, research and development, sales, marketing and manufacturing personnel, who are critical to our business. Except for our Chief Executive Officer and President, we do not have employment agreements with our key employees. Furthermore, the current labor market remains very competitive and challenging for the acquisition and retention of key employees. Larger competitors may be able to offer more generous compensation packages to our executives and key employees, and therefore we risk losing key personnel to those competitors. If we were to lose the services of any of our key personnel, our engineering, product development, manufacturing and sales efforts could be slowed. We may also incur increased operating expenses and be required to divert the attention of our senior executives to search for their replacements. The integration of any new personnel could disrupt our ongoing operations.

 

We may not be able to hire or retain the number of qualified personnel, particularly engineering personnel, required for our business, which would harm the development and sales of our products and limit our ability to grow.

 

Competition in our industry for senior management, technical, sales, marketing and other key personnel is intense and has been made even more challenging in the current labor market. If we are unable to retain our existing personnel, or attract and train additional qualified personnel, our growth may be limited due to a lack of capacity to develop and market our products.

 

We have, from time to time, had trouble in hiring and retaining skilled engineers with appropriate qualifications to support our growth strategy. Our success depends on our ability to identify, hire, train and retain qualified engineering personnel with experience in equipment design. Specifically, we need to continue to attract and retain mechanical, electrical, software and field service engineers to work with our direct sales force to technically qualify and perform on new sales opportunities and orders, and to demonstrate our products.

 

28

 

 

Item 1B.Unresolved Staff Comments

 

None.

 

Item 1C.Cybersecurity

 

We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. We use recognized commercially reasonable measures, tools, and methodologies to manage cybersecurity risk, which are tested regularly. We also monitor and evaluate our cybersecurity posture on an ongoing basis through regular malware scans, penetration tests, and third-party reviews. Specific controls that are used to some extent include endpoint threat detection, identity and access management (IAM), privileged access management (PAM), logging and monitoring, multi-factor authentication (MFA), firewalls and intrusion detection and prevention, and vulnerability and patch management.

 

To manage our material risks from cybersecurity threats and to protect against, detect, and prepare to respond to cybersecurity incidents, we undertake the below listed activities:

 

  ● Monitor emerging data protection laws and implement changes to our compliance processes;
  ● Conduct periodic cybersecurity assessments for employees who use our system to evaluate training needs;
  ● Conduct onboarding and cyber security training for all employees on an ongoing basis;
  ● Conduct regular phishing email simulations for all employees; and
  ● Carry cybersecurity risk insurance that protects against the potential losses from a cybersecurity incident.

 

Our incident response plan coordinates the activities that we and our third-party cybersecurity provider take to prepare to respond to and recover from cybersecurity incidents. These include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate brand and reputational damage. We have an IT continuity plan that we continuously review and update in line with our evolving applications architecture.

 

Our Board of Directors and Audit Committee oversee our cybersecurity efforts to ensure effective governance in managing risks associated with cybersecurity threats. Our Director of Information Technology provides periodic updates to the Board of Directors and Audit Committee regarding our cybersecurity program, including status updates on various projects to enhance our overall cybersecurity posture.

 

We decide whether and how risks from cybersecurity threats have or are reasonably likely to affect our financial position, results of operations, and cash flows under the heading “Risk related to cybersecurity, intellectual property and regulatory compliance,” which is included as part of Item 1A. Risk Factors of this Annual Report on Form 10-K, which disclosures are incorporated by reference herein.

 

Item 2.Properties

 

Our corporate headquarters, research and development, manufacturing and process coating facilities as of December 31, 2024 are as follows:

 

Owned Locations   Size (sf)   Segment   Mortgage/Loan   Principal use
Central Islip, NY   128,000   CVD Equipment / MesoScribe   No   Corporate headquarters; R&D; Manufacturing
                 
Saugerties, NY   22,000   SDC   No   Manufacturing; Administration

 

Item 3.Legal Proceedings.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

29

 

 

PART II

 

Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information for Common Stock

 

Our common stock is traded on the NASDAQ Capital Market under the symbol “CVV”.

 

Dividend Policy

 

We have never paid dividends on our common stock, and we do not anticipate paying dividends on common stock at the present time. We currently intend to retain earnings, if any, for use in our business. There can be no assurance that we will ever pay dividends on our common stock. Our dividend policy with respect to our common stock is within the discretion of the Board of Directors and its policy with respect to dividends in the future will depend on numerous factors, including earnings, financial requirements, and general business conditions.

 

Stockholders

 

As of March 18, 2025, there were approximately 55 holders of record and approximately 3,544 beneficial owners of our common stock.

 

Recent Sales of Unregistered Securities

 

None.

 

Issuer Purchases of Equity Securities

 

None.

 

Item 6. Reserved.

 

30

 

 

Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis in conjunction with our consolidated financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.

 

Executive Summary

 

We have served the advanced materials markets with chemical vapor and thermal process equipment for over 40 years. CVD designs, develops, and manufactures a broad range of chemical vapor deposition, gas control, and other state-of-the-art equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research.

 

During 2024:

 

●Revenue increased by $2.8 million or 11.5% as compared to the prior year due to increases in revenues from aerospace and industrial contracts in progress and our SDC segment that was partially offset by lower revenues of spare parts and lower revenues from Tantaline that was sold in May 2023.
   
●Gross margin increased by $1.3 million or 24.8% as compared to the prior year due to higher revenues and improved margins on contracts in process offset by a $1.3 million non-cash charge to reduce certain PVT inventory to net realizable value.
   
●Total bookings for 2024 were approximately $28.1 million as compared to $25.8 million in 2023, an increase of $2.3 million or 8.9%.
   
●Bookings in 2024 included a $10.0 million multisystem order from an industrial customer that will be used to deposit a silicon carbide protective coating on OEM components.
   
●Bookings in 2024 also included a $3.5 million order from a major aerospace company for the production of CVI systems. This is the fifth system purchased by this customer that will be used by our customer to manufacture CMCs for their gas turbine jet engines.
   
●Our backlog increased from $18.4 million to $19.4 million, an increase of $0.8 million or 4.9%.
   
●Cash balance at December 31, 2024 was $12.6 million as compared to $14.0 million at December 31, 2023

 

31

 

 

Business Update

 

Our core strategy is to focus on growth end markets in applications related to aerospace, microelectronics including markets related to the “electrification of everything,” and industrial applications. With respect to aerospace, our systems are being used by our customers to produce ceramic matrix composite materials (“CMCs”) that will be used in next generation gas turbine jet engines with the objective of reducing jet fuel consumption and to produce specialty coatings for advanced high temperature environments.

 

The phrase “electrification of everything” refers to the shift from fossil fuels to the use of electricity to power devices, buildings, electric vehicles (“EVs”), and many other applications.

 

Our current strategy yielded multisystem orders of PVT150 equipment in 2023 and 2022 that were delivered to one company that planned to use our systems to manufacture silicon carbide wafers. Although we continue to invest in our vision for the “electrification of everything,” we have observed lower-than-anticipated industrywide electric vehicle sales which may reduce demand for silicon carbide and impact sales of our PVT systems. In addition, the current global over capacity of 150 mm silicon carbide wafers has reduced the market for 150 mm silicon carbide growth systems.

 

In February 2024, we received an order from an additional customer for our new PVT200 system used to grow silicon carbide crystals for the manufacture of 200 mm wafers. This represents our second customer for our PVT equipment. This customer plans to evaluate our equipment for potential additional purchases of PVT equipment. We shipped this unit to the customer in the third quarter of 2024.

 

Both technologies are essential for the support of the EV market. These systems should provide us with standard product offerings to continue to support the EV focused market as well as energy storage, power conversion and power transmission. We plan to evaluate opportunities to expand our product offerings in the power electronics market to build off the introduction of the PVT150 and PVT200 systems. We are also evaluating our ability to provide other equipment used in the manufacturing process of silicon carbide wafers.

 

During 2022, we also received an order from an aerospace company for a production chemical vapor infiltration (CVI) system that will be used to manufacture CMCs for gas turbine jet engines. In 2023, we received an order from the same aerospace company for an additional three CVI systems and in November 2024 we received an order from the same aerospace company for an additional CVI system.

 

In February 2024, we received a multisystem order from an industrial customer for approximately $10.0 million that will be used for depositing a silicon carbide protective coating on OEM components and the units are expected to be delivered over 18 to 24 months period.

 

We have generally gained new customers through our industry reputation, as well as print advertising and trade show attendance. We have increased the number of trade shows and industry conferences we attend.

 

Historically, our orders have fluctuated based on end user market conditions, adoption of our new products and acceptance of our products. The order rate as well as other factors in our manufacturing process ultimately impacts the timing of revenue recognition, whether accounted for over time or at a point in time. Accordingly, orders received from customers and the corresponding revenue recognized may fluctuate from quarter to quarter. The sales cycle for our equipment is typically six months, but can range up to twelve to eighteen months, depending on the application and product stage of the equipment. The order cycle to manufacture and test a system also will vary from six to eighteen months for our CVD Equipment segment and two to twelve months for our SDC segment, depending on system complexity and magnitude of the system.

 

32

 

 

Results of Operations

 

Years Ended December 31, 2024 and 2023

 

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the years ended December 31, 2024, and 2023 and the period-over-period dollar and percentage changes for those line items (in thousands, except percentages).

 

   December 31, 2024   December 31, 2023  

Change

  

Percent

 
                 
Revenue  $26,876   $24,109   $2,767    11.5%
                     
Cost of revenue   20,545    19,038    1,507    7.9%
                     
Gross profit   6,331    5,071    1,260    24.8%
                     
Operating expenses                    
Research and development   2,627    2,596    31    1.2%
Selling   1,656    1,632    24    1.5%
General and administrative   5,181    5,451    (270)   (5.0%)
Gain on sales of equipment   (717)   -    (717)   * 
Loss on disposition of Tantaline   -    162    (162)   * 
Impairment charge   -    111    (111)   * 
                     
Total operating expenses   8,747    9,952    (1,205)   (12.1%)
                     
Operating loss   (2,416)   (4,881)   2,465    50.5%
                     
Other income (expense):                    
Interest income   559    577    (18)   (3.1%)
Interest expense   (19)   (23)   4    (17.4%)
Foreign exchange income   -    42    (42)   * 
Other income   2    91    (89)   * 
Total other income, net   542    687    (145)   (21.1%)
                     
Loss before income tax   (1,874)   (4,194)   2,320    (55.3%)
                     
Income tax expense (benefit)   24    (14)   38    *  
                     
Net loss  $(1,898)  $(4,180)  $2,282    54.6%

 

* Not meaningful

 

33

 

 

Revenue

  

December

31, 2024

   December 31, 2023   Change   Percent 
CVD Equipment  $18,288   $16,334   $1,954    12.0%
SDC   8,444    7,139    1,305    18.3%
MesoScribe   778    722    56    7.8%
Tantaline   -    462    (462)   (100.0%)
Intersegment sales elimination   (634)   (548)   (86)   15.7%
Total  $26,876   $24,109   $2,767    11.5%

 

Our revenue for the year ended December 31, 2024 was $26.9 million compared to $24.1 million for the year ended December 31, 2023, an increase of $2.8 million or 11.5%.

 

The increase in revenue versus the prior year period was primarily attributable to higher revenue of $1.9 million from our CVD Equipment segment and a $1.3 million increase in revenue from our SDC segment, offset by lower Tantaline revenues of $0.5 million that was sold in May 2023. Revenue from one aerospace customer for the year ended December 31, 2024 represented 29.5% of our total revenues and 43.4% of CVD Equipment segment revenues.

 

The revenue contributed by our CVD Equipment segment for the year ended December 31, 2024 of $18.3 million represented 68.1% of overall revenue as compared to $16.2 million (net of intersegment sales of $0.1 million) or 67.8% of overall revenue for the year ended December 31, 2023. The increase in external revenues of $2.1 million or 11.3% resulted principally from increases in revenues from aerospace and industrial contracts in progress offset in part by lower revenue for PVT150/200 systems and spare parts.

 

The revenue contributed by our SDC segment for the year ended December 31, 2024 of $7.8 million (net of intersegment sales of $0.6 million) represented 29.1% of overall revenue as compared to $6.7 million (net of intersegment sales of $0.4 million) or 27.8% of overall revenue for the year ended December 31, 2023. External revenue for our SDC segment increased by $1.1 million or 16.4% due to higher demand for gas delivery system products as compared to the prior period.

 

The revenue contributed by our MesoScribe segment for the year ended December 31, 2024 of $0.8 represented 2.9% of our overall revenue as compared to $0.7 million or 3.0% of overall revenue for the year ended December 31, 2023. MesoScribe fulfilled its final orders during 2024 and ceased operations.

 

Our order backlog at December 31, 2024 was approximately $19.4 million as compared to December 31, 2023 of $18.4 million. Our order backlog at December 31, 2024 consists of approximately $17.4 million related to remaining performance obligations of contracts in progress and not yet started and the balance of approximately $1.9 million represents other orders received from customers. As of December 31, 2024, one industrial customer represented 41.8% of our backlog and one aerospace customer represented 27.1% of our backlog. Historically, our revenues and orders have fluctuated based on changes in order rate as well as other factors in our manufacturing process that impacts the timing of revenue recognition. Accordingly, orders received from customers and revenue recognized may fluctuate from quarter to quarter.

 

34

 

 

Gross Profit

 

Gross profit for the year ended December 31, 2024 amounted to $6.3 million, with a gross profit margin of 23.6%, compared to a gross profit of $5.1 million and a gross profit margin of 21.0% for the year ended December 31, 2023. The increase in gross profit of $1.3 million was primarily due to higher revenues as well as improved margins on CVD contracts in progress and final MesoScribe sales that was partially offset by a $1.3 million non-cash charge to reduce certain PVT inventory to net realizable value.

 

Research and Development

 

For the year ended December 31, 2024, research and development expenses were $2.6 million, or 9.8% of revenue as compared to $2.6 million, or 10.8% for the year ended December 31, 2023. There were no significant changes in research and development expenses as compared to the prior year.

 

General engineering support and expenses related to the development of more standard products and value-added development of existing products are reflected as part of research and development expense. General engineering support and expenses are charged to costs of goods sold when work is performed directly on a customer order.

 

Selling

 

Selling expenses were $1.7 million or 6.2% of the revenue for the year ended December 31, 2024 as compared to $1.6 million or 6.8% for the year ended December 31, 2023. There were no significant changes in selling expenses as compared to the prior year.

 

General and Administrative

 

General and administrative expenses for the year ended December 31, 2024 were $5.2 million or 19.3% of revenue compared to $5.4 million or 22.6% of revenue for the year ended December 31, 2023, a decrease of $0.3 million. The decrease in 2024 was due to lower employee compensation and lower professional fees.

 

Gain on Sales of Equipment

 

During 2024, we recognized a gain of $0.6 million on the sale of equipment related to MesoScribe representing the sale price of $0.8 million less the costs of the equipment sold of $0.2 million. We also recognized a gain of $42,000 on the sale of equipment by our CVD Equipment.

 

35

 

 

Loss on Disposition of Tantaline

 

This expense of $162,000 represents the net loss on the sale of our Tantaline subsidiary including professional fees. This disposition was completed in 2023.

 

Impairment Charge

 

This expense represents the loss on the impairment of certain assets of MesoScribe based on the decision to wind down its operations made in 2023.

 

Other Income, Net

 

Other income, net was $0.5 million for the year ended December 31, 2024 as compared to other income, net of $0.7 million for the year ended December 31, 2023. Other income is principally interest income on treasury bills.

 

Income Taxes

 

Income tax expense (benefit) for the years ended December 31, 2024 and 2023, was $24,000 and $(14,000) respectively. We continue to evaluate for potential utilization of our deferred tax asset, which has been fully reserved for, on a quarterly basis, by reviewing our economic models, including projections of future operating results.

 

Inflation and Supply Chain Matters

 

We experienced increased costs on certain materials and components as well as delays in supply chain delivery, which may also impact our ability to recognize revenue and reduce our gross profit margins, as well as extend our manufacturing lead times and reduce our manufacturing efficiencies. We have commenced placing orders with more lead time to help mitigate the manufacturing delays, as well as assessing other suppliers or components to attempt to mitigate the potential cost impacts. In addition, we are utilizing our in-house flexible manufacturing to attempt to further mitigate both potential schedule delivery delays and material cost increase. While we have initiated actions to mitigate the potential negative impacts to our revenue and profitability, there can be no assurance of the ultimate impact and the length of time that the supply chain factors may impact our revenues and profitability.

 

Inflation has also had an impact on salaries and compensation. To remain competitive in the acquisition and retention of our employees, we have reviewed and adjusted salaries and implemented bonus incentives to mitigate the potential negative impacts of inflation on our employees.

 

Any significant increases in tariffs on goods that we purchase could negatively affect our business and results of operations by increasing the cost to manufacture our products.

 

36

 

 

Liquidity and Capital Resources

 

As of December 31, 2024, we had aggregate working capital of $13.9 million compared to aggregate working capital of $14.3 million at December 31, 2023. Our cash and cash equivalents at December 31, 2024 and 2023 were $12.6 million and $14.0 million, respectively.

 

Net cash used in operating activities during 2024 was $1.5 million and was principally due to the net loss of $1.9 million and reductions in contract assets and liabilities of $2.4 million, offset by a reduction in inventory of $0.6 million, and non-cash items of $2.6 million including a provision for excess and obsolete inventory of $1.6 million.

 

Net cash provided by investing activities for the year ended December 31, 2024 consisted of proceeds from the sales of equipment of $0.2 million offset by capital expenditures of $0.1 million.

 

Net cash used in financing activities for the year ended December 31, 2024 consisted of repayments of $0.1 million for an equipment loan.

 

We believe that our cash and cash equivalent positions and our projected cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months from the filing of this Form 10-K. We will continue to assess our operations and take actions anticipated to maintain our operating cash to support the working capital needs.

 

Critical Accounting Estimates

 

Use of Estimates

 

This discussion and analysis of the Company’s financial condition and results of operations is based on the Company’s consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods.

 

In accordance with U.S. GAAP, the Company bases its estimates on historical experience and on various other assumptions the Company believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

 

We consider an accounting estimate to be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.

 

37

 

 

We consider the following estimates within our significant accounting policies to be critical because of their complexity and the high degree of judgment involved in maintaining them. See Note 2 – “Summary of Significant Accounting Policies” of our Consolidated Financial Statements for additional information regarding our accounting policies

 

Revenue Recognition

 

We design, manufacture, and sell custom chemical vapor deposition equipment through contractual agreements. These system sales require us to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. We recognize revenue over time by using an input method based on costs incurred as it depicts our progress toward satisfaction of the performance obligation. Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations.

 

Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as indirect labor, supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process as required by the project’s engineering design. Cost based input methods of revenue recognition require us to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor, and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, we recognize the entire estimated loss in the period the loss becomes known and can be reasonably estimated.

 

We have been engaged in the production and delivery of goods on a continual basis under contractual arrangements for many years. Historically, we have demonstrated an ability to accurately estimate total revenues and total expenses relating to our long-term contracts. However, there exist many inherent risks and uncertainties in estimating revenues, expenses and progress toward completion, particularly on larger or longer-term contracts. If we do not estimate the total sales, related costs, and progress toward completion on such contracts, the estimated gross margins may be significantly impacted, or losses may need to be recognized in future periods. Any such resulting changes in margins or contract losses could be material to our results of operations and financial condition.

 

Long-Lived Assets

 

Long-lived assets consist primarily of property, plant and equipment. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists pursuant to the requirements of ASC 360-10-35, “Impairment or Disposal of Long-Lived Assets.” If the asset is determined to be impaired, the impairment loss is measured on the excess of it carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value. It is not possible for us to predict the likelihood of any possible future impairments or, if such an impairment were to occur, the magnitude of any impairment.

 

38

 

 

Item 7A.Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 8. Financial Statements and Supplementary Data.

 

The consolidated financial statements required by this item are included in this Annual Report on Form 10-K beginning on page F-1.

 

Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A.Controls and Procedures.

 

Disclosure Controls and Procedures. We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 13d-15(e) under the Exchange Act of 1934, as amended, (the “Exchange Act”)). As required by Rule 13a-15(b) under the Exchange Act, management of the Company, under the direction of our Chief Executive Officer and Chief Financial Officer, reviewed and performed an evaluation of the effectiveness of design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2024.

 

Based on that review and evaluation, our Chief Executive Officer and Chief Financial Officer, along with others in our management, have determined that as of the end of the period covered by this Report on Form 10-K, the disclosure controls and procedures were effective to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding disclosures.

 

Changes in Internal Controls

 

There were no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) or Rule 15d-15(f) under the Exchange Act that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the internal controls over financial reporting.

 

Limitations on the Effectiveness of Controls

 

We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

 

39

 

 

Management’s Annual Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining effective internal control over financial reporting (as defined in Rule 13a – 15(f) of the Exchange Act). There are inherent limitations to the effectiveness of any internal control, including the possibility of human error and the circumvention or overriding of controls. Accordingly, even effective internal controls can provide only reasonable assurance with respect to financial statement preparation. Further, because of changes in conditions, the effectiveness of internal control may vary over time. We have assessed the effectiveness of our internal controls over financial reporting (as defined in Rule 13a -15(f) of the Exchange Act) as of December 31, 2024. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control – Integrated Framework (2013)”. Management concluded that, as of December 31, 2024, our internal control over financial reporting was effective based on the criteria established by the COSO Internal Control Framework.

 

This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report on Form 10-K.

 

Item 9B.Other Information.

 

Not applicable.

 

Item 9C.Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.

 

Not applicable.

 

PART III

 

Item 10.Directors, Executive Officers, and Corporate Governance.

 

Background and Experience of Directors

 

When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable the Board of Directors to satisfy its oversight responsibilities effectively in light of our business and structure, the Nominating, Governance and Compliance Committee focused primarily on each person’s background and experience as reflected in the information discussed in each of the directors’ individual biographies set forth immediately below. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. As more specifically described in such person’s individual biographies set forth below, our directors possess relevant and industry-specific experience and knowledge in the engineering, financial and business fields, as the case may be, which we believe enhances the Board’s ability to oversee, evaluate and direct our overall corporate strategy. The Nominating, Governance and Compliance Committee annually reviews and makes recommendations to the Board regarding the composition and size of the Board so that the Board consists of members with the proper expertise, skills, attributes, and personal and professional backgrounds needed by the Board, consistent with applicable regulatory requirements.

 

40

 

 

The Nominating, Governance and Compliance Committee believes that all directors, including nominees, should possess the highest personal and professional ethics, integrity, and values, and be committed to representing the long-term interests of our shareholders. The Nominating, Governance and Compliance Committee will consider criteria including the nominee’s current or recent experience as a senior executive officer, whether the nominee is independent, as that term is defined in existing independence requirements of the NASDAQ Capital Market and the Securities and Exchange Commission, the business, scientific or engineering experience currently desired on the Board, geography, the nominee’s industry experience, and the nominee’s general ability to enhance the overall composition of the Board.

 

The Nominating, Governance and Compliance Committee does not have a formal policy on diversity, however, in recommending directors, the Board and the Committee consider the specific background and experience of the Board members and other personal attributes in an effort to provide a diverse mix of capabilities, contributions and viewpoints which the Board believes enables it to function effectively as the Board of Directors of a company with our size and the nature of our business.

 

The following table sets forth the names, ages and positions with the Company of each of our directors and executive officers, as of March 19, 2025.

 

Name   Age   Position(s) with the Company
Emmanuel Lakios   63   Chief Executive Officer, President, Director
Lawrence J. Waldman   78   Chairman of the Board of Directors, Chairman-Audit Committee
Robert M. Brill   78   Director, Chairman – Nominating, Governance, and Compliance Committee
Ashraf Lotfi   64   Director, Chairman – Compensation Committee
Debra Wasser   60   Director
Andrew Africk   58   Director
Richard A. Catalano   65   Chief Financial Officer, Executive Vice President, Secretary and Treasurer
Kevin R. Collins   59   Vice President and General Manager of SDC
Jeffrey A. Brogan   55   Vice President of Sales and Marketing
Maxim S. Shatalov   54   Vice President of Engineering and Technology
Warren D. Cheesman   52   Vice President of Manufacturing Operations

 

Emmanuel Lakios was appointed to serve as President and Chief Executive Officer of the Company on January 22, 2021, and on July 15, 2021 was elected by the shareholders as a member of the Board of Directors. Mr. Lakios joined the Company as Vice President Sales and Marketing in February 2017. Mr. Lakios has over 30 years of experience serving the aerospace, semiconductor, data storage and optical device industries and is the holder of several patents in the field of process equipment and device structure. From January 2015 through February 2017, Mr. Lakios was the President and Chief Executive Officer at Sensor Electronic Technology, Inc., overseeing that company’s transition from R&D to a leading global commercial UV LED supplier. From 2003 to 2011 he was the Executive Vice President of Field Operations and President and Chief Operating Officer at Imago Scientific, bringing it from pre-revenue to a commercial leadership position in the 3D atomic scale tomography field. Mr. Lakios was previously employed at Veeco Instruments Inc. from 1984 until 2003, where he held several positions, including President of the Process Equipment Group and Executive Vice President of Field Operations. He has been involved in several acquisitions and numerous product line launches. He received his BE in Mechanical Engineering with focus in Material Science from SUNY Stony Brook in 1984.

 

41

 

 

Lawrence J. Waldman was appointed a member of the Board of Directors on October 5, 2016 and currently serves as Chairman of the Board and Chairman of the Audit Committee. Mr. Waldman has over 40 years of experience in public accounting.

 

Mr. Waldman is a member of the board of directors of Comtech Telecommunications Corporation since August 2015 and Lead Independent Director from December 2021 through March 2024. He serves as the chairperson of Comtech’s Audit Committee. Mr. Waldman is a member of the board of directors and Lead Independent Director and Audit Committee Chairperson at APYX Medical Corporation, a Nasdaq-listed advanced energy medical technology company. Mr. Waldman serves as a Senior Advisor at First Long Island Investors, LLC since 2016 and was previously an Advisor to the accounting firm of EisnerAmper LLP following his role as Partner-in-Charge of Commercial Audit Practice Development for Long Island. Mr. Waldman served as the Managing Partner of the Long Island office of KPMG LLP from 1994 through 2006, the accounting firm where he began his career in 1972. During his tenure at KPMG, Mr. Waldman served as audit partner to a number of public and privately held technology companies.

 

Mr. Waldman is currently Chairman of the Board of Directors of the Long Island Association and a member of the boards of directors of the Long Island Angel Network and the Advanced Energy Research Center at Stony Brook University. Through October 21, 2018, Mr. Waldman was a member of the board of directors of Northstar/RXR Metro Income, Inc., an SEC registered non-traded real estate investment trust.

 

Mr. Waldman was Chairman of the Supervisory Committee of Bethpage Federal Credit Union and previously served as the Chairman of the Audit Committee of the State University of New York’s (“SUNY”) Board of Trustees, the largest state university system in the United States. Mr. Waldman previously served as Chairman of the Audit and Finance Committee Board of Trustees of the Long Island Power Authority (“LIPA”), the second largest government utility in the United States, and as the Chairman of the Board. Mr. Waldman also served as an adjunct professor at Hofstra University, teaching graduate courses in advanced accounting theory and advanced auditing. Mr. Waldman is a certified public accountant in New York State. He is a member of the American Institute of Certified Public Accountants and the New York State Society of CPAs. Mr. Waldman holds a Bachelor of Science and a Master of Business Administration from Hofstra University in Hempstead, New York.

 

Mr. Waldman qualifies to serve as a director, Audit Committee Chairman and Lead Independent Director because of his significant experience leading public company boards, his extensive relevant industry and financial and accounting expertise.

 

42

 

 

Dr. Robert M. Brill was appointed a Director of the Company on March 5, 2021. Dr. Brill was co-founder and managing partner of Newlight Management from 1997 to 2019, which managed venture capital funds that focused on early-stage technology companies. Prior to co-founding Newlight, Dr. Brill was a general partner of Poly Ventures, a Long Island based venture capital fund. Dr. Brill is a member of the Board of Directors of the Long Island Angel Network and one private company. Dr. Brill has also previously served on the Board of Directors of multiple public and private companies. Dr. Brill has been the CEO of both public and private companies. Dr. Brill served as General Manager of Harris Corporation’s CMOS Semiconductor Division. He also held various technical and management positions at IBM’s semiconductor operation. Dr. Brill holds a Ph.D. in nuclear physics from Brown University and a B.A. and a B.S. in Engineering Physics from Lehigh University. Dr. Brill had previously served on the Company’s Board from April 2018 until October 2019.

 

Dr. Ashraf Lotfi is currently a venture partner with Deep Sciences Ventures and serves on the board of Lotus Microsystems, ApS, Xonia Ltd., HyperCIM Ltd. Dr. Lotfi previously served as Vice President and a Fellow at Intel Corporation. Prior to Intel, he was Power Chief Technology Officer for Altera Corporation serving its Enpirion Power Business as well as the broader Field Programmable Gate Array community. Altera was acquired by Intel in 2015. Prior to Altera, he served as President and Chief Executive Officer of Enpirion, Inc., which he founded in 2002.

 

From Enpirion’s inception, Dr. Lotfi led its strategic direction with a unique industry-first vision to create the ultimate power converter-on-chip creating ubiquitous DC-DC conversion at the silicon level. In 2013, he led Enpirion’s merger into Altera to realize his vision of highly integrated power management closely coupled to leading-edge digital silicon loads. Prior to founding Enpirion, he was Director of Advanced Power Research at Bell Laboratories.

 

Dr. Lotfi has a B.S. in Electrical Engineering from Cairo University and an M.S. and PhD. in Electrical Engineering from Virginia Tech.

 

Dr. Lotfi currently serves on the boards of Lotus Microsystems ApS, Xonai Ltd., HyperCIM Ltd. and his extensive experience in high power electronics provide a valuable resource to the Board of Directors and Executive Management.

 

Debra Wasser was elected as a member of the Board of Directors on July 13, 2023. Ms. Wasser currently serves as Vice President of Investor Relations for Etsy, Inc. (Nasdaq: ETSY), the global marketplace for unique and creative goods. She is responsible for Etsy’s external shareholder relationships, with a focus on corporate and financial reporting, driving increased analyst coverage and investor connectivity, effective corporate messaging, strategic investor targeting, and governance engagement with the financial community. Ms. Wasser has led investor and broad internal and external communications strategies on multiple financial transactions and offerings, and a host of product and technology launches and marketing initiatives.

 

Prior to joining Etsy in April 2018, Ms. Wasser led Edelman’s Investor Relations practice in the U.S. and advised boards of directors and senior managements of public companies on strategic communications including investor relations, financial and corporate public relations, transaction communications, crisis communications and leadership positioning.

 

43

 

 

Prior to joining Edelman in 2015, Ms. Wasser was Senior Vice President, Investor Relations & Corporate Communications for semiconductor equipment provider Veeco Instruments, Inc. (Nasdaq: VECO) for over 15 years. While at Veeco, Ms. Wasser created and implemented a global investor relations program to raise visibility and deepen ownership to reflect business trends. She led effective communications strategy through positive periods of growth, over a dozen merger and acquisition transactions, a highly successful secondary equity offering, and new market opportunities.

 

Prior to joining Veeco, Ms. Wasser was Vice President of Dewe Rogerson Inc. where she ran the firm’s U.S. investor relations client base, focused on healthcare/biotech, high-tech, consumer products, financial services, publishing, and general industry. During her tenure at the firm, Ms. Wasser serviced clients across the globe and helped grow the firm from four to 80 employees. Deb has a B.S. in Communications and Business from The State University of New York at Albany.

 

Ms. Wasser has provided business and communications advice to Boards of Directors of publicly traded and privately held companies for over three decades. She has served on the Board of Directors of NIRI, the Association of Investor Relations Professionals, including the maximum service of four years on the National Chapter Board, as well as earlier as a Board member of the organizations New York Chapter.

 

Andrew Africk was appointed as a member of the Board of Directors on May 28, 2024. Mr. Africk is the founder of Searay Capital LLC, a private investment company. Mr. Africk established Searay Capital in July 2013 after 21 years leading private equity and capital markets investments for Apollo Global Management. As a Senior Partner at Apollo, Mr. Africk was responsible for investments in technology and communications, and he has 30 years of experience financing, analyzing and investing in public and private companies. In the last five years, Mr. Africk has served on the board of directors of ADT Inc., which provides residential and commercial security systems and services. Additionally, Mr. Africk serves on the Board of Advisors of the University of Pennsylvania School of Engineering and Applied Science. Mr. Africk graduated from UCLA with a B.A. in Economics, from the University of Pennsylvania Law School with a J.D., and from the University of Pennsylvania’s Wharton School of Business with an MBA.

 

Mr. Africk has extensive board experience including previously serving on the board of directors of ADT Inc., and numerous boards of technology companies while a Senior Partner at Apollo.

 

Richard A. Catalano was appointed as the Company’s Vice President and Chief Financial Officer effective as of August 30, 2022. Mr. Catalano began his career at KPMG LLP and became an audit partner in 1993. Throughout his over 35 years as an audit professional at KPMG LLP, Mr. Catalano advised a diverse array of clients through private equity financed transactions, merger-related accounting, and filings with the U.S. Securities and Exchange Commission. Towards the later part of his tenure, Mr. Catalano served as the leader of KPMG LLP’s Metro New York Healthcare and Life Sciences Practice and then co-led KPMG’s Global Audit Methodology Group. Mr. Catalano is a Certified Public Accountant in New York State and received a Bachelor of Business Administration in accounting from Hofstra University.

 

44

 

 

Kevin R. Collins is the Vice President and General Manager of SDC, Mr. Collins served as the General Manager of SDC since 1999. From 1990 to 1999 he was employed by Stainless Design Corp. as Manager of Field Operations and Product Development Advisor. Mr. Collins attended Columbia University School of Engineering and Applied Science.

 

Dr. Jeffrey Brogan was appointed as Vice President Sales and Marketing for the Company on March 23, 2021. Previously he was Director of Sales and Marketing for CVD Materials Corporation since November 2017 with General Management responsibilities of CVD MesoScribe Technologies Corporation. Dr. Brogan served as the President and CEO of MesoScribe Technologies, Inc., spearheading its sale to CVD in 2017. He has over 25 years of experience serving aerospace and defense industries with expertise in strategic sales & marketing, technology management, and advanced Research & Development. He received his PhD in Materials Science and Engineering from Stony Brook University in 1996.

 

Dr. Maxim S. Shatalov was appointed Vice President of Engineering and Technology in April 2018. Prior to CVD, Mr. Shatalov was employed by Sensor Electronic Technology Inc. (SETi) a LED company where he held multiple technical and management positions from 2006 through 2018. In 2017, Dr. Shatalov became Vice President of Technology responsible for UV LED technology and LED application development at SETi. Dr. Shatalov has over twenty years of experience in semiconductor research and devices and holds more than 12 U.S. patents.

 

Warren D. Cheesman was appointed Vice President of Manufacturing Operations in October 2022. He has over 25 years of management experience in the semiconductor, medical device and defense equipment sectors. Mr. Cheesman has held roles of increasing responsibility in engineering, operations, quality and strategic sourcing, at equipment manufacturers including Veeco Instruments, Air Techniques, and Kongsberg Defense & Aerospace. Mr. Cheesman provides strategic leadership across all divisions related to manufacturing, quality, and continuous improvement initiatives, with emphasis on process improvement, lean manufacturing, risk management, and collaboration. He holds two master of science degrees from Stony Brook University in Technology Management and Materials Science & Engineering, and a Bachelor of Science degree in Mechanical Engineering from Virginia Tech. His academic and professional experience is also complemented by a Six Sigma Black Belt certification.

 

Legal Proceedings Involving Directors

 

None.

 

Board Leadership

 

Our Corporate Governance practices contain several features which we believe will ensure that the Board maintains effective and independent oversight of management, including the following:

 

●Executive sessions without management and non-independent directors present are a standing Board agenda item. Executive sessions of the independent directors are held at any time requested by an independent director and, in any event, are held in connection with at least 100% of regularly scheduled Board meetings.

 

45

 

 

●The Board regularly meets in executive session with the CEO without other members of management present.
●All Board committee members are independent directors. The committee chairs have authority to hold executive sessions with management and non-independent directors present.

 

While our Board has no formal policy with respect to separation of the positions of Chairman and CEO or with respect to whether the Chairman should be a member of management or an independent director, we believe that the appointment of Mr. Waldman as Chairman properly facilitates better communication between the Independent Directors on the one hand and the non-Independent Director and members of management on the other hand and leads to improved oversight and discussions by the Board as a whole. The Chief Executive Officer of the Company, Emmanuel Lakios, is tasked with the responsibility of implementing our corporate strategy, we believe he is best suited for leading discussions with input from the Chairman, at the Board level, regarding performance relative to our corporate strategy and this discussion accounts for a significant portion of the time devoted at the Board meetings.

 

Our Certificate of Incorporation and Bylaws provide for our Company to be managed by or under the direction of the Board of Directors. Under our Certificate of Incorporation and Bylaws, the number of directors is fixed from time to time by the Board of Directors. The Board of Directors currently consists of six members. Directors are elected for a period of one year and thereafter serve, subject to the Bylaws, until the next annual meeting at which their successors are duly elected by the shareholders.

 

Code of Ethics

 

We have adopted a Corporate Code of Conduct and Ethics that applies to our employees, senior management and Board of Directors, including the Chief Executive Officer and Chief Financial Officer. The Corporate Code of Conduct and Ethics is available on our website, www.cvdequipment.com, by clicking on “About Us” and then clicking on “Governance.”

 

Insider Trading Policy

 

The Company has adopted an insider trading policy that governs the purchase, sale and/or other dispositions of our securities by our directors, officers and employees, as well as their immediate family members and others who may have access to material nonpublic information concerning the Company, and that is designed to promote compliance with insider trading laws, rules and regulations. A copy of our Insider Trading Policy is filed as Exhibit 19 to this Annual Report on Form 10-K.

 

46

 

 

Audit Committee

 

Our Board of Directors has an Audit Committee that currently consists of Lawrence J. Waldman, Chairman, Robert M. Brill, and Debra Wasser. During the fiscal year ended December 31, 2024, the Audit Committee held four meetings. Pursuant to the Audit Committee Charter, the Audit Committee is directly responsible for the appointment, compensation, retention and oversight of the work of any independent registered public accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for us, and each such independent auditor shall report directly to the Committee. The Audit Committee also reviews with management and the independent auditors, our annual audited financial statements (including the disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”), the scope and results of annual audits and the audit and non-audit fees of the independent registered public accounting firm. Messrs. Waldman and Brill and Ms. Wasser are “independent” under the requirements of the NASDAQ Stock Market.

 

The Board of Directors has determined that Mr. Waldman is an “audit committee financial expert” as that term is defined in the rules and regulations of the Securities and Exchange Commission.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

The rules of the Securities and Exchange Commission require us to disclose late filings of reports of stock ownership and changes in stock ownership by our directors, officers and ten percent shareholders. To our knowledge, based solely on our review of (a) the copies of such reports and amendments thereto furnished to us and (b) written representations that no other reports were required, during our fiscal year ended December 31, 2024, all of the filings for our officers, directors and ten percent shareholders were made on a timely basis.

 

Item 11.Executive Compensation.

 

Summary Compensation Table

 

The following table sets forth the compensation of our chief executive officer and chief financial officer, and our “named executive officers,” for the years ended December 31, 2024 and 2023.

 

Name and principal position  Year   Salary ($)   Bonus ($) (1)   Option Awards ($) (2)   Stock Awards ($) (2)   All Other Compensation ($) (3)  

Total ($)

 
                             
Emmanuel Lakios
   2024    415,000    -    -    -    20,744    435,744 
President and Chief Executive Officer   2023    388,600    -    699,990    -    19,522    1,108,112 
                                    
Richard Catalano Secretary, Chief   2024    283,800    -    -    -    26,772    310,572 
Financial Officer and Executive Vice President   2023    274,700    -    233,330    -    27,201    535,231 
                                    
Jeffrey A. Brogan   2024    206,000    25,000    -    -    7,578    238,578 
Vice President Sales & Marketing   2023    203,300    -    139,998    -    7,863    351,161 

 

(1)Reflects cash bonuses under the Company’s Management Bonus Plan. Bonuses listed for a particular year represents amounts earned with respect to such year even though all or part of such amounts have been paid during the following year.
  
(2)These columns represent the grant date fair value of the stock awards as calculated in accordance with FASB ASC 718 (Stock Compensation). The stock options granted in 2023 vest 25% per year over four years and have a ten-year life. There were no stock options granted in 2024 to the named executive officers
  
(3)All other compensation consists of 1) 401(k) match in 2024 and 2023 of $10,350 and $9,900 for Emmanuel Lakios, $8,514 and $9,179 for Richard Catalano, and $6,930 and $7,863 for Jeffrey Brogan, respectively; and 2) health, life and disability insurance premiums in 2024 and 2023 of $10,394 and $9,622 for Emmanuel Lakios, $18,258 and $18,022 for Richard Catalano and $0 and $648 for Jeffrey Brogan.

 

47

 

 

Employment Agreements and Potential Payments Upon Termination or Change in Control

 

Emmanuel Lakios Employment Agreement

 

On June 1, 2021, the Company entered into an Employment Agreement with Emmanuel Lakios, the Company’s President and Chief Executive Officer (the “Lakios Agreement”). The term of Mr. Lakios’s employment under the Lakios Agreement commenced as of the effective date thereof and shall continue until terminated in accordance with the terms of the Lakios Agreement. Under the Lakios Agreement, Mr. Lakios will receive an initial annual base salary of $288,000, which shall be reviewed from time to time and may be increased, but not decreased, by the Compensation Committee of the Board of Directors (the “Committee”) in its sole and exclusive discretion. Mr. Lakios shall be entitled to participate in any bonus or incentive plan available to the Company’s senior executives generally, on such terms as the Committee may determine in its discretion.

 

In the event of the termination of the Lakios Agreement and Mr. Lakios’s employment thereunder, Mr. Lakios or his estate (in the event of his death) shall be entitled to (A) receive any unpaid base salary earned and accrued under the Lakios Agreement prior to the date of termination (and reimbursement for expenses incurred prior to the date of termination), (B) indemnification in accordance with any applicable indemnification plan, program, corporate governance document or other arrangement, and any vested rights pursuant to any insurance plan, benefit plan or retirement plan, and, except in the event of Mr. Lakios’s termination by the Company for Cause (as defined in the Lakios Agreement), (C) treatment of his stock option grants in accordance with the terms of the applicable plan and award agreement.

 

In the event Mr. Lakios’s employment is terminated as a result of death or disability, Mr. Lakios shall also be entitled to receive a pro rata bonus payment under the Company’s bonus Plan for the year of termination, if applicable.

 

In the event Mr. Lakios’s employment is terminated by the Company for Cause, Mr. Lakios’s stock option grants, whether vested or unvested, shall immediately terminate and be null and void.

 

In the event Mr. Lakios’s employment is terminated by the Company without Cause, or by Mr. Lakios for Good Reason (as defined in the Lakios Agreement), Mr. Lakios shall also be entitled to (A) a pro rata bonus for the year of termination, and (B) continued payment of his base salary and the Company’s portion of Mr. Lakios’s then existing medical benefits for the nine (9) month period following the date of termination.

 

48

 

 

The Lakios Agreement contains customary non-competition, non-solicitation, and confidentiality provisions in favor of the Company.

 

Other then as set forth above, there are no arrangements for compensation of directors or Named Executive Officers and there are no employment contracts between the Company and its directors or any change in control arrangements.

 

Equity Awards

 

From time to time, we grant equity awards, including stock options, to our employees, including our named executive officers. Historically, we have typically granted new-hire option awards on, or within the calendar quarter of, a new hire's employment start date and annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at a regularly scheduled meeting of the Compensation Committee occurring in such quarter. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time of each annual meeting of our stockholders, respectively, pursuant to our non-employee director compensation policy, as further described under the heading, “2024 Director Compensation” below.

 

We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about our company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to our public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation.

 

During fiscal 2024, the Company did not grant any equity awards to its named executive officers.

 

Outstanding Equity Awards at December 31, 2024

 

The following table sets forth the outstanding equity awards held by our named executive officers as of December 31, 2024.

 

OPTION AWARDS  STOCK AWARDS 
Name  Number of Securities Underlying Options Exercisable   Number of Securities Options Unexercisable   Exercise Price   Option Expiration Date  Number of shares or units of stock that have not vested   Market value of shares or units of stock that have not vested   Equity Incentive Plan Awards: Number of unearned shares or units that not vested   Equity Incentive Plan Awards: Market or payout value of unearned shares or units that have not vested 
Emmanuel Lakios   18,750    56,250   $14.11   3/23/2033   -    -    -   $- 
    37,500    37,500   $5.02   8/17/2032                    
    75,000    25,000   $4.26   6/1/2031                    
    100,000    -   $10.30   2/6/2027                    
                                       
Richard Catalano   6,250    18,750   $14.11   3/23/2033   -    -    -   $- 
    10,000    10,000   $5.42   8/30/2032                    
                                       
Jeffrey A. Brogan   3,750    11,250   $14.11   3/23/2033   -    -    -   $ - 
    7,500    7,500   $5.02   8/17/2032                    
    15,000    5,000   $4.01   7/15/2021                
    20,000    -   $11.61   10/31/2027                    

 

2024 Director Compensation

 

The following table sets forth a summary of the compensation we paid to our non-employee directors in 2024.

 

Name  Fees Earned
or
Paid in Cash		   Option Awards   Restricted Stock Awards   Total 
                 
Lawrence J. Waldman  $113,000    -   $40,000   $153,000 
Robert M. Brill   50,000    -    40,000    90,000 
Debra Wasser   40,000    -    40,000    80,000 
Ashraf Lotfi   42,500    -    40,000    82,500 
Andrew Africk   23,736    -    23,738    47,474 
Raymond A. Nielsen   30,435    -    40,000    70,435 

 

49

 

 

On October 11, 2021, the Board of Directors, following the unanimous recommendation of the Board’s Compensation Committee, unanimously approved a director compensation plan, effective October 1, 2021 (the “Plan”). The Plan is based on the recommendations of an independent compensation consultant engaged by the Board’s Compensation Committee. Pursuant to the Plan, each director is entitled to Director Compensation, divided into the following pay components: (i) Annual Board of Directors cash compensation in the amount of $40,000 and (ii) an annual equity retainer in the amount of $40,000, to be automatically granted on the date of the Company’s annual meeting of shareholders. Additionally, a director serving as a chairman for the Board’s Compensation Committee or Nominating, Governance and Compliance Committee is entitled to annual chair compensation in the amount of $10,000. The director serving as the chairman for the Board’s Audit Committee is entitled to chair compensation in the amount of $25,000. Furthermore, the director serving as the Non-Executive Chairman is entitled to Board leadership compensation in the amount of $48,000.

 

Raymond A. Nielsen retired from the Board of Directors on August 9, 2024 and Andrew Africk was appointed to the Board of Directors on May 28, 2024.

 

Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table sets forth, as of March 19, 2025, information regarding the beneficial ownership of our common stock by (a) each person who is known to us to be the owner of more than five percent (5%) of our common stock, (b) each of our directors, (c) each of the named executive officers, and (d) all directors and executive officers and executive employees as a group. For purposes of the table, a person or group of persons is deemed to have beneficial ownership of any shares that such person has the right to acquire within 60 days of March 19, 2025.

 

Name and Address of Beneficial Owner (1)  Amounts and Nature of Beneficial Ownership (2)   Percent of Class (%) 
         
5% or Greater Shareholder:
Leviticus Partners, L.P.		   617,832    9.0 
           
Directors and Executive Officers:
Andrw Africk / ADA Partners LP		   1,303,690(4)   18.9 
Emmanuel Lakios   256,358(3)   3.7 
Kevin R. Collins   102,437(3)   1.5 
Lawrence J. Waldman   80,221(4)   1.2 
Jeffrey A. Brogan   54,519(3)   * 
Robert M. Brill   33,006(4)   * 
Maxim Shatalov   30,000(3)   * 
Richard Catalano   22,500(3)   * 
Warren Cheesman   15,000(3)   * 
Ashraf Lotfi   14,811(4)   * 
Debra Wasser   14,306(4)   * 
 All directors and executive officers and executive employees as a group (eleven persons)   1,926,848    28.0 

 

 

* Less than 1% of the outstanding common stock or less than 1% of the voting power

 

(1)The address of Messrs. Lakios, Waldman, Nielsen, Brogan, Brill, Shatalov, Catalano, Cheesman. Lotfi and Ms. Wasser is c/o CVD Equipment Corporation, 355 South Technology Drive, Central Islip, New York 11722. The address of Mr. Collins is c/o Stainless Design Concepts, 1117 Old Kings Highway, Saugerties, NY 12477. The address of Andrew Africk / ADA Partners is c/o Searay Capital, 111 West 67th Street, New York, NY 10023. The address of Leviticus Partners, L.P. is 200 Park Avenue, Suite 1700, New York, NY 10166.
  
(2)All of such shares are owned directly with sole voting and investment power, unless otherwise noted below.
  
(3)Does not include unvested options to purchase the following shares of our common stock: Lakios – 100,000; Collins – 17,500; Brogan – 20,000; Shatalov – 20,000; Catalano – 22,500; and Cheesman – 15,000
  
(4)Does not include unvested restricted shares of our common stock: Waldman – 2,825; Africk – 2,825; Brill – 2,825; Lotfi – 2,825 and Wasser – 2,825. Does not include shares to be issued per Director compensation agreement related to the Annual Equity Retainer in the amount of $40,000, to be determined at the 2025 Annual Meeting of Shareholders.

 

50

 

 

Equity Compensation Plan Information Table

 

The following table provides information about shares of our common stock that may be issued upon the exercise of options under all of our existing compensation plans as of December 31, 2024.

 

   Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)   Weighted-average exercise price of outstanding options, warrants and rights (2)   Number of securities remaining available for future issuance 

Plan Category

               
                
Equity compensation plans approved by security holders
   823,125   $8.24    183,128 
Equity compensation
plans not approved by security holders		   —    

 

 

N/A

    — 
                
Total   823,125   $8.24    183,128 

 

(1)Reflects aggregate options outstanding under our 2007 Share Incentive Plan, 2016 Equity Incentive Plan and 2022 Equity Incentive Plan.
  
(2)Calculation is exclusive of the value of any unvested restricted stock awards.

 

Item 13.Certain Relationships and Related Transactions, and Director Independence.

 

Transactions with related persons, promoters and certain control persons.

 

None.

 

Director Independence

 

The current members of our Board of Directors are Lawrence J. Waldman, Emmanuel Lakios, Andrew Africk, Robert M. Brill, Debra Wasser and Ashraf Lotfi. Messrs. Waldman, Africk, Brill and Lotfi and Ms. Wasser have been determined to be “independent” as defined under Rule 4200 of the Nasdaq Stock Market.

 

Item 14.Principal Accountant Fees and Services.

 

The following presents fees for professional audit services rendered by Marcum, LLP, Certified Public Accountants, the Company’s independent registered public accounting firm for the years ended December 31, 2024 and 2023.

 

   2024   2023 
         
Audit fees  $224,025   $236,076 
Audit-related fees   25,750    55,002 
All other fees   -    - 
Total fees  $249,775   $291,078 

 

Audit Fees

 

Audit fees consisted of the review of the first three quarters and audit of the year-end.

 

Audit-related Fees

 

Consisted of the audit of the Company’s defined contribution 401(k) plan and fees associated with registration statements and comfort letter.

 

Audit Committee Approval

 

The engagement of the Company’s independent registered public accounting firm is pre-approved by the Company’s Audit Committee. The Audit Committee pre-approves all fees billed and all services rendered by the Company’s independent registered public accounting firm.

 

51

 

 

PART IV

 

Item 15.  Exhibits, Financial Statement Schedules
    
3.1  **Certificate of Incorporation, dated October 12, 1982
    
3.2  **Certificate of Amendment of Certificate of Incorporation, dated April 25, 1985.
    
3.3  **Certificate of Amendment of Certificate of Incorporation, dated August 12, 1985.
    
3.4  **Certificate of Amendment of Certificate of Incorporation, dated June 30, 1989.
    
3.5  Certificate of Amendment of the Certificate of Incorporation, dated December 9, 2016 (Incorporated herein by reference the Company’s Current Report on Form 8-K filed on December 14, 2016).
    
3.6  Amended and restated By-laws of CVD Equipment Corporation, dated as of October 5, 2016 (Incorporated herein by reference to the Company’s Current Report on Form 8-K filed on October 11, 2016).
    
4.1  Description of the Company’s Securities (Incorporated herein by reference to the Company’s Annual Report on Form 10-K filed on March 30, 2020).
    
10.1  Lease Agreement, dated February 9, 2012, by and between FAE Holdings 411519R, LLC and the Company (Incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012).
    
10.2  Assignment Agreement, dated February 9, 2012, by and between FAE Holdings 411519R, LLC and the Company (Incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012).
    
10.3  Joint and Several Hazardous Material Guaranty and Indemnification Agreement, dated March 15, 2012, by and between FAE Holdings 411519R, LLC and the Company (Incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012).
    
10.4  Guaranty of Payment, dated March 15, 2012, by the Company (Incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012).
    
10.5  Agreement to Purchase and Sale, the building and real estate property located at 555 N Research Place, Central Islip, NY, dated March 29, 2021, by and between 555 N Research Corporation, a wholly-owned subsidiary of the Company, and Steel K, LLC. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Commission on May 13, 2021).
    
10.6  Employment Agreement, dated June 1, 2021, by and between Emmanuel Lakios, the Company’s President and Chief Executive Officer, and the Company. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Commission on August 16, 2021).
    
10.7  Employment Agreement, dated June 1, 2021, by and between Thomas McNeill, the Company’s Executive Vice President and Chief Financial Officer, and the Company. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Commission on August 16, 2021).

 

52

 

 

10.8Assignment, Assumption and Amendment Agreement dated as of July 26, 2021, by and between Town of Islip Industrial Development Agency, 555N Research Corporation and Steel 555 NRP, LLC. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q/A filed with the Commission on March 1, 2022).
  
10.9Second Amended and Restated Lease and Project Agreement, dated as of July 1, 2021, by and between Town of Islip Industrial Development Agency and FAE HOLDINGS 411519R, LLC. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q/A filed with the Commission on March 1, 2022).
  
10.10Agency Compliance Agreement, dated as of July 1, 2021, by and between Town of Islip Industrial Development Agency, CVD Equipment Corporation and CVD Materials Corporation. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q/A filed with the Commission on March 1, 2022).
  
10.11Amended and Restated Sublease Agreement, dated as of July 26, 2021, by and between FAE HOLDINGS 411519R, LLC, CVD Equipment Corporation and CVD Materials Corporation. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q/A filed with the Commission on March 1, 2022).
  
19**Insider Trading Policy
  
21.1List of Subsidiaries
  
23.1**Consent of Marcum, LLP, Certified Public Accountants and Advisors, A Professional Corporation (S-8).
  
31.1**Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
  
31.2**Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
  
32.1**Section 1350 Certification of Principal Executive Officer.
  
32.2**Section 1350 Certification of Principal Financial Officer.
  
97CVD Equipment Corporation Executive Compensation Clawback Policy (Incorporated by reference to the Company’s Annual Report on Form 10-K filed with the Commission on March 28, 2024).

 

101.INS*** XBRL Instance

 

101.SCH*** XBRL Taxonomy Extension Schema

 

101.CAL*** XBRL Taxonomy Extension Calculation

 

101.DEF*** XBRL Taxonomy Extension Definition

 

101.LAB*** XBRL Taxonomy Extension Labels

 

101.PRE*** XBRL Taxonomy Extension Presentation

 

 

* Management contract or compensatory plan or arrangement required

 

** Filed herewith

 

*** XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

53

 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

DATE: March 19, 2025  
     
CVD EQUIPMENT CORPORATION  
   
By: /s/ Emmanuel Lakios  
Name: Emmanuel Lakios  
Title: President and Chief Executive Officer  

 

By: /s/ Richard Catalano  
Name: Richard Catalano  
Title: Executive Vice President, Chief Financial Officer and Secretary  
  Principal Financial and Accounting Officer  

 

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated below.

 

NAME   POSITION   DATE
         
/s/ Emmanuel Lakios   President, Chief Executive Officer   3/19/2025
Emmanuel Lakios   (Principal Executive Officer)    
       
/s/ Lawrence J. Waldman   Director, Chairman of the Board   3/19/2025
Lawrence J. Waldman        
         
/s/ Andrew Africk   Director   3/19/2025
Andrew Africk        
         
/s/ Robert M. Brill   Director   3/19/2025
Robert M. Brill        
         

/s/ Ashraf Lotfi

  

Director

  

3/19/2025

Ashraf Lotfi        
         

/s/ Debra Wasser

  

Director

  

3/19/2025

Debra Wasser        

 

54

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARies

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

    Page No.
     
Report of Independent Registered Public Accounting Firm (PCAOB ID Number 688)   F-1
     
Financial Statements:    
     
Consolidated Balance Sheets as of December 31, 2024 and 2023   F-3
     
Consolidated Statements of Operations for the years ended December 31, 2024 and 2023   F-4
     
Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2024 and 2023   F-5
     
Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023   F-6
     
Notes to Consolidated Financial Statements   F-7

 

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors of

CVD Equipment Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of CVD Equipment Corporation and Subsidiaries (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

F-1

 

 

Revenue Recognition – Estimated Total Contract Costs

 

Description of the Matter

 

As discussed in Notes 2 and 3 to the consolidated financial statements, the Company recognizes revenue from the sale of systems (“System Projects”) over time by using an input method based on costs incurred as it best depicts the Company’s progress toward satisfaction of the performance obligation. Under this method, revenue arising from such contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. The estimation of these costs requires judgment by the Company given the unique product specifications and requirements for contracts related to the design, development, and manufacture of the system. During the year ended December 31, 2024, the Company recognized approximately $22.1 million of revenue recognized over time.

 

Subjective judgment is required by management in determining the assumptions in estimating the estimated costs to complete on contracts for which revenue is recognized over time using a cost-to-cost model. Complex auditor judgment was required in evaluating initial cost estimates and expected costs to complete.

 

How We Addressed the Matter in Our Audit

 

The primary procedures we performed to address this critical audit matter included the following:

 

●Obtaining an understanding of management’s process in developing the cost estimates;
●Obtain and review contracts to ensure that the recognition of revenue over time was appropriate;
●Evaluating management’s ability to reasonably estimate costs by performing a comparison of the actual costs to prior period estimates, including evaluating the timely identification of circumstances that may warrant a modification to the estimated costs;
●Evaluate management’s methodologies and the consistency of management’s methodologies over the life of the contracts;
●Tested the original estimated costs and profit margins on System Projects by obtaining the original estimates, comparing the actual costs and profit margins to the original estimates and investigating significant changes; and
●Tested the estimated costs to complete Systems Projects that were not completed during the year ended December 31, 2024 by comparing the estimated cost to complete at December 31, 2024 to actual cost incurred subsequent to December 31, 2024.

 

/s/ Marcum llp

 

Marcum LLP

 

We have served as the Company’s auditor since 2019.

 

Melville, NY

March 19, 2025

 

F-2

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

As of December 31, 2024 and 2023

(in thousands, except share amounts)

 

   2024   2023 
ASSETS          
Current assets:          
Cash and cash equivalents  $12,598   $14,025 
Accounts receivable, net of allowance for credit losses   2,149    1,906 
Contract assets   2,226    1,604 
Inventories   2,115    4,454 
Other current assets   898    852 
Total current assets   19,986    22,841 
           
Property, plant and equipment, net   11,699    12,166 
Other assets   1    18 
Total assets  $31,686   $35,025 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $679   $1,203 
Accrued expenses   2,236    1,765 
Current maturities of long-term debt   87    81 
Deposits from purchasers of MesoScribe assets – note 14   -    597 
Contract liabilities   3,135    4,908 
Total current liabilities   6,137    8,554 
           
Long-term debt, net of current portion   181    268 
           
Total liabilities   6,318    8,822 
           
Commitments and contingencies (see note 15)   -    - 
           
Stockholders’ equity:          
Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,881,838 at December 31, 2024 and 6,824,511 at December 31, 2023   69    68 
Additional paid-in capital   29,757    28,695 
Accumulated deficit   (4,458)   (2,560)
Total stockholders’ equity   25,368    26,203 
           
Total liabilities and stockholders’ equity  $31,686   $35,025 

 

The accompanying notes are an integral part of the consolidated financial statements

 

F-3

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements of Operations

Years ended December 31, 2024 and 2023

(in thousands, except per share amounts)

 

   2024   2023 
         
Revenue  $26,876   $24,109 
Cost of revenue   20,545    19,038 
           
Gross profit   6,331    5,071 
           
Operating expenses:          
Research and development   2,627    2,596 
Selling   1,656    1,632 
General and administrative   5,181    5,451 
Gain on sales of equipment   (717)   - 
Loss on disposition of Tantaline   -    162 
Impairment charge   -    111 
           
Total operating expenses, net   8,747    9,952 
           
Operating loss   (2,416)   (4,881)
           
Other income (expense):          
Interest income   559    577 
Interest expenses   (19)   (23)
Foreign exchange income   -    42 
Other income   2    91 
Total other income, net   542    687 
           
Loss before income tax   (1,874)   (4,194)
           
Income tax expense (benefit)   24    (14)
           
Net loss  $(1,898)  $(4,180)
           
Loss per common share:          
Basic  $(0.28)  $(0.62)
Diluted  $(0.28)  $(0.62)
           
Weighted average number of shares:          
Basic   6,823    6,788 
Diluted   6,823    6,788 

 

The accompanying notes are an integral part of the consolidated financial statements

 

F-4

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements of Changes in Stockholders’ Equity

Years ended December 31, 2024 and 2023

(in thousands, except share amounts)

 

   Shares   Par Value   Capital  

Deficit)

   Total 
   Common stock  

Additional

paid-in

  

Retained Earnings

(Accumulated

     
   Shares   Par Value   Capital  

Deficit)

   Total 
                     
Balance at January 1, 2023   6,760,938    67    27,712    1,620    29,399 
Net loss   -    -    -    (4,180)   (4,180)
Stock-based compensation   41,320    1    907    -    908 
Exercise of stock options and issuance of shares   22,253    -    76    -    76 
Balance at December 31, 2023   6,824,511   $68   $28,695   $(2,560)  $26,203 
Net loss   -    -    -    (1,898)   (1,898)
Stock-based compensation   57,327    1    1,062    -    1,063 
Balance at December 31, 2024   6,881,838   $69   $29,757   $(4,458)  $25,368 

 

The accompanying notes are an integral part of the consolidated financial statements

 

F-5

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements of Cash Flows

Years ended December 31, 2024 and 2023

(in thousands)

 

   2024   2023 
Cash flows from operating activities:          
Net loss  $(1,898)  $(4,180)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation   1,063    908 
Depreciation and amortization   684    792 
Provision for excess and obsolete inventory   1,573    387 
Provision for bad debt   13    - 
Gain on sales of equipment   (717)   - 
Loss on disposition of Tantaline   -    162 
Impairment charge   -    111 
Changes in operating assets and liabilities, net of effects of disposition of Tantaline and sales of equipment:          
Accounts receivable   (256)   1,841 
Contract assets   (622)   566 
Inventories   646    (2,308)
Employee retention credit receivable   -    1,529 
Other assets   (150)   (47)
Accounts payable   (524)   (154)
Accrued expenses   472    (679)
Contract liabilities   (1,773)   866 
Net cash used in operating activities   (1,489)   (206)
           
Cash flows from investing activities:          
Purchase of property and equipment   (106)   (418)
Net proceeds from sales of equipment   250    597 
Net cash used in disposition of Tantaline   -    (312)
Net cash provided by (used in) investing activities   144    (133)
           
Cash flows from financing activities:          
Payments of long-term debt   (82)   (77)
Proceeds from exercise of stock options   -    76 
Net cash used in financing activities   (82)   (1)
           
Net decrease in cash and cash equivalents   (1,427)   (340)
           
Cash and cash equivalents at beginning of year   14,025    14,365 
           
Cash and cash equivalents at end of year  $12,598   $14,025 
           
Supplemental disclosure of cash flow information:          
Income taxes paid  $3   $8 
Interest paid  $19   $24 
Inventory transferred to property, plant and equipment  $110   $- 

 

The accompanying notes are an integral part of the consolidated financial statements

 

F-6

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 1 – Business Description

 

CVD Equipment Corporation and its subsidiaries (the “Company”) is a New York corporation. Its principal business activities include designing, developing, and manufacturing a broad range of chemical vapor deposition, physical vapor transport, gas control, and other equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research. The Company’s products are used in production environments as well as research and development centers, both academic and corporate.

 

Note 2 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Liquidity

 

At December 31, 2024, the Company had $12.6 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of these financial statements.

 

Reclassifications

 

In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net loss.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.

 

F-7

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Revenue Recognition

 

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606”), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.

 

Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to

 

evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the year ended December 31, 2024 and 2023.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

F-8

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because the Company believes these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide the Company with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the years ended December 31, 2024 and 2023, all system equipment sales were recorded over time by using an input method except for a) one contract that was recorded as revenue at the point in time the equipment was transferred to the customer during 2024 and b) one contract that was entered during 2024 and will be recognized as revenue after December 31, 2024 upon transfer of the equipment to the customer.

 

F-9

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Inventories

 

Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.

 

Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.

 

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

 

Income Taxes

 

Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.

 

F-10

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes potential interest and penalties related to uncertain tax positions in income tax expense.

 

The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.

 

Impairment of Long-Lived Assets and Intangibles

 

Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists. If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over 5 to 39 years and for machinery and equipment over 5 to 8 years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.

 

Research and Development

 

Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products.

 

F-11

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Earnings Per Share

 

Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.

 

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

 

Cash and Cash Equivalents

 

The Company had cash and cash equivalents of $12.6 million and $14.0 million at December 31, 2024 and 2023, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $11.9 million and $12.1 million at December 31, 2024 and 2023, respectively.

 

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at December 31, 2024 and 2023 was $0.4 million and $1.5 million, respectively.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.

 

The Company routinely assesses the financial strength of its customers. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.

 

F-12

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Accounts receivable is presented net of an allowance for credit losses of $48,000, $36,000 and $36,000 as of December 31, 2024, 2023 and 2022, respectively. The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for credit losses could be material to our results of operations and financial condition. The provision for bad debt expense was $13,000 and $0 for the years ended December 31, 2024 and 2023, respectively.

 

The Company has accounts receivables from certain customers that exceed 10% of total accounts receivable. As of December 31, 2024, the accounts receivable balance includes amounts from three customers that represented 28.6%, 14.0% and 11.9% of total accounts receivable, and as of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented 37.6%, 13.0% and 12.8% of total accounts receivable.

 

Sales Concentrations

 

Revenue to a single customer in any one year can exceed 10% of our total sales. There was one customer of the CVD Equipment segment in the year ended December 31, 2024 that represented 29.5% of our revenues, while there were three customers of the CVD Equipment segment in the year ended December 31, 2023 that represented 14.3%, 13.5% and 10.9% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.

 

Export sales to customers represented approximately 4.3% and 17.2% of sales years ended December 31, 2024 and 2023 respectively. Export sales in both 2024 and 2023 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.

 

Supplier Risk

 

The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

 

F-13

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Fair Value of Financial Instruments

 

The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates. The value of restricted stock awards are based on the fair value on the date of the grant.

 

Shipping and Handling

 

It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $73,000 and $55,000 for the years ended December 31, 2024 and 2023, respectively.

 

Recently Adopted Accounting Standards

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This update is effective for our annual report for fiscal year 2024, and interim periods thereafter, and was applied retrospectively to the fiscal year 2024 financial statements.. The Company adopted ASU 2023-07 in 2024 and the required disclosures are included in Note 13.

 

Recently Issued Accounting Standards

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. The amendments further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This ASU is effective for our annual report for fiscal year 2026, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the timing of adoption and impact of this ASU on our consolidated financial statements.

 

F-14

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statements Expenses (Subtopic 220-40),” to improve income statement expenses disclosure. The standard requires more detailed information related to the types of expenses, including (among other items) the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included within each interim and annual income statement’s expense caption, as applicable. This authoritative guidance can be applied prospectively or retrospectively and will be effective for financial statements issued for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

 

Note 3 – Revenue

 

The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2024 and 2023 (in thousands):

 

   Over time   Point in time   Total 
   Year Ended December 31, 2024 
   Over time   Point in time   Total 
Energy  $216   $511   $727 
Aerospace   11,205    1,879    13,084 
Industrial   6,921    1,350    8,271 
Research   3,736    1,058    4,794 
Total  $22,216   $4,660   $26,876 

 

   Over time   Point in time   Total 
   Year Ended December 31, 2023 
   Over time   Point in time   Total 
Energy  $4,901   $189   $5,090 
Aerospace   3,427    1,469    4,896 
Industrial   6,123    2,821    8,944 
Research   3,700    1,479    5,179 
Total  $18,151   $5,958   $24,109 

 

F-15

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 3 – Revenue (continued)

 

The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. Research market principally represents customers that are universities and other research institutions.

 

The Company has unrecognized contract revenue of approximately $16.4 million at December 31, 2024, which it expects to substantially recognize as revenue within the next twelve months based on over time revenue recognition.

 

Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine the Company’s progress towards contract completion and to calculate the corresponding amount of revenue to recognize.

 

Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated financial position and results of operations.

 

Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):

 

   2024   2023 
Costs incurred on contracts in progress  $14,696   $9,500 
Estimated earnings   7,052    5,083 
Costs and estimated earnings on uncompleted contracts   21,748    14,583 
Billings to date   (22,059)   (17,553)
Net cost in excess of billings   (311)   (2,970)
Deferred revenue related to non-systems contracts   (598)   (334)
Contract liability in excess of contract assets  $(909)  $(3,304)
Included in accompanying consolidated balance sheets under the following captions (in thousands):          
           
Contract assets  $2,226   $1,604 
Contract liabilities  $3,135   $4,908 

 

Of the contract liability balances at December 31, 2023 and December 31, 2022, $4.7 million and $3.7 million was recognized as revenue during the years ended December 31, 2024 and 2023, respectively. Contract assets and contract liabilities at December 31, 2022 were $2.2 million and $4.0 million, respectively.

 

F-16

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 4 - Inventories

 

Inventories as of December 31 consist of (in thousands):

 

   2024   2023 
         
Raw materials  $1,217   $2,351 
Work-in-process   765    1,248 
Finished goods   133    855 
Total  $2,115   $4,454 

 

Included in inventories are finished goods and raw materials related to PVT 150 systems that were purchased and built, respectively, in anticipation of future orders. During the year ended December 31, 2024, the Company recorded a non-cash charge to reduce the net realizable value of such inventory by approximately $1.3 million based on its assessment of the current market for silicon carbide equipment.

 

As of December 31, 2024, the net amount of PVT 150 systems inventory is approximately $0.5 million. If future PVT 150 orders do not materialize and if the Company is not otherwise able to sell this inventory, the Company could incur additional charges to further reduce the carrying value of such inventory to net realizable value. Such charges may be material to the Company’s financial position and future results of operations.

 

Note 5 – Property, Plant and Equipment

 

Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):

 

   2024   2023 
         
Land  $2,220   $2,220 
Buildings and improvements   12,897    12,798 
Machinery and equipment   7,178    7,536 
Construction in progress   17    167 
Totals at cost   22,312    22,721 
           
Less: accumulated depreciation   (10,613)   (10,555)
Property, plant and equipment, net  $11,699   $12,166 

 

Machinery and equipment also include furniture and fixtures and software.

 

Depreciation expense was $0.7 million and $0.8 million for the years ended December 31, 2024 and 2023, respectively.

 

F-17

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 5 – Property, Plant and Equipment (continued)

 

The Company entered into an agreement with the Town of Islip Industrial Development Agency (Islip IDA) in July 2021 under which the Company was granted tax incentives whereby the Company agreed to make payments in lieu of all real estate taxes and assessments (PILOT payments). The agreement requires the Company to maintain certain employment levels at its Central Islip, New York facility. The agreement provides for the Islip IDA to recapture tax incentives provided to the Company in certain circumstances. Any recapture of such tax benefits could have a material adverse effect on the Company’s financial position and future results of operations and cash flows.

 

Note 6 – Accrued Expenses

 

Accrued expenses consist of the following as of December 31 (in thousands):

 

   2024   2023 
         
Accrued wages and benefits  $395   $358 
Accrued vacation   683    729 
Accrued material purchases   618    289 
Other   540    389 
Total accrued expenses  $2,236   $1,765 

 

Note 7 – Long-term Debt

 

Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):

 

   2024   2023 
Equipment loan payable in monthly repayments of $8 including interest at 6% per annum  $268   $349 
Less: current maturities   87    81 
Long-term debt, net of current maturities  $181   $268 

 

In September 2022, the Company entered into a loan agreement to fund the acquisition of equipment in the amount of $0.4 million.

 

F-18

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 7 – Long-term Debt (continued)

 

Future maturities of long-term debt as of December 31, 2024 are as follows (in thousands):

 

      
2024  $87 
2025   92 
2026   89 
      
Total  $268 

 

Note 8 – Earnings per Share

 

The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):

 

   2024   2023 
         
Basic weighted average shares outstanding   6,823    6,788 
Effect of potentially dilutive share-based awards   -    - 
           
Diluted weighted average shares outstanding   6,823    6,788 

 

At December 31, 2024 and 2023, all stock options and unvested restricted stock were not included in the computation of diluted earnings per share because their effect was antidilutive.

 

Note 9 – Income Taxes

 

Loss before income taxes are as follows:

 

   2024   2023 
         
Domestic  $(1,874)   (4,073)
Foreign   -    (121)
Total  $(1,874)  $(4,194)

 

F-19

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 9 – Income Taxes (continued)

 

The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):

 

   2024   2023 
Current:        
Federal  $14   $(16)
State   10    2 
Total current tax provision   24    (14)
Deferred:          
Federal   -    - 
State   -    - 
Total deferred tax provision   -    - 
Income tax expense (benefit)  $24   $(14)

 

The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):

 

   2024   2023 
Expected provision at federal statutory tax rate at 21%  $(395)  $(881)
Increase in valuation allowance   447    688 
State and local taxes   (197)   21 
Federal research and development credits   -    (75)
Non-deductible expenses   86    37 
Disposition of Tantaline   -    193 
Other   83    3 
Income tax expense (benefit)  $24   $(14)

 

F-20

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 9 – Income Taxes (continued)

 

The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):

 

   2024   2023 
Deferred income tax assets:          
Net operating loss carryforwards  $679   $849 
R&D tax credit carryforwards   1,722    1,863 
Compensation costs   235    113 
Vacation accrual   118    153 
Intangible assets   38    38 
Capitalized research and development   1,096    759 
Other items   676    303 
Deferred income tax assets   4,564    4,078 
Less: valuation allowance   (4,098)   (3,646)
Deferred income tax assets, net of valuation allowance   466    432 
Deferred incomes tax liability:          
Property, plant and equipment   (384)   (365)
Prepaid expenses   (82)   (67)
Deferred income tax asset, net  $-   $- 

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that the deferred tax assets will be realized. The ultimate realization of deferred tax assets is based on the assessment of available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit the utilization of existing deferred tax assets. The Company considered all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the prior three-year period ended December 31, 2024. Such objective evidence limits the ability to consider subjective evidence such as our projections for future growth. Based on this assessment, we maintained a full valuation allowance against our net deferred tax assets as of December 31, 2024, and 2023. If these estimates and assumptions change in the future, we may be required to reduce our existing valuation allowance resulting in less income tax expense.

 

For the year ended December 31, 2024, the valuation allowance increased by approximately $0.5 million from the prior year primarily the result of capitalized research and development costs.

 

F-21

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 9 – Income Taxes (continued)

 

At December 31, 2024, the Company had $2.7 million of U.S. federal net operating loss carryforwards. These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income. The Company also has $1.7 million of federal research and development tax credits which expire in varying amounts in tax years 2028 through 2042.

 

The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2024 and 2023, the Company had no uncertain tax positions. The Company does not expect that its unrecognized tax benefits will significantly increase or decrease within twelve months.

 

The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. The federal tax years open to examination are 2021 to 2024. The Company’s state and local tax years that are open to tax examination are generally 2020 to 2024.

 

The Inflation Reduction Act (“IRA”) and Chips and Science Act (“CHIPS Act”) were both enacted in August 2022. The IRA introduced new provisions including a 15% corporate alternative minimum tax for certain large corporations that have at least an average of $1 billion adjusted financial statement income over a consecutive three-tax-year period and a 1% excise tax surcharge on stock repurchases. The CHIPS Act provides a variety of incentives associated with investments in domestic semiconductor manufacturing and related activities. Both the IRA and CHIPS Act are applicable for tax years beginning after December 31, 2022 and had no impact to the Company’s consolidated financial statements for the years ended December 31, 2024 and 2023.

 

Note 10 – Employee Retention Credit

 

During 2022, the Company conducted an analysis as to whether it was entitled to employee retention credits (“ERC”) under the CARES Act as amended by the Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Plan Act of 2021. Based on the analysis, the Company determined that it was entitled to an ERC of approximately $1.5 million and recognized a receivable of $1.5 million as of December 31, 2022. The Company received the ERC credit in July 2023.

 

F-22

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 11 – Stock-Based Compensation

 

A summary of the Company’s Share Incentive Plans are as follows:

 

2007 Share Incentive Plan

 

On December 12, 2007, shareholders approved the Company’s 2007 Share Incentive Plan (“2017 Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2017 Incentive Plan through December 12, 2017. The Plan expired in December 2017. As of December 31, 2024, there were 120,000 options outstanding under this plan.

 

2016 Share Incentive Plan

 

On December 9, 2016, shareholders approved the Company’s 2016 Share Incentive Plan (“2016 Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2016 Incentive Plan through December 9, 2026. As of December 31, 2024, there were 424,125 options outstanding under this plan.

 

2022 Share Incentive Plan

 

On July 14, 2022, shareholders approved the Company’s 2022 Share Incentive Plan (“2022 Incentive Plan”), in connection therewith, 515,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2022 Incentive Plan through July 14, 2032. As of December 31, 2024, there were 279,000 options outstanding under this plan.

 

Under the 2016 and 2022 Share Incentive Plans, the purchase price of the common stock under each option plan shall be determined by the Committee, provided, however, that such purchase price shall not be less than the fair market value of the shares on the date such option is granted. The stock options generally expire seven to ten years after the date of grant.

 

As of December 31, 2024, there were 44,948 shares available for grant under the 2016 Equity Incentive Plan and 138,180 shares available for grant under the 2022 Equity Incentive Plan.

 

F-23

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 11 – Stock-Based Compensation (continued)

 

The Company recorded stock-based compensation of $1.1 million and $0.9 million for the years ended December 31, 2024 and 2023, respectively, that were included in the following line items in our Consolidated Statements of Operations (in thousands):

 

   2024   2023 
         
Cost of revenue  $152   $120 
Research and development   188    159 
Selling   107    94 
General and administrative   616    535 
           
Total stock-based compensation expense  $1,063   $908 

 

Stock-based compensation expense in both years included approximately $0.2 million related to restricted stock awards pursuant to a Director Compensation plan discussed below. The Company recognizes forfeitures of stock awards as they occur.

 

For the year ended December 31, 2024, the Company granted 5,000 stock options, vesting 25% per year over four years, with a ten-year life. The Company determined the fair value of stock options granted during the year ended December 31, 2024 is based upon weighted average assumptions as provided below.

 

Stock price  $4.75 
Exercise price  $4.75 
Dividend yield   0%
Expected volatility   77%
Risk-free interest rate   4.12%
Expected life (in years)   6.00 

 

The expected life is the number of years the Company estimates that the awards will be outstanding based on the simplified method that considers the vesting period and contractual period of the option. The expected volatility is measured using historical daily price changes of the Company’s common stock over the respective expected term. The Company has 823,125 of outstanding stock options under the three plans at December 31, 2024.

 

F-24

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 11 – Stock-Based Compensation (continued)

 

The following table summarizes stock options awards for the years ended December 31, 2024 and 2023:

 

       Weighted 
  

Awards

(in Shares)

   Average
Exercise Price		 
Outstanding at December 31, 2022   673,000   $11.26 
           
Granted   254,000    14.02 
Expired / cancelled   (44,500)   6.57 
Exercised   (35,625)   4.53 
Outstanding at December 31, 2023   846,875    8.20 
Granted   5,000    4.75 
Expired / cancelled   (28,750)   7.94 
Exercised   -    - 
Outstanding at December 31, 2024   823,125    8.24 

 

At December 31, 2024 and 2023, stock options to purchase 485,000 and 265,000, respectively, shares of common stock were exercisable.

 

The following table summarizes information about the outstanding and exercisable options at December 31, 2024:

 

    Options Outstanding   Options Exercisable 
        Weighted   Weighted           Weighted     
        Average   Average           Average     
Exercise   Number   Remaining   Exercise   Intrinsic   Number   Exercise   Intrinsic 
Price Range   Outstanding   Contractual   Price   Value   Exercisable   Price   Value 
$ 4.00-7.00    444,625    6.7   $4.39   $-    285,375   $5.86   $50,580 
$7.01-10.00    20,000    3.3   $8.07   $-    20,000   $8.07   $- 
$10.01-13.00    130,000    2.7   $10.62   $-    122,500   $10.55   $- 
$13.01-16.00    228,500    8.2   $14.11   $-    57,125   $14.11   $- 

 

As of December 31, 2024, there was $1.6 million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of 2.1 years.

 

Restricted Stock Awards

 

Pursuant to the Director Compensation plan approved on October 11, 2021, each of the five independent directors is entitled to compensation for an annual equity retainer in the amount of $40,000 per director, to be automatically granted on the date of the Company’s annual meeting of shareholders.

 

F-25

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 11 – Stock-Based Compensation (continued)

 

The following table summarizes restricted stock awards for the years ended December 31, 2024 and 2023:

 

       Weighted 
       Average Grant 
   Shares of   Date Fair 
   Restricted Stock   Value 
Unvested outstanding at January 1, 2023   -   $- 
Granted   41,320    6.65 
Vested   (24,187)   6.81 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2023   17,133    6.53 
           
Granted   57,327    3.55 
Vested   (46,210)   4.63 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2024   28,250   $3.54 

 

The fair value of the restricted stock awards is recorded as stock-based compensation expense over the one-year vesting period and totaled $0.2 million for the both years ending December 31, 2024 and 2023, respectively.

 

Note 12 – Defined Contribution Plan

 

The Company maintains a 401(k) Plan for the benefit of all eligible employees. All employees as of the effective date of the 401(k) Plan became eligible. An employee is eligible to become a participant after three months of continuous service.

 

Participants may elect to contribute from their compensation any amount up to the maximum deferral allowed by the Internal Revenue Code. Employer contributions are optional.

 

Effective July 1, 2022, the Company implemented a matching contribution of 50% of an employee’s contributions up to 6% of their compensation. The Company recorded compensation expense of $235,000 and $243,000 during the years ended December 31, 2024 and 2023, respectively, for matching contributions to the 401(k) plan.

 

No discretionary employer contribution has been made for 2024 and 2023.

 

F-26

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 13 - Reportable Segments

 

The Company has determined that it has three reportable segments, organized primarily based on product offerings, as follows:

 

●CVD Equipment – manufactures chemical vapor deposition, physical vapor transport and thermal process equipment.

 

●SDC - manufactures ultra-high purity gas and chemical delivery control systems.

 

●MesoScribe - provided electronic printing services and products (heaters, antennas, and sensors).

 

Both CVD Equipment and SDC also sell spares and parts and provide services related to the equipment each segment sells. One other business, Tantaline, did not meet the quantitative threshold for separate reporting and has been reflected as “Other” below.

 

The chief operating decision maker (“CODM”) of the Company is the Company’s chief executive officer. The CODM assesses performance and decides how to allocate resources, including employees, financial or capital resources, based on segment net income (loss). The CODM considers actual-to-actual variances on a quarterly basis when making decisions about allocating capital and other resources to the segments and to assess the performance for each segment.

 

Financial results for the reportable segments and other business are prepared on a basis consistent with the internal disaggregation of financial information to assist the CODM is making internal operating decisions.

 

Certain income and expenses are excluded from segment net income (loss) and included in the unallocated amounts in the reconciliation of reportable segment net income (loss) to net loss. These items are not used by the CODM in allocating resources or evaluating the results of the segments and include the following: corporate expenses consisting of employment costs of executives, finance, information technology and human resources; board of director fees; professional fees; shareholder and investor relations expense; directors’ and officers’ insurance; interest income and income tax expense. Segment income (loss) from operations may not be consistent with measures used by other companies.

 

F-27

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 13 - Reportable Segments (continued)

 

The following provides segment information as described below (in thousands):

 

   CVD   SDC   MesoScribe   Total 
   For the year ended December 31, 2024 
   CVD   SDC   MesoScribe   Total 
Segment revenue  $18,288   $8,444   $778   $27,510 
Less:                    
Cost of revenue   16,158    4,749    272    21,179 
Research & development   2,398    229    -    2,627 
Selling   1,456    195    5    1,656 
General & administrative   1,064    709    84    1,857 
Gain on sales of equipment   (42)   -    (675)   (717)
Other income   (2)   -    -    (2)
Interest expense   19    -    -    19 
Segment net income (loss)  $(2,763)  $2,562   $1,092   $891 
Segment assets  $15,903   $3,129   $627   $19,659 
Capital expenditures  $69   $37   $-   $106 
Depreciation & amortization  $635   $49   $-   $684 

 

   CVD   SDC   MesoScribe   Total 
   For the year ended December 31, 2023 
   CVD   SDC   MesoScribe   Total 
Segment revenue  $16,334   $7,139   $722   $24,195 
Less:                    
Cost of revenue   14,408    4,313    507    19,228 
Research & development   2,288    299    5    2,592 
Selling   1,414    172    -    1,586 
General & administrative   1,085    679    70    1,834 
Impairment charge   -    -    111    111 
Other income   (86)   -    -    (86)
Interest expense   23    -    -    23 
Segment net income (loss)  $(2,798)  $1,676   $29   $(1,093)
Segment assets  $19,112   $3,468   $211   $22,791 
Capital expenditures  $404   $14   $-   $418 
Depreciation & amortization  $620   $49   $59   $728 

 

F-28

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 13 - Reportable Segments (continued)

 

The following table presents a reconciliation of revenue of reportable segments to consolidated revenue (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Revenue of reportable segments  $27,510   $24,195 
Other - Tantaline   -    462 
Intersegment revenue   (634)   (548)
Consolidated total revenue  $26,876   $24,109 

 

Intersegment revenues are determined based on similar product sales to external customers of the Company.

 

The following table presents a reconciliation of net income (loss) of reportable segments to consolidated net loss (in thousand):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Net income (loss) of reportable segments  $891   $(1,093)
Unallocated amounts:          
Corporate expenses   (3,324)   (3,503)
Other - Tantaline   -    (175)
Interest income   559    577 
Income tax (expense) benefit   (24)   14 
Consolidated net loss  $(1,898)  $(4,180)

 

The following table presents a reconciliation of total assets of reportable segments to consolidated total assets (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Total assets of reportable segments  $19,659   $22,791 
Unallocated amounts:          
Cash equivalents   11,892    12,099 
Other current assets   135    135 
Consolidated total assets  $31,686   $35,025 

 

F-29

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 13 - Reportable Segments (continued)

 

The following table presents a revenue by geographic area (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
United States  $25,720   $19,975 
North America, excluding US   65    56 
Europe, Middle East and Africa   521    1,508 
Asia-Pacific   570    2,570 
Consolidated total revenue  $26,876   $24,109 

 

For geographic reporting, revenues are attributed to the location in which in the customer facility is located. All of the Company’s long-lived assets are located in the United States.

 

Note 14 – MesoScribe and Tantaline

 

MesoScribe

 

On August 8, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with a third-party. Pursuant to the Agreement, the Company sold certain proprietary equipment relating to its plasma spray technology and material deposition system and granted a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate adjusted purchase price of $0.8 million. The purchase price was payable in several installments and contingent upon certain performance metrics and other milestones.

 

The Company received payments under the Agreement in the amount of $0.6 million which had been reflected as “deposits from purchaser” in the accompanying consolidated balance sheet as of December 31, 2023.

 

The Company fulfilled remaining orders for MesoScribe products during 2024 at which time it ceased operations of MesoScribe and recorded a $0.7 million gain upon the completion of the sale of the equipment during the year ended December 31, 2024. During the year ended December 31, 2023, the Company recorded an impairment charge of $0.1 million for other equipment of MesoScribe.

 

The revenues and net income of MesoScribe were $0.8 million and $1.1 million for the year ended December 31, 2024, including the gain on sale of equipment of $0.7 million.

 

The revenues and net income of MesoScribe were $0.7 million and $33,000 for the year ended December 31, 2023, including the impairment charge of $0.1 million.

 

F-30

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 14 – MesoScribe and Tantaline (continued)

 

The total assets and total liabilities of the MesoScribe subsidiary were $0.6 million and $0, respectively, as of December 31, 2024 and $0.2 million and $0.7 million, respectively, as of December 31, 2023.

 

Tantaline

 

On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $0.2 million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt. The Company received a $6,000 earn-out payment in 2024 based on the results of Tantaline’s operations for the year ended December 31, 2023.

 

Including the loss on disposition of $0.2 million, the revenues and net income of Tantaline were $0.5 million and $0.1 million, respectively, for the year ended December 31, 2023.

 

Note 15 – Risks and Uncertainties

 

The Company currently operates in a challenging economic environment as the global economy continues to confront the remaining impacts from the pandemic, geopolitical conflicts, inflationary pressures, and adverse supply chain disruptions. The specific impacts on the Company have included:

 

●Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions.

 

●Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue timelier as it delays the Company’s manufacturing processes.

 

While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties may have on its future results of operations and cash flows.

 

F-31

 

 EX-3.1 2 ex3-1.htm

 

Exhibit 3.1

 

CERTIFICATE OF INCORPORATION

 

OF

 

CVD EQUIPMENT CORP.

 

Under Section 402 of the Business Corporation Law

 

The undersigned, a natural person of the age of eighteen years or over, desiring to form a corporation pursuant to the provisions of the Business Corporation Law of the State of New York, hereby certifies as follows:

 

FIRST: The name of the corporation is

 

CVD EQUIPMENT CORP.

 

hereinafter sometimes called “the corporation.”

 

SECOND: The purposes for which it is formed are as follows:

 

To manufacture, buy, sell, act as manufacturers representatives for, trade and generally deal in and with, at wholesale or retail, import and export equipment of all types and descriptions.

 

To purchase, receive, lease, or otherwise acquire and to manage, hold, own, use, improve, convey, sell, mortgage, or otherwise deal in and with lands, buildings and real property of every description, or any interest therein.

 

To adopt, apply for, obtain, register, purchase, lease or otherwise acquire and to maintain, protect, hold, use, own, exercise, develop, manufacture under, operate and introduce, and to sell and grant licenses or other rights in respect of assign or otherwise dispose of, turn to account, or in any manner deal with and contract with reference to, any trade marks, trade names,, patents, patent rights, concessions, franchises, designs, copyrights and distinctive marks and rights analogous thereto, and inventions, devices, improvements, processes, recipes, formulae and the like, including such thereof as may be covered by, used in connection with, or secured or received under, Letters Patent of the United States of America or elsewhere or otherwise, and any licenses in respect thereof and any or all rights connected therewith or appertaining thereto.

 

In furtherance of its corporate business and subject to the limitations prescribed by statute, to be a promoter, partner, member, associates or manager of other business enterprises or ventures, or to the extent permitted in any other jurisdiction to be an incorporator of other corporations of any type or kind and to organize, or in any way participate in the organization, reorganization, merger or liquidation of any corporation, association or venture and the management thereof.

 

 
 

 

To conduct its business, and to exercise all of its corporate powers and rights, in the State of New York, and in the various other states, territories, possessions and dependencies of the United States, the District of Columbia, and in any foreign countries.

 

To carry out all or any part of the foregoing purposes as principal, factor, agent, broker, contractor or otherwise, either alone or in conjunction with any persons, firms, associations, corporations, or others in any part of the world; and in carrying on its business and for the purpose of attaining or furthering any of its purposes, to make and perform contracts of any kind and description, and to do any-thing and everything necessary, suitable, convenient or proper for the accomplishment of any of the purposes herein enumerated.

 

For the accomplishment of the aforesaid purposes, and in furtherance thereof, the corporation shall have and may exercise all of the powers conferred by the Business Corporation Law upon corporations formed thereunder, subject to any limitations contained in Article 2 of said law or in accordance with the provisions of any other statute of the State of New York.

 

THIRD: The office of the corporation in the State of New York is to be located in the Town of Oyster Bay, County of Nassau.

 

FOURTH: The aggregate number of shares which the corporation shall have the authority to issue is 200, without par value.

 

FIFTH: The Secretary of State is designated as the agent of the corporation upon whom process against the corporation may be served, and the address to which the Secretary of State shall mail a copy of any process against the corporation served upon him is 4 Lucille Lane, Old Bethpage, New York 11804.

 

SIXTH: Shareholders shall not ‘be entitled to preemptive rights, directly or indirectly, in respect of any equity, voting, or other shares of the corporation.

 

SEVENTH: Except as may otherwise be specifically provided in this Certificate of Incorporation, no provision of this Certificate of Incorporation is intended by the corporation to ‘be construed as limiting, prohibiting, denying or abrogating any of the general or specific powers or rights conferred under the Business Corporation Law upon the corporation, upon its shareholders, bondholders, and security holders, and upon its directors, officers, and other corporate personnel, including, in particular, the power of the corporation to furnish indemnification to directors and officers in the capacities defined and prescribed by the Business Corporation Law and the defined and prescribed rights of said persons to indemnification as the same are conferred by the Business Corporation Law.

 

IN WITNESS WHEREOF I hereunto sign my name and affirm that statements made herein are true under the penalties of perjury this 12th day of October 1982.

 

Name & Address   Mary E. Smith    
    284 State Street    
of Incorporator:   Albany, New York 12210   /s/ Mary E. Smith            

 

 

 

 EX-3.2 3 ex3-2.htm

 

Exhibit 3.2

 

CERTIFICATE OF AMENDMENT

OF THE

CERTIFICATE OF INCORPORATION

OF

CVD EQUIPMENT CORP.

Under Section 805 of the

Business Corporation Law

 

We, the undersigned, President and Secretary, respectively, of CVD Equipment Corp., a Corporation organized under the laws of the State of New York, hereby certify that:

 

(1) The name of the Corporation is CVD Equipment Corp.

 

(2) The Certificate of Incorporation was filed by the Department of State on the 13th day of October, 1982.

 

(3) The Certificate of Incorporation of this Corporation is hereby amended to change the location of the Corporation’s office; to change the corporate stock from the presently authorized Two Hundred (200) Shares no par value, of which 99.99 have been issued, to Ten Million (10,000,000) Shares of Common at One Cent ($.01) par value, Five Hundred (500) Shares of Class A Preferred at One Cent ($.0l) par value and Two Hundred Fifty (250) Shares of Class B Preferred at One Cent ($.0l) par value (each presently outstanding no par value Share shall be changed for Fifteen Thousand Shares of One Cent par value Common, Five Shares of Class A Preferred, and Two and One-Half Shares of Class B Preferred); to change the post office address to which the Secretary of State shall mail a copy of any process against the ‘Corporation served upon him; and to change the name of the Corporation to CVD EQUIPMENT CORPORATION.

 

 
 

 

Paragraph “FIRST” of the Certificate of Incorporation of this Corporation, which reads as follows:

 

FIRST: The name of the ‘corporation is CVD Equipment Corp.

 

Is hereby amended to read as follows:

 

FIRST: The name of the Corporation is CVD Equipment Corporation.

 

Paragraph “THIRD” of the Certificate of Incorporation of this Corporation, which read as follows:

 

THIRD: The office of the corporation in the State of New York is to be located in the Town of Oyster Bay, County of Nassau.

 

Is hereby amended to read as follows:

 

THIRD: The office of the Corporation in the State of New York is to be located in the Town of Babylon, County of Suffolk.

 

Paragraph “FOURTH” of the Certificate of Incorporation of this Corporation, which reads as follows:

 

FOURTH: The aggregate number of shares which the corporation shall have authority to issue is 200, without par value.

 

Is hereby amended to read as follows:

 

FOURTH: (a) The Corporation is author-ized to issue three classes of stock to be designated respectively “Common,” “Class A Preferred,” and “Class B Preferred.” The aggregate number of Shares which the Corporation shall have authority to issue is Ten Million Seven Hundred Fifty (10,000,750), which are divided into Ten Million (10,000,000) Shares of Common Stock with a par value of One Cent ($.0l) each, Five Hundred (500) Shares of Class A Preferred Stock with a par value of One Cent ($.0l) each, and Two Hundred Fifty (250) Shares of Class B Preferred Stock with a par value of One Cent ($.0l) each.

 

 
 

 

(b) Class A Preferred Stock shall be entitled to the rights, interests, pref-erences, limitations and restrictions hereinafter set forth:

 

  (1) Each Share of Class A Preferred Stock shall be entitled to One Thousand (1,000) votes on each matter corning before the holders of the Common Stock of the Corporation.
     
  (2) Each Share of Class A Preferred Stock is convertible, at the Option of the holder thereof, into One Thousand (1,000) Shares of the Corporation’s Common Stock if the Corporation’s income before provision for taxes and exclusive of any capital gains or losses and of depreciation of any building to be owned by the Corporation (“Pre-Tax Profit”), as audited by the Corporation’s independent public accountants, is equal to or greater than $1,800,000 for the year ending December 31, 1986 or $3,000,000 for the year ending December 31, 1987. In no event will any Shares of Class A Preferred Stock be convertible subsequent to June 30, 1988.
     
  (3) No dividends may be declared on the Class A Preferred Stock.
     
  (4) In the event of any voluntary or involuntary, complete or partial liquidation, dissolution or winding-up of the Corporation, before any amount shall be paid to or set aside for, or any assets shall be distributed among, the holders of Common Shares of the Corporation, each holder of a Share of Class A Preferred Stock shall be entitled to receive out of the assets of the Corporation or the proceeds thereof a preferential payment in an amount equal to $.01 per Share.
     
  (5) The Corporation will, on July 2, 1990, redeem for One Cent ($.0l) per Share all then outstanding Shares of Class A Preferred Stock. All such Stock which is redeemed shall be cancelled and may not be reissued.

 

 
 

 

(c) Class B Preferred Stock shall be entitled to the rights, interests, preferences, limitations and restrictions hereinafter set forth:

 

  (1) Holders of Class B Preferred Stock shall have no voting rights on any matter, except to the extent required by law.
     
  (2) Each Share of Class B Preferred Stock is convertible, at the option of the holder thereof, into One Thousand (1,000) Shares of the Corporation’s Common Stock if the Corporation’s’ Pre-Tax Profit (as determined in the case of Class A Preferred Stock) is equal to or greater than $1,800,000 for the year ending December 31, 1986 and $3,000,000 for the year ending December31, 1987. In no event will any Shares of Class B Preferred Stock be converted subsequent to June 30, 1988.
     
  (3) No dividends may be declared on the Class B Preferred Stock.
     
  (4) In the event of any voluntary or involuntary complete or partial liquidation, dissolution or winding-up of the Corporation, before any amount shall be paid to or set aside for, or any assets shall be distributed among, the holders of Common Shares ‘of the Corporation, each holder of a share of Class B Preferred Stock shall be entitled to receive out of the assets of the Corporation or the proceeds thereof a preferential payment in an amount equal to $.01 per Share.
     
  (5) The Corporation will, on July 1, 1988, redeem for One Cent ($.01) per Share all then outstanding Shares of Class A Preferred Stock. All such Stock which is redeemed shall be cancelled and may not be reissued.

 

(d) Each of the One Hundred (100) Presently issued and outstanding Shares of no par value Common Stock of the Corporation is hereby changed, effective upon the surrender to the Corporation of the Certificate for such Shares, into Fifteen Thousand (15,000) Shares of One Cent par value Common Stock of the Corporation, Five (5) Shares of One Cent par value Class A Preferred Stock, and Two and One-Half (2 1/2) Shares of One Cent par value Class B Preferred Stock.

 

 
 

 

Paragraph “FIFTH” of the Certificate of Incorporation of this Corporation, which reads as follows:

 

FIFTH: The Secretary of State is designated as the agent of the corporation upon whom process against the corporation maybe served, H and the address to which the Secretary of State shall mail a copy of any process against the corporation served upon him is 4 Lucille Lane, Old Bethpage, New York 11804.

 

Is hereby amended to read as follows:

 

FIFTH: The Secretary of State is designated as the agent of the Corporation upon whom process against the Corporation may be served, and the address to which the Secretary of State shall mail a copy of any process against the Corporation served upon him is do Guberman & Teitelbaum, Esqs., P. 0. Box 514, Smithtown, New York 11787.

 

(4) The amendment to the Certificate of Incorporation was authorized at a meeting of the shareholders by the majority vote of all the outstanding shares entitled to vote, thereon.

 

IN WITNESS WHEREOF, this Certificate has been subscribed this 25th day of April, 1985 by the undersigned who affirm that the statements made herein are true under the penalties of perjury,

 

LEONARD A. ROSENBAUM   President   /s/ LEONARD A. ROSENBAUM         
         
MARY ANN CULLEN   Secretary   /s/ MARY ANN CULLEN                      

 

 

 

 

 

 EX-3.3 4 ex3-3.htm

 

Exhibit 3.3

 

CERTIFICATE OF AMENDMENT

 

OF THE

 

CERTIFICATE OF INCORPORATION

 

OF

 

CVD EQUIPMENT CORPORATION

Under Section 805 of the

 

Business Corporation Law

 

We, the undersigned, President and Secretary, respectively of CVD Equipment Corporation, a Corporation organized under the laws of the State of New York, hereby certify that:

 

(1) The name of the Corporation is CVD Equipment Corporation.

 

(2) The Certificate of Incorporation was filed by the Department of State on the 13th day of October, 1982, and a Certificate of Amendment was filed on July 10, 1985.

 

(3) The Certificate of Incorporation of this Corporation is hereby further amended to change certain of the rights and privileges of the Class A Preferred Stock and Class B Preferred Stock.

 

Paragraph “FOURTH” of the Certificate of Incorporation of this Corporation, which now reads as follows:

 

FOURTH: (a) The Corporation is authorized to three classes of stock to be designated respectively “Common, “Class A Preferred,” and “Class B Preferred.” The aggregate number of Shares, which the Corporation shall have authority to issue is Ten Million Seven Hundred Fifty (10,000,750), which are divided into Ten Million (10,000,000) Shares of Common Stock with a par value of One Cent ($.0l) each, Five Hundred (500) Shares of Class A Preferred Stock with a par value of One Cent ($.0l) each, and Two Hundred Fifty (250) Shares of Class B Preferred Stock with a par value of One Cent ($.0l) each.

 

 
 

 

(b) Class A Preferred Stock shall be entitled to the rights, interests, preferences, limitations and restrictions hereinafter set forth:

 

(1) Each Share of Class A Preferred Stock shall be entitled to One Thousand (1,000) votes on each matter coming before the holders of the Common Stock of the Corporation.

 

(2) Each Share of Class A Preferred Stock is convertible, at the option of the holder thereof, into One Thousand (1,000) Shares of the Corporation’s Common Stock if the Corporation’s income before provision for taxes and exclusive of any capital gains or losses and of depreciation of any building to be owned by the Corporation (“Pre-Tax Profit”), as audited by the Corporation’s independent public accountants, is equal to or greater than $1,800,000 for the year ending December 31, 1986 or $3,000,000 for the year ending December 31, 1987. In no event will any Shares of Class A Preferred Stock be convertible subsequent to June 30, 1988.

 

(3) No dividends may be declared on the Class A Preferred Stock.

 

(4) In the event of any voluntary or involuntary, complete or partial liquidation, dissolution or winding-up of the Corporation, before any amount shall be paid to or set aside for, or any assets shall be distributed among, the holder of Common Shares of the Corporation, each holder of a Share of Class A Preferred Stock shall be entitled to receive out of the assets of the Corporation or proceeds thereof a preferential payment in an amount equal to $.01 per share.

 

(5) The Corporation will, on July 2, 1990, redeem for One Cent ($.0l) per Share all then outstanding Shares of Class A Preferred Stock. All such Stock which is redeemed shall be cancelled and may not be reissued.

 

 
 

 

(c) Class B Preferred Stock shall be entitled to the rights, interests, preferences, limitations and restrictions hereinafter set forth:

 

(1) Holders of Class B Preferred Stock shall have no voting rights on any matter, except to the extent required by law.

 

(2) Each Share of Class B Preferred Stock is convertible, at the option of the holder thereof, into One Thousand (1,000) Shares of the Corporation’s Common Stock if the Corporation’s Pre-Tax Profit (as determined in the case of Class A Preferred Stock) is equal to or greater than $1,800,000 for the year ending December 31, 1986 and $3,000,000 for the year ending December 31, 1987. In no event will any Shares of Class B Preferred Stock be converted subsequent to June 30, 1988.

 

(3) No dividends may be declared on the Class B Preferred Stock.

 

(4) In the event of any voluntary or involuntary, complete or partial liquidation, dissolution or winding-up of the Corporation, before any amount shall be paid to or set aside for, or any assets shall be distributed among, the holders of Common Shares of the Corporation, each holder of a share of Class B Preferred Stock shall be entitled to receive out of the assets of the Corporation or the proceeds thereof a preferential payment in an amount equal to $.0l per Share.

 

(5) The Corporation will, on July 1, 1988, redeem for One Cent ($.0l) per Share all then outstanding Shares of Class A Preferred Stock. All such Stock which is redeemed shall be cancelled and may not: be reissued.

 

(d) Each of the One Hundred (100) presently issued and Outstanding Shares of no par value Common Stock of the Corporation is hereby changed, effective upon the surrender to the Corporation of the Certificate for such Shares, into Fifteen Thousand (15,000) Shares of One Cent par value Common Stock of the Corporation, Five (5) Shares of One Cent par value Class A Preferred Stock, and Two and One-Half (21/2) Shares of One Cent par value Class B Preferred Stock.

 

Is hereby amended to read as follows:

 

FOURTH: (a) The Corporation is authorized to issue three classes of stock to be designated respectively “Common,” “Class A Preferred,” and “Class B Preferred.” The aggregate number of Shares which the Corporation shall have authority to issue is Ten Million Seven Hundred Fifty (10,000,750), which are divided into Ten Million (10,000,000) Shares of Common Stock with a par value of One Cent ($.0l) each, Five Hundred (500) Shares of Class A Preferred Stock with a par value of One Cent ($.0l) each, and Two Hundred Fifty (250) Shares of Class B Preferred Stock with a par value of One Cent ($.0l) each.

 

 
 

 

(b) Class A Preferred Stock shall be entitled to the rights, interests, preferences, limitations and restrictions hereinafter set forth.

 

(1) Each Share of Class A Preferred Stock shall be entitled to Three Thousand (3,000) votes on each matter coming before the holders of the Common Stock of the Corporation.

 

(2) Each Share of Class A Preferred Stock is convertible, at the option of the holder thereof, into One Thousand (1,000) Shares of the Corporation’s Common Stock if the Corporation’s income before provision for taxes and exclusive of any capital gains or losses and of depreciation of any building to be owned by the Corporation (“Pre-Tax Profit”), as audited by the Corporation’s independent public accountants, is equal to or greater than $1,500,000 for the year ending December 31, 1986 or $3,000,000 for the year ending December 31, 1987. In no event will any Shares of Class A Preferred Stock be convertible subsequent to June 30, 1988.

 

(3) No dividends may be declared on the Class A Preferred Stock.

 

(4) In the event of any voluntary or involuntary complete or partial liquidation, dissolution or winding-up of the Corporation, before any amount shall be paid to or set aside for, or any assets shall be distributed among, the holders of Common Shares of the Corporation, each holder of a Share of Class A Preferred Stock shall be entitled to receive out of the assets of the Corporation or the proceeds thereof a preferential payment in an amount equal to $.0l per Share.

 

(5) The Corporation will, on July 2, 1990, redeem for One Cent ($.01) per Share all then outstanding Shares of Class A Preferred Stock. All such Stock which is redeemed shall be cancelled and may not be reissued.

 

(c) Class B Preferred Stock shall be entitled to the rights, interests, preferences, limitations and restrictions hereinafter set forth:

 

(1) Holders of Class B Preferred Stock shall have no voting rights on any matter, except to the extent required by law.

 

(2) Each Share of Class B Preferred Stock is convertible at the Option of the holder thereof, into One Thousand (1,000) Shares of the Corporation’s Common Stock if the Corporation’s Pre-Tax Profit (as determined in the case of Class A Preferred Stock) is equal to or greater than $1,500,000 for the year ending December 31, 1986 and $3,000,000 for the year ending December 31, 1987. In no event will any Shares of Class B Preferred Stock be converted subsequent to June 30, 1988.

 

 
 

 

(3) No dividends may be declared on the Class B Preferred Stock.

 

(4) In the event of any voluntary or involuntary, complete or partial liquidation, dissolution or winding-up of the Corporation, before any amount shall be paid to or set aside for, or any assets shall be distributed among, the holders of Common Shares of the Corporation, each holder of a share of Class B Preferred Stock shall be entitled to receive out of the assets of the Corporation or the proceeds thereof a preferential payment in the amount equal to $.0l per Share.

 

(5) The Corporation will, on July 1, 1988, redeem for One Cent ($.0l) per Share all then outstanding Shares of Class B Preferred Stock. All such Stock which is redeemed shall be cancelled any may not be reissued.

 

(d) Each of the One Hundred (100) presently issued and outstanding Shares of no par value Common Stock of the Corporation is hereby changed, effective upon the surrender to the Corporation of the Certificate for such Shares, into Fifteen Thousand (15,000) Shares of One Cent par value Common Stock of the Corporation, Five (5) Shares of One Cent par value Class A Preferred Stock, and Two and One-Half (21/2) Shares of One Cent par value Class B Preferred Stock.

 

(4) The amendment to the Certificate of Incorporation was authorized at a meeting of the Shareholders by the majority vote of all the outstanding shares entitled to vote thereon.

 

IN WITNESS WHEREOF, this Certificate has been subscribed this 12th day of August, 1985 by the undersigned who affirm that the statements made herein are true under the penalties of perjury.

 

LEONARD A. ROSENBAUM   President   /s/ LEONARD A. ROSENBAUM         
         
MARY ANN CULLEN   Secretary   /s/ MARY ANN CULLEN                      

 

 

 

 EX-3.4 5 ex3-4.htm

 

Exhibit 3.4

 

CERTIFICATE OF AMENDMENT

 

OF THE

 

CERTIFICATE OF INCORPORATION

 

OF

 

CVD EQUIPMENT CORPORATION

 

Under Section 805 of the

 

Business Corporation Law

 

We, the undersigned, President and Secretary, respectively, of CVD Equipment Corporation, a Corporation organized under the laws of the State of New York, hereby certify that:

 

(1) The name of the Corporation is CVD Equipment Corporation.

 

(2) The Certificate of Incorporation was filed by the Department of State on the 13th day of October, 1982, Certificates of Amendment were filed on July 10, 1985 and August 22, 1985.

 

(3) The Certificate of Incorporation of this Corporation is hereby further amended to limit Directors’ Liability by the addition of a new paragraph, hereby designated as paragraph “EIGHTEENTH”, which shall read as follows:

 

“EIGHTEENTH: The personal liability for Directors to the Corporation or its Shareholders for damages for any breach of duty in such capacity is hereby eliminated except that such personal liability shall not be eliminated if a Judgment or other final adjudication adverse to such Director establishes that his acts or omissions were in bad faith or involved intentional misconduct or a knowing violation of law or he personally gained in fact a financial profit or other advantage to which he was not legally entitled or that his acts violated Section 719 of the Business Corporation Law.

 

Any repeal or modification of the foregoing paragraph by the Shareholders of the Corporation shall not adversely affect any right or protection of a Director of the Corporation existing at the time of such repeal or modification.”

 

  (4) This amendment to the Certificate of Incorporation was authorized on the 15th day of June, 1989, at a meeting of the Shareholders by the majority vote of all of the outstanding shares entitled to vote thereon.

 

IN WITNESS WHEREOF, this Certificate has been subscribed as of the 30th day of June, 1989 by the undersigned who affirm that the statements made herein are true under the penalties of perjury.

 

LEONARD A. ROSENBAUM   President   /s/ LEONARD A. ROSENBAUM         
         
MICHAEL LEITER   Secretary   /s/ MICHAEL LEITER                            

  

 

 

 

 EX-19 6 ex19.htm

 

Exhibit 19

 

Policy For the Prevention of

Insider Trading of

CVD Equipment Corporation

 

 

 

In the course of conducting the business of CVD Equipment Corporation, a New York corporation and its subsidiaries (collectively “CVD”), whether as a director, principal, officer, senior executive or employee of CVD, you may come into possession of material information about CVD or other entities that is not available to the investing public (herein referred to as “material, non-public information”). You must maintain the confidentiality of material, non-public information and may not use it in connection with the purchase or sale of securities of CVD or any other entity to which the information relates. CVD has adopted this policy in order to ensure compliance with the law and to avoid even the appearance of improper conduct by anyone associated with CVD. We all work hard to maintain CVD’s reputation for integrity and ethical conduct and are all responsible for preserving and enhancing this reputation.

 

Policy and Procedure Summary

 

As summarized below, no employee of CVD may buy or sell CVD securities while aware of material non-public information. In addition, all Covered Persons, as defined below, must obtain clearance from CVD’s Chief Financial Officer (or, in the absence, from CVD’s Chief Executive Officer) prior to initiating any purchases or sales of CVD securities.

 

Inside Information

 

CVD’s policies and the laws of the United States prohibit any director, principal, officer or employee of CVD, whenever and in whatever capacity employed, from buying or selling securities (including equity securities, convertible securities, options, bonds, and derivatives thereon) of CVD while in possession of “inside information” about CVD. Inside information is any material, non-public information about a company.

 

If you become aware of any inside information concerning CVD, you may not purchase or sell any securities of CVD and should treat the information as strictly confidential. This prohibition applies to securities of CVD, as well as the securities of any other company about which you acquire inside information in the course of your duties for CVD. You are responsible for reviewing this policy and ensuring that your actions do not violate it.

 

Material, Non-Public Information

 

As noted above, it is illegal and a violation of this policy to purchase or sell CVD securities while aware of material, non-public information.

 

Material Information

 

Under this policy and U.S. law, information is material if:

 

●there is a substantial likelihood that a reasonable investor would consider the information important in determining whether to trade in a security; or
●the information, if made public, likely would affect the market price of a company’s securities.

 

Information may be material even if it relates to future, speculative or contingent events and even if it is significant only when considered in combination with publicly available information.

 

Non-public information can be material even with respect to companies that do not have publicly-traded stock, such as those with outstanding bonds or bank loans.

 

1

 

 

Depending on the facts and circumstances, information that could be considered material includes but is not limited to:

 

●earnings announcements or estimates;
●changes to previously released earnings information;
●significant dividend increases or decreases;
●expansion or curtailment of operations;
●potential contracts and/or investments by CVD;
●new products, inventions or discoveries;
●major litigation;
●possible acquisitions, divestitures or joint ventures;
●changes in research recommendations or debt ratings;
●restructurings and recapitalizations;
●unannounced government actions with respect to an issuer of securities;
●anticipated public offerings of securities;
●extraordinary management developments;
●extraordinary borrowing;
●liquidity problems; and
●write-downs and additions to reserves for bad debts.

 

Non-Public Information

 

Information is considered to be non-public unless it has been adequately disclosed to the public, which means that the information must be publicly disseminated and sufficient time must have passed for the securities markets to digest the information.

 

It is important to note that information is not necessarily public merely because it has been discussed in the press, which will sometimes report rumors. You should presume that information is non-public unless you can point to its official release by CVD in at least one of the following ways:

 

●public filings with securities regulatory authorities, including the disclosure of the information in a Form 10-Q, Form 10-K, Form 8-K, proxy statement or prospectus;
●issuance of press releases;
●disclosure of the information in the financial media; or
●meetings with members of the press and the public.

 

You may not attempt to “beat the market” by trading simultaneously with, or shortly after, the official release of material information. Although there is no fixed period for how long it takes the market to absorb information, out of prudence, a person aware of material, non-public information should refrain from purchasing or selling CVD securities for approximately two full business days following its official release; shorter or longer waiting periods might be warranted based upon the liquidity of the security and the nature of the information.

 

Notwithstanding these timing guidelines, it is illegal for you to buy or sell securities while in possession of material, non-public information, including situations in which you are aware of major developments that have not yet been publicly announced by the issuer of the securities.

 

“Tipping” Material, Non-Public Information Is Prohibited

 

In addition to buying or selling securities while in possession of material, non-public information, it is illegal and a violation of this policy to convey such information to another person (herein referred to as “tipping”) if you know or have reason to believe that the person will misuse such information by trading in securities or passing such information to others. This applies regardless of whether the “tippee” is related to the insider or is an entity, such as a trust or a corporation, and regardless of whether you receive any benefit, monetary or otherwise, from the tippee.

 

2

 

 

Trading on or conveying material, non-public information may also breach contractual obligations assumed by CVD. Apart from contractual remedies (such as damages and injunctions), severe, and possibly irreparable, reputation damage to CVD can result from buying or selling based on material, non-public information, tipping or any other improper use of material, non-public information.

 

Scope of Policy

 

The restrictions set forth in this policy, except as noted, apply to all directors, principals, officers, senior management and employees of CVD and to their spouses, minor children, adult family members sharing the same household and any other person over whom the director, principal, officer or employee exercises substantial control over his, her or its securities trading decisions. This policy also applies to any trust or other estate in which an employee has a substantial beneficial interest or as to which he or she serves as trustee or in a similar fiduciary capacity.

 

Certain of the restrictions set forth in this policy, apply only to all directors and officers of CVD, certain employees of CVD and to their spouses, minor children, adult family members sharing the same household and any other person over whom the director, officer or employee exercises substantial control over his, her or its securities trading decisions (the “Covered Persons”). This policy also applies to any trust or other estate in which a Covered Person has a substantial beneficial interest or as to which he or she serves as trustee or in a similar fiduciary capacity. A listing of “Covered Persons” is maintained by CVD’s Chief Financial Officer.

 

Trading Periods – Covered Persons Only

 

Subject to the Pre-Clearance Policy described below, Covered Persons who are not otherwise in possession of undisclosed material information may only purchase or sell securities of CVD during the period:

 

●commencing on the close of business of the second business day after the public release of quarterly financial information with respect to the preceding fiscal quarter and ending seven days before the end of the next fiscal quarter; or
   
●commencing on the close of business of the second business day after the public release of year-end financial information and ending seven days before the end of the first fiscal quarter following such year-end.

 

Blackout Periods – All Employees

 

From time to time, an event may occur in the Trading Periods described above that is material to CVD and is known by only a few directors or executive officers of CVD. So long as the event remains material and non-public, Covered Persons and any persons designated by CVD’s Chief Financial Officer may not buy or sell the securities of CVD even if knowledge of such event occurs during the window described above. The existence of an event-specific blackout will not be announced, other than to those who are aware of the event giving rise to the blackout. Any person made aware of the existence of an event-specific blackout should not disclose the existence of the blackout to any other person. The failure of CVD’s Chief Financial Officer to designate a person as being subject to an event-specific blackout will not relieve that person of the obligation not to buy or sell while aware of material, non-public information.

 

Pre-Clearance Policy – Covered Persons Only

 

Covered Persons who are not otherwise in possession of undisclosed material information and wish to buy or sell securities of CVD during the Trading Periods described above, must obtain prior clearance from CVD’s Chief Financial Officer, before he or she trades in CVD’s securities. Each proposed transaction will be evaluated to determine if it raises insider trading concerns or other concerns under the federal or state securities laws, rules and regulations. Any advice will relate solely to the restraints imposed by law and will not constitute advice regarding the merits of the investment aspects of any transaction. Clearance of a transaction is valid only for a 48-hour period. If a transaction order is not placed within the 48-hour period, the person who requested the clearance must re-submit the request for clearance. If clearance is denied, the fact of such denial must be kept confidential by the person requesting the clearance.

 

3

 

 

Safeguarding Confidential Information

 

If material information relating to CVD or its business has not been disclosed to the general public, such information must be kept in strict confidence and should be discussed only with persons who have a “need to know” the information for a legitimate business purpose. The utmost care and circumspection must be exercised at all times in order to protect CVD’s confidential information. The following practices should be followed to help prevent the misuse of confidential information:

 

●Avoid discussing confidential information in places where you may be overheard by people who do not have a valid need to know such information, such as on elevators, in restaurants and on airplanes.
   
●Avoid discussing confidential information on cellular phones, and take great care when discussing such information on speakerphones. Do not discuss such information with relatives or social acquaintances.
   
●Do not give your computer IDs and passwords to any other person. Password protect computers and log off computers when they are not in use.
   
●Always put confidential documents away when not in use and, based upon the sensitivity of the material, keep such documents in a locked desk or office. Do not leave documents containing confidential information where they may be seen by persons who do not have a need to know the content of the documents.

 

●Be aware that the Internet and electronic mail carriers are not secure environments for the transmission of confidential information.
   
●Comply with the specific terms of any confidentiality agreements of which you are aware.
   
●Upon termination of your employment, you must return to CVD, as applicable, all physical (including electronic) copies of confidential information, as well as all other material embodied in any physical or electronic form that is based on or derived from such information, without retaining any copies.
   
●You may not bring the confidential information of any former employer to CVD.

 

4

 

 

Responding to Requests for Information

 

You may find yourself the recipient of questions concerning various activities of CVD. Such inquiries can come from the media, securities analysts and others regarding CVD’s business, rumors, trading activity, current and future prospects and plans, acquisition or divestiture activities and other similar important information. Under no circumstance should you attempt to handle these inquiries without prior authorization. Only personnel of CVD specifically authorized to do so may answer questions about or disclose information concerning CVD.

 

●Refer requests for information regarding CVD from the financial community, such as securities analysts, brokers or investors, to CVD’s Chief Executive Officer, or, if the Chief Executive Officer is not available, CVD’s Chief Financial Officer.
   
●Refer requests for information regarding CVD from the media or press to CVD’s Chief Executive Officer, or, if the Chief Executive Officer is not available, CVD’s Chief Financial Officer.
   
●Refer requests for information from the U.S. Securities and Exchange Commission (the “SEC”) or other regulators to CVD’s Chief Financial Officer, or, if the Chief Financial Officer is not available, CVD’s Executive Officer.

 

Regulation FD

 

CVD is committed to fair disclosure to investors in compliance with all applicable securities laws and regulations, including Regulation FD adopted by the SEC. Regulation FD prohibits public corporations from selectively disclosing material, non-public information to securities analysts, broker-dealers, other securities market professionals and stockholders (“Securities Professionals”) who may buy or sell CVD securities on the basis of the information.

 

Whenever a company (or person acting on its behalf) discloses material, non-public information to Securities Professionals, Regulation FD requires that the company simultaneously make public disclosure of the information in question. If CVD learns that it has unintentionally disclosed material, non-public information, it must issue a press release making the information public within 24 hours.

 

For a discussion of what types of information are likely to be deemed material, see the section of this policy on “Material, Non-Public Information,” above.

 

To avoid a violation of Regulation FD, CVD must strictly adhere to disciplined procedures and record keeping with respect to formal and informal contacts with Securities Professionals. If possible, CVD’s Chief Financial Officer (or, if the Chief Financial Officer is not available, the Chief Executive Officer) should be included in any and all contacts with Securities Professionals. If CVD’s Chief Financial Officer (or, if the Chief Financial Officer is not available, the Chief Executive Officer) is not included in the contact, then the CVD’s Chief Financial Officer (or, if the Chief Financial Officer is not available, the Chief Executive Officer) must be briefed on the substance of any discussions within two hours after any such contact occurs.

 

Reporting Violations/Seeking Advice

 

You should refer suspected violations of this policy to CVD’s Chief Financial Officer (or, if the Chief Financial Officer (is not available, the Chief Executive Officer). In addition, if you:

 

●receive material, non-public information that you are not authorized to receive or that you do not legitimately need to know to perform your employment responsibilities, or

 

●receive confidential information and are unsure if it is within the definition of material, non-public information or whether its release might be contrary to a fiduciary or other duty or obligation,

 

you should not share it with anyone. To seek advice about what to do under those circumstances, you should contact CVD’s Chief Financial Officer (or, if the Chief Financial Officer is not available, the Chief Executive Officer). Consulting your colleagues can have the effect of exacerbating the problem. Containment of the information, until the legal implications of possessing it are determined, is critical.

 

Penalties for Violations of the Insider Trading Policy and Laws

 

The personal consequences to you of illegally trading securities using material, non-public information can be quite severe. U.S. securities laws provide that an individual is subject to possible imprisonment and significant fines. These laws apply to all employees – not just officers, directors, investment bankers and lawyers. Subject to applicable law, personnel of CVD who violate this policy may also be subject to discipline by CVD, up to and including termination of employment.

 

5


 

 EX-21.1 7 ex21-1.htm

 

Exhibit 21.1

 

CVD EQUIPMENT CORPORATION

SUBSIDIARIES OF REGISTRANT

 

SUBSIDIARY

NAME

  

STATE OR OTHER JURISDICTION

OF INCORPORATION OR ORGANIZATION

CVD Materials Corporation   New York
CVD MesoScribe Technologies Corporation   New York
FAE Holdings 411519R, LLC   New York

 

 

 

 EX-23.1 8 ex23-1.htm

 

Exhibit 23.1

 

Independent Registered Public Accounting Firm’s Consent

 

We consent to the incorporation by reference in the Registration Statement of CVD Equipment Corporation on Form S-8 (File No. 333-138903, 333-153186, and 333-217439) and Form S-3 (File No. 333-271066) of our report dated March 19, 2025 with respect to our audits of the consolidated financial statements of CVD Equipment Corporation and Subsidiaries as of December 31, 2024 and 2023 and for each of the two years in the period ended December 31, 2024, which report is included in this Annual Report on Form 10-K of CVD Equipment Corporation for the year ended December 31, 2024.

 

/s/ Marcum LLP

 

Marcum LLP

Melville, NY

March 19, 2025

 

 

 

 EX-31.1 9 ex31-1.htm

 

Exhibit 31.1

 

Certification of Principal Executive Officer

 

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Emmanuel Lakios, certify that:

 

1. I have reviewed this annual report on Form 10-K of CVD Equipment Corporation;

 

2. Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3 Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 19, 2025 /s/ Emmanuel Lakios
  President, Chief Executive Officer

 

 

 

 EX-31.2 10 ex31-2.htm

 

Exhibit 31.2

 

Certification of Principal Financial Officer

 

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Richard Catalano, certify that:

 

1. I have reviewed this annual report on Form 10-K of CVD Equipment Corporation;

 

2. Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3 Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 19, 2025 /s/ Richard Catalano
 

Executive Vice President and

  Chief Financial Officer

 

 

 

 EX-32.1 11 ex32-1.htm

 

Exhibit 32.1

 

Certification of Principal Executive Officer

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

 

I, Emmanuel Lakios, President and Chief Executive Officer of CVD Equipment Corporation, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the annual report on Form 10-K for the period ending December 31, 2024 of CVD Equipment Corporation (the “Form 10-K”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of CVD Equipment Corporation.

 

Dated: March 19, 2025 /s/ Emmanuel Lakios
  Emmanuel Lakios
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 EX-32.2 12 ex32-2.htm

 

Exhibit 32.2

 

Certification of Principal Financial Officer

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

 

I, Richard Catalano, Chief Financial Officer of CVD Equipment Corporation, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the annual report on Form 10-K for the period ending December 31, 2024 of CVD Equipment Corporation (the “Form 10-K”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of CVD Equipment Corporation.

 

Dated: March 19, 2025 /s/ Richard Catalano
  Richard Catalano
 

Executive Vice President and

  Chief Financial Officer
  (Principal Financial Officer)

 

 

 

 EX-101.SCH 13 cvv-20241231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 999014 - Disclosure - Business Description link:presentationLink link:calculationLink link:definitionLink 999015 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 999016 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 999017 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 999018 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 999019 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 999020 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 999021 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 999022 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 999023 - Disclosure - Employee Retention Credit link:presentationLink link:calculationLink link:definitionLink 999024 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 999025 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 999026 - Disclosure - Reportable Segments link:presentationLink link:calculationLink link:definitionLink 999027 - Disclosure - MesoScribe and Tantaline link:presentationLink link:calculationLink link:definitionLink 999028 - Disclosure - Risks and Uncertainties link:presentationLink link:calculationLink link:definitionLink 999029 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 999030 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 999031 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 999032 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 999033 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 999034 - Disclosure - Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 999035 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 999036 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 999037 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 999038 - Disclosure - Reportable Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 999039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999040 - Disclosure - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 999041 - Disclosure - Schedule of Cost and Estimated Earnings in Excess of Billings (Details) link:presentationLink link:calculationLink link:definitionLink 999042 - Disclosure - Revenue (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999043 - Disclosure - Schedule of Inventories, net (Details) link:presentationLink link:calculationLink link:definitionLink 999044 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999045 - Disclosure - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 999046 - Disclosure - Property, Plant and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999047 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 999048 - Disclosure - Schedule of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 999049 - Disclosure - Schedule of Long Term Debt (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 999050 - Disclosure - Schedule of Maturities of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 999051 - Disclosure - Long-term Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999052 - Disclosure - Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 999053 - Disclosure - Schedule of Loss Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 999054 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 999056 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 999057 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 999058 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999059 - Disclosure - Employee Retention Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999060 - Disclosure - Schedule of Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 999061 - Disclosure - Schedule of Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 999062 - Disclosure - Schedule of Stock Options Awards (Details) link:presentationLink link:calculationLink link:definitionLink 999063 - Disclosure - Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details) link:presentationLink link:calculationLink link:definitionLink 999064 - Disclosure - Schedule of Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 999065 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999066 - Disclosure - Defined Contribution Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999067 - Disclosure - Schedule of Segments (Details) link:presentationLink link:calculationLink link:definitionLink 999068 - Disclosure - Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 999069 - Disclosure - Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss (Details) link:presentationLink link:calculationLink link:definitionLink 999070 - Disclosure - Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets (Details) link:presentationLink link:calculationLink link:definitionLink 999071 - Disclosure - Schedule of Revenue by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 999072 - Disclosure - Reportable Segments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 999073 - Disclosure - MesoScribe and Tantaline (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 cvv-20241231_cal.xml XBRL CALCULATION FILE EX-101.DEF 15 cvv-20241231_def.xml XBRL DEFINITION FILE EX-101.LAB 16 cvv-20241231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Long-Lived Tangible Asset [Axis] Building and Building Improvements [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Machinery and Equipment [Member] Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] Customer [Member] Customer One [Member] Customer Two [Member] Customer Three [Member] Revenue Benchmark [Member] Customer A [Member] Customer B [Member] Customer C [Member] Export Sales [Member] Geographic Distribution [Axis] Geographic Distribution, Foreign [Member] Product and Service [Axis] Cargo and Freight [Member] Timing of Transfer of Good or Service [Axis] Transferred over Time [Member] Energy [Member] Transferred at Point in Time [Member] Aerospace [Member] Industrial [Member] Research [Member] Inventory [Axis] PVT 150 Systems [Member] Land [Member] Construction in Progress [Member] Income Tax Jurisdiction [Axis] Domestic Tax Jurisdiction [Member] Income Tax Authority, Name [Axis] Internal Revenue Service (IRS) [Member] Tax Credit Carryforward [Axis] Research Tax Credit Carryforward [Member] Plan Name [Axis] 2007 Share Incentive Plan [Member] 2016 Share Incentive Plan [Member] 2022 Share Incentive Plan [Member] Award Type [Axis] Restricted Stock [Member] Title and Position [Axis] Director [Member] Share-Based Payment Arrangement, Option [Member] Five Directors [Member] Statement of Income Location, Balance [Axis] Cost of Revenue [Member] Research and Development Expense [Member] Selling Expense [Member] General and Administrative Expense [Member] Exercise Price Range [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Consolidation Items [Axis] Operating Segments [Member] Segments [Axis] CVD [Member] SDC [Member] Meso Scribe Technologies Inc [Member] Related and Nonrelated Parties [Axis] Other - Tantaline [Member] Intersegment Eliminations [Member] Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Geographical [Axis] Americas [Member] North America [Member] EMEA [Member] Asia Pacific [Member] Consolidated Entities [Axis] Disposal Group Name [Axis] Tantaline A/S of Nordborg [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Listing, Par Value Per Share Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Accounts receivable, net of allowance for credit losses Contract assets Inventories Other current assets Total current assets Property, plant and equipment, net Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses Current maturities of long-term debt Deposits from purchasers of MesoScribe assets – note 14 Contract liabilities Total current liabilities Long-term debt, net of current portion Total liabilities Commitments and contingencies (see note 15) Stockholders’ equity: Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,881,838 at December 31, 2024 and 6,824,511 at December 31, 2023 Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses: Research and development Selling General and administrative Gain on sales of equipment Loss on disposition of Tantaline Impairment charge Total operating expenses, net Operating loss Other income (expense): Interest income Interest expenses Foreign exchange income Other income Total other income, net Loss before income tax Income tax expense (benefit) Net loss Loss per common share: Basic Diluted Weighted average number of shares: Basic Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Net loss Stock-based compensation Stock-based compensation, shares Exercise of stock options and issuance of shares Exercise of stock options and issuance of shares, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Depreciation and amortization Provision for excess and obsolete inventory Provision for bad debt Changes in operating assets and liabilities, net of effects of disposition of Tantaline and sales of equipment: Accounts receivable Contract assets Inventories Employee retention credit receivable Other assets Accounts payable Accrued expenses Contract liabilities Net cash used in operating activities Cash flows from investing activities: Purchase of property and equipment Net proceeds from sales of equipment Net cash used in disposition of Tantaline Net cash provided by (used in) investing activities Cash flows from financing activities: Payments of long-term debt Proceeds from exercise of stock options Net cash used in financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Supplemental disclosure of cash flow information: Income taxes paid Interest paid Inventory transferred to property, plant and equipment Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Award Timing Disclosures [Line Items] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration No Insider Trading Flag Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Material Cybersecurity Incident [Abstract] Material Cybersecurity Incident Nature [Text Block] Material Cybersecurity Incident Scope [Text Block] Material Cybersecurity Incident Timing [Text Block] Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block] Material Cybersecurity Incident Information Not Available or Undetermined [Text Block] Accounting Policies [Abstract] Business Description Summary of Significant Accounting Policies Revenue from Contract with Customer [Abstract] Revenue Inventory Disclosure [Abstract] Inventories Property, Plant and Equipment [Abstract] Property, Plant and Equipment Payables and Accruals [Abstract] Accrued Expenses Debt Disclosure [Abstract] Long-term Debt Earnings Per Share [Abstract] Earnings per Share Income Tax Disclosure [Abstract] Income Taxes Employee Retention Credit Employee Retention Credit Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Retirement Benefits [Abstract] Defined Contribution Plan Segment Reporting [Abstract] Reportable Segments Discontinued Operations and Disposal Groups [Abstract] MesoScribe and Tantaline Risks And Uncertainties Risks and Uncertainties Basis of Presentation Liquidity Reclassifications Principles of Consolidation Use of Estimates Revenue Recognition Inventories Product Warranty Income Taxes Impairment of Long-Lived Assets and Intangibles Property, Plant and Equipment Research and Development Earnings Per Share Cash and Cash Equivalents Concentration of Credit Risk Sales Concentrations Supplier Risk Fair Value of Financial Instruments Stock-Based Compensation Shipping and Handling Recently Adopted Accounting Standards Recently Issued Accounting Standards Schedule of Disaggregation of Revenue Schedule of Cost and Estimated Earnings in Excess of Billings Schedule of Inventories, net Schedule of Property, Plant and Equipment Schedule of Accrued Expenses Schedule of Long Term Debt Schedule of Maturities of Long Term Debt Schedule of Basic and Diluted Weighted Average Common Shares Outstanding Schedule of Loss Before Income Taxes Schedule of Components of Income Tax Expense (Benefit) Schedule of Effective Income Tax Rate Reconciliation Schedule of Deferred Tax Assets and Liabilities Schedule of Stock Based Compensation Schedule of Weighted Average Assumptions Schedule of Stock Options Awards Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices Schedule of Restricted Stock Awards Schedule of Segments Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets Schedule of Revenue by Geographic Area Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] Contract assets, impairment loss Standard product warranty description Income tax examination, description Property plant and equipment useful life Cash equivalents Cash uninsured amount Allowance for credit loss Accounts Receivable, Credit Loss Expense (Reversal) Concentration risk percentage Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Total Costs incurred on contracts in progress Estimated earnings Costs and estimated earnings on uncompleted contracts Billings to date Net cost in excess of billings Deferred revenue related to non-systems contracts Contract liability in excess of contract assets Unrecognized contract revenue Contract liability recognized as revenue Contract assets Contract liability Raw materials Work-in-process Finished goods Total Inventory, Current [Table] Inventory [Line Items] Non-cash charge to reduce net realizable value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Totals at cost Less: accumulated depreciation Property, plant and equipment, net Depreciation expense Accrued wages and benefits Accrued vacation Accrued material purchases Other Total accrued expenses Equipment loan payable in monthly repayments of $8 including interest at 6% per annum Less: current maturities Long-term debt, net of current maturities Debt Instrument, Periodic Payment Debt instrument interest rate 2024 2025 2026 Total Loan to fund acquisition of machinery equipment Basic weighted average shares outstanding Effect of potentially dilutive share-based awards Diluted weighted average shares outstanding Domestic Foreign Federal State Total current tax provision Federal State Total deferred tax provision Income tax expense (benefit) Expected provision at federal statutory tax rate at 21% Increase in valuation allowance State and local taxes Federal research and development credits Non-deductible expenses Disposition of Tantaline Other Federal statutory tax rate Net operating loss carryforwards R&D tax credit carryforwards Compensation costs Vacation accrual Intangible assets Capitalized research and development Other items Deferred income tax assets Less: valuation allowance Deferred income tax assets, net of valuation allowance Property, plant and equipment Prepaid expenses Deferred income tax asset, net Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Line Items] Increase in valuation allowance Operating loss carryforwards Operating loss carryforwards, limitations Tax credit carryforward. Tax credit carryforward expiration Uncertain tax positions Income tax examination, year Corporate tax rate Excise tax rate Employee retention credit eligible amount Employee retention credit receivable Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation expense Stock price Exercise price Dividend yield Expected volatility Risk-free interest rate Expected life (in years) Awards outstanding, beginning balance Weighted average exercise price outstanding, beginning balance Awards, granted Weighted average exercise price, granted Awards, expired / cancelled Weighted average exercise price, expired / cancelled Awards, exercised Weighted average exercise price, exercised Awards outstanding, ending balance Weighted average exercise price outstanding, ending balance Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price range, lower limit Exercise price range, upper limit Number of options outstanding Number of options outstanding, weighted average remaining contractual term Number of options outstanding, weighted average exercise price Number of options outstanding, intrinsic value Number of options exercisable Number of options exercisable, weighted average exercise price Number of options exercisable, intrinsic value Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares of restricted stock, unvested outstanding beginning balance Weighted average grant date fair value, unvested outstanding beginning balance Shares of restricted stock, granted Weighted average grant date fair value, granted Shares of restricted stock, vested Weighted average grant date fair value, vested Shares of restricted stock, forfeited or cancelled Weighted average grant date fair value, forfeited or cancelled Shares of restricted stock, unvested outstanding ending balance Weighted average grant date fair value, unvested outstanding ending balance Common shares reserved for future issuance. Outstanding stock options Expiration period Number of shares available for grant Stock based compensation Stock option granted Stock option vesting percentage Stock options exercisable Unrecognized compensation costs Unrecognized compensation costs, weighted average recoginition period Annual equity retainer amount Vesting period Defined contribution plan percentage Defined contribution plan percentage of employees contribution Defined contribution plan cost Defined contribution plan, employer discretionary contribution amount Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Segment revenue Research & development General & administrative Interest expense Segment net income (loss) Segment assets Capital expenditures Depreciation & amortization Consolidated total revenue Unallocated amounts Income tax (expense) benefit Consolidated total assets Cash equivalents Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Number of operating segments Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Aggregate purchase price Deposits from purchaser of equipment Gain on sale of equipment Assets Liabilities Loss on disposition of tantaline Earn-out payment No Insider Trading Flag Accrued material purchases. Deposits from purchaser of MesoScribe assets. Loan to fund acquisition of machinery equipment. Deferred tax assets capitalized research and development. Increase decrease in employee retention credit receivable. Employee Retention Credit [Text Block] Employee retention credit receivable noncurrent. 2007 Share Incentive Plan [Member] 2016 Share Incentive Plan [Member] 2022 Share Incentive Plan [Member] Inventory transferred to property plant and equipment. Liquidity [Policy Text Block] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Share based payment arrangement annual equity retainer amount. Five Directors [Member] Customer [Member] Customer One [Member] Customer Two [Member] Customer Three [Member] SDC [Member] CVD [Member] Sales Concentrations Policy [Policy Text Block] Customer A [Member] Customer B [Member] Customer C [Member] Export Sales [Member] Supplier Risk [Policy Text Block] Shipping And Handling Policy [Policy Text Block] Recently Issued Accounting Standards [Policy Text Block] Schedule Of Cost And Estimated Earnings In Excess Of Billings [Table Text Block] Costs incurred on uncompleted contracts. Estimated earnings. Costs and estimated earnings on uncompleted contracts. Billings to date. Net cost in excess of billings. Deferred revenues related to contracts. Contract liability in excess of contract assets. PVT 150 Systems [Member] Capital expenditures. Other - Tantaline [Member] Sale of proprietary assets and license certain propriety information aggregate purchase price. Meso Scribe Technologies Inc [Member] Tantaline A/S of Nordborg [Member] Risks And Uncertainties [Text Block] Earn-out payment. Energy [Member] Aerospace [Member] Industrial [Member] Research [Member] Cost of Revenue [Member] Selling Expense [Member] Excise tax rate. Employee retention credit receivable. Revenue of Reportable Segments [Member] Assets, Current Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Accounts Receivable Increase (Decrease) in Contract with Customer, Asset Increase (Decrease) in Inventories Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Cash Divested from Deconsolidation Net Cash Provided by (Used in) Investing Activities Repayments of Long-Term Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Revenue from Contract with Customer [Text Block] Inventory Disclosure [Text Block] EmployeeRetentionCreditTextBlock Inventory, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Share-Based Payment Arrangement [Policy Text Block] CostsAndEstimatedEarningsOnUncompletedContracts BillingsToDate NetCostInExcessOfBillings DeferredRevenuesRelatedToContracts ContractLiabilityInExcessOfContractAssets Contract with Customer, Asset, after Allowance for Credit Loss Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Long-Term Debt Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Prepaid Expenses Deferred Tax Assets, Net Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Other Expenses EX-101.PRE 17 cvv-20241231_pre.xml XBRL PRESENTATION FILE XML 19 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 19, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 1-16525    
Entity Registrant Name CVD EQUIPMENT CORPORATION    
Entity Central Index Key 0000766792    
Entity Tax Identification Number 11-2621692    
Entity Incorporation, State or Country Code NY    
Entity Address, Address Line One 355 South Technology Drive    
Entity Address, City or Town Central Islip    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 11722    
City Area Code (631)    
Local Phone Number 981-7081    
Title of 12(b) Security Common Stock, Par value $0.01    
Trading Symbol CVV    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 20,795,415
Entity Common Stock, Shares Outstanding   6,881,838  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.01    
Auditor Firm ID 688    
Auditor Name Marcum LLP    
Auditor Location Melville, NY    
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 12,598 $ 14,025
Accounts receivable, net of allowance for credit losses 2,149 1,906
Contract assets 2,226 1,604
Inventories 2,115 4,454
Other current assets 898 852
Total current assets 19,986 22,841
Property, plant and equipment, net 11,699 12,166
Other assets 1 18
Total assets 31,686 35,025
Current liabilities:    
Accounts payable 679 1,203
Accrued expenses 2,236 1,765
Current maturities of long-term debt 87 81
Deposits from purchasers of MesoScribe assets – note 14 597
Contract liabilities 3,135 4,908
Total current liabilities 6,137 8,554
Long-term debt, net of current portion 181 268
Total liabilities 6,318 8,822
Commitments and contingencies (see note 15)
Stockholders’ equity:    
Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,881,838 at December 31, 2024 and 6,824,511 at December 31, 2023 69 68
Additional paid-in capital 29,757 28,695
Accumulated deficit (4,458) (2,560)
Total stockholders’ equity 25,368 26,203
Total liabilities and stockholders’ equity $ 31,686 $ 35,025
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 20,000,000 20,000,000
Common stock, shares issued 6,881,838 6,824,511
Common stock, shares outstanding 6,881,838 6,824,511
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Revenue $ 26,876 $ 24,109
Cost of revenue 20,545 19,038
Gross profit 6,331 5,071
Operating expenses:    
Research and development 2,627 2,596
Selling 1,656 1,632
General and administrative 5,181 5,451
Gain on sales of equipment (717)
Loss on disposition of Tantaline 162
Impairment charge 111
Total operating expenses, net 8,747 9,952
Operating loss (2,416) (4,881)
Other income (expense):    
Interest income 559 577
Interest expenses (19) (23)
Foreign exchange income 42
Other income 2 91
Total other income, net 542 687
Loss before income tax (1,874) (4,194)
Income tax expense (benefit) 24 (14)
Net loss $ (1,898) $ (4,180)
Loss per common share:    
Basic $ (0.28) $ (0.62)
Diluted $ (0.28) $ (0.62)
Weighted average number of shares:    
Basic 6,823 6,788
Diluted 6,823 6,788
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2022 $ 67 $ 27,712 $ 1,620 $ 29,399
Balance, shares at Dec. 31, 2022 6,760,938      
Net loss (4,180) (4,180)
Stock-based compensation $ 1 907 908
Stock-based compensation, shares 41,320      
Exercise of stock options and issuance of shares 76 $ 76
Exercise of stock options and issuance of shares, shares 22,253     35,625
Balance at Dec. 31, 2023 $ 68 28,695 (2,560) $ 26,203
Balance, shares at Dec. 31, 2023 6,824,511      
Net loss (1,898) (1,898)
Stock-based compensation $ 1 1,062 $ 1,063
Stock-based compensation, shares 57,327      
Exercise of stock options and issuance of shares, shares      
Balance at Dec. 31, 2024 $ 69 $ 29,757 $ (4,458) $ 25,368
Balance, shares at Dec. 31, 2024 6,881,838      
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net loss $ (1,898,000) $ (4,180,000)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation 1,063,000 908,000  
Depreciation and amortization 684,000 792,000  
Provision for excess and obsolete inventory 1,573,000 387,000  
Provision for bad debt 13,000  
Gain on sales of equipment (717,000)  
Loss on disposition of Tantaline 162,000  
Impairment charge 111,000  
Changes in operating assets and liabilities, net of effects of disposition of Tantaline and sales of equipment:      
Accounts receivable (256,000) 1,841,000  
Contract assets (622,000) 566,000  
Inventories 646,000 (2,308,000)  
Employee retention credit receivable 1,529,000 $ (1,500,000)
Other assets (150,000) (47,000)  
Accounts payable (524,000) (154,000)  
Accrued expenses 472,000 (679,000)  
Contract liabilities (1,773,000) 866,000  
Net cash used in operating activities (1,489,000) (206,000)  
Cash flows from investing activities:      
Purchase of property and equipment (106,000) (418,000)  
Net proceeds from sales of equipment 250,000 597,000  
Net cash used in disposition of Tantaline (312,000)  
Net cash provided by (used in) investing activities 144,000 (133,000)  
Cash flows from financing activities:      
Payments of long-term debt (82,000) (77,000)  
Proceeds from exercise of stock options 76,000  
Net cash used in financing activities (82,000) (1,000)  
Net decrease in cash and cash equivalents (1,427,000) (340,000)  
Cash and cash equivalents at beginning of year 14,025,000 14,365,000  
Cash and cash equivalents at end of year 12,598,000 14,025,000 $ 14,365,000
Supplemental disclosure of cash flow information:      
Income taxes paid 3,000 8,000  
Interest paid 19,000 24,000  
Inventory transferred to property, plant and equipment $ 110,000  
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure [Table]    
Net Income (Loss) $ (1,898) $ (4,180)
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Award Timing Disclosure
 12 Months Ended
Dec. 31, 2024
Award Timing Disclosures [Line Items]  
Award Timing MNPI Disclosure From time to time, we grant equity awards, including stock options, to our employees, including our named executive officers. Historically, we have typically granted new-hire option awards on, or within the calendar quarter of, a new hire's employment start date and annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at a regularly scheduled meeting of the Compensation Committee occurring in such quarter. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time of each annual meeting of our stockholders, respectively, pursuant to our non-employee director compensation policy, as further described under the heading, “2024 Director Compensation” below.
Award Timing MNPI Considered false
Award Timing, How MNPI Considered The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about our company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to our public disclosure of MNPI
MNPI Disclosure Timed for Compensation Value false
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
 12 Months Ended
Dec. 31, 2024
Insider Trading Arrangements [Line Items]  
No Insider Trading Flag true
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Abstract]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. We use recognized commercially reasonable measures, tools, and methodologies to manage cybersecurity risk, which are tested regularly. We also monitor and evaluate our cybersecurity posture on an ongoing basis through regular malware scans, penetration tests, and third-party reviews. Specific controls that are used to some extent include endpoint threat detection, identity and access management (IAM), privileged access management (PAM), logging and monitoring, multi-factor authentication (MFA), firewalls and intrusion detection and prevention, and vulnerability and patch management. 

To manage our material risks from cybersecurity threats and to protect against, detect, and prepare to respond to cybersecurity incidents, we undertake the below listed activities:

 

  ● Monitor emerging data protection laws and implement changes to our compliance processes;
  ● Conduct periodic cybersecurity assessments for employees who use our system to evaluate training needs;
  ● Conduct onboarding and cyber security training for all employees on an ongoing basis;
  ● Conduct regular phishing email simulations for all employees; and
  ● Carry cybersecurity risk insurance that protects against the potential losses from a cybersecurity incident.

 

Our incident response plan coordinates the activities that we and our third-party cybersecurity provider take to prepare to respond to and recover from cybersecurity incidents. These include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate brand and reputational damage. We have an IT continuity plan that we continuously review and update in line with our evolving applications architecture.

 
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block] We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. We use recognized commercially reasonable measures, tools, and methodologies to manage cybersecurity risk, which are tested regularly. We also monitor and evaluate our cybersecurity posture on an ongoing basis through regular malware scans, penetration tests, and third-party reviews.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Board of Directors Oversight [Text Block] Our Board of Directors and Audit Committee oversee our cybersecurity efforts to ensure effective governance in managing risks associated with cybersecurity threats. Our Director of Information Technology provides periodic updates to the Board of Directors and Audit Committee regarding our cybersecurity program, including status updates on various projects to enhance our overall cybersecurity posture.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Our Board of Directors and Audit Committee oversee our cybersecurity efforts to ensure effective governance in managing risks associated with cybersecurity threats.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Our Director of Information Technology provides periodic updates to the Board of Directors and Audit Committee regarding our cybersecurity program, including status updates on various projects to enhance our overall cybersecurity posture.
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Business Description
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Business Description

Note 1 – Business Description

 

CVD Equipment Corporation and its subsidiaries (the “Company”) is a New York corporation. Its principal business activities include designing, developing, and manufacturing a broad range of chemical vapor deposition, physical vapor transport, gas control, and other equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research. The Company’s products are used in production environments as well as research and development centers, both academic and corporate.

 
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Liquidity

 

At December 31, 2024, the Company had $12.6 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of these financial statements.

 

Reclassifications

 

In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net loss.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Revenue Recognition

 

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606”), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.

 

Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to

 

evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the year ended December 31, 2024 and 2023.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because the Company believes these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide the Company with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the years ended December 31, 2024 and 2023, all system equipment sales were recorded over time by using an input method except for a) one contract that was recorded as revenue at the point in time the equipment was transferred to the customer during 2024 and b) one contract that was entered during 2024 and will be recognized as revenue after December 31, 2024 upon transfer of the equipment to the customer.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Inventories

 

Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.

 

Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.

 

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

 

Income Taxes

 

Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes potential interest and penalties related to uncertain tax positions in income tax expense.

 

The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.

 

Impairment of Long-Lived Assets and Intangibles

 

Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists. If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over 5 to 39 years and for machinery and equipment over 5 to 8 years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.

 

Research and Development

 

Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Earnings Per Share

 

Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.

 

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

 

Cash and Cash Equivalents

 

The Company had cash and cash equivalents of $12.6 million and $14.0 million at December 31, 2024 and 2023, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $11.9 million and $12.1 million at December 31, 2024 and 2023, respectively.

 

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at December 31, 2024 and 2023 was $0.4 million and $1.5 million, respectively.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.

 

The Company routinely assesses the financial strength of its customers. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Accounts receivable is presented net of an allowance for credit losses of $48,000, $36,000 and $36,000 as of December 31, 2024, 2023 and 2022, respectively. The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for credit losses could be material to our results of operations and financial condition. The provision for bad debt expense was $13,000 and $0 for the years ended December 31, 2024 and 2023, respectively.

 

The Company has accounts receivables from certain customers that exceed 10% of total accounts receivable. As of December 31, 2024, the accounts receivable balance includes amounts from three customers that represented 28.6%, 14.0% and 11.9% of total accounts receivable, and as of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented 37.6%, 13.0% and 12.8% of total accounts receivable.

 

Sales Concentrations

 

Revenue to a single customer in any one year can exceed 10% of our total sales. There was one customer of the CVD Equipment segment in the year ended December 31, 2024 that represented 29.5% of our revenues, while there were three customers of the CVD Equipment segment in the year ended December 31, 2023 that represented 14.3%, 13.5% and 10.9% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.

 

Export sales to customers represented approximately 4.3% and 17.2% of sales years ended December 31, 2024 and 2023 respectively. Export sales in both 2024 and 2023 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.

 

Supplier Risk

 

The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Fair Value of Financial Instruments

 

The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates. The value of restricted stock awards are based on the fair value on the date of the grant.

 

Shipping and Handling

 

It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $73,000 and $55,000 for the years ended December 31, 2024 and 2023, respectively.

 

Recently Adopted Accounting Standards

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This update is effective for our annual report for fiscal year 2024, and interim periods thereafter, and was applied retrospectively to the fiscal year 2024 financial statements.. The Company adopted ASU 2023-07 in 2024 and the required disclosures are included in Note 13.

 

Recently Issued Accounting Standards

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. The amendments further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This ASU is effective for our annual report for fiscal year 2026, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the timing of adoption and impact of this ASU on our consolidated financial statements.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statements Expenses (Subtopic 220-40),” to improve income statement expenses disclosure. The standard requires more detailed information related to the types of expenses, including (among other items) the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included within each interim and annual income statement’s expense caption, as applicable. This authoritative guidance can be applied prospectively or retrospectively and will be effective for financial statements issued for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

 
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue

Note 3 – Revenue

 

The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2024 and 2023 (in thousands):

 

   Over time   Point in time   Total 
   Year Ended December 31, 2024 
   Over time   Point in time   Total 
Energy  $216   $511   $727 
Aerospace   11,205    1,879    13,084 
Industrial   6,921    1,350    8,271 
Research   3,736    1,058    4,794 
Total  $22,216   $4,660   $26,876 

 

   Over time   Point in time   Total 
   Year Ended December 31, 2023 
   Over time   Point in time   Total 
Energy  $4,901   $189   $5,090 
Aerospace   3,427    1,469    4,896 
Industrial   6,123    2,821    8,944 
Research   3,700    1,479    5,179 
Total  $18,151   $5,958   $24,109 

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 3 – Revenue (continued)

 

The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. Research market principally represents customers that are universities and other research institutions.

 

The Company has unrecognized contract revenue of approximately $16.4 million at December 31, 2024, which it expects to substantially recognize as revenue within the next twelve months based on over time revenue recognition.

 

Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine the Company’s progress towards contract completion and to calculate the corresponding amount of revenue to recognize.

 

Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated financial position and results of operations.

 

Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):

 

   2024   2023 
Costs incurred on contracts in progress  $14,696   $9,500 
Estimated earnings   7,052    5,083 
Costs and estimated earnings on uncompleted contracts   21,748    14,583 
Billings to date   (22,059)   (17,553)
Net cost in excess of billings   (311)   (2,970)
Deferred revenue related to non-systems contracts   (598)   (334)
Contract liability in excess of contract assets  $(909)  $(3,304)
Included in accompanying consolidated balance sheets under the following captions (in thousands):          
           
Contract assets  $2,226   $1,604 
Contract liabilities  $3,135   $4,908 

 

Of the contract liability balances at December 31, 2023 and December 31, 2022, $4.7 million and $3.7 million was recognized as revenue during the years ended December 31, 2024 and 2023, respectively. Contract assets and contract liabilities at December 31, 2022 were $2.2 million and $4.0 million, respectively.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories
 12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Inventories

Note 4 - Inventories

 

Inventories as of December 31 consist of (in thousands):

 

   2024   2023 
         
Raw materials  $1,217   $2,351 
Work-in-process   765    1,248 
Finished goods   133    855 
Total  $2,115   $4,454 

 

Included in inventories are finished goods and raw materials related to PVT 150 systems that were purchased and built, respectively, in anticipation of future orders. During the year ended December 31, 2024, the Company recorded a non-cash charge to reduce the net realizable value of such inventory by approximately $1.3 million based on its assessment of the current market for silicon carbide equipment.

 

As of December 31, 2024, the net amount of PVT 150 systems inventory is approximately $0.5 million. If future PVT 150 orders do not materialize and if the Company is not otherwise able to sell this inventory, the Company could incur additional charges to further reduce the carrying value of such inventory to net realizable value. Such charges may be material to the Company’s financial position and future results of operations.

 
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Property, Plant and Equipment
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment

Note 5 – Property, Plant and Equipment

 

Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):

 

   2024   2023 
         
Land  $2,220   $2,220 
Buildings and improvements   12,897    12,798 
Machinery and equipment   7,178    7,536 
Construction in progress   17    167 
Totals at cost   22,312    22,721 
           
Less: accumulated depreciation   (10,613)   (10,555)
Property, plant and equipment, net  $11,699   $12,166 

 

Machinery and equipment also include furniture and fixtures and software.

 

Depreciation expense was $0.7 million and $0.8 million for the years ended December 31, 2024 and 2023, respectively.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 5 – Property, Plant and Equipment (continued)

 

The Company entered into an agreement with the Town of Islip Industrial Development Agency (Islip IDA) in July 2021 under which the Company was granted tax incentives whereby the Company agreed to make payments in lieu of all real estate taxes and assessments (PILOT payments). The agreement requires the Company to maintain certain employment levels at its Central Islip, New York facility. The agreement provides for the Islip IDA to recapture tax incentives provided to the Company in certain circumstances. Any recapture of such tax benefits could have a material adverse effect on the Company’s financial position and future results of operations and cash flows.

 
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
Accrued Expenses

Note 6 – Accrued Expenses

 

Accrued expenses consist of the following as of December 31 (in thousands):

 

   2024   2023 
         
Accrued wages and benefits  $395   $358 
Accrued vacation   683    729 
Accrued material purchases   618    289 
Other   540    389 
Total accrued expenses  $2,236   $1,765 

 
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.25.1
Long-term Debt
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Long-term Debt

Note 7 – Long-term Debt

 

Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):

 

   2024   2023 
Equipment loan payable in monthly repayments of $8 including interest at 6% per annum  $268   $349 
Less: current maturities   87    81 
Long-term debt, net of current maturities  $181   $268 

 

In September 2022, the Company entered into a loan agreement to fund the acquisition of equipment in the amount of $0.4 million.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 7 – Long-term Debt (continued)

 

Future maturities of long-term debt as of December 31, 2024 are as follows (in thousands):

 

      
2024  $87 
2025   92 
2026   89 
      
Total  $268 

 
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Earnings per Share
 12 Months Ended
Dec. 31, 2024
Loss per common share:  
Earnings per Share

Note 8 – Earnings per Share

 

The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):

 

   2024   2023 
         
Basic weighted average shares outstanding   6,823    6,788 
Effect of potentially dilutive share-based awards   -    - 
           
Diluted weighted average shares outstanding   6,823    6,788 

 

At December 31, 2024 and 2023, all stock options and unvested restricted stock were not included in the computation of diluted earnings per share because their effect was antidilutive.

 
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes

Note 9 – Income Taxes

 

Loss before income taxes are as follows:

 

   2024   2023 
         
Domestic  $(1,874)   (4,073)
Foreign   -    (121)
Total  $(1,874)  $(4,194)

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 9 – Income Taxes (continued)

 

The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):

 

   2024   2023 
Current:        
Federal  $14   $(16)
State   10    2 
Total current tax provision   24    (14)
Deferred:          
Federal   -    - 
State   -    - 
Total deferred tax provision   -    - 
Income tax expense (benefit)  $24   $(14)

 

The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):

 

   2024   2023 
Expected provision at federal statutory tax rate at 21%  $(395)  $(881)
Increase in valuation allowance   447    688 
State and local taxes   (197)   21 
Federal research and development credits   -    (75)
Non-deductible expenses   86    37 
Disposition of Tantaline   -    193 
Other   83    3 
Income tax expense (benefit)  $24   $(14)

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 9 – Income Taxes (continued)

 

The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):

 

   2024   2023 
Deferred income tax assets:          
Net operating loss carryforwards  $679   $849 
R&D tax credit carryforwards   1,722    1,863 
Compensation costs   235    113 
Vacation accrual   118    153 
Intangible assets   38    38 
Capitalized research and development   1,096    759 
Other items   676    303 
Deferred income tax assets   4,564    4,078 
Less: valuation allowance   (4,098)   (3,646)
Deferred income tax assets, net of valuation allowance   466    432 
Deferred incomes tax liability:          
Property, plant and equipment   (384)   (365)
Prepaid expenses   (82)   (67)
Deferred income tax asset, net  $-   $- 

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that the deferred tax assets will be realized. The ultimate realization of deferred tax assets is based on the assessment of available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit the utilization of existing deferred tax assets. The Company considered all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the prior three-year period ended December 31, 2024. Such objective evidence limits the ability to consider subjective evidence such as our projections for future growth. Based on this assessment, we maintained a full valuation allowance against our net deferred tax assets as of December 31, 2024, and 2023. If these estimates and assumptions change in the future, we may be required to reduce our existing valuation allowance resulting in less income tax expense.

 

For the year ended December 31, 2024, the valuation allowance increased by approximately $0.5 million from the prior year primarily the result of capitalized research and development costs.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 9 – Income Taxes (continued)

 

At December 31, 2024, the Company had $2.7 million of U.S. federal net operating loss carryforwards. These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income. The Company also has $1.7 million of federal research and development tax credits which expire in varying amounts in tax years 2028 through 2042.

 

The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2024 and 2023, the Company had no uncertain tax positions. The Company does not expect that its unrecognized tax benefits will significantly increase or decrease within twelve months.

 

The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. The federal tax years open to examination are 2021 to 2024. The Company’s state and local tax years that are open to tax examination are generally 2020 to 2024.

 

The Inflation Reduction Act (“IRA”) and Chips and Science Act (“CHIPS Act”) were both enacted in August 2022. The IRA introduced new provisions including a 15% corporate alternative minimum tax for certain large corporations that have at least an average of $1 billion adjusted financial statement income over a consecutive three-tax-year period and a 1% excise tax surcharge on stock repurchases. The CHIPS Act provides a variety of incentives associated with investments in domestic semiconductor manufacturing and related activities. Both the IRA and CHIPS Act are applicable for tax years beginning after December 31, 2022 and had no impact to the Company’s consolidated financial statements for the years ended December 31, 2024 and 2023.

 
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Employee Retention Credit
 12 Months Ended
Dec. 31, 2024
Employee Retention Credit  
Employee Retention Credit

Note 10 – Employee Retention Credit

 

During 2022, the Company conducted an analysis as to whether it was entitled to employee retention credits (“ERC”) under the CARES Act as amended by the Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Plan Act of 2021. Based on the analysis, the Company determined that it was entitled to an ERC of approximately $1.5 million and recognized a receivable of $1.5 million as of December 31, 2022. The Company received the ERC credit in July 2023.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 
XML 40 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 11 – Stock-Based Compensation

 

A summary of the Company’s Share Incentive Plans are as follows:

 

2007 Share Incentive Plan

 

On December 12, 2007, shareholders approved the Company’s 2007 Share Incentive Plan (“2017 Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2017 Incentive Plan through December 12, 2017. The Plan expired in December 2017. As of December 31, 2024, there were 120,000 options outstanding under this plan.

 

2016 Share Incentive Plan

 

On December 9, 2016, shareholders approved the Company’s 2016 Share Incentive Plan (“2016 Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2016 Incentive Plan through December 9, 2026. As of December 31, 2024, there were 424,125 options outstanding under this plan.

 

2022 Share Incentive Plan

 

On July 14, 2022, shareholders approved the Company’s 2022 Share Incentive Plan (“2022 Incentive Plan”), in connection therewith, 515,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2022 Incentive Plan through July 14, 2032. As of December 31, 2024, there were 279,000 options outstanding under this plan.

 

Under the 2016 and 2022 Share Incentive Plans, the purchase price of the common stock under each option plan shall be determined by the Committee, provided, however, that such purchase price shall not be less than the fair market value of the shares on the date such option is granted. The stock options generally expire seven to ten years after the date of grant.

 

As of December 31, 2024, there were 44,948 shares available for grant under the 2016 Equity Incentive Plan and 138,180 shares available for grant under the 2022 Equity Incentive Plan.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 11 – Stock-Based Compensation (continued)

 

The Company recorded stock-based compensation of $1.1 million and $0.9 million for the years ended December 31, 2024 and 2023, respectively, that were included in the following line items in our Consolidated Statements of Operations (in thousands):

 

   2024   2023 
         
Cost of revenue  $152   $120 
Research and development   188    159 
Selling   107    94 
General and administrative   616    535 
           
Total stock-based compensation expense  $1,063   $908 

 

Stock-based compensation expense in both years included approximately $0.2 million related to restricted stock awards pursuant to a Director Compensation plan discussed below. The Company recognizes forfeitures of stock awards as they occur.

 

For the year ended December 31, 2024, the Company granted 5,000 stock options, vesting 25% per year over four years, with a ten-year life. The Company determined the fair value of stock options granted during the year ended December 31, 2024 is based upon weighted average assumptions as provided below.

 

Stock price  $4.75 
Exercise price  $4.75 
Dividend yield   0%
Expected volatility   77%
Risk-free interest rate   4.12%
Expected life (in years)   6.00 

 

The expected life is the number of years the Company estimates that the awards will be outstanding based on the simplified method that considers the vesting period and contractual period of the option. The expected volatility is measured using historical daily price changes of the Company’s common stock over the respective expected term. The Company has 823,125 of outstanding stock options under the three plans at December 31, 2024.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 11 – Stock-Based Compensation (continued)

 

The following table summarizes stock options awards for the years ended December 31, 2024 and 2023:

 

       Weighted 
  

Awards

(in Shares)

   Average
Exercise Price		 
Outstanding at December 31, 2022   673,000   $11.26 
           
Granted   254,000    14.02 
Expired / cancelled   (44,500)   6.57 
Exercised   (35,625)   4.53 
Outstanding at December 31, 2023   846,875    8.20 
Granted   5,000    4.75 
Expired / cancelled   (28,750)   7.94 
Exercised   -    - 
Outstanding at December 31, 2024   823,125    8.24 

 

At December 31, 2024 and 2023, stock options to purchase 485,000 and 265,000, respectively, shares of common stock were exercisable.

 

The following table summarizes information about the outstanding and exercisable options at December 31, 2024:

 

    Options Outstanding   Options Exercisable 
        Weighted   Weighted           Weighted     
        Average   Average           Average     
Exercise   Number   Remaining   Exercise   Intrinsic   Number   Exercise   Intrinsic 
Price Range   Outstanding   Contractual   Price   Value   Exercisable   Price   Value 
$ 4.00-7.00    444,625    6.7   $4.39   $-    285,375   $5.86   $50,580 
$7.01-10.00    20,000    3.3   $8.07   $-    20,000   $8.07   $- 
$10.01-13.00    130,000    2.7   $10.62   $-    122,500   $10.55   $- 
$13.01-16.00    228,500    8.2   $14.11   $-    57,125   $14.11   $- 

 

As of December 31, 2024, there was $1.6 million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of 2.1 years.

 

Restricted Stock Awards

 

Pursuant to the Director Compensation plan approved on October 11, 2021, each of the five independent directors is entitled to compensation for an annual equity retainer in the amount of $40,000 per director, to be automatically granted on the date of the Company’s annual meeting of shareholders.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 11 – Stock-Based Compensation (continued)

 

The following table summarizes restricted stock awards for the years ended December 31, 2024 and 2023:

 

       Weighted 
       Average Grant 
   Shares of   Date Fair 
   Restricted Stock   Value 
Unvested outstanding at January 1, 2023   -   $- 
Granted   41,320    6.65 
Vested   (24,187)   6.81 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2023   17,133    6.53 
           
Granted   57,327    3.55 
Vested   (46,210)   4.63 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2024   28,250   $3.54 

 

The fair value of the restricted stock awards is recorded as stock-based compensation expense over the one-year vesting period and totaled $0.2 million for the both years ending December 31, 2024 and 2023, respectively.

 
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Defined Contribution Plan
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Defined Contribution Plan

Note 12 – Defined Contribution Plan

 

The Company maintains a 401(k) Plan for the benefit of all eligible employees. All employees as of the effective date of the 401(k) Plan became eligible. An employee is eligible to become a participant after three months of continuous service.

 

Participants may elect to contribute from their compensation any amount up to the maximum deferral allowed by the Internal Revenue Code. Employer contributions are optional.

 

Effective July 1, 2022, the Company implemented a matching contribution of 50% of an employee’s contributions up to 6% of their compensation. The Company recorded compensation expense of $235,000 and $243,000 during the years ended December 31, 2024 and 2023, respectively, for matching contributions to the 401(k) plan.

 

No discretionary employer contribution has been made for 2024 and 2023.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable Segments
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Reportable Segments

Note 13 - Reportable Segments

 

The Company has determined that it has three reportable segments, organized primarily based on product offerings, as follows:

 

●CVD Equipment – manufactures chemical vapor deposition, physical vapor transport and thermal process equipment.

 

●SDC - manufactures ultra-high purity gas and chemical delivery control systems.

 

●MesoScribe - provided electronic printing services and products (heaters, antennas, and sensors).

 

Both CVD Equipment and SDC also sell spares and parts and provide services related to the equipment each segment sells. One other business, Tantaline, did not meet the quantitative threshold for separate reporting and has been reflected as “Other” below.

 

The chief operating decision maker (“CODM”) of the Company is the Company’s chief executive officer. The CODM assesses performance and decides how to allocate resources, including employees, financial or capital resources, based on segment net income (loss). The CODM considers actual-to-actual variances on a quarterly basis when making decisions about allocating capital and other resources to the segments and to assess the performance for each segment.

 

Financial results for the reportable segments and other business are prepared on a basis consistent with the internal disaggregation of financial information to assist the CODM is making internal operating decisions.

 

Certain income and expenses are excluded from segment net income (loss) and included in the unallocated amounts in the reconciliation of reportable segment net income (loss) to net loss. These items are not used by the CODM in allocating resources or evaluating the results of the segments and include the following: corporate expenses consisting of employment costs of executives, finance, information technology and human resources; board of director fees; professional fees; shareholder and investor relations expense; directors’ and officers’ insurance; interest income and income tax expense. Segment income (loss) from operations may not be consistent with measures used by other companies.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 13 - Reportable Segments (continued)

 

The following provides segment information as described below (in thousands):

 

   CVD   SDC   MesoScribe   Total 
   For the year ended December 31, 2024 
   CVD   SDC   MesoScribe   Total 
Segment revenue  $18,288   $8,444   $778   $27,510 
Less:                    
Cost of revenue   16,158    4,749    272    21,179 
Research & development   2,398    229    -    2,627 
Selling   1,456    195    5    1,656 
General & administrative   1,064    709    84    1,857 
Gain on sales of equipment   (42)   -    (675)   (717)
Other income   (2)   -    -    (2)
Interest expense   19    -    -    19 
Segment net income (loss)  $(2,763)  $2,562   $1,092   $891 
Segment assets  $15,903   $3,129   $627   $19,659 
Capital expenditures  $69   $37   $-   $106 
Depreciation & amortization  $635   $49   $-   $684 

 

   CVD   SDC   MesoScribe   Total 
   For the year ended December 31, 2023 
   CVD   SDC   MesoScribe   Total 
Segment revenue  $16,334   $7,139   $722   $24,195 
Less:                    
Cost of revenue   14,408    4,313    507    19,228 
Research & development   2,288    299    5    2,592 
Selling   1,414    172    -    1,586 
General & administrative   1,085    679    70    1,834 
Impairment charge   -    -    111    111 
Other income   (86)   -    -    (86)
Interest expense   23    -    -    23 
Segment net income (loss)  $(2,798)  $1,676   $29   $(1,093)
Segment assets  $19,112   $3,468   $211   $22,791 
Capital expenditures  $404   $14   $-   $418 
Depreciation & amortization  $620   $49   $59   $728 

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 13 - Reportable Segments (continued)

 

The following table presents a reconciliation of revenue of reportable segments to consolidated revenue (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Revenue of reportable segments  $27,510   $24,195 
Other - Tantaline   -    462 
Intersegment revenue   (634)   (548)
Consolidated total revenue  $26,876   $24,109 

 

Intersegment revenues are determined based on similar product sales to external customers of the Company.

 

The following table presents a reconciliation of net income (loss) of reportable segments to consolidated net loss (in thousand):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Net income (loss) of reportable segments  $891   $(1,093)
Unallocated amounts:          
Corporate expenses   (3,324)   (3,503)
Other - Tantaline   -    (175)
Interest income   559    577 
Income tax (expense) benefit   (24)   14 
Consolidated net loss  $(1,898)  $(4,180)

 

The following table presents a reconciliation of total assets of reportable segments to consolidated total assets (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Total assets of reportable segments  $19,659   $22,791 
Unallocated amounts:          
Cash equivalents   11,892    12,099 
Other current assets   135    135 
Consolidated total assets  $31,686   $35,025 

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 13 - Reportable Segments (continued)

 

The following table presents a revenue by geographic area (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
United States  $25,720   $19,975 
North America, excluding US   65    56 
Europe, Middle East and Africa   521    1,508 
Asia-Pacific   570    2,570 
Consolidated total revenue  $26,876   $24,109 

 

For geographic reporting, revenues are attributed to the location in which in the customer facility is located. All of the Company’s long-lived assets are located in the United States.

 
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.25.1
MesoScribe and Tantaline
 12 Months Ended
Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]  
MesoScribe and Tantaline

Note 14 – MesoScribe and Tantaline

 

MesoScribe

 

On August 8, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with a third-party. Pursuant to the Agreement, the Company sold certain proprietary equipment relating to its plasma spray technology and material deposition system and granted a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate adjusted purchase price of $0.8 million. The purchase price was payable in several installments and contingent upon certain performance metrics and other milestones.

 

The Company received payments under the Agreement in the amount of $0.6 million which had been reflected as “deposits from purchaser” in the accompanying consolidated balance sheet as of December 31, 2023.

 

The Company fulfilled remaining orders for MesoScribe products during 2024 at which time it ceased operations of MesoScribe and recorded a $0.7 million gain upon the completion of the sale of the equipment during the year ended December 31, 2024. During the year ended December 31, 2023, the Company recorded an impairment charge of $0.1 million for other equipment of MesoScribe.

 

The revenues and net income of MesoScribe were $0.8 million and $1.1 million for the year ended December 31, 2024, including the gain on sale of equipment of $0.7 million.

 

The revenues and net income of MesoScribe were $0.7 million and $33,000 for the year ended December 31, 2023, including the impairment charge of $0.1 million.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 14 – MesoScribe and Tantaline (continued)

 

The total assets and total liabilities of the MesoScribe subsidiary were $0.6 million and $0, respectively, as of December 31, 2024 and $0.2 million and $0.7 million, respectively, as of December 31, 2023.

 

Tantaline

 

On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $0.2 million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt. The Company received a $6,000 earn-out payment in 2024 based on the results of Tantaline’s operations for the year ended December 31, 2023.

 

Including the loss on disposition of $0.2 million, the revenues and net income of Tantaline were $0.5 million and $0.1 million, respectively, for the year ended December 31, 2023.

 
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Risks and Uncertainties
 12 Months Ended
Dec. 31, 2024
Risks And Uncertainties  
Risks and Uncertainties

Note 15 – Risks and Uncertainties

 

The Company currently operates in a challenging economic environment as the global economy continues to confront the remaining impacts from the pandemic, geopolitical conflicts, inflationary pressures, and adverse supply chain disruptions. The specific impacts on the Company have included:

 

●Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions.

 

●Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue timelier as it delays the Company’s manufacturing processes.

 

While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties may have on its future results of operations and cash flows.
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 
Liquidity

Liquidity

 

At December 31, 2024, the Company had $12.6 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of these financial statements.

 
Reclassifications

Reclassifications

 

In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net loss.

 
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 
Revenue Recognition

Revenue Recognition

 

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606”), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.

 

Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to

 

evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the year ended December 31, 2024 and 2023.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because the Company believes these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide the Company with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the years ended December 31, 2024 and 2023, all system equipment sales were recorded over time by using an input method except for a) one contract that was recorded as revenue at the point in time the equipment was transferred to the customer during 2024 and b) one contract that was entered during 2024 and will be recognized as revenue after December 31, 2024 upon transfer of the equipment to the customer.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 
Inventories

Inventories

 

Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.

 

Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.

 
Product Warranty

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

 
Income Taxes

Income Taxes

 

Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes potential interest and penalties related to uncertain tax positions in income tax expense.

 

The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.

 
Impairment of Long-Lived Assets and Intangibles

Impairment of Long-Lived Assets and Intangibles

 

Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists. If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.

 
Property, Plant and Equipment

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over 5 to 39 years and for machinery and equipment over 5 to 8 years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.

 
Research and Development

Research and Development

 

Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 
Earnings Per Share

Earnings Per Share

 

Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.

 

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company had cash and cash equivalents of $12.6 million and $14.0 million at December 31, 2024 and 2023, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $11.9 million and $12.1 million at December 31, 2024 and 2023, respectively.

 

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at December 31, 2024 and 2023 was $0.4 million and $1.5 million, respectively.

 
Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.

 

The Company routinely assesses the financial strength of its customers. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Accounts receivable is presented net of an allowance for credit losses of $48,000, $36,000 and $36,000 as of December 31, 2024, 2023 and 2022, respectively. The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for credit losses could be material to our results of operations and financial condition. The provision for bad debt expense was $13,000 and $0 for the years ended December 31, 2024 and 2023, respectively.

 

The Company has accounts receivables from certain customers that exceed 10% of total accounts receivable. As of December 31, 2024, the accounts receivable balance includes amounts from three customers that represented 28.6%, 14.0% and 11.9% of total accounts receivable, and as of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented 37.6%, 13.0% and 12.8% of total accounts receivable.

 
Sales Concentrations

Sales Concentrations

 

Revenue to a single customer in any one year can exceed 10% of our total sales. There was one customer of the CVD Equipment segment in the year ended December 31, 2024 that represented 29.5% of our revenues, while there were three customers of the CVD Equipment segment in the year ended December 31, 2023 that represented 14.3%, 13.5% and 10.9% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.

 

Export sales to customers represented approximately 4.3% and 17.2% of sales years ended December 31, 2024 and 2023 respectively. Export sales in both 2024 and 2023 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.

 
Supplier Risk

Supplier Risk

 

The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates. The value of restricted stock awards are based on the fair value on the date of the grant.

 
Shipping and Handling

Shipping and Handling

 

It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $73,000 and $55,000 for the years ended December 31, 2024 and 2023, respectively.

 
Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This update is effective for our annual report for fiscal year 2024, and interim periods thereafter, and was applied retrospectively to the fiscal year 2024 financial statements.. The Company adopted ASU 2023-07 in 2024 and the required disclosures are included in Note 13.

 
Recently Issued Accounting Standards

Recently Issued Accounting Standards

 

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. The amendments further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This ASU is effective for our annual report for fiscal year 2026, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the timing of adoption and impact of this ASU on our consolidated financial statements.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2024 and 2023

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statements Expenses (Subtopic 220-40),” to improve income statement expenses disclosure. The standard requires more detailed information related to the types of expenses, including (among other items) the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included within each interim and annual income statement’s expense caption, as applicable. This authoritative guidance can be applied prospectively or retrospectively and will be effective for financial statements issued for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue

The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2024 and 2023 (in thousands):

 

   Over time   Point in time   Total 
   Year Ended December 31, 2024 
   Over time   Point in time   Total 
Energy  $216   $511   $727 
Aerospace   11,205    1,879    13,084 
Industrial   6,921    1,350    8,271 
Research   3,736    1,058    4,794 
Total  $22,216   $4,660   $26,876 

 

   Over time   Point in time   Total 
   Year Ended December 31, 2023 
   Over time   Point in time   Total 
Energy  $4,901   $189   $5,090 
Aerospace   3,427    1,469    4,896 
Industrial   6,123    2,821    8,944 
Research   3,700    1,479    5,179 
Total  $18,151   $5,958   $24,109 
Schedule of Cost and Estimated Earnings in Excess of Billings

Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):

 

   2024   2023 
Costs incurred on contracts in progress  $14,696   $9,500 
Estimated earnings   7,052    5,083 
Costs and estimated earnings on uncompleted contracts   21,748    14,583 
Billings to date   (22,059)   (17,553)
Net cost in excess of billings   (311)   (2,970)
Deferred revenue related to non-systems contracts   (598)   (334)
Contract liability in excess of contract assets  $(909)  $(3,304)
Included in accompanying consolidated balance sheets under the following captions (in thousands):          
           
Contract assets  $2,226   $1,604 
Contract liabilities  $3,135   $4,908 
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories (Tables)
 12 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories, net

Inventories as of December 31 consist of (in thousands):

 

   2024   2023 
         
Raw materials  $1,217   $2,351 
Work-in-process   765    1,248 
Finished goods   133    855 
Total  $2,115   $4,454 
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Property, Plant and Equipment (Tables)
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment

Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):

 

   2024   2023 
         
Land  $2,220   $2,220 
Buildings and improvements   12,897    12,798 
Machinery and equipment   7,178    7,536 
Construction in progress   17    167 
Totals at cost   22,312    22,721 
           
Less: accumulated depreciation   (10,613)   (10,555)
Property, plant and equipment, net  $11,699   $12,166 
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consist of the following as of December 31 (in thousands):

 

   2024   2023 
         
Accrued wages and benefits  $395   $358 
Accrued vacation   683    729 
Accrued material purchases   618    289 
Other   540    389 
Total accrued expenses  $2,236   $1,765 
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Long-term Debt (Tables)
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long Term Debt

Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):

 

   2024   2023 
Equipment loan payable in monthly repayments of $8 including interest at 6% per annum  $268   $349 
Less: current maturities   87    81 
Long-term debt, net of current maturities  $181   $268 
Schedule of Maturities of Long Term Debt

Future maturities of long-term debt as of December 31, 2024 are as follows (in thousands):

 

      
2024  $87 
2025   92 
2026   89 
      
Total  $268 
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Earnings per Share (Tables)
 12 Months Ended
Dec. 31, 2024
Loss per common share:  
Schedule of Basic and Diluted Weighted Average Common Shares Outstanding

The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):

 

   2024   2023 
         
Basic weighted average shares outstanding   6,823    6,788 
Effect of potentially dilutive share-based awards   -    - 
           
Diluted weighted average shares outstanding   6,823    6,788 
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Loss Before Income Taxes

Loss before income taxes are as follows:

 

   2024   2023 
         
Domestic  $(1,874)   (4,073)
Foreign   -    (121)
Total  $(1,874)  $(4,194)
Schedule of Components of Income Tax Expense (Benefit)

The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):

 

   2024   2023 
Current:        
Federal  $14   $(16)
State   10    2 
Total current tax provision   24    (14)
Deferred:          
Federal   -    - 
State   -    - 
Total deferred tax provision   -    - 
Income tax expense (benefit)  $24   $(14)
Schedule of Effective Income Tax Rate Reconciliation

The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):

 

   2024   2023 
Expected provision at federal statutory tax rate at 21%  $(395)  $(881)
Increase in valuation allowance   447    688 
State and local taxes   (197)   21 
Federal research and development credits   -    (75)
Non-deductible expenses   86    37 
Disposition of Tantaline   -    193 
Other   83    3 
Income tax expense (benefit)  $24   $(14)
Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):

 

   2024   2023 
Deferred income tax assets:          
Net operating loss carryforwards  $679   $849 
R&D tax credit carryforwards   1,722    1,863 
Compensation costs   235    113 
Vacation accrual   118    153 
Intangible assets   38    38 
Capitalized research and development   1,096    759 
Other items   676    303 
Deferred income tax assets   4,564    4,078 
Less: valuation allowance   (4,098)   (3,646)
Deferred income tax assets, net of valuation allowance   466    432 
Deferred incomes tax liability:          
Property, plant and equipment   (384)   (365)
Prepaid expenses   (82)   (67)
Deferred income tax asset, net  $-   $- 
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Based Compensation

 

   2024   2023 
         
Cost of revenue  $152   $120 
Research and development   188    159 
Selling   107    94 
General and administrative   616    535 
           
Total stock-based compensation expense  $1,063   $908 
Schedule of Weighted Average Assumptions

 

Stock price  $4.75 
Exercise price  $4.75 
Dividend yield   0%
Expected volatility   77%
Risk-free interest rate   4.12%
Expected life (in years)   6.00 
Schedule of Stock Options Awards

The following table summarizes stock options awards for the years ended December 31, 2024 and 2023:

 

       Weighted 
  

Awards

(in Shares)

   Average
Exercise Price		 
Outstanding at December 31, 2022   673,000   $11.26 
           
Granted   254,000    14.02 
Expired / cancelled   (44,500)   6.57 
Exercised   (35,625)   4.53 
Outstanding at December 31, 2023   846,875    8.20 
Granted   5,000    4.75 
Expired / cancelled   (28,750)   7.94 
Exercised   -    - 
Outstanding at December 31, 2024   823,125    8.24 
Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices

The following table summarizes information about the outstanding and exercisable options at December 31, 2024:

 

    Options Outstanding   Options Exercisable 
        Weighted   Weighted           Weighted     
        Average   Average           Average     
Exercise   Number   Remaining   Exercise   Intrinsic   Number   Exercise   Intrinsic 
Price Range   Outstanding   Contractual   Price   Value   Exercisable   Price   Value 
$ 4.00-7.00    444,625    6.7   $4.39   $-    285,375   $5.86   $50,580 
$7.01-10.00    20,000    3.3   $8.07   $-    20,000   $8.07   $- 
$10.01-13.00    130,000    2.7   $10.62   $-    122,500   $10.55   $- 
$13.01-16.00    228,500    8.2   $14.11   $-    57,125   $14.11   $- 
Schedule of Restricted Stock Awards

The following table summarizes restricted stock awards for the years ended December 31, 2024 and 2023:

 

       Weighted 
       Average Grant 
   Shares of   Date Fair 
   Restricted Stock   Value 
Unvested outstanding at January 1, 2023   -   $- 
Granted   41,320    6.65 
Vested   (24,187)   6.81 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2023   17,133    6.53 
           
Granted   57,327    3.55 
Vested   (46,210)   4.63 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2024   28,250   $3.54 
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable Segments (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segments

The following provides segment information as described below (in thousands):

 

   CVD   SDC   MesoScribe   Total 
   For the year ended December 31, 2024 
   CVD   SDC   MesoScribe   Total 
Segment revenue  $18,288   $8,444   $778   $27,510 
Less:                    
Cost of revenue   16,158    4,749    272    21,179 
Research & development   2,398    229    -    2,627 
Selling   1,456    195    5    1,656 
General & administrative   1,064    709    84    1,857 
Gain on sales of equipment   (42)   -    (675)   (717)
Other income   (2)   -    -    (2)
Interest expense   19    -    -    19 
Segment net income (loss)  $(2,763)  $2,562   $1,092   $891 
Segment assets  $15,903   $3,129   $627   $19,659 
Capital expenditures  $69   $37   $-   $106 
Depreciation & amortization  $635   $49   $-   $684 

 

   CVD   SDC   MesoScribe   Total 
   For the year ended December 31, 2023 
   CVD   SDC   MesoScribe   Total 
Segment revenue  $16,334   $7,139   $722   $24,195 
Less:                    
Cost of revenue   14,408    4,313    507    19,228 
Research & development   2,288    299    5    2,592 
Selling   1,414    172    -    1,586 
General & administrative   1,085    679    70    1,834 
Impairment charge   -    -    111    111 
Other income   (86)   -    -    (86)
Interest expense   23    -    -    23 
Segment net income (loss)  $(2,798)  $1,676   $29   $(1,093)
Segment assets  $19,112   $3,468   $211   $22,791 
Capital expenditures  $404   $14   $-   $418 
Depreciation & amortization  $620   $49   $59   $728 
Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue

The following table presents a reconciliation of revenue of reportable segments to consolidated revenue (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Revenue of reportable segments  $27,510   $24,195 
Other - Tantaline   -    462 
Intersegment revenue   (634)   (548)
Consolidated total revenue  $26,876   $24,109 
Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss

The following table presents a reconciliation of net income (loss) of reportable segments to consolidated net loss (in thousand):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Net income (loss) of reportable segments  $891   $(1,093)
Unallocated amounts:          
Corporate expenses   (3,324)   (3,503)
Other - Tantaline   -    (175)
Interest income   559    577 
Income tax (expense) benefit   (24)   14 
Consolidated net loss  $(1,898)  $(4,180)
Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets

The following table presents a reconciliation of total assets of reportable segments to consolidated total assets (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Total assets of reportable segments  $19,659   $22,791 
Unallocated amounts:          
Cash equivalents   11,892    12,099 
Other current assets   135    135 
Consolidated total assets  $31,686   $35,025 
Schedule of Revenue by Geographic Area

The following table presents a revenue by geographic area (in thousands):

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
United States  $25,720   $19,975 
North America, excluding US   65    56 
Europe, Middle East and Africa   521    1,508 
Asia-Pacific   570    2,570 
Consolidated total revenue  $26,876   $24,109 
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]      
Cash and cash equivalents $ 12,598,000 $ 14,025,000  
Contract assets, impairment loss $ 0 0  
Standard product warranty description The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period.    
Income tax examination, description 50% likely to be realized upon ultimate settlement    
Cash equivalents $ 11,900,000 12,100,000  
Cash uninsured amount 400,000 1,500,000  
Allowance for credit loss 48,000 36,000 $ 36,000
Accounts Receivable, Credit Loss Expense (Reversal) 13,000  
Revenue 26,876,000 24,109,000  
Cargo and Freight [Member]      
Product Information [Line Items]      
Revenue $ 73,000 $ 55,000  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer [Member]      
Product Information [Line Items]      
Concentration risk percentage 10.00%    
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]      
Product Information [Line Items]      
Concentration risk percentage 28.60% 37.60%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]      
Product Information [Line Items]      
Concentration risk percentage 14.00% 13.00%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]      
Product Information [Line Items]      
Concentration risk percentage 11.90% 12.80%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member]      
Product Information [Line Items]      
Concentration risk percentage 10.00%    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer A [Member]      
Product Information [Line Items]      
Concentration risk percentage 29.50% 14.30%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer B [Member]      
Product Information [Line Items]      
Concentration risk percentage   13.50%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer C [Member]      
Product Information [Line Items]      
Concentration risk percentage   10.90%  
Export Sales [Member] | Customer Concentration Risk [Member] | Geographic Distribution, Foreign [Member]      
Product Information [Line Items]      
Concentration risk percentage 4.30% 17.20%  
Building and Building Improvements [Member] | Minimum [Member]      
Product Information [Line Items]      
Property plant and equipment useful life 5 years    
Building and Building Improvements [Member] | Maximum [Member]      
Product Information [Line Items]      
Property plant and equipment useful life 39 years    
Machinery and Equipment [Member] | Minimum [Member]      
Product Information [Line Items]      
Property plant and equipment useful life 5 years    
Machinery and Equipment [Member] | Maximum [Member]      
Product Information [Line Items]      
Property plant and equipment useful life 8 years    
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]    
Total $ 26,876 $ 24,109
Energy [Member]    
Disaggregation of Revenue [Line Items]    
Total 727 5,090
Aerospace [Member]    
Disaggregation of Revenue [Line Items]    
Total 13,084 4,896
Industrial [Member]    
Disaggregation of Revenue [Line Items]    
Total 8,271 8,944
Research [Member]    
Disaggregation of Revenue [Line Items]    
Total 4,794 5,179
Transferred over Time [Member]    
Disaggregation of Revenue [Line Items]    
Total 22,216 18,151
Transferred over Time [Member] | Energy [Member]    
Disaggregation of Revenue [Line Items]    
Total 216 4,901
Transferred over Time [Member] | Aerospace [Member]    
Disaggregation of Revenue [Line Items]    
Total 11,205 3,427
Transferred over Time [Member] | Industrial [Member]    
Disaggregation of Revenue [Line Items]    
Total 6,921 6,123
Transferred over Time [Member] | Research [Member]    
Disaggregation of Revenue [Line Items]    
Total 3,736 3,700
Transferred at Point in Time [Member]    
Disaggregation of Revenue [Line Items]    
Total 4,660 5,958
Transferred at Point in Time [Member] | Energy [Member]    
Disaggregation of Revenue [Line Items]    
Total 511 189
Transferred at Point in Time [Member] | Aerospace [Member]    
Disaggregation of Revenue [Line Items]    
Total 1,879 1,469
Transferred at Point in Time [Member] | Industrial [Member]    
Disaggregation of Revenue [Line Items]    
Total 1,350 2,821
Transferred at Point in Time [Member] | Research [Member]    
Disaggregation of Revenue [Line Items]    
Total $ 1,058 $ 1,479
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Cost and Estimated Earnings in Excess of Billings (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]      
Costs incurred on contracts in progress $ 14,696 $ 9,500  
Estimated earnings 7,052 5,083  
Costs and estimated earnings on uncompleted contracts 21,748 14,583  
Billings to date (22,059) (17,553)  
Net cost in excess of billings (311) (2,970)  
Deferred revenue related to non-systems contracts (598) (334)  
Contract liability in excess of contract assets (909) (3,304)  
Contract assets 2,226 1,604  
Contract liabilities $ 3,135 $ 4,908 $ 4,000
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]      
Unrecognized contract revenue $ 16,400    
Contract liability recognized as revenue 4,700 $ 3,700  
Contract assets     $ 2,200
Contract liability $ 3,135 $ 4,908 $ 4,000
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Inventories, net (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 1,217 $ 2,351
Work-in-process 765 1,248
Finished goods 133 855
Total $ 2,115 $ 4,454
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Inventories (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Inventory [Line Items]    
Inventories $ 2,115 $ 4,454
PVT 150 Systems [Member]    
Inventory [Line Items]    
Non-cash charge to reduce net realizable value 1,300  
Inventories $ 500  
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Totals at cost $ 22,312 $ 22,721
Less: accumulated depreciation (10,613) (10,555)
Property, plant and equipment, net 11,699 12,166
Land [Member]    
Property, Plant and Equipment [Line Items]    
Totals at cost 2,220 2,220
Building and Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Totals at cost 12,897 12,798
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Totals at cost 7,178 7,536
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Totals at cost $ 17 $ 167
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Property, Plant and Equipment (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 0.7 $ 0.8
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Accrued wages and benefits $ 395 $ 358
Accrued vacation 683 729
Accrued material purchases 618 289
Other 540 389
Total accrued expenses $ 2,236 $ 1,765
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Long Term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
Equipment loan payable in monthly repayments of $8 including interest at 6% per annum $ 268 $ 349
Less: current maturities 87 81
Long-term debt, net of current maturities $ 181 $ 268
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Long Term Debt (Details) (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
Debt Instrument, Periodic Payment $ 8 $ 8
Debt instrument interest rate 6.00% 6.00%
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Maturities of Long Term Debt (Details)
$ in Thousands
Dec. 31, 2024
USD ($)
Debt Disclosure [Abstract]  
2024 $ 87
2025 92
2026 89
Total $ 268
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Long-term Debt (Details Narrative)
$ in Millions
Sep. 30, 2022
USD ($)
Debt Disclosure [Abstract]  
Loan to fund acquisition of machinery equipment $ 0.4
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Loss per common share:    
Basic weighted average shares outstanding 6,823 6,788
Effect of potentially dilutive share-based awards
Diluted weighted average shares outstanding 6,823 6,788
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Loss Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Domestic $ (1,874) $ (4,073)
Foreign (121)
Loss before income tax $ (1,874) $ (4,194)
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Federal $ 14 $ (16)
State 10 2
Total current tax provision 24 (14)
Federal
State
Total deferred tax provision
Income tax expense (benefit) $ 24 $ (14)
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Expected provision at federal statutory tax rate at 21% $ (395) $ (881)
Increase in valuation allowance 447 688
State and local taxes (197) 21
Federal research and development credits (75)
Non-deductible expenses 86 37
Disposition of Tantaline 193
Other 83 3
Income tax expense (benefit) $ 24 $ (14)
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Federal statutory tax rate 21.00% 21.00%
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards $ 679 $ 849
R&D tax credit carryforwards 1,722 1,863
Compensation costs 235 113
Vacation accrual 118 153
Intangible assets 38 38
Capitalized research and development 1,096 759
Other items 676 303
Deferred income tax assets 4,564 4,078
Less: valuation allowance (4,098) (3,646)
Deferred income tax assets, net of valuation allowance 466 432
Property, plant and equipment (384) (365)
Prepaid expenses (82) (67)
Deferred income tax asset, net
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Effective Income Tax Rate Reconciliation [Line Items]    
Increase in valuation allowance $ 500,000  
Uncertain tax positions $ 0 $ 0
Income tax examination, year The federal tax years open to examination are 2021 to 2024. The Company’s state and local tax years that are open to tax examination are generally 2020 to 2024.  
Corporate tax rate 15.00%  
Excise tax rate 1.00%  
Domestic Tax Jurisdiction [Member] | Internal Revenue Service (IRS) [Member]    
Effective Income Tax Rate Reconciliation [Line Items]    
Operating loss carryforwards $ 2,700,000  
Operating loss carryforwards, limitations These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income.  
Domestic Tax Jurisdiction [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]    
Effective Income Tax Rate Reconciliation [Line Items]    
Tax credit carryforward. $ 1,700,000  
Tax credit carryforward expiration expire in varying amounts in tax years 2028 through 2042.  
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Employee Retention Credit (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Employee Retention Credit      
Employee retention credit eligible amount $ (1,529) $ 1,500
Employee retention credit receivable     $ 1,500
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Stock Based Compensation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 1,063 $ 908
Cost of Revenue [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 152 120
Research and Development Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 188 159
Selling Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 107 94
General and Administrative Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 616 $ 535
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Weighted Average Assumptions (Details)
 12 Months Ended
Dec. 31, 2024
$ / shares
Share-Based Payment Arrangement [Abstract]  
Stock price $ 4.75
Exercise price $ 4.75
Dividend yield 0.00%
Expected volatility 77.00%
Risk-free interest rate 4.12%
Expected life (in years) 6 years
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Stock Options Awards (Details) - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Awards outstanding, beginning balance 846,875 673,000
Weighted average exercise price outstanding, beginning balance $ 8.20 $ 11.26
Awards, granted 5,000 254,000
Weighted average exercise price, granted $ 4.75 $ 14.02
Awards, expired / cancelled (28,750) (44,500)
Weighted average exercise price, expired / cancelled $ 7.94 $ 6.57
Awards, exercised (35,625)
Weighted average exercise price, exercised $ 4.53
Awards outstanding, ending balance 823,125 846,875
Weighted average exercise price outstanding, ending balance $ 8.24 $ 8.20
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Exercise Price Range One [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price range, lower limit $ 4.00
Exercise price range, upper limit $ 7.00
Number of options outstanding | shares 444,625
Number of options outstanding, weighted average remaining contractual term 6 years 8 months 12 days
Number of options outstanding, weighted average exercise price $ 4.39
Number of options outstanding, intrinsic value | $
Number of options exercisable | shares 285,375
Number of options exercisable, weighted average exercise price $ 5.86
Number of options exercisable, intrinsic value | $ $ 50,580
Exercise Price Range Two [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price range, lower limit $ 7.01
Exercise price range, upper limit $ 10.00
Number of options outstanding | shares 20,000
Number of options outstanding, weighted average remaining contractual term 3 years 3 months 18 days
Number of options outstanding, weighted average exercise price $ 8.07
Number of options outstanding, intrinsic value | $
Number of options exercisable | shares 20,000
Number of options exercisable, weighted average exercise price $ 8.07
Number of options exercisable, intrinsic value | $
Exercise Price Range Three [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price range, lower limit $ 10.01
Exercise price range, upper limit $ 13.00
Number of options outstanding | shares 130,000
Number of options outstanding, weighted average remaining contractual term 2 years 8 months 12 days
Number of options outstanding, weighted average exercise price $ 10.62
Number of options outstanding, intrinsic value | $
Number of options exercisable | shares 122,500
Number of options exercisable, weighted average exercise price $ 10.55
Number of options exercisable, intrinsic value | $
Exercise Price Range Four [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price range, lower limit $ 13.01
Exercise price range, upper limit $ 16.00
Number of options outstanding | shares 228,500
Number of options outstanding, weighted average remaining contractual term 8 years 2 months 12 days
Number of options outstanding, weighted average exercise price $ 14.11
Number of options outstanding, intrinsic value | $
Number of options exercisable | shares 57,125
Number of options exercisable, weighted average exercise price $ 14.11
Number of options exercisable, intrinsic value | $
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Shares of restricted stock, unvested outstanding beginning balance 17,133
Weighted average grant date fair value, unvested outstanding beginning balance $ 6.53
Shares of restricted stock, granted 57,327 41,320
Weighted average grant date fair value, granted $ 3.55 $ 6.65
Shares of restricted stock, vested (46,210) (24,187)
Weighted average grant date fair value, vested $ 4.63 $ 6.81
Shares of restricted stock, forfeited or cancelled
Weighted average grant date fair value, forfeited or cancelled
Shares of restricted stock, unvested outstanding ending balance 28,250 17,133
Weighted average grant date fair value, unvested outstanding ending balance $ 3.54 $ 6.53
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Details Narrative) - USD ($)
 12 Months Ended
Jul. 14, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Oct. 11, 2021
Dec. 09, 2016
Dec. 12, 2007
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Outstanding stock options   823,125 846,875 673,000      
Stock based compensation   $ 1,063,000 $ 908,000        
Stock option granted   5,000 254,000        
Stock options exercisable   485,000 265,000        
Five Directors [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Annual equity retainer amount         $ 40,000    
Restricted Stock [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Stock based compensation   $ 200,000 $ 200,000        
Vesting period   1 year          
Restricted Stock [Member] | Director [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Stock based compensation   $ 200,000 $ 200,000        
Share-Based Payment Arrangement, Option [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Expiration period   10 years          
Stock option granted   5,000          
Stock option vesting percentage   25.00%          
Unrecognized compensation costs   $ 1,600,000          
Unrecognized compensation costs, weighted average recoginition period   2 years 1 month 6 days          
2007 Share Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Common shares reserved for future issuance.             750,000
Outstanding stock options   120,000          
2016 Share Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Common shares reserved for future issuance.           750,000  
Outstanding stock options   424,125          
Number of shares available for grant   44,948          
2022 Share Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Common shares reserved for future issuance. 515,000            
Outstanding stock options   279,000          
Number of shares available for grant   138,180          
2022 Share Incentive Plan [Member] | Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Expiration period 7 years            
2022 Share Incentive Plan [Member] | Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Expiration period 10 years            
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.25.1
Defined Contribution Plan (Details Narrative) - USD ($)
 12 Months Ended
Jul. 01, 2022
Dec. 31, 2024
Dec. 31, 2023
Retirement Benefits [Abstract]      
Defined contribution plan percentage 50.00%    
Defined contribution plan percentage of employees contribution 6.00%    
Defined contribution plan cost   $ 235,000 $ 243,000
Defined contribution plan, employer discretionary contribution amount   $ 0 $ 0
XML 83 R65.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Segments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Segment revenue $ 26,876 $ 24,109
Cost of revenue 20,545 19,038
Research & development 2,627 2,596
Selling 1,656 1,632
General & administrative 5,181 5,451
Gain on sales of equipment (717)
Impairment charge 111
Other income 2 91
Interest expense 19 23
Segment net income (loss) (1,898) (4,180)
Segment assets 31,686 35,025
Depreciation & amortization 684 792
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Segment revenue 27,510 24,195
Cost of revenue 21,179 19,228
Research & development 2,627 2,592
Selling 1,656 1,586
General & administrative 1,857 1,834
Gain on sales of equipment (717)  
Impairment charge   111
Other income (2) (86)
Interest expense 19 23
Segment net income (loss) 891 (1,093)
Segment assets 19,659 22,791
Capital expenditures 106 418
Depreciation & amortization 684 728
Operating Segments [Member] | CVD [Member]    
Segment Reporting Information [Line Items]    
Segment revenue 18,288 16,334
Cost of revenue 16,158 14,408
Research & development 2,398 2,288
Selling 1,456 1,414
General & administrative 1,064 1,085
Gain on sales of equipment (42)  
Impairment charge  
Other income (2) (86)
Interest expense 19 23
Segment net income (loss) (2,763) (2,798)
Segment assets 15,903 19,112
Capital expenditures 69 404
Depreciation & amortization 635 620
Operating Segments [Member] | SDC [Member]    
Segment Reporting Information [Line Items]    
Segment revenue 8,444 7,139
Cost of revenue 4,749 4,313
Research & development 229 299
Selling 195 172
General & administrative 709 679
Gain on sales of equipment  
Impairment charge  
Other income
Interest expense
Segment net income (loss) 2,562 1,676
Segment assets 3,129 3,468
Capital expenditures 37 14
Depreciation & amortization 49 49
Operating Segments [Member] | Meso Scribe Technologies Inc [Member]    
Segment Reporting Information [Line Items]    
Segment revenue 778 722
Cost of revenue 272 507
Research & development 5
Selling 5
General & administrative 84 70
Gain on sales of equipment (675)  
Impairment charge   111
Other income
Interest expense
Segment net income (loss) 1,092 29
Segment assets 627 211
Capital expenditures
Depreciation & amortization $ 59
XML 84 R66.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Consolidated total revenue $ 26,876 $ 24,109
Other - Tantaline [Member]    
Segment Reporting Information [Line Items]    
Consolidated total revenue 462
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Consolidated total revenue 27,510 24,195
Intersegment Eliminations [Member]    
Segment Reporting Information [Line Items]    
Consolidated total revenue $ (634) $ (548)
XML 85 R67.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Net loss $ (1,898) $ (4,180)
Interest income 559 577
Income tax (expense) benefit (24) 14
Other - Tantaline [Member]    
Segment Reporting Information [Line Items]    
Unallocated amounts (175)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Net loss 891 (1,093)
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]    
Segment Reporting Information [Line Items]    
Unallocated amounts $ (3,324) $ (3,503)
XML 86 R68.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Consolidated total assets $ 31,686 $ 35,025
Cash equivalents 12,598 14,025
Other current assets 898 852
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Consolidated total assets 19,659 22,791
Cash equivalents 11,892 12,099
Other current assets $ 135 $ 135
XML 87 R69.htm IDEA: XBRL DOCUMENT v3.25.1
Schedule of Revenue by Geographic Area (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]    
Consolidated total revenue $ 26,876 $ 24,109
Americas [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Consolidated total revenue 25,720 19,975
North America [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Consolidated total revenue 65 56
EMEA [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Consolidated total revenue 521 1,508
Asia Pacific [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Consolidated total revenue $ 570 $ 2,570
XML 88 R70.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable Segments (Details Narrative)
 12 Months Ended
Dec. 31, 2024
Segment
Segment Reporting [Abstract]  
Number of operating segments 3
XML 89 R71.htm IDEA: XBRL DOCUMENT v3.25.1
MesoScribe and Tantaline (Details Narrative) - USD ($)
 12 Months Ended
May 26, 2023
Dec. 31, 2024
Dec. 31, 2023
Aug. 08, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Deposits from purchaser of equipment   $ 597,000  
Gain on sale of equipment   717,000  
Impairment charge   111,000  
Revenue   26,876,000 24,109,000  
Net loss   (1,898,000) (4,180,000)  
Assets   31,686,000 35,025,000  
Liabilities   6,318,000 8,822,000  
Loss on disposition of tantaline   (162,000)  
Tantaline A/S of Nordborg [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenue     500,000  
Net loss     100,000  
Loss on disposition of tantaline $ 200,000   200,000  
Earn-out payment     6,000  
Meso Scribe Technologies Inc [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Aggregate purchase price       $ 800,000
Deposits from purchaser of equipment     600,000  
Gain on sale of equipment   700,000    
Impairment charge     100,000  
Revenue   800,000 700,000  
Net loss   1,100,000 33,000  
Assets   600,000 200,000  
Liabilities   $ 0 $ 700,000  
EXCEL 90 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 91 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 92 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 94 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 158 318 1 false 60 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://cvdequipment.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://cvdequipment.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://cvdequipment.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://cvdequipment.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://cvdequipment.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995443 - Disclosure - Award Timing Disclosure Sheet http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure Award Timing Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 10 false false R11.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 11 false false R12.htm 999014 - Disclosure - Business Description Sheet http://cvdequipment.com/role/BusinessDescription Business Description Notes 12 false false R13.htm 999015 - Disclosure - Summary of Significant Accounting Policies Sheet http://cvdequipment.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 13 false false R14.htm 999016 - Disclosure - Revenue Sheet http://cvdequipment.com/role/Revenue Revenue Notes 14 false false R15.htm 999017 - Disclosure - Inventories Sheet http://cvdequipment.com/role/Inventories Inventories Notes 15 false false R16.htm 999018 - Disclosure - Property, Plant and Equipment Sheet http://cvdequipment.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 16 false false R17.htm 999019 - Disclosure - Accrued Expenses Sheet http://cvdequipment.com/role/AccruedExpenses Accrued Expenses Notes 17 false false R18.htm 999020 - Disclosure - Long-term Debt Sheet http://cvdequipment.com/role/Long-termDebt Long-term Debt Notes 18 false false R19.htm 999021 - Disclosure - Earnings per Share Sheet http://cvdequipment.com/role/EarningsPerShare Earnings per Share Notes 19 false false R20.htm 999022 - Disclosure - Income Taxes Sheet http://cvdequipment.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 999023 - Disclosure - Employee Retention Credit Sheet http://cvdequipment.com/role/EmployeeRetentionCredit Employee Retention Credit Notes 21 false false R22.htm 999024 - Disclosure - Stock-Based Compensation Sheet http://cvdequipment.com/role/Stock-basedCompensation Stock-Based Compensation Notes 22 false false R23.htm 999025 - Disclosure - Defined Contribution Plan Sheet http://cvdequipment.com/role/DefinedContributionPlan Defined Contribution Plan Notes 23 false false R24.htm 999026 - Disclosure - Reportable Segments Sheet http://cvdequipment.com/role/ReportableSegments Reportable Segments Notes 24 false false R25.htm 999027 - Disclosure - MesoScribe and Tantaline Sheet http://cvdequipment.com/role/MesoscribeAndTantaline MesoScribe and Tantaline Notes 25 false false R26.htm 999028 - Disclosure - Risks and Uncertainties Sheet http://cvdequipment.com/role/RisksAndUncertainties Risks and Uncertainties Notes 26 false false R27.htm 999029 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://cvdequipment.com/role/SummaryOfSignificantAccountingPolicies 27 false false R28.htm 999030 - Disclosure - Revenue (Tables) Sheet http://cvdequipment.com/role/RevenueTables Revenue (Tables) Tables http://cvdequipment.com/role/Revenue 28 false false R29.htm 999031 - Disclosure - Inventories (Tables) Sheet http://cvdequipment.com/role/InventoriesTables Inventories (Tables) Tables http://cvdequipment.com/role/Inventories 29 false false R30.htm 999032 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://cvdequipment.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://cvdequipment.com/role/PropertyPlantAndEquipment 30 false false R31.htm 999033 - Disclosure - Accrued Expenses (Tables) Sheet http://cvdequipment.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://cvdequipment.com/role/AccruedExpenses 31 false false R32.htm 999034 - Disclosure - Long-term Debt (Tables) Sheet http://cvdequipment.com/role/Long-termDebtTables Long-term Debt (Tables) Tables http://cvdequipment.com/role/Long-termDebt 32 false false R33.htm 999035 - Disclosure - Earnings per Share (Tables) Sheet http://cvdequipment.com/role/EarningsPerShareTables Earnings per Share (Tables) Tables http://cvdequipment.com/role/EarningsPerShare 33 false false R34.htm 999036 - Disclosure - Income Taxes (Tables) Sheet http://cvdequipment.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://cvdequipment.com/role/IncomeTaxes 34 false false R35.htm 999037 - Disclosure - Stock-Based Compensation (Tables) Sheet http://cvdequipment.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://cvdequipment.com/role/Stock-basedCompensation 35 false false R36.htm 999038 - Disclosure - Reportable Segments (Tables) Sheet http://cvdequipment.com/role/ReportableSegmentsTables Reportable Segments (Tables) Tables http://cvdequipment.com/role/ReportableSegments 36 false false R37.htm 999039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies 37 false false R38.htm 999040 - Disclosure - Schedule of Disaggregation of Revenue (Details) Sheet http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails Schedule of Disaggregation of Revenue (Details) Details 38 false false R39.htm 999041 - Disclosure - Schedule of Cost and Estimated Earnings in Excess of Billings (Details) Sheet http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails Schedule of Cost and Estimated Earnings in Excess of Billings (Details) Details 39 false false R40.htm 999042 - Disclosure - Revenue (Details Narrative) Sheet http://cvdequipment.com/role/RevenueDetailsNarrative Revenue (Details Narrative) Details http://cvdequipment.com/role/RevenueTables 40 false false R41.htm 999043 - Disclosure - Schedule of Inventories, net (Details) Sheet http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails Schedule of Inventories, net (Details) Details 41 false false R42.htm 999044 - Disclosure - Inventories (Details Narrative) Sheet http://cvdequipment.com/role/InventoriesDetailsNarrative Inventories (Details Narrative) Details http://cvdequipment.com/role/InventoriesTables 42 false false R43.htm 999045 - Disclosure - Schedule of Property, Plant and Equipment (Details) Sheet http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails Schedule of Property, Plant and Equipment (Details) Details 43 false false R44.htm 999046 - Disclosure - Property, Plant and Equipment (Details Narrative) Sheet http://cvdequipment.com/role/PropertyPlantAndEquipmentDetailsNarrative Property, Plant and Equipment (Details Narrative) Details http://cvdequipment.com/role/PropertyPlantAndEquipmentTables 44 false false R45.htm 999047 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 45 false false R46.htm 999048 - Disclosure - Schedule of Long Term Debt (Details) Sheet http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails Schedule of Long Term Debt (Details) Details 46 false false R47.htm 999049 - Disclosure - Schedule of Long Term Debt (Details) (Parenthetical) Sheet http://cvdequipment.com/role/ScheduleOfLongTermDebtDetailsParenthetical Schedule of Long Term Debt (Details) (Parenthetical) Details 47 false false R48.htm 999050 - Disclosure - Schedule of Maturities of Long Term Debt (Details) Sheet http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails Schedule of Maturities of Long Term Debt (Details) Details 48 false false R49.htm 999051 - Disclosure - Long-term Debt (Details Narrative) Sheet http://cvdequipment.com/role/Long-termDebtDetailsNarrative Long-term Debt (Details Narrative) Details http://cvdequipment.com/role/Long-termDebtTables 49 false false R50.htm 999052 - Disclosure - Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details) Sheet http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details) Details 50 false false R51.htm 999053 - Disclosure - Schedule of Loss Before Income Taxes (Details) Sheet http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails Schedule of Loss Before Income Taxes (Details) Details 51 false false R52.htm 999054 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details) Sheet http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails Schedule of Components of Income Tax Expense (Benefit) (Details) Details 52 false false R53.htm 999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 53 false false R54.htm 999056 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical) Sheet http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetailsParenthetical Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical) Details 54 false false R55.htm 999057 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 55 false false R56.htm 999058 - Disclosure - Income Taxes (Details Narrative) Sheet http://cvdequipment.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://cvdequipment.com/role/IncomeTaxesTables 56 false false R57.htm 999059 - Disclosure - Employee Retention Credit (Details Narrative) Sheet http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative Employee Retention Credit (Details Narrative) Details http://cvdequipment.com/role/EmployeeRetentionCredit 57 false false R58.htm 999060 - Disclosure - Schedule of Stock Based Compensation (Details) Sheet http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails Schedule of Stock Based Compensation (Details) Details 58 false false R59.htm 999061 - Disclosure - Schedule of Weighted Average Assumptions (Details) Sheet http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails Schedule of Weighted Average Assumptions (Details) Details 59 false false R60.htm 999062 - Disclosure - Schedule of Stock Options Awards (Details) Sheet http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails Schedule of Stock Options Awards (Details) Details 60 false false R61.htm 999063 - Disclosure - Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details) Sheet http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details) Details 61 false false R62.htm 999064 - Disclosure - Schedule of Restricted Stock Awards (Details) Sheet http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails Schedule of Restricted Stock Awards (Details) Details 62 false false R63.htm 999065 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://cvdequipment.com/role/Stock-basedCompensationTables 63 false false R64.htm 999066 - Disclosure - Defined Contribution Plan (Details Narrative) Sheet http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative Defined Contribution Plan (Details Narrative) Details http://cvdequipment.com/role/DefinedContributionPlan 64 false false R65.htm 999067 - Disclosure - Schedule of Segments (Details) Sheet http://cvdequipment.com/role/ScheduleOfSegmentsDetails Schedule of Segments (Details) Details 65 false false R66.htm 999068 - Disclosure - Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue (Details) Sheet http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue (Details) Details 66 false false R67.htm 999069 - Disclosure - Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss (Details) Sheet http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss (Details) Details 67 false false R68.htm 999070 - Disclosure - Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets (Details) Sheet http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets (Details) Details 68 false false R69.htm 999071 - Disclosure - Schedule of Revenue by Geographic Area (Details) Sheet http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails Schedule of Revenue by Geographic Area (Details) Details 69 false false R70.htm 999072 - Disclosure - Reportable Segments (Details Narrative) Sheet http://cvdequipment.com/role/ReportableSegmentsDetailsNarrative Reportable Segments (Details Narrative) Details http://cvdequipment.com/role/ReportableSegmentsTables 70 false false R71.htm 999073 - Disclosure - MesoScribe and Tantaline (Details Narrative) Sheet http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative MesoScribe and Tantaline (Details Narrative) Details http://cvdequipment.com/role/MesoscribeAndTantaline 71 false false All Reports Book All Reports cvv-20241231.xsd cvv-20241231_cal.xml cvv-20241231_def.xml cvv-20241231_lab.xml cvv-20241231_pre.xml form10-k.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 97 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "CVV", "nsuri": "http://cvdequipment.com/20241231", "dts": { "schema": { "local": [ "cvv-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "cvv-20241231_cal.xml" ] }, "definitionLink": { "local": [ "cvv-20241231_def.xml" ] }, "labelLink": { "local": [ "cvv-20241231_lab.xml" ] }, "presentationLink": { "local": [ "cvv-20241231_pre.xml" ] }, "inline": { "local": [ "form10-k.htm" ] } }, "keyStandard": 290, "keyCustom": 28, "axisStandard": 24, "axisCustom": 0, "memberStandard": 31, "memberCustom": 28, "hidden": { "total": 77, "http://xbrl.sec.gov/dei/2024": 3, "http://cvdequipment.com/20241231": 5, "http://fasb.org/us-gaap/2024": 69 }, "contextCount": 158, "entityCount": 1, "segmentCount": 60, "elementCount": 597, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 717, "http://xbrl.sec.gov/dei/2024": 39, "http://xbrl.sec.gov/cyd/2024": 7, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://cvdequipment.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://cvdequipment.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R3": { "role": "http://cvdequipment.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R4": { "role": "http://cvdequipment.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:GrossProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R5": { "role": "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://cvdequipment.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "longName": "995443 - Disclosure - Award Timing Disclosure", "shortName": "Award Timing Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "ecd:AwardTmgMnpiDiscTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "ecd:AwardTmgMnpiDiscTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "CVV:NoInsiderTradingFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "CVV:NoInsiderTradingFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://cvdequipment.com/role/BusinessDescription", "longName": "999014 - Disclosure - Business Description", "shortName": "Business Description", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://cvdequipment.com/role/SummaryOfSignificantAccountingPolicies", "longName": "999015 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://cvdequipment.com/role/Revenue", "longName": "999016 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://cvdequipment.com/role/Inventories", "longName": "999017 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://cvdequipment.com/role/PropertyPlantAndEquipment", "longName": "999018 - Disclosure - Property, Plant and Equipment", "shortName": "Property, Plant and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://cvdequipment.com/role/AccruedExpenses", "longName": "999019 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://cvdequipment.com/role/Long-termDebt", "longName": "999020 - Disclosure - Long-term Debt", "shortName": "Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://cvdequipment.com/role/EarningsPerShare", "longName": "999021 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://cvdequipment.com/role/IncomeTaxes", "longName": "999022 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://cvdequipment.com/role/EmployeeRetentionCredit", "longName": "999023 - Disclosure - Employee Retention Credit", "shortName": "Employee Retention Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "CVV:EmployeeRetentionCreditTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "CVV:EmployeeRetentionCreditTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://cvdequipment.com/role/Stock-basedCompensation", "longName": "999024 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://cvdequipment.com/role/DefinedContributionPlan", "longName": "999025 - Disclosure - Defined Contribution Plan", "shortName": "Defined Contribution Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://cvdequipment.com/role/ReportableSegments", "longName": "999026 - Disclosure - Reportable Segments", "shortName": "Reportable Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://cvdequipment.com/role/MesoscribeAndTantaline", "longName": "999027 - Disclosure - MesoScribe and Tantaline", "shortName": "MesoScribe and Tantaline", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://cvdequipment.com/role/RisksAndUncertainties", "longName": "999028 - Disclosure - Risks and Uncertainties", "shortName": "Risks and Uncertainties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "CVV:RisksAndUncertaintiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "CVV:RisksAndUncertaintiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "999029 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "27", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://cvdequipment.com/role/RevenueTables", "longName": "999030 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://cvdequipment.com/role/InventoriesTables", "longName": "999031 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://cvdequipment.com/role/PropertyPlantAndEquipmentTables", "longName": "999032 - Disclosure - Property, Plant and Equipment (Tables)", "shortName": "Property, Plant and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://cvdequipment.com/role/AccruedExpensesTables", "longName": "999033 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R32": { "role": "http://cvdequipment.com/role/Long-termDebtTables", "longName": "999034 - Disclosure - Long-term Debt (Tables)", "shortName": "Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://cvdequipment.com/role/EarningsPerShareTables", "longName": "999035 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://cvdequipment.com/role/IncomeTaxesTables", "longName": "999036 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R35": { "role": "http://cvdequipment.com/role/Stock-basedCompensationTables", "longName": "999037 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R36": { "role": "http://cvdequipment.com/role/ReportableSegmentsTables", "longName": "999038 - Disclosure - Reportable Segments (Tables)", "shortName": "Reportable Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R37": { "role": "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "999039 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CapitalizedContractCostImpairmentLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R38": { "role": "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails", "longName": "999040 - Disclosure - Schedule of Disaggregation of Revenue (Details)", "shortName": "Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R39": { "role": "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails", "longName": "999041 - Disclosure - Schedule of Cost and Estimated Earnings in Excess of Billings (Details)", "shortName": "Schedule of Cost and Estimated Earnings in Excess of Billings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "CVV:CostsIncurredOnUncompletedContracts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "CVV:ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "CVV:CostsIncurredOnUncompletedContracts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "CVV:ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://cvdequipment.com/role/RevenueDetailsNarrative", "longName": "999042 - Disclosure - Revenue (Details Narrative)", "shortName": "Revenue (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R41": { "role": "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails", "longName": "999043 - Disclosure - Schedule of Inventories, net (Details)", "shortName": "Schedule of Inventories, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R42": { "role": "http://cvdequipment.com/role/InventoriesDetailsNarrative", "longName": "999044 - Disclosure - Inventories (Details Narrative)", "shortName": "Inventories (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:InventoryNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_PVTOneFiftySystemsMember", "name": "us-gaap:OtherNoncashExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R43": { "role": "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "longName": "999045 - Disclosure - Schedule of Property, Plant and Equipment (Details)", "shortName": "Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R44": { "role": "http://cvdequipment.com/role/PropertyPlantAndEquipmentDetailsNarrative", "longName": "999046 - Disclosure - Property, Plant and Equipment (Details Narrative)", "shortName": "Property, Plant and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R45": { "role": "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails", "longName": "999047 - Disclosure - Schedule of Accrued Expenses (Details)", "shortName": "Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R46": { "role": "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails", "longName": "999048 - Disclosure - Schedule of Long Term Debt (Details)", "shortName": "Schedule of Long Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LoansPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LoansPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R47": { "role": "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetailsParenthetical", "longName": "999049 - Disclosure - Schedule of Long Term Debt (Details) (Parenthetical)", "shortName": "Schedule of Long Term Debt (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DebtInstrumentPeriodicPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:DebtInstrumentPeriodicPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R48": { "role": "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails", "longName": "999050 - Disclosure - Schedule of Maturities of Long Term Debt (Details)", "shortName": "Schedule of Maturities of Long Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R49": { "role": "http://cvdequipment.com/role/Long-termDebtDetailsNarrative", "longName": "999051 - Disclosure - Long-term Debt (Details Narrative)", "shortName": "Long-term Debt (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2022-09-30", "name": "CVV:LoanToFundAcquisitionOfMachineryEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-09-30", "name": "CVV:LoanToFundAcquisitionOfMachineryEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R50": { "role": "http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails", "longName": "999052 - Disclosure - Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details)", "shortName": "Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails", "longName": "999053 - Disclosure - Schedule of Loss Before Income Taxes (Details)", "shortName": "Schedule of Loss Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R52": { "role": "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "longName": "999054 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details)", "shortName": "Schedule of Components of Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R53": { "role": "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "longName": "999055 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R54": { "role": "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetailsParenthetical", "longName": "999056 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical)", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R55": { "role": "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "999057 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R56": { "role": "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative", "longName": "999058 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R57": { "role": "http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative", "longName": "999059 - Disclosure - Employee Retention Credit (Details Narrative)", "shortName": "Employee Retention Credit (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "CVV:IncreaseDecreaseInEmployeeRetentionCreditReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "CVV:EmployeeRetentionCreditReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "CVV:EmployeeRetentionCreditTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R58": { "role": "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails", "longName": "999060 - Disclosure - Schedule of Stock Based Compensation (Details)", "shortName": "Schedule of Stock Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_CostOfRevenueMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R59": { "role": "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails", "longName": "999061 - Disclosure - Schedule of Weighted Average Assumptions (Details)", "shortName": "Schedule of Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R60": { "role": "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails", "longName": "999062 - Disclosure - Schedule of Stock Options Awards (Details)", "shortName": "Schedule of Stock Options Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R61": { "role": "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails", "longName": "999063 - Disclosure - Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details)", "shortName": "Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_custom_ExercisePriceRangeOneMember", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R62": { "role": "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "longName": "999064 - Disclosure - Schedule of Restricted Stock Awards (Details)", "shortName": "Schedule of Restricted Stock Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R63": { "role": "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "longName": "999065 - Disclosure - Stock-Based Compensation (Details Narrative)", "shortName": "Stock-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R64": { "role": "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative", "longName": "999066 - Disclosure - Defined Contribution Plan (Details Narrative)", "shortName": "Defined Contribution Plan (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "From2022-07-012022-07-01", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-012022-07-01", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R65": { "role": "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "longName": "999067 - Disclosure - Schedule of Segments (Details)", "shortName": "Schedule of Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_us-gaap_OperatingSegmentsMember", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R66": { "role": "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails", "longName": "999068 - Disclosure - Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue (Details)", "shortName": "Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_OtherTantalineMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R67": { "role": "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "longName": "999069 - Disclosure - Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss (Details)", "shortName": "Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_OtherTantalineMember", "name": "us-gaap:OtherExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R68": { "role": "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails", "longName": "999070 - Disclosure - Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets (Details)", "shortName": "Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_us-gaap_OperatingSegmentsMember", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R69": { "role": "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails", "longName": "999071 - Disclosure - Schedule of Revenue by Geographic Area (Details)", "shortName": "Schedule of Revenue by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31_srt_AmericasMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R70": { "role": "http://cvdequipment.com/role/ReportableSegmentsDetailsNarrative", "longName": "999072 - Disclosure - Reportable Segments (Details Narrative)", "shortName": "Reportable Segments (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-12-31", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R71": { "role": "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative", "longName": "999073 - Disclosure - MesoScribe and Tantaline (Details Narrative)", "shortName": "MesoScribe and Tantaline (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "CVV:DepositsFromPurchaserOfMesoscribeAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_TantalineASOfNordborgMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r67", "r69", "r73", "r907" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r67", "r699" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r636" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net of allowance for credit losses", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r867" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r69" ] }, "CVV_AccruedMaterialPurchasesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "AccruedMaterialPurchasesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued material purchases", "documentation": "Accrued material purchases." } } }, "auth_ref": [] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued wages and benefits", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r69", "r655" ] }, "us-gaap_AccruedVacationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedVacationCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued vacation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42", "r69" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r37", "r168", "r527" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r787" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r78" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r568", "r854", "r855", "r856", "r857", "r918", "r967" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r793" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r793" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r793" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r793" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "CVV_AerospaceMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "AerospaceMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Aerospace [Member]", "documentation": "Aerospace [Member]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r754", "r765", "r779", "r805" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r757", "r768", "r782", "r808" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r793" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r800" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r758", "r769", "r783", "r800", "r809", "r813", "r821" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total stock-based compensation expense", "verboseLabel": "Stock based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r385", "r394" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Allowance for credit loss", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r173", "r264", "r268" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AmericasMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Americas [Member]" } } }, "auth_ref": [ "r969", "r970", "r971", "r972" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r761" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaPacificMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r969", "r970", "r971", "r972" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 }, "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfCashFlows", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Impairment charge", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r3", "r35" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Segment assets", "verboseLabel": "Consolidated total assets", "terseLabel": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r118", "r127", "r170", "r193", "r227", "r233", "r251", "r255", "r265", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r443", "r446", "r461", "r519", "r595", "r665", "r666", "r699", "r726", "r874", "r875", "r924" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r163", "r177", "r193", "r265", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r443", "r446", "r461", "r699", "r874", "r875", "r924" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r761" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r738", "r740", "r761" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r738", "r740", "r761" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r738", "r740", "r761" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r816" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r817" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r812" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r356", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r380", "r381", "r382", "r383", "r384" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r815" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r814" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r813" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "CVV_BillingsToDate": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "BillingsToDate", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_NetCostInExcessOfBillings", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Billings to date", "documentation": "Billings to date.", "label": "BillingsToDate" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://cvdequipment.com/role/BusinessDescription" ], "lang": { "en-us": { "role": { "label": "Business Description", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r56", "r101", "r102" ] }, "CVV_CVDMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CVDMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "CVD [Member]", "documentation": "CVD [Member]" } } }, "auth_ref": [] }, "CVV_CapitalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CapitalExpenditures", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Capital expenditures", "documentation": "Capital expenditures." } } }, "auth_ref": [] }, "us-gaap_CapitalizedContractCostImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostImpairmentLoss", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contract assets, impairment loss", "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r274" ] }, "us-gaap_CargoAndFreightMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CargoAndFreightMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cargo and Freight [Member]", "documentation": "Product transported between locations." } } }, "auth_ref": [ "r880" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "verboseLabel": "Cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r17", "r166", "r653" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r18" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of year", "periodEndLabel": "Cash and cash equivalents at end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r17", "r98", "r191" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r98" ] }, "us-gaap_CashDivestedFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashDivestedFromDeconsolidation", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Net cash used in disposition of Tantaline", "label": "Cash Divested from Deconsolidation", "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r842", "r934" ] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash uninsured amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r791" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r792" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r792" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (see note 15)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r74", "r120", "r521", "r582" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common shares reserved for future issuance.", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r77" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r854", "r855", "r857", "r918", "r965", "r967" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://cvdequipment.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r77" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://cvdequipment.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r77", "r583" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://cvdequipment.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r77" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://cvdequipment.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r77", "r583", "r601", "r967", "r968" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock - $0.01 par value \u2013 20,000,000 shares authorized; issued and outstanding 6,881,838 at December 31, 2024 and 6,824,511 at December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r77", "r522", "r699" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r797" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r796" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r798" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r795" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r22", "r23", "r51", "r52", "r262", "r636" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r22", "r23", "r51", "r52", "r262", "r562", "r636" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r22", "r23", "r51", "r52", "r262", "r636", "r839" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r55", "r132" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r22", "r23", "r51", "r52", "r262" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r22", "r23", "r51", "r52", "r262", "r636" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r196", "r443", "r444", "r446", "r447", "r478", "r641", "r873", "r876", "r877" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "auth_ref": [ "r196", "r443", "r444", "r446", "r447", "r478", "r641", "r873", "r876", "r877" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r125", "r196", "r227", "r235", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r665", "r666", "r874", "r875" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "auth_ref": [ "r125", "r196", "r227", "r235", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r296", "r297", "r298", "r299", "r301", "r302", "r303", "r304", "r305", "r665", "r666", "r874", "r875" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r50", "r656" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "CVV_ContractLiabilityInExcessOfContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ContractLiabilityInExcessOfContractAssets", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Contract liability in excess of contract assets", "documentation": "Contract liability in excess of contract assets.", "label": "ContractLiabilityInExcessOfContractAssets" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract assets", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r312", "r314", "r333" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r312", "r314", "r333" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/RevenueDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Contract liabilities", "verboseLabel": "Contract liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r312", "r313", "r333" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contract liability recognized as revenue", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r334" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r13", "r250", "r251", "r252", "r253", "r256", "r862" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r88", "r193", "r265", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r461", "r665", "r874" ] }, "CVV_CostOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CostOfRevenueMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Member]", "documentation": "Cost of Revenue [Member]" } } }, "auth_ref": [] }, "CVV_CostsAndEstimatedEarningsOnUncompletedContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CostsAndEstimatedEarningsOnUncompletedContracts", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_NetCostInExcessOfBillings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Costs and estimated earnings on uncompleted contracts", "documentation": "Costs and estimated earnings on uncompleted contracts.", "label": "CostsAndEstimatedEarningsOnUncompletedContracts" } } }, "auth_ref": [] }, "CVV_CostsIncurredOnUncompletedContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CostsIncurredOnUncompletedContracts", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_CostsAndEstimatedEarningsOnUncompletedContracts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Costs incurred on contracts in progress", "documentation": "Costs incurred on uncompleted contracts." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r840", "r852", "r917" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current tax provision", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r427", "r852" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r840", "r852", "r917" ] }, "CVV_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CustomerAMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer A [Member]", "documentation": "Customer A [Member]" } } }, "auth_ref": [] }, "CVV_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CustomerBMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer B [Member]", "documentation": "Customer B [Member]" } } }, "auth_ref": [] }, "CVV_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CustomerCMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer C [Member]", "documentation": "Customer C [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r103", "r262" ] }, "CVV_CustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CustomerMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Member]", "documentation": "Customer [Member]" } } }, "auth_ref": [] }, "CVV_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CustomerOneMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "Customer One [Member]" } } }, "auth_ref": [] }, "CVV_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CustomerThreeMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "Customer Three [Member]" } } }, "auth_ref": [] }, "CVV_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "CustomerTwoMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "Customer Two [Member]" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r748", "r831" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r748", "r831" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r750", "r833" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r750", "r833" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r743", "r826" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r744", "r827" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r744", "r827" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r742", "r825" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r745", "r828" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r747", "r830" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r747", "r830" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r748", "r831" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r749", "r832" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r746", "r829" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt instrument interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r71", "r307" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r14", "r54" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r852", "r916", "r917" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax provision", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r3", "r139", "r852" ] }, "CVV_DeferredRevenuesRelatedToContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "DeferredRevenuesRelatedToContracts", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_ContractLiabilityInExcessOfContractAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred revenue related to non-systems contracts", "documentation": "Deferred revenues related to contracts.", "label": "DeferredRevenuesRelatedToContracts" } } }, "auth_ref": [] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r852", "r916", "r917" ] }, "CVV_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized research and development", "documentation": "Deferred tax assets capitalized research and development." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r419" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax asset, net", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r912" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax assets, net of valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r912" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other items", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "R&D tax credit carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Vacation accrual", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days)." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Compensation costs", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r420" ] }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Deferred Tax Liabilities, Prepaid Expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Property, plant and equipment", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r914" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r349" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan, employer discretionary contribution amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan percentage of employees contribution", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan percentage", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "CVV_DepositsFromPurchaserOfMesoscribeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "DepositsFromPurchaserOfMesoscribeAssets", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deposits from purchasers of MesoScribe assets \u2013 note 14", "verboseLabel": "Deposits from purchaser of equipment", "documentation": "Deposits from purchaser of MesoScribe assets." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r3", "r36" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "verboseLabel": "Depreciation & amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r3", "r36" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r866", "r966" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r332", "r678", "r679", "r680", "r681", "r682", "r683", "r684" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r332", "r678", "r679", "r680", "r681", "r682", "r683", "r684" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://cvdequipment.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregation of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r879" ] }, "CVV_DisclosureEmployeeRetentionCreditAbstract": { "xbrltype": "stringItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "DisclosureEmployeeRetentionCreditAbstract", "lang": { "en-us": { "role": { "label": "Employee Retention Credit" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r351", "r355", "r386", "r387", "r389", "r689" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "CVV_DisclosureRisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "DisclosureRisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks And Uncertainties" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantaline" ], "lang": { "en-us": { "role": { "label": "MesoScribe and Tantaline", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r57", "r106" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group." } } }, "auth_ref": [ "r686", "r687" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r740" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r738", "r740", "r761" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r738", "r740", "r761", "r801" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r739" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r727" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r740" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r740" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r786" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r730" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r404" ] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EMEAMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r969", "r970", "r971", "r972" ] }, "CVV_EarnOutPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "EarnOutPayment", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Earn-out payment", "documentation": "Earn-out payment." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss per common share:", "verboseLabel": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r184", "r202", "r203", "r204", "r205", "r206", "r207", "r212", "r214", "r219", "r220", "r221", "r226", "r439", "r442", "r455", "r456", "r515", "r532", "r658" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r184", "r202", "r203", "r204", "r205", "r206", "r207", "r214", "r219", "r220", "r221", "r226", "r439", "r442", "r455", "r456", "r515", "r532", "r658" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r20", "r21", "r223" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://cvdequipment.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r211", "r222", "r224", "r225" ] }, "CVV_EffectiveIncomeTaxRateReconciliationAtExciseIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "EffectiveIncomeTaxRateReconciliationAtExciseIncomeTaxRate", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Excise tax rate", "documentation": "Excise tax rate." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Federal statutory tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r195", "r404", "r430", "r692" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationLineItems", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r404", "r405", "r692" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Corporate tax rate", "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law." } } }, "auth_ref": [ "r909" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r404", "r405", "r692" ] }, "CVV_EmployeeRetentionCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "EmployeeRetentionCreditReceivable", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee retention credit receivable", "documentation": "Employee retention credit receivable." } } }, "auth_ref": [] }, "CVV_EmployeeRetentionCreditTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "EmployeeRetentionCreditTextBlock", "presentation": [ "http://cvdequipment.com/role/EmployeeRetentionCredit" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Retention Credit", "documentation": "Employee Retention Credit [Text Block]", "label": "EmployeeRetentionCreditTextBlock" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation costs", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r388" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation costs, weighted average recoginition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r388" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "CVV_EnergyMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "EnergyMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Energy [Member]", "documentation": "Energy [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r733" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r729" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r729" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r837" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r729" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r834" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r761" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r729" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r729" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r729" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r729" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r835" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r160", "r181", "r182", "r183", "r197", "r198", "r199", "r201", "r206", "r208", "r210", "r228", "r266", "r267", "r285", "r311", "r428", "r429", "r436", "r437", "r438", "r440", "r441", "r442", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r531", "r556", "r557", "r558", "r568", "r622" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r794" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r754", "r765", "r779", "r805" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r751", "r762", "r776", "r802" ] }, "CVV_EstimatedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "EstimatedEarnings", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_CostsAndEstimatedEarningsOnUncompletedContracts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Estimated earnings", "documentation": "Estimated earnings." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r800" ] }, "CVV_ExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ExercisePriceRangeFourMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range Four [Member]", "documentation": "Exercise Price Range Four [Member]" } } }, "auth_ref": [] }, "CVV_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ExercisePriceRangeOneMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range One [Member]", "documentation": "Exercise Price Range One [Member]" } } }, "auth_ref": [] }, "CVV_ExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ExercisePriceRangeThreeMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range Three [Member]", "documentation": "Exercise Price Range Three [Member]" } } }, "auth_ref": [] }, "CVV_ExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ExercisePriceRangeTwoMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range Two [Member]", "documentation": "Exercise Price Range Two [Member]" } } }, "auth_ref": [] }, "CVV_ExportSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ExportSalesMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Export Sales [Member]", "documentation": "Export Sales [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r6" ] }, "CVV_FiveDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "FiveDirectorsMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Five Directors [Member]", "documentation": "Five Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Foreign exchange income", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r462", "r463", "r464", "r465", "r619" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r758", "r769", "r783", "r809" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r758", "r769", "r783", "r809" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r758", "r769", "r783", "r809" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r758", "r769", "r783", "r809" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r758", "r769", "r783", "r809" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 5.0 }, "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative", "http://cvdequipment.com/role/StatementsOfCashFlows", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposition of Tantaline", "label": "Loss on disposition of tantaline", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r445", "r850" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 4.0 }, "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfCashFlows", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on sales of equipment", "label": "Gain on sale of equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r3" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "verboseLabel": "General & administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r90", "r605" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r90" ] }, "us-gaap_GeographicDistributionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicDistributionAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographic Distribution [Axis]", "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r516", "r517", "r671" ] }, "us-gaap_GeographicDistributionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicDistributionDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r516", "r517" ] }, "us-gaap_GeographicDistributionForeignMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeographicDistributionForeignMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographic Distribution, Foreign [Member]", "documentation": "Allocation of business activity identified as foreign." } } }, "auth_ref": [ "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r516", "r517", "r672" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r86", "r88", "r126", "r193", "r265", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r461", "r660", "r665", "r859", "r861", "r863", "r864", "r865", "r874" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r738", "r740", "r761" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets and Intangibles", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r194", "r403" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r87", "r122", "r126", "r517", "r529", "r660", "r665", "r859", "r861", "r863", "r864", "r865" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r194", "r403" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r686", "r687" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r7", "r12", "r15", "r58", "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r66", "r108" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r286", "r288", "r289", "r458", "r459", "r460", "r553", "r555", "r606", "r649", "r693", "r936" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r288", "r289", "r458", "r459", "r460", "r553", "r555", "r606", "r649", "r693", "r936" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r190", "r404", "r405", "r414", "r424", "r692", "r913" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r190", "r404", "r405", "r414", "r424", "r692", "r913" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r414", "r913" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r414", "r913" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r195", "r398", "r404", "r411", "r412", "r413", "r416", "r422", "r431", "r433", "r434", "r435", "r567", "r692" ] }, "us-gaap_IncomeTaxExaminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationDescription", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax examination, year", "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings." } } }, "auth_ref": [ "r911" ] }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax examination, description", "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority." } } }, "auth_ref": [ "r911" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income tax expense (benefit)", "totalLabel": "Income tax expense (benefit)", "negatedLabel": "Income tax (expense) benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r128", "r140", "r209", "r210", "r227", "r241", "r255", "r402", "r404", "r432", "r533", "r692" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r180", "r400", "r401", "r416", "r417", "r421", "r426", "r564" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Increase in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r408", "r692", "r908" ] }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationDispositionOfBusiness", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Disposition of Tantaline", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation." } } }, "auth_ref": [ "r908", "r909" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Expected provision at federal statutory tax rate at 21%", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r404", "r692" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Non-deductible expenses", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r409", "r410", "r908" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r692", "r908", "r909" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "State and local taxes", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r407", "r692", "r908" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Federal research and development credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r692", "r908", "r910" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r19", "r190", "r423", "r424" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Contract assets", "label": "Increase (Decrease) in Contract with Customer, Asset", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r849" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract liabilities", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r482", "r849" ] }, "CVV_IncreaseDecreaseInEmployeeRetentionCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "IncreaseDecreaseInEmployeeRetentionCreditReceivable", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative", "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee retention credit receivable", "label": "Employee retention credit eligible amount", "documentation": "Increase decrease in employee retention credit receivable." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities, net of effects of disposition of Tantaline and sales of equipment:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r849" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Effect of potentially dilutive share-based awards", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r215", "r216", "r217", "r221", "r354" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r758", "r769", "r783", "r800", "r809", "r813", "r821" ] }, "CVV_IndustrialMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "IndustrialMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Industrial [Member]", "documentation": "Industrial [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r819" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r741", "r824" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r741", "r824" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r741", "r824" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expenses", "label": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r237", "r848" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r186", "r188", "r189" ] }, "us-gaap_InternalRevenueServiceIRSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalRevenueServiceIRSMember", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Internal Revenue Service (IRS) [Member]", "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r125", "r227", "r235", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r665" ] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryCurrentTable", "presentation": [ "http://cvdequipment.com/role/InventoriesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/Inventories" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r270" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r843" ] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLineItems", "presentation": [ "http://cvdequipment.com/role/InventoriesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/InventoriesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails" ], "lang": { "en-us": { "role": { "label": "Inventories", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r175", "r654", "r699" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r129", "r165", "r174", "r270", "r271", "r273", "r483", "r657" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r845" ] }, "CVV_InventoryTransferredToPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "InventoryTransferredToPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory transferred to property, plant and equipment", "documentation": "Inventory transferred to property plant and equipment." } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails" ], "lang": { "en-us": { "role": { "label": "Work-in-process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r844" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Provision for excess and obsolete inventory", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r272" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r227", "r236", "r255", "r665", "r847" ] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r880" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r14", "r68", "r69", "r70", "r72", "r73", "r74", "r75", "r193", "r265", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r444", "r446", "r447", "r461", "r581", "r659", "r726", "r874", "r924", "r925" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r82", "r121", "r524", "r699", "r851", "r868", "r920" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r70", "r164", "r193", "r265", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r444", "r446", "r447", "r461", "r699", "r874", "r924", "r925" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "CVV_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "LiquidityPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Liquidity", "documentation": "Liquidity [Policy Text Block]" } } }, "auth_ref": [] }, "CVV_LoanToFundAcquisitionOfMachineryEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "LoanToFundAcquisitionOfMachineryEquipment", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/Long-termDebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan to fund acquisition of machinery equipment", "documentation": "Loan to fund acquisition of machinery equipment." } } }, "auth_ref": [] }, "us-gaap_LoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayable", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Equipment loan payable in monthly repayments of $8 including interest at 6% per annum", "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r14", "r119", "r933" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r14", "r119", "r308", "r310", "r674", "r675", "r698", "r933" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Current maturities of long-term debt", "verboseLabel": "Less: current maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r171" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r5", "r196", "r309" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r5", "r196", "r309" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r5", "r196", "r309" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-term debt, net of current portion", "verboseLabel": "Long-term debt, net of current maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r172" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": [ "http://cvdequipment.com/role/Long-termDebt" ], "lang": { "en-us": { "role": { "label": "Long-term Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r109" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r262", "r680", "r709", "r714", "r879", "r935", "r937", "r938", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "cyd_MaterialCybersecurityIncidentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentAbstract", "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Abstract]" } } }, "auth_ref": [ "r772", "r773" ] }, "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]" } } }, "auth_ref": [ "r772", "r774" ] }, "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]" } } }, "auth_ref": [ "r772", "r775" ] }, "cyd_MaterialCybersecurityIncidentNatureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentNatureTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Nature [Text Block]" } } }, "auth_ref": [ "r772", "r775" ] }, "cyd_MaterialCybersecurityIncidentScopeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentScopeTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Scope [Text Block]" } } }, "auth_ref": [ "r772", "r775" ] }, "cyd_MaterialCybersecurityIncidentTimingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentTimingTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Timing [Text Block]" } } }, "auth_ref": [ "r772", "r775" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r350", "r395", "r457", "r481", "r552", "r554", "r561", "r573", "r574", "r626", "r628", "r630", "r631", "r633", "r647", "r648", "r670", "r677", "r688", "r694", "r695", "r696", "r697", "r710", "r878", "r926", "r927", "r928", "r929", "r930", "r931" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r792" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r792" ] }, "CVV_MesoScribeTechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "MesoScribeTechnologiesIncMember", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Meso Scribe Technologies Inc [Member]", "documentation": "Meso Scribe Technologies Inc [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r350", "r395", "r457", "r481", "r552", "r554", "r561", "r573", "r574", "r626", "r628", "r630", "r631", "r633", "r647", "r648", "r670", "r677", "r688", "r694", "r695", "r696", "r710", "r878", "r926", "r927", "r928", "r929", "r930", "r931" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r812" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r820" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r262", "r680", "r709", "r714", "r879", "r935", "r937", "r938", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r793" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r187" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r187" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r98", "r99", "r100" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "CVV_NetCostInExcessOfBillings": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "NetCostInExcessOfBillings", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_ContractLiabilityInExcessOfContractAssets", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cost in excess of billings", "documentation": "Net cost in excess of billings.", "label": "NetCostInExcessOfBillings" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfCashFlows", "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity", "http://cvdequipment.com/role/StatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss)", "terseLabel": "Segment net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r89", "r100", "r123", "r162", "r178", "r179", "r183", "r193", "r200", "r202", "r203", "r204", "r205", "r206", "r209", "r210", "r218", "r265", "r296", "r297", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r439", "r442", "r456", "r461", "r530", "r603", "r620", "r621", "r725", "r874" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Adopted Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "CVV_NoInsiderTradingFlag": { "xbrltype": "booleanItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "NoInsiderTradingFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "No Insider Trading Flag", "documentation": "No Insider Trading Flag" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r792" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r790" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r789" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r820" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r820" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r92" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "srt_NorthAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NorthAmericaMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "North America [Member]" } } }, "auth_ref": [ "r969", "r970", "r971", "r972" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://cvdequipment.com/role/ReportableSegmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r666", "r860" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses, net", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r126", "r660", "r859", "r861", "r863", "r864", "r865" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r425" ] }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLimitationsOnUse", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards, limitations", "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income." } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r249", "r250", "r251", "r252", "r253", "r256", "r665", "r666" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r69" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r176", "r699" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r169" ] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Unallocated amounts", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r90", "r91" ] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashExpense", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/InventoriesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-cash charge to reduce net realizable value", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r93" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r792" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r740" ] }, "CVV_OtherTantalineMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "OtherTantalineMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Other - Tantaline [Member]", "documentation": "Other - Tantaline [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r756", "r767", "r781", "r807" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r759", "r770", "r784", "r810" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r759", "r770", "r784", "r810" ] }, "CVV_PVTOneFiftySystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "PVTOneFiftySystemsMember", "presentation": [ "http://cvdequipment.com/role/InventoriesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "PVT 150 Systems [Member]", "documentation": "PVT 150 Systems [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r788" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r96" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r791" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r791" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlan" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r685" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r790" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r793" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r789" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r790" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r734" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r736" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r841" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net proceeds from sales of equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r94" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r11" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r258", "r484", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r651", "r678", "r708", "r710", "r711", "r715", "r716", "r870", "r871", "r879", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r258", "r484", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r651", "r678", "r708", "r710", "r711", "r715", "r716", "r870", "r871", "r879", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r4", "r474" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/PropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r106", "r133", "r137", "r138" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Totals at cost", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r107", "r167", "r528" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r474" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r474", "r518", "r528", "r699" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r4", "r133", "r137", "r526" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://cvdequipment.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property, Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r107", "r474" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property plant and equipment useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Provision for bad debt", "verboseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r185", "r269" ] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryAxis", "presentation": [ "http://cvdequipment.com/role/InventoriesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": [ "r846" ] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": [ "http://cvdequipment.com/role/InventoriesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": [ "r846" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r788" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r788" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r292", "r293", "r294", "r295", "r337", "r350", "r381", "r382", "r383", "r395", "r457", "r479", "r480", "r481", "r552", "r554", "r561", "r573", "r574", "r626", "r628", "r630", "r631", "r633", "r647", "r648", "r670", "r677", "r688", "r694", "r695", "r696", "r697", "r710", "r719", "r869", "r878", "r919", "r927", "r928", "r929", "r930", "r931" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r292", "r293", "r294", "r295", "r337", "r350", "r381", "r382", "r383", "r395", "r457", "r479", "r480", "r481", "r552", "r554", "r561", "r573", "r574", "r626", "r628", "r630", "r631", "r633", "r647", "r648", "r670", "r677", "r688", "r694", "r695", "r696", "r697", "r710", "r719", "r869", "r878", "r919", "r927", "r928", "r929", "r930", "r931" ] }, "CVV_RecentlyIssuedAccountingStandardsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "RecentlyIssuedAccountingStandardsPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Standards", "documentation": "Recently Issued Accounting Standards [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": [ "http://cvdequipment.com/role/ReportableSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r32", "r33" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://cvdequipment.com/role/ReportableSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r31", "r33" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://cvdequipment.com/role/ReportableSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r30", "r33" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r751", "r762", "r776", "r802" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r263", "r341", "r476", "r477", "r520", "r525", "r576", "r577", "r578", "r579", "r580", "r600", "r602", "r625" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r263", "r341", "r476", "r477", "r520", "r525", "r576", "r577", "r578", "r579", "r580", "r600", "r602", "r625", "r923" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r97", "r565" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "verboseLabel": "Research & development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r397", "r649", "r665", "r932" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r396" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchMember", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r913" ] }, "CVV_ResearchOneMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ResearchOneMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Research [Member]", "documentation": "Research [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r752", "r763", "r777", "r803" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r753", "r764", "r778", "r804" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r760", "r771", "r785", "r811" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r20" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r79", "r112", "r523", "r559", "r560", "r566", "r584", "r699" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r160", "r197", "r198", "r199", "r201", "r206", "r208", "r210", "r266", "r267", "r285", "r428", "r429", "r436", "r437", "r438", "r440", "r441", "r442", "r448", "r450", "r451", "r453", "r454", "r472", "r473", "r556", "r558", "r568", "r967" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails", "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue", "verboseLabel": "Segment revenue", "terseLabel": "Consolidated total revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r124", "r125", "r227", "r234", "r235", "r249", "r255", "r258", "r260", "r262", "r331", "r332", "r484" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r124", "r125", "r227", "r234", "r235", "r249", "r255", "r258", "r260", "r262", "r331", "r332", "r484" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r141", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r650" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://cvdequipment.com/role/Revenue" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r141", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r335" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://cvdequipment.com/role/ReportableSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Geographic Area", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r104" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized contract revenue", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r136" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "CVV_RisksAndUncertaintiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "RisksAndUncertaintiesTextBlock", "presentation": [ "http://cvdequipment.com/role/RisksAndUncertainties" ], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties", "documentation": "Risks And Uncertainties [Text Block]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r820" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r820" ] }, "CVV_SDCMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "SDCMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "SDC [Member]", "documentation": "SDC [Member]" } } }, "auth_ref": [] }, "CVV_SaleOfProprietaryAssetsAndLicenseCertainProprietyInformationAggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "SaleOfProprietaryAssetsAndLicenseCertainProprietyInformationAggregatePurchasePrice", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate purchase price", "documentation": "Sale of proprietary assets and license certain propriety information aggregate purchase price." } } }, "auth_ref": [] }, "CVV_SalesConcentrationsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "SalesConcentrationsPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Sales Concentrations", "documentation": "Sales Concentrations Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r262", "r838" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://cvdequipment.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit)", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r915" ] }, "CVV_ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock", "presentation": [ "http://cvdequipment.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cost and Estimated Earnings in Excess of Billings", "documentation": "Schedule Of Cost And Estimated Earnings In Excess Of Billings [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://cvdequipment.com/role/Long-termDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long Term Debt", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r14", "r40", "r41", "r53", "r110", "r111", "r674", "r676", "r853", "r921" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r912" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://cvdequipment.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Basic and Diluted Weighted Average Common Shares Outstanding", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r858" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r406", "r692", "r908" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Based Compensation", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Loss Before Income Taxes", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r852" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://cvdequipment.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventories, net", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r16", "r83", "r84", "r85" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://cvdequipment.com/role/Long-termDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long Term Debt", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nature of Operation, Product Information, Concentration of Risk [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4", "r474" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r34", "r86" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r27", "r28", "r29" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://cvdequipment.com/role/ReportableSegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segments", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r27", "r28", "r29" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r352", "r353", "r356", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r380", "r381", "r382", "r383", "r384" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Options Awards", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r113" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r117" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Awards", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r728" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r732" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r731" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r737" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r124", "r125", "r126", "r127", "r227", "r230", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r262", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r290", "r291", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r662", "r665", "r666", "r673", "r713", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails" ], "auth_ref": [ "r260", "r261", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r570", "r571", "r572", "r627", "r629", "r632", "r634", "r635", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r652", "r679", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r712", "r719", "r879", "r935", "r937", "r938", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/ReportableSegments" ], "lang": { "en-us": { "role": { "label": "Reportable Segments", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r127", "r227", "r229", "r230", "r231", "r232", "r233", "r245", "r247", "r248", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r262", "r661", "r663", "r664", "r665", "r667", "r668", "r669" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfReconciliationOfNetIncomeLossOfReportableSegmentsToConsolidatedNetLossDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfRevenueOfReportableSegmentsToConsolidatedRevenueDetails", "http://cvdequipment.com/role/ScheduleOfReconciliationOfTotalAssetsOfReportableSegmentsToConsolidatedTotalAssetsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling", "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services." } } }, "auth_ref": [ "r90" ] }, "CVV_SellingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "SellingExpenseMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Selling Expense [Member]", "documentation": "Selling Expense [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r689" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Shares of restricted stock, forfeited or cancelled", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, forfeited or cancelled", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r373" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Shares of restricted stock, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares of restricted stock, unvested outstanding beginning balance", "periodEndLabel": "Shares of restricted stock, unvested outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r368", "r369" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value, unvested outstanding beginning balance", "periodEndLabel": "Weighted average grant date fair value, unvested outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r368", "r369" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares of restricted stock, vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r372" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r372" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r381" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r352", "r353", "r356", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r380", "r381", "r382", "r383", "r384" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock options exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r362" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Awards, expired / cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r887" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, expired / cancelled", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r887" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Awards, granted", "verboseLabel": "Stock option granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r364" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Awards outstanding, beginning balance", "periodEndLabel": "Awards outstanding, ending balance", "label": "Outstanding stock options", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r360", "r361" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price outstanding, beginning balance", "periodEndLabel": "Weighted average exercise price outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r360", "r361" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r356", "r357", "r358", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r380", "r381", "r382", "r383", "r384" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r365" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r364" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r351", "r359", "r378", "r379", "r380", "r381", "r384", "r390", "r391", "r392", "r393" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price range, lower limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r114", "r115" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price range, upper limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r48" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Stock price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock option vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r881" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r690" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r380" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options exercisable, intrinsic value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r43" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options exercisable, weighted average exercise price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r44" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, weighted average exercise price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r114", "r115" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r116" ] }, "CVV_SharebasedPaymentArrangementAnnualEquityRetainerAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "SharebasedPaymentArrangementAnnualEquityRetainerAmount", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual equity retainer amount", "documentation": "Share based payment arrangement annual equity retainer amount." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "CVV_ShippingAndHandlingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "ShippingAndHandlingPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Shipping and Handling", "documentation": "Shipping And Handling Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r101", "r192" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r735" ] }, "us-gaap_StandardProductWarrantyDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyDescription", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Standard product warranty description", "documentation": "Describes the nature of the product warranty, including the approximate term of the product warranty, how the product warranty arose, and the events or circumstances that would require the warrantor to perform under the product warranty." } } }, "auth_ref": [ "r38", "r39" ] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Product Warranty", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r872" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r124", "r125", "r126", "r127", "r161", "r227", "r230", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r255", "r256", "r257", "r262", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r287", "r290", "r291", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r662", "r665", "r666", "r673", "r713", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r77", "r80", "r81", "r160", "r181", "r182", "r183", "r197", "r198", "r199", "r201", "r206", "r208", "r210", "r228", "r266", "r267", "r285", "r311", "r428", "r429", "r436", "r437", "r438", "r440", "r441", "r442", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r531", "r556", "r557", "r558", "r568", "r622" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRevenueByGeographicAreaDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r260", "r261", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r570", "r571", "r572", "r627", "r629", "r632", "r634", "r635", "r637", "r638", "r639", "r640", "r642", "r643", "r644", "r645", "r646", "r652", "r679", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r712", "r719", "r879", "r935", "r937", "r938", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r197", "r198", "r199", "r228", "r473", "r484", "r563", "r569", "r575", "r576", "r577", "r578", "r579", "r580", "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r602", "r604", "r605", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r622", "r720" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r197", "r198", "r199", "r228", "r263", "r473", "r484", "r563", "r569", "r575", "r576", "r577", "r578", "r579", "r580", "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r602", "r604", "r605", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r622", "r720" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r755", "r766", "r780", "r806" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r8", "r76", "r77", "r112" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails", "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of stock options and issuance of shares, shares", "negatedLabel": "Awards, exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r76", "r77", "r112", "r365" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r46", "r76", "r77", "r112" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of stock options and issuance of shares", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r8", "r77", "r80", "r81", "r112" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r77", "r80", "r81", "r105", "r585", "r601", "r623", "r624", "r699", "r726", "r851", "r868", "r920", "r967" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "CVV_SupplierRiskPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "SupplierRiskPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Supplier Risk", "documentation": "Supplier Risk [Policy Text Block]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r799" ] }, "CVV_TantalineASOfNordborgMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "TantalineASOfNordborgMember", "presentation": [ "http://cvdequipment.com/role/MesoscribeAndTantalineDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tantaline A/S of Nordborg [Member]", "documentation": "Tantaline A/S of Nordborg [Member]" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax credit carryforward.", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r425" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r425" ] }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardLimitationsOnUse", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax credit carryforward expiration", "documentation": "Description of the limitation related to use of the tax credit carryforward." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r425" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r683", "r879" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r683", "r879" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r866", "r922" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r791" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r798" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredAtPointInTimeMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": [ "r683" ] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferredOverTimeMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r683" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r822" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r823" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r823" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r821" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r821" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r822" ] }, "CVV_TwoThousandSevenShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "TwoThousandSevenShareIncentivePlanMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2007 Share Incentive Plan [Member]", "documentation": "2007 Share Incentive Plan [Member]" } } }, "auth_ref": [] }, "CVV_TwoThousandSixteenShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "TwoThousandSixteenShareIncentivePlanMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2016 Share Incentive Plan [Member]", "documentation": "2016 Share Incentive Plan [Member]" } } }, "auth_ref": [] }, "CVV_TwoThousandTwentyTwoShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20241231", "localname": "TwoThousandTwentyTwoShareIncentivePlanMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 Share Incentive Plan [Member]", "documentation": "2022 Share Incentive Plan [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r818" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Uncertain tax positions", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r399", "r415", "r691" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r24", "r25", "r26", "r130", "r131", "r134", "r135" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase in valuation allowance", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r418" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted", "label": "Diluted weighted average shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r213", "r221" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic", "label": "Basic weighted average shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r212", "r221" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r836" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Subparagraph": "(Instruction 5)", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)(Instruction 5)", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)(Instruction 5)", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)(Instruction 5)", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(4)(Instruction 5)", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(5)(Instruction 5)", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(1)(i)(Instruction 5)", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(1)(ii)(Instruction 5)", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)(Instruction 5)", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)(Instruction 5)", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)(Instruction 5)", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Subparagraph": "(Instruction 5)", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(3)", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(4)", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "a", "Subparagraph": "(5)", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "c", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 6-K", "Section": "General Instruction", "Subsection": "B" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "Instruction", "Paragraph": "2" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "a" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 98 0001493152-25-010917-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-25-010917-xbrl.zip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�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�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end XML 99 form10-k_htm.xml IDEA: XBRL DOCUMENT 0000766792 2024-01-01 2024-12-31 0000766792 2024-06-30 0000766792 2025-03-19 0000766792 2024-12-31 0000766792 2023-12-31 0000766792 2023-01-01 2023-12-31 0000766792 us-gaap:CommonStockMember 2022-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000766792 us-gaap:RetainedEarningsMember 2022-12-31 0000766792 2022-12-31 0000766792 us-gaap:CommonStockMember 2023-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000766792 us-gaap:RetainedEarningsMember 2023-12-31 0000766792 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000766792 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000766792 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000766792 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000766792 us-gaap:CommonStockMember 2024-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000766792 us-gaap:RetainedEarningsMember 2024-12-31 0000766792 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000766792 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000766792 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0000766792 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-12-31 0000766792 CVV:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000766792 CVV:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000766792 CVV:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000766792 CVV:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000766792 CVV:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000766792 CVV:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000766792 CVV:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:ExportSalesMember us-gaap:CustomerConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2024-01-01 2024-12-31 0000766792 CVV:ExportSalesMember us-gaap:CustomerConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2023-01-01 2023-12-31 0000766792 us-gaap:CargoAndFreightMember 2024-01-01 2024-12-31 0000766792 us-gaap:CargoAndFreightMember 2023-01-01 2023-12-31 0000766792 CVV:EnergyMember us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0000766792 CVV:EnergyMember us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0000766792 CVV:EnergyMember 2024-01-01 2024-12-31 0000766792 CVV:AerospaceMember us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0000766792 CVV:AerospaceMember us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0000766792 CVV:AerospaceMember 2024-01-01 2024-12-31 0000766792 CVV:IndustrialMember us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0000766792 CVV:IndustrialMember us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0000766792 CVV:IndustrialMember 2024-01-01 2024-12-31 0000766792 CVV:ResearchOneMember us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0000766792 CVV:ResearchOneMember us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0000766792 CVV:ResearchOneMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredOverTimeMember 2024-01-01 2024-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-12-31 0000766792 CVV:EnergyMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 CVV:EnergyMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:EnergyMember 2023-01-01 2023-12-31 0000766792 CVV:AerospaceMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 CVV:AerospaceMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:AerospaceMember 2023-01-01 2023-12-31 0000766792 CVV:IndustrialMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 CVV:IndustrialMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:IndustrialMember 2023-01-01 2023-12-31 0000766792 CVV:ResearchOneMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 CVV:ResearchOneMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:ResearchOneMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:PVTOneFiftySystemsMember 2024-01-01 2024-12-31 0000766792 CVV:PVTOneFiftySystemsMember 2024-12-31 0000766792 us-gaap:LandMember 2024-12-31 0000766792 us-gaap:LandMember 2023-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000766792 us-gaap:MachineryAndEquipmentMember 2024-12-31 0000766792 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000766792 us-gaap:ConstructionInProgressMember 2024-12-31 0000766792 us-gaap:ConstructionInProgressMember 2023-12-31 0000766792 2022-09-30 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2024-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2024-01-01 2024-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2024-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2024-01-01 2024-12-31 0000766792 2022-01-01 2022-12-31 0000766792 CVV:TwoThousandSevenShareIncentivePlanMember 2007-12-12 0000766792 CVV:TwoThousandSevenShareIncentivePlanMember 2024-12-31 0000766792 CVV:TwoThousandSixteenShareIncentivePlanMember 2016-12-09 0000766792 CVV:TwoThousandSixteenShareIncentivePlanMember 2024-12-31 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2022-07-14 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2024-12-31 0000766792 srt:MinimumMember CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2022-07-14 2022-07-14 0000766792 srt:MaximumMember CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2022-07-14 2022-07-14 0000766792 srt:DirectorMember us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0000766792 srt:DirectorMember us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000766792 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000766792 us-gaap:EmployeeStockOptionMember 2024-12-31 0000766792 CVV:FiveDirectorsMember 2021-10-11 0000766792 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0000766792 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000766792 CVV:CostOfRevenueMember 2024-01-01 2024-12-31 0000766792 CVV:CostOfRevenueMember 2023-01-01 2023-12-31 0000766792 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0000766792 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000766792 CVV:SellingExpenseMember 2024-01-01 2024-12-31 0000766792 CVV:SellingExpenseMember 2023-01-01 2023-12-31 0000766792 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0000766792 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeOneMember 2024-01-01 2024-12-31 0000766792 CVV:ExercisePriceRangeOneMember 2024-12-31 0000766792 CVV:ExercisePriceRangeTwoMember 2024-01-01 2024-12-31 0000766792 CVV:ExercisePriceRangeTwoMember 2024-12-31 0000766792 CVV:ExercisePriceRangeThreeMember 2024-01-01 2024-12-31 0000766792 CVV:ExercisePriceRangeThreeMember 2024-12-31 0000766792 CVV:ExercisePriceRangeFourMember 2024-01-01 2024-12-31 0000766792 CVV:ExercisePriceRangeFourMember 2024-12-31 0000766792 us-gaap:RestrictedStockMember 2022-12-31 0000766792 us-gaap:RestrictedStockMember 2023-12-31 0000766792 us-gaap:RestrictedStockMember 2024-12-31 0000766792 2022-07-01 2022-07-01 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMember 2024-01-01 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2024-01-01 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:MesoScribeTechnologiesIncMember 2024-01-01 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMember 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:MesoScribeTechnologiesIncMember 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember 2024-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:MesoScribeTechnologiesIncMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:MesoScribeTechnologiesIncMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember 2023-12-31 0000766792 CVV:OtherTantalineMember 2024-01-01 2024-12-31 0000766792 CVV:OtherTantalineMember 2023-01-01 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2024-01-01 2024-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0000766792 srt:AmericasMember 2024-01-01 2024-12-31 0000766792 srt:AmericasMember 2023-01-01 2023-12-31 0000766792 srt:NorthAmericaMember 2024-01-01 2024-12-31 0000766792 srt:NorthAmericaMember 2023-01-01 2023-12-31 0000766792 us-gaap:EMEAMember 2024-01-01 2024-12-31 0000766792 us-gaap:EMEAMember 2023-01-01 2023-12-31 0000766792 srt:AsiaPacificMember 2024-01-01 2024-12-31 0000766792 srt:AsiaPacificMember 2023-01-01 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-08-08 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2024-01-01 2024-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-01-01 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2024-12-31 0000766792 CVV:TantalineASOfNordborgMember 2023-05-26 2023-05-26 0000766792 CVV:TantalineASOfNordborgMember 2023-01-01 2023-12-31 iso4217:USD shares iso4217:USD shares pure CVV:Segment false FY 0000766792 P7Y P10Y P1Y 10-K true 2024-12-31 --12-31 2024 false 1-16525 CVD EQUIPMENT CORPORATION NY 11-2621692 355 South Technology Drive Central Islip NY 11722 (631) 981-7081 Common Stock, Par value $0.01 CVV NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 20795415 6881838 0.01 None <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_z0jLThZ4OM21">We have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zDCXjT8104Ph">implemented</span> a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. We use recognized commercially reasonable measures, tools, and methodologies to manage cybersecurity risk, which are tested regularly. We also monitor and evaluate our cybersecurity posture on an ongoing basis through regular malware scans, penetration tests, and third-party reviews.</span> Specific controls that are used to some extent include endpoint threat detection, identity and access management (IAM), privileged access management (PAM), logging and monitoring, multi-factor authentication (MFA), firewalls and intrusion detection and prevention, and vulnerability and patch management.</span> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To manage our material risks from cybersecurity threats and to protect against, detect, and prepare to respond to cybersecurity incidents, we undertake the below listed activities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monitor emerging data protection laws and implement changes to our compliance processes;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct periodic cybersecurity assessments for employees who use our system to evaluate training needs;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct onboarding and cyber security training for all employees on an ongoing basis;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct regular phishing email simulations for all employees; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carry cybersecurity risk insurance that protects against the potential losses from a cybersecurity incident.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our incident response plan coordinates the activities that we and our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_zE5LxNHpmpK2">third-party</span> cybersecurity provider take to prepare to respond to and recover from cybersecurity incidents. These include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate brand and reputational damage. We have an IT continuity plan that we continuously review and update in line with our evolving applications architecture.</span></p>   We have <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zDCXjT8104Ph">implemented</span> a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. We use recognized commercially reasonable measures, tools, and methodologies to manage cybersecurity risk, which are tested regularly. We also monitor and evaluate our cybersecurity posture on an ongoing basis through regular malware scans, penetration tests, and third-party reviews. true true <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_ztvd6jwmF7lk">Our Board of Directors and Audit Committee oversee our cybersecurity efforts to ensure effective governance in managing risks associated with cybersecurity threats.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240101__20241231_z11Pt6ZFBckd">Our Director of Information Technology provides periodic updates to the Board of Directors and Audit Committee regarding our cybersecurity program, including status updates on various projects to enhance our overall cybersecurity posture.</span></span> Our Board of Directors and Audit Committee oversee our cybersecurity efforts to ensure effective governance in managing risks associated with cybersecurity threats. Our Director of Information Technology provides periodic updates to the Board of Directors and Audit Committee regarding our cybersecurity program, including status updates on various projects to enhance our overall cybersecurity posture. true true From time to time, we grant equity awards, including stock options, to our employees, including our named executive officers. Historically, we have typically granted new-hire option awards on, or within the calendar quarter of, a new hire's employment start date and annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at a regularly scheduled meeting of the Compensation Committee occurring in such quarter. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time of each annual meeting of our stockholders, respectively, pursuant to our non-employee director compensation policy, as further described under the heading, “2024 Director Compensation” below. The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about our company when determining the timing of stock option grants and does <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEF3YXJkIFRpbWluZyBEaXNjbG9zdXJlAA__" id="xdx_90E_eecd--AwardTmgMnpiCnsdrdFlag_dbF_c20240101__20241231_zZ3ETicThXyc">no</span>t seek to time the award of stock options in relation to our public disclosure of MNPI false false 688 Marcum LLP Melville, NY 12598000 14025000 2149000 1906000 2226000 1604000 2115000 4454000 898000 852000 19986000 22841000 11699000 12166000 1000 18000 31686000 35025000 679000 1203000 2236000 1765000 87000 81000 597000 3135000 4908000 6137000 8554000 181000 268000 6318000 8822000 0.01 0.01 20000000 20000000 6881838 6881838 6824511 6824511 69000 68000 29757000 28695000 -4458000 -2560000 25368000 26203000 31686000 35025000 26876000 24109000 20545000 19038000 6331000 5071000 2627000 2596000 1656000 1632000 5181000 5451000 717000 -162000 111000 8747000 9952000 -2416000 -4881000 559000 577000 19000 23000 42000 2000 91000 542000 687000 -1874000 -4194000 24000 -14000 -1898000 -4180000 -0.28 -0.62 -0.28 -0.62 6823000 6788000 6823000 6788000 6760938 67000 27712000 1620000 29399000 -4180000 -4180000 41320 1000 907000 908000 22253 76000 76000 6824511 68000 28695000 -2560000 26203000 6824511 68000 28695000 -2560000 26203000 -1898000 -1898000 57327 1000 1062000 1063000 6881838 69000 29757000 -4458000 25368000 6881838 69000 29757000 -4458000 25368000 -1898000 -4180000 1063000 908000 684000 792000 1573000 387000 13000 717000 -162000 111000 256000 -1841000 622000 -566000 -646000 2308000 -1529000 150000 47000 -524000 -154000 472000 -679000 -1773000 866000 -1489000 -206000 106000 418000 250000 597000 312000 144000 -133000 82000 77000 76000 -82000 -1000 -1427000 -340000 14025000 14365000 12598000 14025000 3000 8000 19000 24000 110000 <p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zi5U6k4W4Rga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_820_zMkIKGqGRt03">Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVD Equipment Corporation and its subsidiaries (the “Company”) is a New York corporation. Its principal business activities include <span style="background-color: white">designing, developing, and manufacturing a broad range of chemical vapor deposition, physical vapor transport, gas control, and other equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research. The Company’s products are used in production environments as well as research and development centers, both academic and corporate.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zPwgbwmDkBb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - <span id="xdx_820_zUYZOfT6CSpd">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zPfajvLjp7hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--LiquidityPolicyTextBlock_zNiuzcwcdmFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline">Liquidity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At December 31, 2024, the Company had $<span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zfcb0kjRFFQ8" title="Cash and cash equivalents">12.6</span> million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zsXAvcc4W3X" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration: underline"><span id="xdx_868_zFwhkWAQ0INf">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="background-color: white">In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zuzUWSbcwPr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Principles of Consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zddIYR1c0eNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zdQyxDmzWrKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue Recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606<i>”</i>), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606<i>,</i> the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Over time</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. <span style="background-color: white">There were <span id="xdx_907_eus-gaap--CapitalizedContractCostImpairmentLoss_do_c20240101__20241231_zIJX6ZUGixQg" title="Contract assets, impairment loss"><span id="xdx_903_eus-gaap--CapitalizedContractCostImpairmentLoss_do_c20230101__20231231_zA3Bdl9U6RJc" title="Contract assets, impairment loss">no</span></span> material impairment losses recognized on contract assets during the year ended December 31, 2024 and 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because the Company believes these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide the Company with some measure of assurance that the customer will perform on its obligations under the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Point in time</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the years ended December 31, 2024 and 2023, all system equipment sales were recorded over time by using an input method except for a) one contract that was recorded as revenue at the point in time the equipment was transferred to the customer during 2024 and b) one contract that was entered during 2024 and will be recognized as revenue after December 31, 2024 upon transfer of the equipment to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zIuviYKN6L6g" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Inventories</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. <span style="background-color: white">Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--StandardProductWarrantyPolicy_zSViCtN7F0d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Product Warranty</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StandardProductWarrantyDescription_c20240101__20241231_zFJMtJALaGPf" title="Standard product warranty description">The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period.</span> The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zaxI0Rlfmoel" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Income Taxes</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than <span id="xdx_90E_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zQKCi1cy28li" title="Income tax examination, description">50% likely to be realized upon ultimate settlement</span> with the related tax authority. The Company recognizes potential interest and penalties related to uncertain tax positions in income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z3msG79KJ1M1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Impairment of Long-Lived Assets and Intangibles</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists. If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zFlXs3GRepa2" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Property, Plant and Equipment</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZb7nAwsgCJf" title="Property plant and equipment useful life">5</span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember__srt--RangeAxis__srt--MaximumMember_zyx9bKChFk3j" title="Property plant and equipment useful life">39</span> years and for machinery and equipment over <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zlL6225XKdpi" title="Property plant and equipment useful life">5</span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z5scTKgzKip1" title="Property plant and equipment useful life">8</span> years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zEXsuIcZNbla" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research and Development</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_zcIJL4WNfxg5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Earnings Per Share</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zsP0DdhukNH" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Cash and Cash Equivalents</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The Company had cash and cash equivalents of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zoz1cOsCrH58" title="Cash and cash equivalents">12.6</span> million and $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_z4FlWveW7mA5" title="Cash and cash equivalents">14.0</span> million at December 31, 2024 and 2023, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $<span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zUCrAvhAQ8A" title="Cash equivalents">11.9</span> million and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zJ6bLORYCek6" title="Cash equivalents">12.1</span> million at December 31, 2024 and 2023, respectively.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at December 31, 2024 and 2023 was $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zivtuANYSAjj" title="Cash uninsured amount">0.4</span> million and $<span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zt9GdUaOo5F2" title="Cash uninsured amount">1.5</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z3tUS1qf6C5a" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Concentration of Credit Risk</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely assesses the financial strength of its customers<i>.</i> In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts<i>. </i>The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable is presented net of an allowance for credit losses of $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20241231_zjcgPv6hWvb6">48,000</span>, </span>$<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zxcBIlEyWG2d" title="Allowance for credit loss">36,000</span> and $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zVS1hs9Yr9z9" title="Allowance for credit loss">36,000</span> as of December 31, 2024, 2023 and 2022, respectively. <span style="background-color: white">The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for credit losses could be material to our results of operations and financial condition. The provision for bad debt expense was $<span id="xdx_909_eus-gaap--ProvisionForDoubtfulAccounts_c20240101__20241231_zpfFnT4miGCb">13,000 </span></span><span style="background-color: white">and $<span id="xdx_901_eus-gaap--ProvisionForDoubtfulAccounts_dxL_c20230101__20231231_zpn5kLJYn8xc" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0490">0 </span></span></span><span style="background-color: white">for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has accounts receivables from certain customers that exceed <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zinIO9O8oRUb" title="Concentration risk percentage">10</span>% of total accounts receivable. As of December 31, 2024, the accounts receivable balance includes amounts from three customers that represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z6XoLhSUyA32" title="Concentration risk percentage">28.6</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zBNnMGzQdMT1" title="Concentration risk percentage">14.0</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_ziIXgUqj4h79" title="Concentration risk percentage">11.9</span>% of total accounts receivable, and as of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zPiEbS9jnWq3" title="Concentration risk percentage">37.6</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z0gb1w51zI78" title="Concentration risk percentage">13.0</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zwsejy8IUtOk" title="Concentration risk percentage">12.8</span>% of total accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--SalesConcentrationsPolicyPolicyTextBlock_zas9UjbJqCn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Sales Concentrations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue to a single customer in any one year can exceed <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zT1aWbeeWwk6" title="Concentration risk percentage">10</span>% of our total sales. There was one customer of the CVD Equipment segment in the year ended December 31, 2024 that represented <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zvWMUf2vkl0d" title="Concentration risk percentage">29.5</span>% of our revenues, while there were three customers of the CVD Equipment segment in the year ended December 31, 2023 that represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxdxk3NAv93b" title="Concentration risk percentage">14.3</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zXjJw7K9vRH5" title="Concentration risk percentage">13.5</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z3QGC1YjE23g" title="Concentration risk percentage">10.9</span>% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Export sales to customers represented approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ExportSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--GeographicDistributionAxis__us-gaap--GeographicDistributionForeignMember_zLdnQMabNfSd" title="Concentration risk percentage">4.3</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ExportSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--GeographicDistributionAxis__us-gaap--GeographicDistributionForeignMember_zPqKqhzmTdVd" title="Concentration risk percentage">17.2</span>% of sales years ended December 31, 2024 and 2023 respectively. Export sales in both 2024 and 2023 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--SupplierRiskPolicyTextBlock_zT1xK9FHxSl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Supplier Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjHtNFyl5cai" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Fair Value of Financial Instruments</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zRi33NojOJwb" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Stock-Based Compensation</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates. The value of restricted stock awards are based on the fair value on the date of the grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--ShippingAndHandlingPolicyPolicyTextBlock_zweT5JgJYuA6" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Shipping and Handling</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__us-gaap--CargoAndFreightMember_ze4MCdAr99M1" title="Revenue">73,000</span> and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--CargoAndFreightMember_ztroT70lxy5i" title="Revenue">55,000</span> for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zsx63MSrWgu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recently Adopted Accounting Standards</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting</i> (Topic 280): <i>Improvements to Reportable Segment Disclosures</i>. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This update is effective for our annual report for fiscal year 2024, and interim periods thereafter, and was applied retrospectively to the fiscal year 2024 financial statements.. The Company adopted ASU 2023-07 in 2024 and the required disclosures are included in Note 13.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--RecentlyIssuedAccountingStandardsPolicyTextBlock_zgMXnhMEwZzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recently Issued Accounting Standards</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes</i> (Topic 740): <i>Improvement to Income Tax Disclosures</i>. The amendments further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This ASU is effective for our annual report for fiscal year 2026, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the timing of adoption and impact of this ASU on our consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statements Expenses (Subtopic 220-40),” to improve income statement expenses disclosure. The standard requires more detailed information related to the types of expenses, including (among other items) the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included within each interim and annual income statement’s expense caption, as applicable. This authoritative guidance can be applied prospectively or retrospectively and will be effective for financial statements issued for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.</span></p> <p id="xdx_85F_zYGJf4F2Na86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zPfajvLjp7hc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--LiquidityPolicyTextBlock_zNiuzcwcdmFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline">Liquidity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At December 31, 2024, the Company had $<span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zfcb0kjRFFQ8" title="Cash and cash equivalents">12.6</span> million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of these financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 12600000 <p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zsXAvcc4W3X" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="background-color: white"><span style="text-decoration: underline"><span id="xdx_868_zFwhkWAQ0INf">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="background-color: white">In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ConsolidationPolicyTextBlock_zuzUWSbcwPr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Principles of Consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zddIYR1c0eNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zdQyxDmzWrKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue Recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606<i>”</i>), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606<i>,</i> the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Over time</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. <span style="background-color: white">There were <span id="xdx_907_eus-gaap--CapitalizedContractCostImpairmentLoss_do_c20240101__20241231_zIJX6ZUGixQg" title="Contract assets, impairment loss"><span id="xdx_903_eus-gaap--CapitalizedContractCostImpairmentLoss_do_c20230101__20231231_zA3Bdl9U6RJc" title="Contract assets, impairment loss">no</span></span> material impairment losses recognized on contract assets during the year ended December 31, 2024 and 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because the Company believes these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide the Company with some measure of assurance that the customer will perform on its obligations under the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Point in time</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the years ended December 31, 2024 and 2023, all system equipment sales were recorded over time by using an input method except for a) one contract that was recorded as revenue at the point in time the equipment was transferred to the customer during 2024 and b) one contract that was entered during 2024 and will be recognized as revenue after December 31, 2024 upon transfer of the equipment to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0 0 <p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zIuviYKN6L6g" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Inventories</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. <span style="background-color: white">Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--StandardProductWarrantyPolicy_zSViCtN7F0d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Product Warranty</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StandardProductWarrantyDescription_c20240101__20241231_zFJMtJALaGPf" title="Standard product warranty description">The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period.</span> The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zaxI0Rlfmoel" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Income Taxes</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than <span id="xdx_90E_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zQKCi1cy28li" title="Income tax examination, description">50% likely to be realized upon ultimate settlement</span> with the related tax authority. The Company recognizes potential interest and penalties related to uncertain tax positions in income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 50% likely to be realized upon ultimate settlement <p id="xdx_84E_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_z3msG79KJ1M1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Impairment of Long-Lived Assets and Intangibles</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists. If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zFlXs3GRepa2" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Property, Plant and Equipment</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZb7nAwsgCJf" title="Property plant and equipment useful life">5</span> to <span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember__srt--RangeAxis__srt--MaximumMember_zyx9bKChFk3j" title="Property plant and equipment useful life">39</span> years and for machinery and equipment over <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zlL6225XKdpi" title="Property plant and equipment useful life">5</span> to <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_z5scTKgzKip1" title="Property plant and equipment useful life">8</span> years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y P39Y P5Y P8Y <p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zEXsuIcZNbla" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research and Development</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_zcIJL4WNfxg5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Earnings Per Share</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zsP0DdhukNH" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Cash and Cash Equivalents</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The Company had cash and cash equivalents of $<span id="xdx_903_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zoz1cOsCrH58" title="Cash and cash equivalents">12.6</span> million and $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_z4FlWveW7mA5" title="Cash and cash equivalents">14.0</span> million at December 31, 2024 and 2023, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $<span id="xdx_908_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20241231_zUCrAvhAQ8A" title="Cash equivalents">11.9</span> million and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zJ6bLORYCek6" title="Cash equivalents">12.1</span> million at December 31, 2024 and 2023, respectively.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at December 31, 2024 and 2023 was $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20241231_zivtuANYSAjj" title="Cash uninsured amount">0.4</span> million and $<span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zt9GdUaOo5F2" title="Cash uninsured amount">1.5</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 12600000 14000000.0 11900000 12100000 400000 1500000 <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z3tUS1qf6C5a" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Concentration of Credit Risk</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely assesses the financial strength of its customers<i>.</i> In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts<i>. </i>The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable is presented net of an allowance for credit losses of $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20241231_zjcgPv6hWvb6">48,000</span>, </span>$<span id="xdx_908_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zxcBIlEyWG2d" title="Allowance for credit loss">36,000</span> and $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zVS1hs9Yr9z9" title="Allowance for credit loss">36,000</span> as of December 31, 2024, 2023 and 2022, respectively. <span style="background-color: white">The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for credit losses could be material to our results of operations and financial condition. The provision for bad debt expense was $<span id="xdx_909_eus-gaap--ProvisionForDoubtfulAccounts_c20240101__20241231_zpfFnT4miGCb">13,000 </span></span><span style="background-color: white">and $<span id="xdx_901_eus-gaap--ProvisionForDoubtfulAccounts_dxL_c20230101__20231231_zpn5kLJYn8xc" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0490">0 </span></span></span><span style="background-color: white">for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has accounts receivables from certain customers that exceed <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zinIO9O8oRUb" title="Concentration risk percentage">10</span>% of total accounts receivable. As of December 31, 2024, the accounts receivable balance includes amounts from three customers that represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z6XoLhSUyA32" title="Concentration risk percentage">28.6</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zBNnMGzQdMT1" title="Concentration risk percentage">14.0</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_ziIXgUqj4h79" title="Concentration risk percentage">11.9</span>% of total accounts receivable, and as of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zPiEbS9jnWq3" title="Concentration risk percentage">37.6</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_z0gb1w51zI78" title="Concentration risk percentage">13.0</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zwsejy8IUtOk" title="Concentration risk percentage">12.8</span>% of total accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 48000 36000 36000 13000 0.10 0.286 0.140 0.119 0.376 0.130 0.128 <p id="xdx_84A_ecustom--SalesConcentrationsPolicyPolicyTextBlock_zas9UjbJqCn8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Sales Concentrations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue to a single customer in any one year can exceed <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zT1aWbeeWwk6" title="Concentration risk percentage">10</span>% of our total sales. There was one customer of the CVD Equipment segment in the year ended December 31, 2024 that represented <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zvWMUf2vkl0d" title="Concentration risk percentage">29.5</span>% of our revenues, while there were three customers of the CVD Equipment segment in the year ended December 31, 2023 that represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zxdxk3NAv93b" title="Concentration risk percentage">14.3</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_zXjJw7K9vRH5" title="Concentration risk percentage">13.5</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_z3QGC1YjE23g" title="Concentration risk percentage">10.9</span>% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Export sales to customers represented approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ExportSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--GeographicDistributionAxis__us-gaap--GeographicDistributionForeignMember_zLdnQMabNfSd" title="Concentration risk percentage">4.3</span>% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ExportSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--GeographicDistributionAxis__us-gaap--GeographicDistributionForeignMember_zPqKqhzmTdVd" title="Concentration risk percentage">17.2</span>% of sales years ended December 31, 2024 and 2023 respectively. Export sales in both 2024 and 2023 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 0.295 0.143 0.135 0.109 0.043 0.172 <p id="xdx_848_ecustom--SupplierRiskPolicyTextBlock_zT1xK9FHxSl3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Supplier Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zjHtNFyl5cai" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Fair Value of Financial Instruments</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zRi33NojOJwb" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Stock-Based Compensation</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates. The value of restricted stock awards are based on the fair value on the date of the grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--ShippingAndHandlingPolicyPolicyTextBlock_zweT5JgJYuA6" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Shipping and Handling</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20241231__srt--ProductOrServiceAxis__us-gaap--CargoAndFreightMember_ze4MCdAr99M1" title="Revenue">73,000</span> and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--CargoAndFreightMember_ztroT70lxy5i" title="Revenue">55,000</span> for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> 73000 55000 <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zsx63MSrWgu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recently Adopted Accounting Standards</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting</i> (Topic 280): <i>Improvements to Reportable Segment Disclosures</i>. The amendments in this update expand annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses. This update is effective for our annual report for fiscal year 2024, and interim periods thereafter, and was applied retrospectively to the fiscal year 2024 financial statements.. The Company adopted ASU 2023-07 in 2024 and the required disclosures are included in Note 13.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--RecentlyIssuedAccountingStandardsPolicyTextBlock_zgMXnhMEwZzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recently Issued Accounting Standards</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Income Taxes</i> (Topic 740): <i>Improvement to Income Tax Disclosures</i>. The amendments further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. This ASU is effective for our annual report for fiscal year 2026, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the timing of adoption and impact of this ASU on our consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statements Expenses (Subtopic 220-40),” to improve income statement expenses disclosure. The standard requires more detailed information related to the types of expenses, including (among other items) the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization included within each interim and annual income statement’s expense caption, as applicable. This authoritative guidance can be applied prospectively or retrospectively and will be effective for financial statements issued for annual periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the process of evaluating the impact of adoption on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.</span></p> <p id="xdx_803_eus-gaap--RevenueFromContractWithCustomerTextBlock_zw4P3SD7RFv7" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 3 – <span id="xdx_82C_z7mKVvgtNqtd">Revenue</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zf4NVozeSYpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2024 and 2023 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zXcty2bkoPB2" style="display: none">Schedule of Disaggregation of Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z0qVkymi4nE9" style="border-bottom: Black 1pt solid; text-align: center">Over time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zJ97fJdS1QAe" style="border-bottom: Black 1pt solid; text-align: center">Point in time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20241231_ztHimMdCIeNk" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Over time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Point in time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--EnergyMember_zIwt3is1v1y4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Energy</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">216</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">511</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">727</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--AerospaceMember_zyQdKnNNeWoj" style="vertical-align: bottom; background-color: White"> <td>Aerospace</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,879</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,084</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--IndustrialMember_z5qcDn88ZyP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Industrial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,921</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,271</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchOneMember_zCcQuJGYc1i" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Research</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,736</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,058</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,794</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zcQPRUKjhg26" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,216</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,660</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zG2o6qUGL8N7" style="border-bottom: Black 1pt solid; text-align: center">Over time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zINy94LqbBaj" style="border-bottom: Black 1pt solid; text-align: center">Point in time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231_zNFJPRgcNfHl" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Over time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Point in time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--EnergyMember_zDz8oYEnDv1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Energy</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,901</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">189</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,090</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--AerospaceMember_zR47OBq3h0O4" style="vertical-align: bottom; background-color: White"> <td>Aerospace</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,427</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,469</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,896</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--IndustrialMember_zT7yI8o1xfab" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Industrial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,944</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchOneMember_zLAQXx1Vu88g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Research</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,700</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,479</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,179</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zI4M2v5gUBt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,151</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,109</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z13Bjptm8EU6" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 3 – Revenue (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. Research market principally represents customers that are universities and other research institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has unrecognized contract revenue of approximately $<span id="xdx_905_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn5n6_c20241231_zVHWfs9M7uTe" title="Unrecognized contract revenue">16.4</span> million at December 31, 2024, which it expects to substantially recognize as revenue within the next twelve months based on over time revenue recognition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine the Company’s progress towards contract completion and to calculate the corresponding amount of revenue to recognize.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated financial position and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_ecustom--ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock_zWzoI3Nvy1Pf" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zspiKx9drVcb" style="display: none">Schedule of Cost and Estimated Earnings in Excess of Billings</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic"> </td><td style="padding-bottom: 1pt; font-style: normal"> </td> <td colspan="2" id="xdx_495_20241231_zqnM9mkpiWik" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-style: normal"> </td><td style="padding-bottom: 1pt; font-style: normal"> </td> <td colspan="2" id="xdx_496_20231231_zo33xjQ0k1Si" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-style: normal"> </td></tr> <tr id="xdx_406_ecustom--CostsIncurredOnUncompletedContracts_iI_pn3n3_maCAEEOzw4R_zpgYuDJx3Ylc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-style: normal; text-align: left">Costs incurred on contracts in progress</td><td style="width: 2%; font-style: normal"> </td> <td style="width: 1%; font-style: normal; text-align: left">$</td><td style="width: 16%; font-style: normal; text-align: right">14,696</td><td style="width: 1%; font-style: normal; text-align: left"> </td><td style="width: 2%; font-style: normal"> </td> <td style="width: 1%; font-style: normal; text-align: left">$</td><td style="width: 16%; font-style: normal; text-align: right">9,500</td><td style="width: 1%; font-style: normal; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EstimatedEarnings_iI_pn3n3_maCAEEOzw4R_zw7EJmR9odzc" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt">Estimated earnings</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">7,052</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">5,083</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CostsAndEstimatedEarningsOnUncompletedContracts_iTI_pn3n3_mtCAEEOzw4R_maNCIEOzQmN_zgMr8Hf0kcA5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and estimated earnings on uncompleted contracts</span></td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right">21,748</td><td style="font-style: normal; text-align: left"> </td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right">14,583</td><td style="font-style: normal; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BillingsToDate_iNI_pn3n3_di_msNCIEOzQmN_zaL8jhJbuqn2" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt">Billings to date</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">(22,059</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left">)</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">(17,553</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NetCostInExcessOfBillings_iTI_pn3n3_mtNCIEOzQmN_msCLIEOzoWe_zqylcZLDrIo7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cost in excess of billings</span></td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right">(311</td><td style="font-style: normal; text-align: left">)</td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right">(2,970</td><td style="font-style: normal; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--DeferredRevenuesRelatedToContracts_iNI_pn3n3_di_maCLIEOzoWe_zHmKugo3Blac" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt">Deferred revenue related to non-systems contracts</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">(598</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left">)</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">(334</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ContractLiabilityInExcessOfContractAssets_iNTI_pn3n3_di_mtCLIEOzoWe_zz2oWDKV2Hq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liability in excess of contract assets</span></td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">(909</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left">)</td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">(3,304</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left">Included in accompanying consolidated balance sheets under the following captions (in thousands):</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right"> </td><td style="font-style: italic; text-align: left"> </td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right"> </td><td style="font-style: italic; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"> </td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right"> </td><td style="font-style: italic; text-align: left"> </td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right"> </td><td style="font-style: italic; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ContractWithCustomerAssetNetCurrent_iI_pn3n3_z7nWeMGbPSV6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-style: normal; text-align: left; padding-bottom: 2.5pt">Contract assets</td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">2,226</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">1,604</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_zVoaYce23wJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-style: normal; text-align: left; padding-bottom: 2.5pt">Contract liabilities</td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">3,135</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">4,908</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zFFZJR35L2F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the contract liability balances at December 31, 2023 and December 31, 2022, $<span id="xdx_905_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20240101__20241231_zE2LTthkSHJc" title="Contract liability recognized as revenue">4.7</span> million and $<span id="xdx_904_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20230101__20231231_zaP34zywHI9" title="Contract liability recognized as revenue">3.7</span> million was recognized as revenue during the years ended December 31, 2024 and 2023, respectively. Contract assets and contract liabilities at December 31, 2022 were $<span id="xdx_909_eus-gaap--ContractWithCustomerAssetNet_iI_pn5n6_c20221231_zGgBAaZWjhIi" title="Contract assets">2.2</span> million and $<span id="xdx_900_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn5n6_c20221231_z26hxbMCqeCe" title="Contract liability">4.0</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_zf4NVozeSYpj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2024 and 2023 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zXcty2bkoPB2" style="display: none">Schedule of Disaggregation of Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z0qVkymi4nE9" style="border-bottom: Black 1pt solid; text-align: center">Over time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240101__20241231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zJ97fJdS1QAe" style="border-bottom: Black 1pt solid; text-align: center">Point in time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20241231_ztHimMdCIeNk" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Over time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Point in time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--EnergyMember_zIwt3is1v1y4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Energy</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">216</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">511</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">727</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--AerospaceMember_zyQdKnNNeWoj" style="vertical-align: bottom; background-color: White"> <td>Aerospace</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,879</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,084</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--IndustrialMember_z5qcDn88ZyP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Industrial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,921</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,350</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,271</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchOneMember_zCcQuJGYc1i" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Research</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,736</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,058</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,794</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zcQPRUKjhg26" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,216</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,660</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zG2o6qUGL8N7" style="border-bottom: Black 1pt solid; text-align: center">Over time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zINy94LqbBaj" style="border-bottom: Black 1pt solid; text-align: center">Point in time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231_zNFJPRgcNfHl" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Over time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Point in time</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--EnergyMember_zDz8oYEnDv1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Energy</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,901</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">189</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,090</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--AerospaceMember_zR47OBq3h0O4" style="vertical-align: bottom; background-color: White"> <td>Aerospace</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,427</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,469</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,896</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--IndustrialMember_zT7yI8o1xfab" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Industrial</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,944</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchOneMember_zLAQXx1Vu88g" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Research</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,700</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,479</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,179</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zI4M2v5gUBt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,151</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,109</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 216000 511000 727000 11205000 1879000 13084000 6921000 1350000 8271000 3736000 1058000 4794000 22216000 4660000 26876000 4901000 189000 5090000 3427000 1469000 4896000 6123000 2821000 8944000 3700000 1479000 5179000 18151000 5958000 24109000 16400000 <p id="xdx_891_ecustom--ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock_zWzoI3Nvy1Pf" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zspiKx9drVcb" style="display: none">Schedule of Cost and Estimated Earnings in Excess of Billings</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic"> </td><td style="padding-bottom: 1pt; font-style: normal"> </td> <td colspan="2" id="xdx_495_20241231_zqnM9mkpiWik" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1pt; font-style: normal"> </td><td style="padding-bottom: 1pt; font-style: normal"> </td> <td colspan="2" id="xdx_496_20231231_zo33xjQ0k1Si" style="border-bottom: Black 1pt solid; font-style: normal; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1pt; font-style: normal"> </td></tr> <tr id="xdx_406_ecustom--CostsIncurredOnUncompletedContracts_iI_pn3n3_maCAEEOzw4R_zpgYuDJx3Ylc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-style: normal; text-align: left">Costs incurred on contracts in progress</td><td style="width: 2%; font-style: normal"> </td> <td style="width: 1%; font-style: normal; text-align: left">$</td><td style="width: 16%; font-style: normal; text-align: right">14,696</td><td style="width: 1%; font-style: normal; text-align: left"> </td><td style="width: 2%; font-style: normal"> </td> <td style="width: 1%; font-style: normal; text-align: left">$</td><td style="width: 16%; font-style: normal; text-align: right">9,500</td><td style="width: 1%; font-style: normal; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EstimatedEarnings_iI_pn3n3_maCAEEOzw4R_zw7EJmR9odzc" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt">Estimated earnings</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">7,052</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">5,083</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CostsAndEstimatedEarningsOnUncompletedContracts_iTI_pn3n3_mtCAEEOzw4R_maNCIEOzQmN_zgMr8Hf0kcA5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and estimated earnings on uncompleted contracts</span></td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right">21,748</td><td style="font-style: normal; text-align: left"> </td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right">14,583</td><td style="font-style: normal; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--BillingsToDate_iNI_pn3n3_di_msNCIEOzQmN_zaL8jhJbuqn2" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt">Billings to date</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">(22,059</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left">)</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">(17,553</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--NetCostInExcessOfBillings_iTI_pn3n3_mtNCIEOzQmN_msCLIEOzoWe_zqylcZLDrIo7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cost in excess of billings</span></td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right">(311</td><td style="font-style: normal; text-align: left">)</td><td style="font-style: normal"> </td> <td style="font-style: normal; text-align: left"> </td><td style="font-style: normal; text-align: right">(2,970</td><td style="font-style: normal; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--DeferredRevenuesRelatedToContracts_iNI_pn3n3_di_maCLIEOzoWe_zHmKugo3Blac" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1pt">Deferred revenue related to non-systems contracts</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">(598</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left">)</td><td style="font-style: normal; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-style: normal; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-style: normal; text-align: right">(334</td><td style="padding-bottom: 1pt; font-style: normal; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ContractLiabilityInExcessOfContractAssets_iNTI_pn3n3_di_mtCLIEOzoWe_zz2oWDKV2Hq2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liability in excess of contract assets</span></td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">(909</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left">)</td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">(3,304</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left">Included in accompanying consolidated balance sheets under the following captions (in thousands):</td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right"> </td><td style="font-style: italic; text-align: left"> </td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right"> </td><td style="font-style: italic; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"> </td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right"> </td><td style="font-style: italic; text-align: left"> </td><td style="font-style: italic"> </td> <td style="font-style: italic; text-align: left"> </td><td style="font-style: italic; text-align: right"> </td><td style="font-style: italic; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ContractWithCustomerAssetNetCurrent_iI_pn3n3_z7nWeMGbPSV6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-style: normal; text-align: left; padding-bottom: 2.5pt">Contract assets</td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">2,226</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">1,604</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_zVoaYce23wJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-style: normal; text-align: left; padding-bottom: 2.5pt">Contract liabilities</td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">3,135</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"> </td><td style="font-style: normal; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right">4,908</td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"> </td></tr> </table> 14696000 9500000 7052000 5083000 21748000 14583000 22059000 17553000 -311000 -2970000 598000 334000 909000 3304000 2226000 1604000 3135000 4908000 4700000 3700000 2200000 4000000.0 <p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_zutthAde06ua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 - <span id="xdx_823_z94dmrRVH2wi">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zXdGIhpFPmXg" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Inventories as of December 31 consist of (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span><span id="xdx_8B5_zvKYTAdv2fdl" style="display: none">Schedule of Inventories, net</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20241231_za3rP28eYb73" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231231_zdruGvIsKQm7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzesC_zfwa4uazsM3f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,217</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,351</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzesC_z8WeeKNyQsT7" style="vertical-align: bottom; background-color: White"> <td>Work-in-process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,248</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzesC_zyrYpCQvdoy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">133</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">855</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzesC_zHTG0e7G1CI8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,115</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zNmHNULcxfs9" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Included in inventories are finished goods and raw materials related to PVT 150 systems that were purchased and built, respectively, in anticipation of future orders. During the year ended December 31, 2024, the Company recorded a non-cash charge to reduce the net realizable value of such inventory by approximately $<span id="xdx_907_eus-gaap--OtherNoncashExpense_pn5n6_c20240101__20241231__us-gaap--PublicUtilitiesInventoryAxis__custom--PVTOneFiftySystemsMember_zRjWzcLG9GZf" title="Non-cash charge to reduce net realizable value">1.3</span> million based on its assessment of the current market for silicon carbide equipment.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">As of December 31, 2024, the net amount of PVT 150 systems inventory is approximately $<span id="xdx_901_eus-gaap--InventoryNet_iI_pn5n6_c20241231__us-gaap--PublicUtilitiesInventoryAxis__custom--PVTOneFiftySystemsMember_zR7G4ZciIoZk" title="Inventories">0.5</span> million. If future PVT 150 orders do not materialize and if the Company is not otherwise able to sell this inventory, the Company could incur additional charges to further reduce the carrying value of such inventory to net realizable value. Such charges may be material to the Company’s financial position and future results of operations.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zXdGIhpFPmXg" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Inventories as of December 31 consist of (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span><span id="xdx_8B5_zvKYTAdv2fdl" style="display: none">Schedule of Inventories, net</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20241231_za3rP28eYb73" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231231_zdruGvIsKQm7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzesC_zfwa4uazsM3f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,217</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,351</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzesC_z8WeeKNyQsT7" style="vertical-align: bottom; background-color: White"> <td>Work-in-process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">765</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,248</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzesC_zyrYpCQvdoy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">133</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">855</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzesC_zHTG0e7G1CI8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,115</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,454</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1217000 2351000 765000 1248000 133000 855000 2115000 4454000 1300000 500000 <p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z6t5Agl3Pbbd" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 5 – <span id="xdx_82E_zM63eTurGdtd">Property, Plant and Equipment</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zoc7xUPMP1w2" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span><span id="xdx_8B1_zu8KT6a4viUf" style="display: none">Schedule of Property, Plant and Equipment</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241231_zPl77ACISzWe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231231_zzkk4xGyq43c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zrUjrVsJmW7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Land</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_z8HxpHkVqmq7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Buildings and improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,897</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,798</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zUm0EktMdYpb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,536</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zlK6KUO13kzh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">167</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzCuC_zessA749JPT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Totals at cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,312</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,721</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzCuC_zBWjUv9jQbG2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,613</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,555</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzCuC_zb4jzesfFRpc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,699</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,166</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zJaX6FKHs4Fe" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Machinery and equipment also include furniture and fixtures and software.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Depreciation expense was $<span id="xdx_90A_eus-gaap--Depreciation_pn5n6_c20240101__20241231_zLiVwqXmrpa2" title="Depreciation expense">0.7</span> million and $<span id="xdx_904_eus-gaap--Depreciation_pn5n6_c20230101__20231231_zz8r0OPtxKb" title="Depreciation expense">0.8</span> million for the years ended December 31, 2024 and 2023, respectively.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 5 – Property, Plant and Equipment (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The Company entered into an agreement with the Town of Islip Industrial Development Agency (Islip IDA) in July 2021 under which the Company was granted tax incentives whereby the Company agreed to make payments in lieu of all real estate taxes and assessments (PILOT payments). The agreement requires the Company to maintain certain employment levels at its Central Islip, New York facility. The agreement provides for the Islip IDA to recapture tax incentives provided to the Company in certain circumstances. Any recapture of such tax benefits could have a material adverse effect on the Company’s financial position and future results of operations and cash flows.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zoc7xUPMP1w2" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span><span id="xdx_8B1_zu8KT6a4viUf" style="display: none">Schedule of Property, Plant and Equipment</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20241231_zPl77ACISzWe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231231_zzkk4xGyq43c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zrUjrVsJmW7a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Land</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_z8HxpHkVqmq7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Buildings and improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,897</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,798</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zUm0EktMdYpb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Machinery and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,536</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zlK6KUO13kzh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">167</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzCuC_zessA749JPT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Totals at cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,312</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">22,721</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzCuC_zBWjUv9jQbG2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,613</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,555</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzCuC_zb4jzesfFRpc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,699</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,166</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2220000 2220000 12897000 12798000 7178000 7536000 17000 167000 22312000 22721000 10613000 10555000 11699000 12166000 700000 800000 <p id="xdx_807_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zIAB4F6zTts9" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 6 – <span id="xdx_82F_zfL3qSiNWl89">Accrued Expenses</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_ziElr3eaaa42" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Accrued expenses consist of the following as of December 31 (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span><span id="xdx_8B9_zKk6BCnyOyu1" style="display: none">Schedule of Accrued Expenses</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zLCVlCuIuh4e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20231231_zWevIu7JKuEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maALCz7TQ_zaP714R3bhfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued wages and benefits</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">395</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">358</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedVacationCurrent_iI_pn3n3_maALCz7TQ_zNQc6AVFThjj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued vacation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">729</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedMaterialPurchasesCurrent_iI_pn3n3_maALCz7TQ_zopus10mo4b4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued material purchases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">618</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7TQ_zk4vvvXy5Dw5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">540</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">389</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7TQ_zHFIfdKqply1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,765</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zM3rNyyLnCQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_ziElr3eaaa42" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Accrued expenses consist of the following as of December 31 (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span><span id="xdx_8B9_zKk6BCnyOyu1" style="display: none">Schedule of Accrued Expenses</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zLCVlCuIuh4e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20231231_zWevIu7JKuEd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maALCz7TQ_zaP714R3bhfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued wages and benefits</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">395</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">358</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedVacationCurrent_iI_pn3n3_maALCz7TQ_zNQc6AVFThjj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued vacation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">729</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedMaterialPurchasesCurrent_iI_pn3n3_maALCz7TQ_zopus10mo4b4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued material purchases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">618</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">289</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7TQ_zk4vvvXy5Dw5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">540</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">389</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7TQ_zHFIfdKqply1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,236</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,765</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 395000 358000 683000 729000 618000 289000 540000 389000 2236000 1765000 <p id="xdx_809_eus-gaap--LongTermDebtTextBlock_zcOSpyXxRzTc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_825_zCB6oaGsBE4j">Long-term Debt</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zVlRwmPUdnKj" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8B3_zGI7u2PwHcLe" style="display: none">Schedule of Long Term Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241231_zQATQf6aYNag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_z713mByOjbLl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--LoansPayable_iI_pn3n3_zyrqv5dJoWR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Equipment loan payable in monthly repayments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240101__20241231_zSaMHz1lyGw5"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20230101__20231231_zUUtreZVgxL6">8</span> </span>including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231_zLtHWXZbLs26" title="Debt instrument interest rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231_zDcWqgq5zRc9" title="Debt instrument interest rate">6</span></span>% per annum</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">268</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">349</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtCurrent_iI_pn3n3_z5nGnd5tpWZ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: current maturities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">81</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_z8WuEpQRckM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current maturities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zOOpzD6Uc9vh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022<i>, </i>the Company entered into a loan agreement to fund the acquisition of equipment in the amount of $<span id="xdx_902_ecustom--LoanToFundAcquisitionOfMachineryEquipment_iI_pn5n6_c20220930_zxapGssLpkd2" title="Loan to fund acquisition of machinery equipment">0.4</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – Long-term Debt (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zAPLSuZrtt53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future maturities of long-term debt as of December 31, 2024 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zJGuROCSbAek" style="display: none">Schedule of Maturities of Long Term Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20241231_zbQTBUQyHfMi" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzMa5_ziYidUbckxQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">87</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzMa5_zhrGGDrwGdve" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzMa5_zpQeZcyAB8N3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">89</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzMa5_zudOJHHyX7la" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zZtwNCBnLpp1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zVlRwmPUdnKj" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span><span id="xdx_8B3_zGI7u2PwHcLe" style="display: none">Schedule of Long Term Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241231_zQATQf6aYNag" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_z713mByOjbLl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--LoansPayable_iI_pn3n3_zyrqv5dJoWR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Equipment loan payable in monthly repayments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240101__20241231_zSaMHz1lyGw5"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20230101__20231231_zUUtreZVgxL6">8</span> </span>including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241231_zLtHWXZbLs26" title="Debt instrument interest rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231_zDcWqgq5zRc9" title="Debt instrument interest rate">6</span></span>% per annum</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">268</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">349</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtCurrent_iI_pn3n3_z5nGnd5tpWZ7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: current maturities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">81</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_z8WuEpQRckM7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current maturities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 8000 8000 0.06 0.06 268000 349000 87000 81000 181000 268000 400000 <p id="xdx_893_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zAPLSuZrtt53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future maturities of long-term debt as of December 31, 2024 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zJGuROCSbAek" style="display: none">Schedule of Maturities of Long Term Debt</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20241231_zbQTBUQyHfMi" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzMa5_ziYidUbckxQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">87</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzMa5_zhrGGDrwGdve" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzMa5_zpQeZcyAB8N3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">89</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzMa5_zudOJHHyX7la" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">268</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 87000 92000 89000 268000 <p id="xdx_806_eus-gaap--EarningsPerShareTextBlock_z6S28ZQ1P5Ac" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_826_zoBatqDnmsGg">Earnings per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpnJBAl1tpUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zfvAgcHdyh9b" style="display: none">Schedule of Basic and Diluted Weighted Average Common Shares Outstanding</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231_zC3i1lX2Ujsl" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_z3ftCf8wvcuh" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zvyePhkr7CI8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Basic weighted average shares outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">6,823</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">6,788</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_zDe1QBloVk1e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Effect of potentially dilutive share-based awards</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zuu48aMTb6ni" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Diluted weighted average shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,823</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,788</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zb3B2OT1n1o" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2024 and 2023, all stock options and unvested restricted stock were not included in the computation of diluted earnings per share because their effect was antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zpnJBAl1tpUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zfvAgcHdyh9b" style="display: none">Schedule of Basic and Diluted Weighted Average Common Shares Outstanding</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231_zC3i1lX2Ujsl" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230101__20231231_z3ftCf8wvcuh" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zvyePhkr7CI8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Basic weighted average shares outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">6,823</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">6,788</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_zDe1QBloVk1e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Effect of potentially dilutive share-based awards</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_zuu48aMTb6ni" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Diluted weighted average shares outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,823</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">6,788</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6823000 6788000 6823000 6788000 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zbdqf4E4sGba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_827_zLEfRX2Ehk77">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zdPHI36G3FCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before income taxes are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zJmmRFUcu452" style="display: none">Schedule of Loss Before Income Taxes</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zn2FUC1HpDN5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zjuNdLeD7PCg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maILFCOzXdM_zIReuMz2XLa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,874</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(4,073</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maILFCOzXdM_zCsysI1ZNen5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(121</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzXdM_z4PjpFVKFrij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,874</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,194</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AB_zBE2nYespcua" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – Income Taxes (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z5pAwS9kFjv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_z4m9YQvEsmq8" style="display: none">Schedule of Components of Income Tax Expense (Benefit)</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20240101__20241231_zeK2oXWJYhIc" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20230101__20231231_zwQa8Ex7AwT1" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzswH_zxYII987G2c5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(16</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzswH_zVyWT9M7kPXe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzswH_maITEBzuuP_zQKxcp5up3vg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total current tax provision</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzJTX_zIR5URTsqnP2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzJTX_zqP7qPp1ZXqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0761">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzJTX_maITEBzuuP_zW8VG3IkRrx2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total deferred tax provision</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzuuP_zKR1UMbqr1M7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A5_zcLwLmKmZzAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z4UN2UJ64Y2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zrvqTWVGj3nf" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20240101__20241231_z8kSUBMkkXxk" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zi0GgNXH4rae" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzHAV_zq7YKLU6lTaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected provision at federal statutory tax rate at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVmZmVjdGl2ZSBJbmNvbWUgVGF4IFJhdGUgUmVjb25jaWxpYXRpb24gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zZvFMnU117n2" title="Federal statutory tax rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVmZmVjdGl2ZSBJbmNvbWUgVGF4IFJhdGUgUmVjb25jaWxpYXRpb24gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zs2uBHXxB7gj" title="Federal statutory tax rate">21</span></span>%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(395</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(881</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzHAV_zyXWB4tF0xW2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increase in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">447</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzHAV_z4c61hxtu6w5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">State and local taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(197</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_msITEBzHAV_z7MCmmmeRfv3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(75</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_pn3n3_maITEBzHAV_zC8iaieTKWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationDispositionOfBusiness_pn3n3_maITEBzHAV_z4YOvZsTtB07" style="vertical-align: bottom; background-color: White"> <td>Disposition of Tantaline</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">193</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maITEBzHAV_zlnqenCVegfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">83</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzHAV_zPaMGiTNrXPc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A6_zbdGPshPXVmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – Income Taxes (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zwjzPyFUMyxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span><span id="xdx_8B2_zAOpttMymRll" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20241231_ziOZkcFMaS9j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20231231_zeHH0Pl02x6g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzjWa_z8C2paWxZfqd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">679</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">849</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzjWa_zBfDM33RiADb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">R&amp;D tax credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,722</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,863</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pn3n3_maDTAGzjWa_zIOZGRoDmz18" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Compensation costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_pn3n3_maDTAGzjWa_zBB5b7IXPcQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Vacation accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzjWa_zA9H0ALDjDI2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzjWa_zUfAU83jeRY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Capitalized research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,096</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">759</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzjWa_z6hZ0pPPDaBc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">676</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">303</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzjWa_maDTANz0Q9_zC6qjTHLojmc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,078</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANz0Q9_zHItysgv7zYf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,098</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,646</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANz0Q9_maDTALNz5Um_z99xHwxeVzB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Deferred income tax assets, net of valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">466</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">432</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred incomes tax liability:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_msDTALNz5Um_zn1QVSjr2zoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property, plant and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(384</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(365</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_pn3n3_di_msDTALNz5Um_z8eAUojEMNgf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(82</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(67</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNz5Um_zQqtR7De8m5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Deferred income tax asset, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zR54av3OjzT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that the deferred tax assets will be realized. The ultimate realization of deferred tax assets is based on the assessment of available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit the utilization of existing deferred tax assets. The Company considered all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the prior three-year period ended December 31, 2024. Such objective evidence limits the ability to consider subjective evidence such as our projections for future growth. Based on this assessment, we maintained a full valuation allowance against our net deferred tax assets as of December 31, 2024, and 2023. If these estimates and assumptions change in the future, we may be required to reduce our existing valuation allowance resulting in less income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2024, the valuation allowance increased by approximately $<span id="xdx_90A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20240101__20241231_zG6JekhplIg6" title="Increase in valuation allowance">0.5</span> million from the prior year primarily the result of capitalized research and development costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – Income Taxes (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2024, the Company had $<span id="xdx_903_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_z5pbreGTdyC7" title="Operating loss carryforwards">2.7</span> million of U.S. federal net operating loss carryforwards. <span id="xdx_905_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_pid_dp_uPure_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_zOQEYGSVKow" title="Operating loss carryforwards, limitations">These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income.</span> The Company also has $<span id="xdx_90C_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zeIfL0kN7gv3" title="Tax credit carryforward.">1.7</span> million of federal research and development tax credits which <span id="xdx_901_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_pn5n6_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_z6ZgouZJIsHg" title="Tax credit carryforward expiration">expire in varying amounts in tax years 2028 through 2042.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2024 and 2023, the Company had <span id="xdx_90F_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20241231_zwzv3VaCF0hj" title="Uncertain tax positions"><span id="xdx_907_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20231231_zs306nVu5ah8" title="Uncertain tax positions">no</span></span> uncertain tax positions. The Company does not expect that its unrecognized tax benefits will significantly increase or decrease within twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. <span id="xdx_905_eus-gaap--IncomeTaxExaminationDescription_c20240101__20241231_zRGgg9e2j0Cl" title="Income tax examination, year">The federal tax years open to examination are 2021 to 2024. The Company’s state and local tax years that are open to tax examination are generally 2020 to 2024.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Inflation Reduction Act (“IRA”) and Chips and Science Act (“CHIPS Act”) were both enacted in August 2022. The IRA introduced new provisions including a <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_c20240101__20241231_zvUWvjLCjO0b" title="Corporate tax rate">15</span>% corporate alternative minimum tax for certain large corporations that have at least an average of $1 billion adjusted financial statement income over a consecutive three-tax-year period and a <span id="xdx_90C_ecustom--EffectiveIncomeTaxRateReconciliationAtExciseIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zjKQBKo4TjT7" title="Excise tax rate">1</span>% excise tax surcharge on stock repurchases. The CHIPS Act provides a variety of incentives associated with investments in domestic semiconductor manufacturing and related activities. Both the IRA and CHIPS Act are applicable for tax years beginning after December 31, 2022 and had no impact to the Company’s consolidated financial statements for the years ended December 31, 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zdPHI36G3FCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before income taxes are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zJmmRFUcu452" style="display: none">Schedule of Loss Before Income Taxes</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zn2FUC1HpDN5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_zjuNdLeD7PCg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maILFCOzXdM_zIReuMz2XLa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,874</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(4,073</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maILFCOzXdM_zCsysI1ZNen5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(121</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzXdM_z4PjpFVKFrij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,874</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,194</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -1874000 -4073000 -121000 -1874000 -4194000 <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z5pAwS9kFjv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_z4m9YQvEsmq8" style="display: none">Schedule of Components of Income Tax Expense (Benefit)</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20240101__20241231_zeK2oXWJYhIc" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20230101__20231231_zwQa8Ex7AwT1" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzswH_zxYII987G2c5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">14</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(16</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzswH_zVyWT9M7kPXe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzswH_maITEBzuuP_zQKxcp5up3vg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total current tax provision</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(14</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzJTX_zIR5URTsqnP2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0758">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzJTX_zqP7qPp1ZXqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">State</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0761">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzJTX_maITEBzuuP_zW8VG3IkRrx2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total deferred tax provision</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0763">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzuuP_zKR1UMbqr1M7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 14000 -16000 10000 2000 24000 -14000 24000 -14000 <p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z4UN2UJ64Y2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zrvqTWVGj3nf" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20240101__20241231_z8kSUBMkkXxk" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20230101__20231231_zi0GgNXH4rae" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzHAV_zq7YKLU6lTaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected provision at federal statutory tax rate at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVmZmVjdGl2ZSBJbmNvbWUgVGF4IFJhdGUgUmVjb25jaWxpYXRpb24gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20240101__20241231_zZvFMnU117n2" title="Federal statutory tax rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVmZmVjdGl2ZSBJbmNvbWUgVGF4IFJhdGUgUmVjb25jaWxpYXRpb24gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zs2uBHXxB7gj" title="Federal statutory tax rate">21</span></span>%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(395</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(881</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzHAV_zyXWB4tF0xW2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increase in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">447</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">688</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzHAV_z4c61hxtu6w5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">State and local taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(197</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_msITEBzHAV_z7MCmmmeRfv3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(75</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_pn3n3_maITEBzHAV_zC8iaieTKWl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-deductible expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationDispositionOfBusiness_pn3n3_maITEBzHAV_z4YOvZsTtB07" style="vertical-align: bottom; background-color: White"> <td>Disposition of Tantaline</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">193</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maITEBzHAV_zlnqenCVegfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">83</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzHAV_zPaMGiTNrXPc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax expense (benefit)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 0.21 0.21 -395000 -881000 447000 688000 -197000 21000 75000 86000 37000 193000 83000 3000 24000 -14000 <p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zwjzPyFUMyxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span><span id="xdx_8B2_zAOpttMymRll" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20241231_ziOZkcFMaS9j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20231231_zeHH0Pl02x6g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzjWa_z8C2paWxZfqd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">679</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">849</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzjWa_zBfDM33RiADb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">R&amp;D tax credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,722</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,863</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pn3n3_maDTAGzjWa_zIOZGRoDmz18" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Compensation costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">235</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_pn3n3_maDTAGzjWa_zBB5b7IXPcQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Vacation accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">153</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzjWa_zA9H0ALDjDI2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzjWa_zUfAU83jeRY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Capitalized research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,096</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">759</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzjWa_z6hZ0pPPDaBc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">676</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">303</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzjWa_maDTANz0Q9_zC6qjTHLojmc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,078</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANz0Q9_zHItysgv7zYf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,098</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,646</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANz0Q9_maDTALNz5Um_z99xHwxeVzB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Deferred income tax assets, net of valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">466</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">432</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred incomes tax liability:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_msDTALNz5Um_zn1QVSjr2zoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property, plant and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(384</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(365</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_pn3n3_di_msDTALNz5Um_z8eAUojEMNgf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(82</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(67</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNz5Um_zQqtR7De8m5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Deferred income tax asset, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 679000 849000 1722000 1863000 235000 113000 118000 153000 38000 38000 1096000 759000 676000 303000 4564000 4078000 4098000 3646000 466000 432000 384000 365000 82000 67000 500000 2700000 These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income. 1700000 expire in varying amounts in tax years 2028 through 2042. 0 0 The federal tax years open to examination are 2021 to 2024. The Company’s state and local tax years that are open to tax examination are generally 2020 to 2024. 0.15 0.01 <p id="xdx_806_ecustom--EmployeeRetentionCreditTextBlock_z8ybsuJYkf8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_825_z9q7ayAupzBd">Employee Retention Credit</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022, the Company conducted an analysis as to whether it was entitled to employee retention credits (“ERC”) under the CARES Act as amended by the Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Plan Act of 2021. Based on the analysis, the Company determined that it was entitled to an ERC of approximately $<span id="xdx_90C_ecustom--IncreaseDecreaseInEmployeeRetentionCreditReceivable_pn5n6_c20220101__20221231_ztYjUcre38w3" title="Employee retention credit eligible amount">1.5</span> million and recognized a receivable of $<span id="xdx_903_ecustom--EmployeeRetentionCreditReceivable_iI_pn5n6_c20221231_zC0QpU3VinC8" title="Employee retention credit receivable">1.5</span> million as of December 31, 2022. The Company received the ERC credit in July 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1500000 1500000 <p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zNn92VvgXvni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_826_zvk8MPTFQvVd">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s Share Incentive Plans are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2007 Share Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 12, 2007, shareholders approved the Company’s 2007 Share Incentive Plan (“2017 Incentive Plan”), in connection therewith, <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20071212__us-gaap--PlanNameAxis__custom--TwoThousandSevenShareIncentivePlanMember_zbs6Tk9HpEmj" title="Common shares reserved for future issuance.">750,000</span> shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2017 Incentive Plan through December 12, 2017. The Plan expired in December 2017. As of December 31, 2024, there were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSevenShareIncentivePlanMember_zJ2xaxmTkXN" title="Number of options outstanding">120,000</span> options outstanding under this plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2016 Share Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2016, shareholders approved the Company’s 2016 Share Incentive Plan (“2016 Incentive Plan”), in connection therewith, <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20161209__us-gaap--PlanNameAxis__custom--TwoThousandSixteenShareIncentivePlanMember_zD6F5o1hy8B8" title="Common shares reserved for future issuance.">750,000</span> shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2016 Incentive Plan through December 9, 2026. As of December 31, 2024, there were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenShareIncentivePlanMember_zS9cp1rOtHCb" title="Number of options outstanding">424,125</span> options outstanding under this plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2022 Share Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2022, shareholders approved the Company’s 2022 Share Incentive Plan (“2022 Incentive Plan”), in connection therewith, <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220714__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember_zPK22pQNPxoh" title="Common shares reserved for future issuance.">515,000</span> shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2022 Incentive Plan through July 14, 2032. As of December 31, 2024, there were <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember_zNMy6GHzl6Je" title="Number of options outstanding">279,000</span> options outstanding under this plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the 2016 and 2022 Share Incentive Plans, the purchase price of the common stock under each option plan shall be determined by the Committee, provided, however, that such purchase price shall not be less than the fair market value of the shares on the date such option is granted. The stock options generally expire <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dxL_c20220714__20220714__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zcUMNJiW0e2k" title="Share based compensation arrangement by share based payment award expiration Period::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0880">seven</span></span> to <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220714__20220714__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zzeAjK2p2v04" title="Share based compensation arrangement by share based payment award expiration Period">ten years</span> after the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of December 31, 2024<i>, </i>there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenShareIncentivePlanMember_zwGwTgZFl6hd" title="Share based compensation arrangement by share based payment award, number of shares available for grant">44,948</span> shares available for grant under the 2016 Equity Incentive Plan and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember_zypxwYzM64kl" title="Number of shares available for grant">138,180</span> shares available for grant under the 2022 Equity Incentive Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – Stock-Based Compensation (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation of $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231_zhq7WZEWCot7" title="Stock based compensation">1.1</span> million and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231_zu0Pln8D356g" title="Stock based compensation">0.9</span> million for the years ended December 31, 2024 and 2023, respectively, that were included in the following line items in our Consolidated Statements of Operations (in thousands):</span></p> <p id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zhKncurKQlMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zTO71RkrtTN8" style="display: none">Schedule of Stock Based Compensation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240101__20241231_zf3th4l7E9ql" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_z98BiLX58ehk" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_zQ8WisZTS1Zb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cost of revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">152</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQrs52Qkwpgl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--SellingExpenseMember_zgiklMZSaPw2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Selling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zdlcV2BhVq34" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">616</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">535</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zz17ERlxJ3N2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,063</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">908</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z2ibSuppD5Ae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense in both years included approximately $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zKWDRcjFvcB6" title="Stock based compensation expenses"><span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zhHFv4jG5JB8" title="Stock based compensation expenses">0.2</span></span> million related to restricted stock awards pursuant to a Director Compensation plan discussed below. The Company recognizes forfeitures of stock awards as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2024, the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrYKL5ZOTYGh" title="Stock option granted">5,000</span> stock options, vesting <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zztkPvvjpuF2" title="Stock option vesting percentage">25</span>% per year over four years, with a <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zESqIhRO0ZSe" title="Expiration period::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0917">ten-year</span></span> life. The Company determined the fair value of stock options granted during the year ended December 31, 2024 is based upon weighted average assumptions as provided below.</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zZ1e3OgFs6W8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_z6JvdXbdeCJ7" style="display: none">Schedule of Weighted Average Assumptions</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20241231_zjIS7KYwpbtk" style="width: 16%; text-align: right" title="Stock price">4.75</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231_zVzxq2z7YuA" style="text-align: right" title="Exercise price">4.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zaKfF6Kmnsvi" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_z2EtU7lmRx3c" title="Expected volatility">77</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_z0n6r3PCAm1k" title="Risk-free interest rate">4.12</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zgwR2zJyjkM8" title="Expected life (in years)">6.00</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AE_zoj8bkPuanS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected life is the number of years the Company estimates that the awards will be outstanding based on the simplified method that considers the vesting period and contractual period of the option. The expected volatility is measured using historical daily price changes of the Company’s common stock over the respective expected term. The Company has <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20241231_zGwcFWbRU5Xf" title="Outstanding stock options">823,125</span> of outstanding stock options under the three plans at December 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – Stock-Based Compensation (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCtkdWGjfW5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock options awards for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zd3upwMb0sOd" style="display: none">Schedule of Stock Options Awards</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: double; font-family: Times New Roman, Times, Serif; font-size: 10pt">(in Shares)</span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average <br/>Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zkm8r9bhX6c" style="width: 16%; text-align: right" title="Awards outstanding, beginning balance">673,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zJVuIYCA7rAa" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, beginning balance">11.26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zB2Sya7P90E" style="text-align: right" title="Awards, granted">254,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zHS1rWhRpaL1" style="text-align: right" title="Weighted average exercise price, granted">14.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired / cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zNqn08vACJ38" style="text-align: right" title="Awards, expired / cancelled">(44,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zPKhqekaBsh9" style="text-align: right" title="Weighted average exercise price, expired / cancelled">6.57</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zZlEasLQTqp1" style="border-bottom: Black 1pt solid; text-align: right" title="Awards, exercised">(35,625</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zYQE9uoWECj5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised">4.53</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Outstanding at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zDu18g87KEe1" style="text-align: right" title="Awards outstanding, beginning balance">846,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zppyA6ARvNPk" style="text-align: right" title="Weighted average exercise price outstanding, beginning balance">8.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_z0UuPN5BQTK" style="text-align: right" title="Awards, granted">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zfLYdgfUhZfd" style="text-align: right" title="Weighted average exercise price, granted">4.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired / cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zfDGelc4m6Vl" style="text-align: right" title="Awards, expired / cancelled">(28,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zhvCIFngUNLj" style="text-align: right" title="Weighted average exercise price, expired / cancelled">7.94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_zrewXkg0Vytj" style="border-bottom: Black 1pt solid; text-align: right" title="Awards, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zPis4wvCSE6i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zM7OC5349Hl5" style="border-bottom: Black 2.5pt double; text-align: right" title="Awards outstanding, ending balance">823,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_z0W6mRV3Wqal" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, ending balance">8.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_z9SkdSD53dQh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2024 and 2023, stock options to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20241231_zkx38OFUQYmc" title="Stock options exercisable">485,000</span> and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_zU8Rr10hqGaf" title="Stock options exercisable">265,000</span>, respectively, shares of common stock were exercisable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zOnqcA4MOtJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about the outstanding and exercisable options at December 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zzPP1tJFaaD2" style="display: none">Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price Range</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contractual</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zxLlAfoybVDf" title="Exercise Price Range">4.00</span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zb0emjE6n4E4" title="Exercise Price Range">7.00</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zsx3KlRQjixa" style="width: 9%; text-align: right" title="Number of options outstanding">444,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zCDyhLqozcY4" title="Number of options outstanding, weighted average remaining contractual term">6.7</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zW7RwjMCAU1g" style="width: 9%; text-align: right" title="Number of options outstanding, weighted average exercise price">4.39</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zHFvlfER6lPj" style="width: 9%; text-align: right" title="Number of options outstanding, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zETFAOC3MGNi" style="width: 9%; text-align: right" title="Number of options exercisable">285,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zlBn6Nxd5nZi" style="width: 8%; text-align: right" title="Number of options exercisable, weighted average exercise price">5.86</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zWIYEuhqtDs7" style="width: 8%; text-align: right" title="Number of options exercisable, intrinsic value">50,580</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zdma3ylHUGtj" title="Exercise Price Range">7.01</span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zyvgYGtCkGFl" title="Exercise Price Range">10.00</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zXODarX8Mbq1" style="text-align: right" title="Number of options outstanding">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zkjsomx6i4n9" title="Number of options outstanding, weighted average remaining contractual term">3.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zEZp5hQThLZa" style="text-align: right" title="Number of options outstanding, weighted average exercise price">8.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWpG9tgvsHk7" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zLN464hH1Wbh" style="text-align: right" title="Number of options exercisable">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zY9Ki41rDVwb" style="text-align: right" title="Number of options exercisable, weighted average exercise price">8.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zR7F7RMmrind" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zrxa7zyr41k1" title="Exercise Price Range">10.01</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zR8GqjjbTtJ9" title="Exercise Price Range">13.00</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z4t0OCfEW1d" style="text-align: right" title="Number of options outstanding">130,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z4kGcRpMHkz1" title="Number of options outstanding, weighted average remaining contractual term">2.7</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zgS123z52RDg" style="text-align: right" title="Number of options outstanding, weighted average exercise price">10.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zi5VRoJX91B5" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJeglZ3krHWa" style="text-align: right" title="Number of options exercisable">122,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvA8xRU7klCi" style="text-align: right" title="Number of options exercisable, weighted average exercise price">10.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z2uGSTaqkG11" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zwiVQxuq4ABl" title="Exercise price range, lower limit">13.01</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_z1cUVxoNb093" title="Exercise price range, upper limit">16.00</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zz5BmJgwY72l" style="text-align: right" title="Number of options outstanding">228,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zrACz8KJBQfc" title="Number of options outstanding, weighted average remaining contractual term">8.2</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zC8PEqelhp9i" style="text-align: right" title="Number of options outstanding, weighted average exercise price">14.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zyk7dJKfetWi" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zUO0vdSvwP7g" style="text-align: right" title="Number of options exercisable">57,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_znlZr199JDa" style="text-align: right" title="Number of options exercisable, weighted average exercise price">14.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_z0LsiFu0Gkk1" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AE_zLSaabK4nGm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2024, there was $<span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeDzJYQ33TMf" title="Unrecognized compensation costs">1.6</span> million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zq0kkSWF3Ve9" title="Unrecognized compensation costs, weighted average recoginition period">2.1</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Restricted Stock Awards</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Director Compensation plan approved on October 11, 2021<i>, </i>each of the five independent directors is entitled to compensation for an annual equity retainer in the amount of $<span id="xdx_905_ecustom--SharebasedPaymentArrangementAnnualEquityRetainerAmount_iI_c20211011__srt--TitleOfIndividualAxis__custom--FiveDirectorsMember_zZE1R33puSSe" title="Annual equity retainer amount">40,000</span> per director, to be automatically granted on the date of the Company’s annual meeting of shareholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – Stock-Based Compensation (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zu1gFEZ1F5g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes restricted stock awards for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zGlVwuGV4pU2" style="display: none">Schedule of Restricted Stock Awards</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average Grant</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Shares of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Date Fair</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Restricted Stock</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Unvested outstanding at January 1, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOFOB1kHpBH7" style="text-align: right" title="Shares of restricted stock, unvested outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOluJUWsYwDb" style="text-align: right" title="Weighted average grant date fair value, unvested outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvKlrwxOB5f7" style="width: 16%; text-align: right" title="Shares of restricted stock, granted">41,320</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCb7UvNusgT7" style="width: 16%; text-align: right" title="Weighted average grant date fair value, granted">6.65</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zv3Evrr3nWY7" style="text-align: right" title="Shares of restricted stock, vested">(24,187</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJKbZtaiybUh" style="text-align: right" title="Weighted average grant date fair value, vested">6.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Forfeited or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZk4FcWHMAol" style="border-bottom: Black 1pt solid; text-align: right" title="Shares of restricted stock, forfeited or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zI7ybcy1Wko4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Unvested outstanding at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1pFRSKlfi8a" style="text-align: right" title="Shares of restricted stock, unvested outstanding beginning balance">17,133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zURjV9pp75Rd" style="text-align: right" title="Weighted average grant date fair value, unvested outstanding beginning balance">6.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRLvZyd1u6e2" style="text-align: right" title="Shares of restricted stock, granted">57,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBW99a65xSIg" style="text-align: right" title="Weighted average grant date fair value, granted">3.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zALUYcvHAXwc" style="text-align: right" title="Shares of restricted stock, vested">(46,210</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVEXFIemMpQb" style="text-align: right" title="Weighted average grant date fair value, vested">4.63</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdqHFA1DZvU3" style="border-bottom: Black 1pt solid; text-align: right" title="Shares of restricted stock, forfeited or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFEPP1Esqh7f" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Unvested outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z87FBi2U2yI9" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares of restricted stock, unvested outstanding ending balance">28,250</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zslolfo4Z6s1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, unvested outstanding ending balance">3.54</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_znrOopMhwoDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the restricted stock awards is recorded as stock-based compensation expense over the <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQwuLelD2UD1" title="Vesting period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1095">one-year</span></span> vesting period and totaled $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn4n6_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSoZSncuHwIj" title="Stock based compensation"><span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn4n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zlI4cqfbK7Wb" title="Stock based compensation">0.2</span></span> million for the both years ending December 31, 2024 and 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 750000 120000 750000 424125 515000 279000 P10Y 44948 138180 1100000 900000 <p id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zhKncurKQlMi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zTO71RkrtTN8" style="display: none">Schedule of Stock Based Compensation</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240101__20241231_zf3th4l7E9ql" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231_z98BiLX58ehk" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_zQ8WisZTS1Zb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Cost of revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">152</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">120</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zQrs52Qkwpgl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--SellingExpenseMember_zgiklMZSaPw2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Selling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zdlcV2BhVq34" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">616</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">535</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zz17ERlxJ3N2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,063</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">908</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 152000 120000 188000 159000 107000 94000 616000 535000 1063000 908000 200000 200000 5000 0.25 <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zZ1e3OgFs6W8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_z6JvdXbdeCJ7" style="display: none">Schedule of Weighted Average Assumptions</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20241231_zjIS7KYwpbtk" style="width: 16%; text-align: right" title="Stock price">4.75</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20241231_zVzxq2z7YuA" style="text-align: right" title="Exercise price">4.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zaKfF6Kmnsvi" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_z2EtU7lmRx3c" title="Expected volatility">77</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_z0n6r3PCAm1k" title="Risk-free interest rate">4.12</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zgwR2zJyjkM8" title="Expected life (in years)">6.00</span></td><td style="text-align: left"> </td></tr> </table> 4.75 4.75 0 0.77 0.0412 P6Y 823125 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zCtkdWGjfW5k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock options awards for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zd3upwMb0sOd" style="display: none">Schedule of Stock Options Awards</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="text-decoration: double; font-family: Times New Roman, Times, Serif; font-size: 10pt">(in Shares)</span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average <br/>Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zkm8r9bhX6c" style="width: 16%; text-align: right" title="Awards outstanding, beginning balance">673,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zJVuIYCA7rAa" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, beginning balance">11.26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zB2Sya7P90E" style="text-align: right" title="Awards, granted">254,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zHS1rWhRpaL1" style="text-align: right" title="Weighted average exercise price, granted">14.02</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired / cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zNqn08vACJ38" style="text-align: right" title="Awards, expired / cancelled">(44,500</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zPKhqekaBsh9" style="text-align: right" title="Weighted average exercise price, expired / cancelled">6.57</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zZlEasLQTqp1" style="border-bottom: Black 1pt solid; text-align: right" title="Awards, exercised">(35,625</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zYQE9uoWECj5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised">4.53</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Outstanding at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zDu18g87KEe1" style="text-align: right" title="Awards outstanding, beginning balance">846,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231_zppyA6ARvNPk" style="text-align: right" title="Weighted average exercise price outstanding, beginning balance">8.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231_z0UuPN5BQTK" style="text-align: right" title="Awards, granted">5,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zfLYdgfUhZfd" style="text-align: right" title="Weighted average exercise price, granted">4.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expired / cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zfDGelc4m6Vl" style="text-align: right" title="Awards, expired / cancelled">(28,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zhvCIFngUNLj" style="text-align: right" title="Weighted average exercise price, expired / cancelled">7.94</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231_zrewXkg0Vytj" style="border-bottom: Black 1pt solid; text-align: right" title="Awards, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0965">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231_zPis4wvCSE6i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zM7OC5349Hl5" style="border-bottom: Black 2.5pt double; text-align: right" title="Awards outstanding, ending balance">823,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231_z0W6mRV3Wqal" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, ending balance">8.24</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 673000 11.26 254000 14.02 44500 6.57 35625 4.53 846875 8.20 5000 4.75 28750 7.94 823125 8.24 485000 265000 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zOnqcA4MOtJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about the outstanding and exercisable options at December 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BC_zzPP1tJFaaD2" style="display: none">Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price Range</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Contractual</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zxLlAfoybVDf" title="Exercise Price Range">4.00</span>-<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zb0emjE6n4E4" title="Exercise Price Range">7.00</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zsx3KlRQjixa" style="width: 9%; text-align: right" title="Number of options outstanding">444,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zCDyhLqozcY4" title="Number of options outstanding, weighted average remaining contractual term">6.7</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zW7RwjMCAU1g" style="width: 9%; text-align: right" title="Number of options outstanding, weighted average exercise price">4.39</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zHFvlfER6lPj" style="width: 9%; text-align: right" title="Number of options outstanding, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zETFAOC3MGNi" style="width: 9%; text-align: right" title="Number of options exercisable">285,375</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zlBn6Nxd5nZi" style="width: 8%; text-align: right" title="Number of options exercisable, weighted average exercise price">5.86</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zWIYEuhqtDs7" style="width: 8%; text-align: right" title="Number of options exercisable, intrinsic value">50,580</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zdma3ylHUGtj" title="Exercise Price Range">7.01</span>-<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zyvgYGtCkGFl" title="Exercise Price Range">10.00</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zXODarX8Mbq1" style="text-align: right" title="Number of options outstanding">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zkjsomx6i4n9" title="Number of options outstanding, weighted average remaining contractual term">3.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zEZp5hQThLZa" style="text-align: right" title="Number of options outstanding, weighted average exercise price">8.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWpG9tgvsHk7" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zLN464hH1Wbh" style="text-align: right" title="Number of options exercisable">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zY9Ki41rDVwb" style="text-align: right" title="Number of options exercisable, weighted average exercise price">8.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zR7F7RMmrind" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zrxa7zyr41k1" title="Exercise Price Range">10.01</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zR8GqjjbTtJ9" title="Exercise Price Range">13.00</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z4t0OCfEW1d" style="text-align: right" title="Number of options outstanding">130,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z4kGcRpMHkz1" title="Number of options outstanding, weighted average remaining contractual term">2.7</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zgS123z52RDg" style="text-align: right" title="Number of options outstanding, weighted average exercise price">10.62</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zi5VRoJX91B5" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1025">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zJeglZ3krHWa" style="text-align: right" title="Number of options exercisable">122,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zvA8xRU7klCi" style="text-align: right" title="Number of options exercisable, weighted average exercise price">10.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z2uGSTaqkG11" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1031">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zwiVQxuq4ABl" title="Exercise price range, lower limit">13.01</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_z1cUVxoNb093" title="Exercise price range, upper limit">16.00</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zz5BmJgwY72l" style="text-align: right" title="Number of options outstanding">228,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zrACz8KJBQfc" title="Number of options outstanding, weighted average remaining contractual term">8.2</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zC8PEqelhp9i" style="text-align: right" title="Number of options outstanding, weighted average exercise price">14.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zyk7dJKfetWi" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zUO0vdSvwP7g" style="text-align: right" title="Number of options exercisable">57,125</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_znlZr199JDa" style="text-align: right" title="Number of options exercisable, weighted average exercise price">14.11</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_z0LsiFu0Gkk1" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></td><td style="text-align: left"> </td></tr> </table> 4.00 7.00 444625 P6Y8M12D 4.39 285375 5.86 50580000 7.01 10.00 20000 P3Y3M18D 8.07 20000 8.07 10.01 13.00 130000 P2Y8M12D 10.62 122500 10.55 13.01 16.00 228500 P8Y2M12D 14.11 57125 14.11 1600000 P2Y1M6D 40000 <p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zu1gFEZ1F5g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes restricted stock awards for the years ended December 31, 2024 and 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zGlVwuGV4pU2" style="display: none">Schedule of Restricted Stock Awards</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average Grant</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Shares of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Date Fair</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Restricted Stock</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Unvested outstanding at January 1, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOFOB1kHpBH7" style="text-align: right" title="Shares of restricted stock, unvested outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOluJUWsYwDb" style="text-align: right" title="Weighted average grant date fair value, unvested outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvKlrwxOB5f7" style="width: 16%; text-align: right" title="Shares of restricted stock, granted">41,320</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCb7UvNusgT7" style="width: 16%; text-align: right" title="Weighted average grant date fair value, granted">6.65</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zv3Evrr3nWY7" style="text-align: right" title="Shares of restricted stock, vested">(24,187</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJKbZtaiybUh" style="text-align: right" title="Weighted average grant date fair value, vested">6.81</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Forfeited or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zZk4FcWHMAol" style="border-bottom: Black 1pt solid; text-align: right" title="Shares of restricted stock, forfeited or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zI7ybcy1Wko4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Unvested outstanding at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1pFRSKlfi8a" style="text-align: right" title="Shares of restricted stock, unvested outstanding beginning balance">17,133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zURjV9pp75Rd" style="text-align: right" title="Weighted average grant date fair value, unvested outstanding beginning balance">6.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRLvZyd1u6e2" style="text-align: right" title="Shares of restricted stock, granted">57,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBW99a65xSIg" style="text-align: right" title="Weighted average grant date fair value, granted">3.55</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zALUYcvHAXwc" style="text-align: right" title="Shares of restricted stock, vested">(46,210</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVEXFIemMpQb" style="text-align: right" title="Weighted average grant date fair value, vested">4.63</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdqHFA1DZvU3" style="border-bottom: Black 1pt solid; text-align: right" title="Shares of restricted stock, forfeited or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFEPP1Esqh7f" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited or cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Unvested outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z87FBi2U2yI9" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares of restricted stock, unvested outstanding ending balance">28,250</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zslolfo4Z6s1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, unvested outstanding ending balance">3.54</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 41320 6.65 24187 6.81 17133 6.53 57327 3.55 46210 4.63 28250 3.54 200000 200000 <p id="xdx_804_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zt12nLFIYzA3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_82F_z0l0JkfJjYgl">Defined Contribution Plan</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains a 401(k) Plan for the benefit of all eligible employees. All employees as of the effective date of the 401(k) Plan became eligible. An employee is eligible to become a participant after three months of continuous service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participants may elect to contribute from their compensation any amount up to the maximum deferral allowed by the Internal Revenue Code. Employer contributions are optional.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective July 1, 2022, the Company implemented a matching contribution of <span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20220701__20220701_z3cBPlDFNO51" title="Defined contribution plan percentage">50</span>% of an employee’s contributions up to <span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_dp_uPure_c20220701__20220701_za28dwcchO07" title="Defined contribution plan percentage of employees contribution">6</span>% of their compensation. The Company recorded compensation expense of $<span id="xdx_908_eus-gaap--DefinedContributionPlanCostRecognized_c20240101__20241231_zSARPRTNF5T" title="Defined contribution plan cost">235,000</span> and $<span id="xdx_90E_eus-gaap--DefinedContributionPlanCostRecognized_c20230101__20231231_zeLeceiOV267" title="Defined contribution plan cost">243,000</span> during the years ended December 31, 2024 and 2023, respectively, for matching contributions to the 401(k) plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_do_c20240101__20241231_zmOuorrU8Cx2" title="Defined contribution plan, employer discretionary contribution amount"><span id="xdx_90E_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_do_c20230101__20231231_zNP94Pr7fsE9" title="Defined contribution plan, employer discretionary contribution amount">No</span></span> discretionary employer contribution has been made for 2024 and 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.50 0.06 235000 243000 0 0 <p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_zkPPxYX8nNl8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 - <span id="xdx_823_zg6Z0rTnFVx2">Reportable Segments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has determined that it has <span id="xdx_901_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zVXVfeIYP9Qj" title="Number of operating segments">three</span> reportable segments, organized primarily based on product offerings, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVD Equipment – manufactures chemical vapor deposition, physical vapor transport and thermal process equipment.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SDC - manufactures ultra-high purity gas and chemical delivery control systems.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MesoScribe - provided electronic printing services and products (heaters, antennas, and sensors).</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both CVD Equipment and SDC also sell spares and parts and provide services related to the equipment each segment sells. One other business, Tantaline, did not meet the quantitative threshold for separate reporting and has been reflected as “Other” below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The chief operating decision maker (“CODM”) of the Company is the Company’s chief executive officer. The CODM assesses performance and decides how to allocate resources, including employees, financial or capital resources, based on segment net income (loss). The CODM considers actual-to-actual variances on a quarterly basis when making decisions about allocating capital and other resources to the segments and to assess the performance for each segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial results for the reportable segments and other business are prepared on a basis consistent with the internal disaggregation of financial information to assist the CODM is making internal operating decisions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain income and expenses are excluded from segment net income (loss) and included in the unallocated amounts in the reconciliation of reportable segment net income (loss) to net loss. These items are not used by the CODM in allocating resources or evaluating the results of the segments and include the following: corporate expenses consisting of employment costs of executives, finance, information technology and human resources; board of director fees; professional fees; shareholder and investor relations expense; directors’ and officers’ insurance; interest income and income tax expense. Segment income (loss) from operations may not be consistent with measures used by other companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 - Reportable Segments (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_893_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zoZunXbhAJqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following provides segment information as described below (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zNqk6uPmZSri" style="display: none">Schedule of Segments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMember_zZw6RQLrng12" style="border-bottom: Black 1pt solid; text-align: center">CVD</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_z3VzYbktbmEd" style="border-bottom: Black 1pt solid; text-align: center">SDC</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MesoScribeTechnologiesIncMember_zSG5xSPJg9bh" style="border-bottom: Black 1pt solid; text-align: center">MesoScribe</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zaCSdZzPJu38" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">CVD</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">SDC</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">MesoScribe</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zHutzrfCA6qe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Segment revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">18,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,510</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_pn3n3_z7cg5fA6GtP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,158</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,749</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,179</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zCttmcQmgj7l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Research &amp; development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,627</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--SellingExpense_pn3n3_zejSEMWduFsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Selling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,656</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_zD82zoEQPQG4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">General &amp; administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,064</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">709</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,857</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_pn3n3_di_zm8VWPcaWycd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Gain on sales of equipment</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">(42</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">(675</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">(717</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--AssetImpairmentCharges_pn3n3_zaMOoLkVXhUe" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Impairment charge</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zVOAVoHtInM2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--InterestExpenseNonoperating_pn3n3_zlhzabVo4SK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_pn3n3_zsScS0M0nrIf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment net income (loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,763</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,092</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">891</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Segment assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMember_z9dEhBndkMqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">15,903</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zF6stuBMfh66" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">3,129</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MesoScribeTechnologiesIncMember_zj6ssv6VuuBc" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">627</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Assets_iI_pn3n3_c20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLLNmmunWIKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">19,659</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--CapitalExpenditures_pn3n3_zGEfLLdsdE7g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Capital expenditures</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">106</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_zpLiwQq7pXwh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Depreciation &amp; amortization</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">635</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMember_z6FzQpapEhKb" style="border-bottom: Black 1pt solid; text-align: center">CVD</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_z6OjbRXfJBmd" style="border-bottom: Black 1pt solid; text-align: center">SDC</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MesoScribeTechnologiesIncMember_zH3uZXkohqnf" style="border-bottom: Black 1pt solid; text-align: center">MesoScribe</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zaNHjGygWLF1" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">CVD</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">SDC</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">MesoScribe</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqzI5Y3hsNx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Segment revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">16,334</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,139</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">722</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">24,195</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CostOfRevenue_pn3n3_zPgCnqe0NZkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,408</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,313</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">507</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,228</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zLbdPrMl93wg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Research &amp; development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">299</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,592</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SellingExpense_pn3n3_zjejKW2x71c5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Selling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,414</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,586</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_z652MriLxcH9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">General &amp; administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,834</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetImpairmentCharges_pn3n3_zFeHLk1MtZW5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Impairment charge</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">111</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">111</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zlDsWtNETRLk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(86</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(86</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--InterestExpenseNonoperating_pn3n3_zMxrowfvywZb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_zooLcoHwf0db" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment net income (loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,798</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,093</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Segment assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMember_zji7hevDJEob" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">19,112</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zZ4rCebuKaMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">3,468</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MesoScribeTechnologiesIncMember_zmeaJxBEvmDi" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">211</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zniC1ZRoo8Ii" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">22,791</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CapitalExpenditures_pn3n3_zG1vkwUVMFOe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Capital expenditures</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">404</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">418</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_zVzEJ1Hj0R1h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Depreciation &amp; amortization</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">620</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zMpJi1Z9DMJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-underline-style: double"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 - Reportable Segments (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_894_eus-gaap--ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_zSVLZQHsZyif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of revenue of reportable segments to consolidated revenue (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zrZPShepybh2" style="display: none">Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20241231_zLlgnuSkBUp5" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_z3XjOMW8kNi5" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zetyA3EW4wue" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Revenue of reportable segments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">27,510</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,195</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherTantalineMember_zRKFposAujLi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other - Tantaline</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">462</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_zLT56jyxdBq5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Intersegment revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(634</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(548</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zgX4uu41pTy1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated total revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,109</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zgRoXvUZpENj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intersegment revenues are determined based on similar product sales to external customers of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zrskoEjYHsm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of net income (loss) of reportable segments to consolidated net loss (in thousand):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zAIBh2661Ef6" style="display: none">Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20241231_zYQI8ZVp0Kqf" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zEmTS57bUCDb" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zucA7T4eg9jg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net income (loss) of reportable segments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">891</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,093</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unallocated amounts:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherExpenses_iN_pn3n3_di_hsrt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_ztn3BmCjQNWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Corporate expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,324</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,503</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OtherExpenses_iN_pn3n3_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherTantalineMember_znERwXLYRZ6c" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other - Tantaline</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(175</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OtherExpenses_iN_pn3n3_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherTantalineMember_zf7sTEYaobyb" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unallocated amounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(175</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--InvestmentIncomeInterest_pn3n3_zrPTTcCMxhD4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Interest income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">577</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_zynj15V8p7L6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Income tax (expense) benefit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(24</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zUOwFC5g18H6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,898</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,180</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A1_zZ7eJF6UmUa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_zRO5muFUuTSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of total assets of reportable segments to consolidated total assets (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zD7RBTYra957" style="display: none">Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_zMtYyzEeA6ye" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231231_z5G0S6yC3EJk" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--Assets_iI_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zz3gxgEkhRx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Total assets of reportable segments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,659</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">22,791</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unallocated amounts:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zOJgdsqjqTx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Cash equivalents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,099</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zl0vNd2wrAQj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">135</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">135</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Assets_iI_pn3n3_z3QyCOnhxvDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Consolidated total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,025</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zgAztxYNT3j3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 - Reportable Segments (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_895_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zHofG3VgeOA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a revenue by geographic area (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zGCzm4XNgrl1" style="display: none">Schedule of Revenue by Geographic Area</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zHNQ7BUw0sv6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_znVaoWd9hwf3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AmericasMember_zy1N9yZwzsP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,720</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,975</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--NorthAmericaMember_zIOkKI9YBfxd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">North America, excluding US</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__us-gaap--EMEAMember_zQx4QhPUDmd4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Europe, Middle East and Africa</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,508</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AsiaPacificMember_zj8QENF21que" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Asia-Pacific</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">570</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,570</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zMcqZwdYDW27" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Consolidated total revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,109</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zh3VWlepsUsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For geographic reporting, revenues are attributed to the location in which in the customer facility is located. All of the Company’s long-lived assets are located in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3 <p id="xdx_893_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zoZunXbhAJqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following provides segment information as described below (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zNqk6uPmZSri" style="display: none">Schedule of Segments</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMember_zZw6RQLrng12" style="border-bottom: Black 1pt solid; text-align: center">CVD</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_z3VzYbktbmEd" style="border-bottom: Black 1pt solid; text-align: center">SDC</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MesoScribeTechnologiesIncMember_zSG5xSPJg9bh" style="border-bottom: Black 1pt solid; text-align: center">MesoScribe</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zaCSdZzPJu38" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">CVD</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">SDC</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">MesoScribe</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zHutzrfCA6qe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Segment revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">18,288</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,444</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">778</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">27,510</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CostOfRevenue_pn3n3_z7cg5fA6GtP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,158</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,749</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,179</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zCttmcQmgj7l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Research &amp; development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,398</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,627</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--SellingExpense_pn3n3_zejSEMWduFsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Selling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,656</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_zD82zoEQPQG4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">General &amp; administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,064</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">709</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,857</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_iN_pn3n3_di_zm8VWPcaWycd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Gain on sales of equipment</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">(42</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1147">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">(675</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">(717</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--AssetImpairmentCharges_pn3n3_zaMOoLkVXhUe" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Impairment charge</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zVOAVoHtInM2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--InterestExpenseNonoperating_pn3n3_zlhzabVo4SK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1162">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_pn3n3_zsScS0M0nrIf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment net income (loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,763</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,562</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,092</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">891</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Segment assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMember_z9dEhBndkMqk" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">15,903</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--Assets_iI_pn3n3_c20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zF6stuBMfh66" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">3,129</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MesoScribeTechnologiesIncMember_zj6ssv6VuuBc" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">627</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--Assets_iI_pn3n3_c20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zLLNmmunWIKj" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">19,659</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--CapitalExpenditures_pn3n3_zGEfLLdsdE7g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Capital expenditures</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">106</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_zpLiwQq7pXwh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Depreciation &amp; amortization</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">635</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">684</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMember_z6FzQpapEhKb" style="border-bottom: Black 1pt solid; text-align: center">CVD</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_z6OjbRXfJBmd" style="border-bottom: Black 1pt solid; text-align: center">SDC</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MesoScribeTechnologiesIncMember_zH3uZXkohqnf" style="border-bottom: Black 1pt solid; text-align: center">MesoScribe</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zaNHjGygWLF1" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">For the year ended December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">CVD</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">SDC</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">MesoScribe</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zqzI5Y3hsNx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Segment revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">16,334</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,139</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">722</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">24,195</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CostOfRevenue_pn3n3_zPgCnqe0NZkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Cost of revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,408</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,313</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">507</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,228</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zLbdPrMl93wg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Research &amp; development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,288</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">299</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,592</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SellingExpense_pn3n3_zjejKW2x71c5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Selling</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,414</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">172</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1206">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,586</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_pn3n3_z652MriLxcH9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">General &amp; administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,085</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,834</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetImpairmentCharges_pn3n3_zFeHLk1MtZW5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Impairment charge</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1214">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">111</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right">111</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zlDsWtNETRLk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(86</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1221">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(86</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--InterestExpenseNonoperating_pn3n3_zMxrowfvywZb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLoss_pn3n3_zooLcoHwf0db" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Segment net income (loss)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,798</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,093</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Segment assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMember_zji7hevDJEob" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">19,112</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zZ4rCebuKaMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">3,468</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MesoScribeTechnologiesIncMember_zmeaJxBEvmDi" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">211</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zniC1ZRoo8Ii" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment assets">22,791</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CapitalExpenditures_pn3n3_zG1vkwUVMFOe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Capital expenditures</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">404</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">418</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_pn3n3_zVzEJ1Hj0R1h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Depreciation &amp; amortization</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">620</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">49</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">728</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 18288000 8444000 778000 27510000 16158000 4749000 272000 21179000 2398000 229000 2627000 1456000 195000 5000 1656000 1064000 709000 84000 1857000 42000 675000 717000 -2000 -2000 19000 19000 -2763000 2562000 1092000 891000 15903000 3129000 627000 19659000 69000 37000 106000 635000 49000 684000 16334000 7139000 722000 24195000 14408000 4313000 507000 19228000 2288000 299000 5000 2592000 1414000 172000 1586000 1085000 679000 70000 1834000 111000 111000 -86000 -86000 23000 23000 -2798000 1676000 29000 -1093000 19112000 3468000 211000 22791000 404000 14000 418000 620000 49000 59000 728000 <p id="xdx_894_eus-gaap--ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_zSVLZQHsZyif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of revenue of reportable segments to consolidated revenue (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zrZPShepybh2" style="display: none">Schedule of Reconciliation of Revenue of Reportable Segments to Consolidated Revenue</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20241231_zLlgnuSkBUp5" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_z3XjOMW8kNi5" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zetyA3EW4wue" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Revenue of reportable segments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">27,510</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,195</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherTantalineMember_zRKFposAujLi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other - Tantaline</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">462</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_zLT56jyxdBq5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Intersegment revenue</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(634</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(548</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zgX4uu41pTy1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated total revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,109</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 27510000 24195000 462000 -634000 -548000 26876000 24109000 <p id="xdx_894_eus-gaap--ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_zrskoEjYHsm6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of net income (loss) of reportable segments to consolidated net loss (in thousand):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zAIBh2661Ef6" style="display: none">Schedule of Reconciliation of Net Income (Loss) of Reportable Segments to Consolidated Net Loss</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240101__20241231_zYQI8ZVp0Kqf" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230101__20231231_zEmTS57bUCDb" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zucA7T4eg9jg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net income (loss) of reportable segments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">891</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,093</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unallocated amounts:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherExpenses_iN_pn3n3_di_hsrt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_ztn3BmCjQNWg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Corporate expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,324</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,503</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OtherExpenses_iN_pn3n3_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherTantalineMember_znERwXLYRZ6c" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other - Tantaline</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(175</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--OtherExpenses_iN_pn3n3_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherTantalineMember_zf7sTEYaobyb" style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Unallocated amounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1277">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(175</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--InvestmentIncomeInterest_pn3n3_zrPTTcCMxhD4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Interest income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">577</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_zynj15V8p7L6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Income tax (expense) benefit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(24</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zUOwFC5g18H6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Consolidated net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,898</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,180</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> 891000 -1093000 3324000 3503000 175000 175000 559000 577000 24000 -14000 -1898000 -4180000 <p id="xdx_891_eus-gaap--ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_zRO5muFUuTSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of total assets of reportable segments to consolidated total assets (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zD7RBTYra957" style="display: none">Schedule of Reconciliation of Total Assets of Reportable Segments to Consolidated Total Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_zMtYyzEeA6ye" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231231_z5G0S6yC3EJk" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--Assets_iI_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zz3gxgEkhRx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Total assets of reportable segments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,659</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">22,791</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unallocated amounts:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zOJgdsqjqTx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Cash equivalents</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,099</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetsCurrent_iI_pn3n3_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zl0vNd2wrAQj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">135</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">135</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Assets_iI_pn3n3_z3QyCOnhxvDh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Consolidated total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">35,025</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 19659000 22791000 11892000 12099000 135000 135000 31686000 35025000 <p id="xdx_895_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zHofG3VgeOA2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a revenue by geographic area (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zGCzm4XNgrl1" style="display: none">Schedule of Revenue by Geographic Area</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zHNQ7BUw0sv6" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20230101__20231231_znVaoWd9hwf3" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AmericasMember_zy1N9yZwzsP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">25,720</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19,975</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--NorthAmericaMember_zIOkKI9YBfxd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">North America, excluding US</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__us-gaap--EMEAMember_zQx4QhPUDmd4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Europe, Middle East and Africa</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">521</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,508</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--AsiaPacificMember_zj8QENF21que" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Asia-Pacific</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">570</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,570</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zMcqZwdYDW27" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Consolidated total revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">26,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,109</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 25720000 19975000 65000 56000 521000 1508000 570000 2570000 26876000 24109000 <p id="xdx_801_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zYxE9moKdoee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – <span id="xdx_824_zGh311RwMbj4">MesoScribe and Tantaline</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>MesoScribe</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On August 8, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with a third-party. Pursuant to the Agreement, the Company sold certain proprietary equipment relating to its plasma spray technology and material deposition system and granted a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate adjusted purchase price of $<span id="xdx_901_ecustom--SaleOfProprietaryAssetsAndLicenseCertainProprietyInformationAggregatePurchasePrice_iI_pn5n6_c20230808__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zYtiiBmXqMS4" title="Aggregate purchase price">0.8</span> million. The purchase price was payable in several installments and contingent upon certain performance metrics and other milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company received payments under the Agreement in the amount of $<span id="xdx_90A_ecustom--DepositsFromPurchaserOfMesoscribeAssets_iI_pn5n6_c20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zCbpdFdXJlab" title="Deposits from purchaser of equipment">0.6</span> million which had been reflected as “deposits from purchaser” in the accompanying consolidated balance sheet as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company fulfilled remaining orders for MesoScribe products during 2024 at which time it ceased operations of MesoScribe and recorded a $<span id="xdx_90C_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn5n6_c20240101__20241231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zSx1Ple8A0xf" title="Gain on sale of equipment">0.7</span> million gain upon the completion of the sale of the equipment during the year ended December 31, 2024. During the year ended December 31, 2023, the Company recorded an impairment charge of $<span id="xdx_90C_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_z4uOOGbtXtE1" title="Impairment charge">0.1</span> million for other equipment of MesoScribe.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The revenues and net income of MesoScribe were $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20240101__20241231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_z4F77wQyc8xk" title="Revenue">0.8</span> million and $<span id="xdx_90D_eus-gaap--NetIncomeLoss_pn5n6_c20240101__20241231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_z8Pf1zkClYu7" title="Net income (loss)">1.1</span> million for the year ended December 31, 2024, including the gain on sale of equipment of $<span id="xdx_90C_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pn5n6_c20240101__20241231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zfWvAsdIVVh8" title="Gain on sale of equipment">0.7</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The revenues and net income of MesoScribe were $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zT7jgwVmqPIj" title="Revenue">0.7</span> million and $<span id="xdx_903_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zuejq2SbpkB8" title="Net income (loss)">33,000</span> for the year ended December 31, 2023, including the impairment charge of $<span id="xdx_909_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_z3VqNPr8Hqz7" title="Impairment charge">0.1</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2024 and 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – MesoScribe and Tantaline (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The total assets and total liabilities of the MesoScribe subsidiary were $<span id="xdx_907_eus-gaap--Assets_iI_pn5n6_c20241231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zVq7dd2K6KGb">0.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million and $<span id="xdx_90D_eus-gaap--Liabilities_iI_pp0p0_c20241231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zTkIdAWbNWnb">0</span>, respectively, as of December 31, 2024 and $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_907_eus-gaap--Assets_iI_pn5n6_c20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_znYd3FWNOau" title="Assets">0.2</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million and $</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span id="xdx_90C_eus-gaap--Liabilities_iI_pn5n6_c20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zRLECGI4YLI9" title="Liabilities">0.7</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">million, respectively, as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Tantaline</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $<span id="xdx_905_eus-gaap--GainLossOnSaleOfBusiness_pn5n6_c20230526__20230526__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zd57COedij2h" title="Loss on disposition of tantaline">0.2</span> million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt. The Company received a $<span id="xdx_90E_ecustom--EarnOutPayment_pp0p0_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_z9Ld6inbTwhh" title="Earn-out payment">6,000</span> earn-out payment in 2024 based on the results of Tantaline’s operations for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Including the loss on disposition of $<span id="xdx_90F_eus-gaap--GainLossOnSaleOfBusiness_pn5n6_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zRQ7INa6nf5h" title="Loss on disposition of tantaline">0.2</span> million, the revenues and net income of Tantaline were $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zKXXIRrvfuu5" title="Revenues">0.5</span> million and $<span id="xdx_90B_eus-gaap--NetIncomeLoss_pn5n6_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zhYXLZeU0AMl" title="Net income">0.1</span> million, respectively, for the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 800000 600000 700000 100000 800000 1100000 700000 700000 33000 100000 600000 0 200000 700000 200000 6000 200000 500000 100000 <p id="xdx_803_ecustom--RisksAndUncertaintiesTextBlock_zpEQghuCf55i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 15 – <span id="xdx_821_z3y8WdUFGIQ">Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently operates in a challenging economic environment as the global economy continues to confront the remaining impacts from the pandemic, geopolitical conflicts, inflationary pressures, and adverse supply chain disruptions. The specific impacts on the Company have included:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue timelier as it delays the Company’s manufacturing processes.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties may have on its future results of operations and cash flows.</span></p>